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Summary {#efs25778-sec-0001}
=======

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver a Scientific Opinion on dietary reference values (DRVs) for the European population, including sodium.

Sodium (Na^+^) is the dominant cation in the extracellular fluid (ECF) of the body. The functions of sodium lie in its participation in the control of the volume and systemic distribution of total body water; enabling the cellular uptake of solutes; and the generation via interactions with potassium of transmembrane electrochemical potentials.

Dietary sodium deficiency is rare in healthy European populations. Sodium chloride and other sodium salts are ubiquitous in the diet, and there are adaptive physiological mechanisms that reduce the losses of sodium in urine, faeces and sweat at low levels of sodium intake. Sodium chloride added during industrial food processing and discretionary use or food preservation is the major source of dietary sodium in Western diets. Other sources of sodium include inherently native sources and sodium‐containing food additives, in which sodium may be associated with anions other than chloride.

In healthy people, almost all dietary sodium is absorbed, even at very high level of intake. Following absorption, sodium ions are distributed by portal and systemic circulations, where their concentrations are maintained within a narrow range. Up to 95% of sodium body content is in the ECF, including a large proportion in bone, skin and muscle. The pool of sodium in bone, muscle and skin has been proposed to be a sodium depot or reserve, but could also have a homeostatic and adaptive role as an extra‐renal clearance depository for handling excessive systemic accumulation of sodium. The excretion and retention (i.e. homeostasis) of sodium is effected by an integrated neurohormonal control from centres located in the hypothalamus. The kidney is the main organ mediating the excretion and retention of sodium. It efficiently excretes sodium in response to high dietary intakes and salvages sodium when dietary intake is low. By contrast, sodium losses in the faeces are relatively stable and typically limited to a few mmol/day. The amount of sodium lost in sweat can vary widely, depending on, for example environmental conditions or the levels of physical activity.

The Panel reviewed the reliability of the methods and biomarkers used to assess sodium intake. Urinary sodium excretion in 24‐h collections is considered the most reliable biomarker of sodium daily intake. However, a single 24‐h urine collection may not reliably reflect an individual\'s usual intake. Also, incomplete collections of 24‐h urine samples can introduce bias in measuring daily sodium excretion. Multiple collections and quality control procedures are required to estimate an individual\'s usual sodium intake reliably.

Homeostatic mechanisms maintain the plasma sodium concentration of healthy individuals within a narrow range. Hyponatraemia and hypernatraemia are typically related to disorders affecting water and electrolyte balances. They are seldom due to inappropriate sodium intake. The Panel considers that there is no biomarker of sodium status that can be used for setting DRVs for sodium in the general population.

Evidence from balance studies on sodium and on the relationship between sodium intake and health outcomes, in particular cardiovascular disease (CVD)‐related endpoints and bone health, was reviewed.

Balance studies indicate that adaptation mechanisms enable the maintenance of sodium balance over a wide range of sodium intakes. Recent data from a long‐term study of sodium and other electrolytes metabolism suggest that rhythmical variations in the sodium body pools may occur independently from sodium intake. This complicates the interpretation of balance studies and of 24‐h urine collections. Overall, the Panel considers that balance studies cannot be used to determine sodium requirements.

The literature on the relationship between sodium intake and selected health outcomes, i.e. blood pressure, cardiovascular disease‐related endpoints and bone health, was systematically reviewed. To minimise the risk of bias in the evidence used in the assessment, the review was restricted to randomised controlled trials (RCTs) and prospective studies, studies that excluded participants with pre‐existing medical conditions, and studies that used at least one 24‐h urinary collection to estimate sodium intake. Risk of bias in eligible studies was assessed using the OHAT‐NTP critical appraisal tool. Studies were categorised according to their risk of bias based on a three‐tier system (i.e. at low, moderate or high risk of bias).

Eligible studies on bone health provided limited and inconsistent evidence for an association between sodium intake and bone mineral density and could not be used to set DRVs for sodium.

Meta‐analyses and modelling of the dose--response between 24‐h sodium urinary excretion (UNa) and blood pressure were conducted. Random effects meta‐analyses of the 32 eligible RCTs showed significant effects of sodium reduction on systolic blood pressure (SBP) (−3.9 (95% CI −5.1, −2.8) mm Hg; I^2^ 61.9%, p \< 0.001) and diastolic blood pressure (DBP) (−2.0 (−2.8, −1.2) mm Hg; I^2^ 60.6%, p \< 0.001). Using mixed‐effects meta‐regression models, mean SBP increased by 5.3 mm Hg (95% CI: 3.6--6.9 mm Hg) and mean DBP increased by 2.6 mm Hg (95% CI: 1.6--3.7 mm Hg) for each 100 mmol (2.3 g)/24 h increase in mean UNa. The Panel considers that there is strong evidence for a positive relationship between UNa and SBP and DBP over the range of mean UNa observed in the studies (between 49 and 209 mmol/24 h (1.3--4.8 g/day)). This is also supported by an eligible prospective observational study that investigated the long‐term relationship between UNa and blood pressure levels and by the eligible studies that assessed the relationship between UNa and risk of hypertension (two RCTs and two prospective observational studies).

A small number of prospective observational studies assessing the relationship between UNa and CVD risk was eligible for the assessment: three cohort studies investigated the association between UNa and risk of stroke or coronary heart disease (CHD); three cohort studies investigated the association between UNa and risk of total CVD. Overall, only limited conclusions can be drawn on the relationship between UNa and risk of CVD. The Panel considers that, over the range of UNa observed in these studies: There is some evidence for a positive association between UNa and risk of CHD. The positive relationship between UNa and blood pressure levels/incidence of hypertension, which is an established independent risk factor for CHD, supports this association.There is some evidence for an inverse association between UNa and risk of stroke. However, the number of eligible studies available investigating this outcome is small and the mechanisms by which UNa could be inversely associated with the risk of stroke are unclear, particularly considering the positive relationship between UNa and blood pressure, which is an established risk factor for stroke.There is some evidence for a positive association between UNa and risk of total CVD, which is consistent with the evidence for a positive association between UNa and risk of CHD and the positive relationship between UNa and blood pressure levels/incidence of hypertension.

Overall, the Panel considers that the available evidence cannot be used to determine the sodium requirement in the population; so, an average requirement (AR) and population reference intake (PRI) for sodium cannot be established. Data on the relationship between sodium intake and blood pressure or CVD risks could inform about the levels of sodium intake associated with a reduced risk of chronic diseases. Balance studies could inform about the levels of sodium intake that are adequate to maintain a null sodium balance. Expert judgement was used to weigh the available evidence and take account of the associated uncertainties by means of a formal expert knowledge elicitation (EKE). The EKE allows a representation of the uncertainty about the quantity (parameter) of interest using a probability distribution.

Integrating the available evidence and associated uncertainties, the Panel considers that a sodium intake of 2.0 g/day represents a level of sodium for which there is sufficient confidence in a reduced risk of CVD in the general adult population. Also, a sodium intake of 2.0 g/day is likely to allow most of the general adult population to maintain physiological sodium balance. Therefore, the Panel considers that 2.0 g sodium/day is a safe and adequate intake for the general EU population of adults.

The requirement for the daily accretion rate of sodium in fetal and maternal tissues can be met by the adaptive changes that maintain sodium homeostasis during pregnancy. There is no evidence that the sodium requirement of lactating women differs from the requirement of non‐lactating women. So, 2.0 g of sodium/day is a safe and adequate intake for pregnant and lactating women.

Sodium intakes that are considered safe and adequate for children are extrapolated from the value for adults, adjusting for their respective energy requirement and including a growth factor, and are as follows: 1.1 g/day for children aged 1--3 years, 1.3 g/day for children aged 4--6 years, 1.7 g/day for children aged 7--10 years and 2.0 g/day for children aged 11--17 years, respectively.

For infants aged 7--11 months, an Adequate Intake (AI) of 0.2 g/day is proposed based on upwards extrapolation of the estimated sodium intake in exclusively breast‐fed infants aged 0--6 months, on the basis of the energy requirements of the respective age groups.

The Panel notes that the mean/median intake of sodium in the European adult populations exceeds the safe and adequate intakes set for sodium. The risk of inadequate (insufficient) intake in European populations is low. Concerns for European populations instead relate to excess intake of sodium. Therefore, in practice, the values proposed can be used to inform the setting of population goals for the reduction in sodium intake.

Background as provided by the European Commission {#efs25778-sec-0003}
=================================================

The scientific advice on nutrient intakes is important as the basis of Community action in the field of nutrition, for example such advice has in the past been used as the basis of nutrition labelling. The Scientific Committee for Food (SCF) report on nutrient and energy intakes for the European Community dates from 1993. There is a need to review and if necessary to update these earlier recommendations to ensure that the Community action in the area of nutrition is underpinned by the latest scientific advice.

In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community.[1](#efs25778-note-1006){ref-type="fn"} The report provided Reference Intakes for energy, certain macronutrients and micronutrients, but it did not include certain substances of physiological importance, for example dietary fibre.

Since then new scientific data have become available for some of the nutrients, and scientific advisory bodies in many European Union Member States and in the United States have reported on recommended dietary intakes. For a number of nutrients these newly established (national) recommendations differ from the reference intakes in the SCF ([1993](#efs25778-bib-0267){ref-type="ref"}) report. Although there is considerable consensus between these newly derived (national) recommendations, differing opinions remain on some of the recommendations. Therefore, there is a need to review the existing EU Reference Intakes in the light of new scientific evidence, and taking into account the more recently reported national recommendations. There is also a need to include dietary components that were not covered in the SCF opinion of 1993, such as dietary fibre, and to consider whether it might be appropriate to establish reference intakes for other (essential) substances with a physiological effect.

In this context the EFSA is requested to consider the existing Population Reference Intakes for energy, micro‐ and macronutrients and certain other dietary components, to review and complete the SCF recommendations, in the light of new evidence, and in addition advise on a Population Reference Intake for dietary fibre.

For communication of nutrition and healthy eating messages to the public it is generally more appropriate to express recommendations for the intake of individual nutrients or substances in food‐based terms. In this context the EFSA is asked to provide assistance on the translation of nutrient based recommendations for a healthy diet into food based recommendations intended for the population as a whole.

Terms of reference as provided by the European Commission {#efs25778-sec-0004}
=========================================================

In accordance with Article 29(1)(a) and Article 31 of Regulation No 178/2002,[2](#efs25778-note-1007){ref-type="fn"} the Commission requests EFSA to review the existing advice of the Scientific Committee for Food on population reference intakes for energy, nutrients and other substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

In the first instance the EFSA is asked to provide advice on energy, macronutrients and dietary fibre. Specifically advice is requested on the following dietary components: Carbohydrates, including sugars;Fats, including saturated fatty acids, polyunsaturated fatty acids and monounsaturated fatty acids, trans fatty acids;Protein;Dietary fibre.

Following on from the first part of the task, the EFSA is asked to advise on population reference intakes of micronutrients in the diet and, if considered appropriate, other essential substances with a nutritional or physiological effect in the context of a balanced diet which, when part of an overall healthy lifestyle, contribute to good health through optimal nutrition.

Finally, the EFSA is asked to provide guidance on the translation of nutrient based dietary advice into guidance, intended for the European population as a whole, on the contribution of different foods or categories of foods to an overall diet that would help to maintain good health through optimal nutrition (food‐based dietary guidelines).

Data and methodologies {#efs25778-sec-0005}
======================

The assessment is conducted in accordance with the NDA Panel\'s Scientific Opinion on principles for deriving and applying dietary reference values (DRVs), thereafter referred to as 'the opinion on principles' (EFSA NDA Panel, [2010](#efs25778-bib-0084){ref-type="ref"}).

In addition, some parts of the assessment were undertaken by applying the four‐step approach for evidence use (i.e. plan/carry out/verify/report) described in the EFSA report on principles and process for dealing with data and evidence[3](#efs25778-note-1008){ref-type="fn"} (the 'PROMETHEUS approach') (EFSA, [2015](#efs25778-bib-0079){ref-type="ref"}).

The opinion is structured as follows: •Sections [1](#efs25778-sec-0007){ref-type="sec"}, [2](#efs25778-sec-0008){ref-type="sec"}, [2.1](#efs25778-sec-0009){ref-type="sec"}, [2.2](#efs25778-sec-0010){ref-type="sec"}, [2.2.1](#efs25778-sec-0011){ref-type="sec"}, [2.2.2](#efs25778-sec-0012){ref-type="sec"}, [2.2.2.1](#efs25778-sec-0013){ref-type="sec"}, [2.2.2.2](#efs25778-sec-0014){ref-type="sec"}, [2.3](#efs25778-sec-0015){ref-type="sec"}, [2.3.1](#efs25778-sec-0016){ref-type="sec"}, [2.3.2](#efs25778-sec-0017){ref-type="sec"}, [2.3.3](#efs25778-sec-0018){ref-type="sec"}, [2.3.4](#efs25778-sec-0019){ref-type="sec"}, [2.3.4.1](#efs25778-sec-0020){ref-type="sec"}, [2.3.4.2](#efs25778-sec-0021){ref-type="sec"}, [2.3.4.3](#efs25778-sec-0022){ref-type="sec"}, [2.3.4.4](#efs25778-sec-0023){ref-type="sec"}, [2.4](#efs25778-sec-0024){ref-type="sec"}, [2.5](#efs25778-sec-0025){ref-type="sec"}, [2.5.1](#efs25778-sec-0026){ref-type="sec"}, [2.5.2](#efs25778-sec-0027){ref-type="sec"}, [2.5.3](#efs25778-sec-0028){ref-type="sec"}, [2.6](#efs25778-sec-0029){ref-type="sec"}, [2.6.1](#efs25778-sec-0030){ref-type="sec"}, [2.6.1.1](#efs25778-sec-0031){ref-type="sec"}, [2.6.1.2](#efs25778-sec-0032){ref-type="sec"}, [2.6.2](#efs25778-sec-0033){ref-type="sec"}, [2.7](#efs25778-sec-0034){ref-type="sec"}, [3](#efs25778-sec-0035){ref-type="sec"}, [3.1](#efs25778-sec-0036){ref-type="sec"}, [3.2](#efs25778-sec-0037){ref-type="sec"}, [3.2.1](#efs25778-sec-0038){ref-type="sec"}, [3.2.2](#efs25778-sec-0039){ref-type="sec"}--[4](#efs25778-sec-0040){ref-type="sec"} include relevant background information on sodium; this encompasses an introduction (Section [1](#efs25778-sec-0007){ref-type="sec"}), information on chemistry, function, physiology, metabolism, interaction with other nutrients and biomarkers of intake and status (Section [2](#efs25778-sec-0008){ref-type="sec"}), information on dietary sources and intake data (Section [3](#efs25778-sec-0035){ref-type="sec"}) and an overview of DRVs and recommendations from other bodies (Section [4](#efs25778-sec-0040){ref-type="sec"}).•Section [5](#efs25778-sec-0044){ref-type="sec"} covers the assessment of the evidence on the criteria (endpoints) on which to base DRVs.•Section [6](#efs25778-sec-0075){ref-type="sec"} provides the integration of the available evidence and derivation of DRVs.

The data and methodologies used to inform the respective sections are described below.

Collection of relevant background information

To inform Sections [1](#efs25778-sec-0007){ref-type="sec"}, [2](#efs25778-sec-0008){ref-type="sec"}, [2.1](#efs25778-sec-0009){ref-type="sec"}, [2.2](#efs25778-sec-0010){ref-type="sec"}, [2.2.1](#efs25778-sec-0011){ref-type="sec"}, [2.2.2](#efs25778-sec-0012){ref-type="sec"}, [2.2.2.1](#efs25778-sec-0013){ref-type="sec"}, [2.2.2.2](#efs25778-sec-0014){ref-type="sec"}, [2.3](#efs25778-sec-0015){ref-type="sec"}, [2.3.1](#efs25778-sec-0016){ref-type="sec"}, [2.3.2](#efs25778-sec-0017){ref-type="sec"}, [2.3.3](#efs25778-sec-0018){ref-type="sec"}, [2.3.4](#efs25778-sec-0019){ref-type="sec"}, [2.3.4.1](#efs25778-sec-0020){ref-type="sec"}, [2.3.4.2](#efs25778-sec-0021){ref-type="sec"}, [2.3.4.3](#efs25778-sec-0022){ref-type="sec"}, [2.3.4.4](#efs25778-sec-0023){ref-type="sec"}, [2.4](#efs25778-sec-0024){ref-type="sec"}, [2.5](#efs25778-sec-0025){ref-type="sec"}, [2.5.1](#efs25778-sec-0026){ref-type="sec"}, [2.5.2](#efs25778-sec-0027){ref-type="sec"}, [2.5.3](#efs25778-sec-0028){ref-type="sec"}, [2.6](#efs25778-sec-0029){ref-type="sec"}, [2.6.1](#efs25778-sec-0030){ref-type="sec"}, [2.6.1.1](#efs25778-sec-0031){ref-type="sec"}, [2.6.1.2](#efs25778-sec-0032){ref-type="sec"}, [2.6.2](#efs25778-sec-0033){ref-type="sec"}, [2.7](#efs25778-sec-0034){ref-type="sec"}, [3](#efs25778-sec-0035){ref-type="sec"}, [3.1](#efs25778-sec-0036){ref-type="sec"}, [3.2](#efs25778-sec-0037){ref-type="sec"}, [3.2.1](#efs25778-sec-0038){ref-type="sec"}, [3.2.2](#efs25778-sec-0039){ref-type="sec"}--[4](#efs25778-sec-0040){ref-type="sec"} of the Scientific Opinion, a literature search covering sodium physiology and metabolism in healthy adults, biomarkers of intake, and genotypes affecting sodium metabolism was commissioned to the University of Hertfordshire (Lewis et al., [2015](#efs25778-bib-0188){ref-type="ref"}).

To complement the information gathered in a previous opinion (SCF, [2003](#efs25778-bib-0269){ref-type="ref"}), a comprehensive review of the literature published from January 2000 on the concentration of sodium in breast milk from healthy women living in Europe, North America and Australia was conducted by LASER Analytica (LASER Analytica, [2014](#efs25778-bib-0181){ref-type="ref"}).

An ad hoc questionnaire developed by the members of the working group on DRVs for minerals was disseminated to EFSA focal points and the members of the EFSA Food Consumption Network to collect information on the levels of urinary sodium excretion, to ascertain current information on sodium intake by European populations.

Additional background information was gathered by the members of the working group on DRVs for minerals and EFSA staff. Recent textbooks, authoritative reviews and research papers were used as sources of information. They were retrieved through searches in bibliographic databases, and were selected on the basis of their relevance.

Identification of the criteria on which to base DRVs

In Section [5](#efs25778-sec-0044){ref-type="sec"}, the NDA Panel assesses the evidence on possible criteria on which to base DRVs. To that end, the Panel considers: •biomarkers as indicators of sodium requirement (Section [5.1](#efs25778-sec-0045){ref-type="sec"});•studies on sodium balance (Section [5.2](#efs25778-sec-0046){ref-type="sec"});•indicators of sodium requirement in pregnancy and lactation (Section [5.3](#efs25778-sec-0051){ref-type="sec"});•indicators of sodium requirement in children (Section [5.4](#efs25778-sec-0052){ref-type="sec"});•sodium intake and health consequences (Section [5.5](#efs25778-sec-0053){ref-type="sec"}).

The NDA Panel assessed the suitability of each criterion to set DRVs for the nutrient on the basis of considerations of the available evidence and its inherent uncertainty and the possibility of deriving quantitative estimates.

Sections [5.1](#efs25778-sec-0045){ref-type="sec"}, [5.2](#efs25778-sec-0046){ref-type="sec"}, [5.2.1](#efs25778-sec-0047){ref-type="sec"}, [5.2.2](#efs25778-sec-0048){ref-type="sec"}, [5.2.3](#efs25778-sec-0049){ref-type="sec"}, [5.2.4](#efs25778-sec-0050){ref-type="sec"}, [5.3](#efs25778-sec-0051){ref-type="sec"}, [5.4](#efs25778-sec-0052){ref-type="sec"} draw from the background information gathered in Sections [2](#efs25778-sec-0008){ref-type="sec"} and [4](#efs25778-sec-0040){ref-type="sec"} of the Scientific Opinion, expert knowledge from the members of the working group on DRVs for minerals, and targeted searches in bibliographic databases.

In line with the PROMETHEUS approach, a draft protocol (Annex [A](#efs25778-sec-2001){ref-type="sec"}) was developed for Section [5.5](#efs25778-sec-0053){ref-type="sec"} of the Scientific Opinion. Systematic reviews were conducted on the relationship between sodium intake and selected health outcomes. The protocol describes the steps followed for the collection, selection, appraisal and synthesis of evidence.

Integration of the available evidence and derivation of DRVs

Section [6](#efs25778-sec-0075){ref-type="sec"} outlines the criteria considered by the NDA Panel as the most appropriate for setting DRVs, and provides DRVs for sodium. To that end, the Panel considered the quantitative relationships between sodium intake and the selected criteria together with the related uncertainties. The principles of the EFSA Scientific Committee guidance documents on uncertainties analysis and on the use of weight of evidence approaches in scientific assessments (EFSA Scientific Committee et al., [2017](#efs25778-bib-0802){ref-type="ref"}; EFSA Scientific Committee et al., [2018a](#efs25778-bib-0809){ref-type="ref"}a; EFSA Scientific Committee et al., [2018b](#efs25778-bib-0810){ref-type="ref"}b) were applied. In view of the limited evidence available and of the associated uncertainties, a formal expert knowledge elicitation (EKE) was undertaken by the members of the working group on DRVs for minerals to integrate the evidence and express related uncertainties. EKE is a systematic, documented and reviewable process to retrieve expert judgements from a group of experts in the form of a probability distribution. Several methods are described in the EFSA guidance to elicit knowledge of the experts (EFSA, [2014](#efs25778-bib-0078){ref-type="ref"}). For the sodium mandate, the roulette method was chosen. This is a formal approach that allows the experts to draw their own distribution of uncertainty on the parameter to be estimated by placing different numbers of plastic counters along the range of possible parameter values conveniently split in subintervals. The judgements were elicited following the Sheffield protocol, in which experts first make separate judgements about the distribution, then share and discuss their distributions, and finally develop a consensus distribution and document their reasoning (EFSA, [2014](#efs25778-bib-0078){ref-type="ref"}).

Public consultations

In September 2017, Sections [1](#efs25778-sec-0007){ref-type="sec"}, [2](#efs25778-sec-0008){ref-type="sec"}, [2.1](#efs25778-sec-0009){ref-type="sec"}, [2.2](#efs25778-sec-0010){ref-type="sec"}, [2.2.1](#efs25778-sec-0011){ref-type="sec"}, [2.2.2](#efs25778-sec-0012){ref-type="sec"}, [2.2.2.1](#efs25778-sec-0013){ref-type="sec"}, [2.2.2.2](#efs25778-sec-0014){ref-type="sec"}, [2.3](#efs25778-sec-0015){ref-type="sec"}, [2.3.1](#efs25778-sec-0016){ref-type="sec"}, [2.3.2](#efs25778-sec-0017){ref-type="sec"}, [2.3.3](#efs25778-sec-0018){ref-type="sec"}, [2.3.4](#efs25778-sec-0019){ref-type="sec"}, [2.3.4.1](#efs25778-sec-0020){ref-type="sec"}, [2.3.4.2](#efs25778-sec-0021){ref-type="sec"}, [2.3.4.3](#efs25778-sec-0022){ref-type="sec"}, [2.3.4.4](#efs25778-sec-0023){ref-type="sec"}, [2.4](#efs25778-sec-0024){ref-type="sec"}, [2.5](#efs25778-sec-0025){ref-type="sec"}, [2.5.1](#efs25778-sec-0026){ref-type="sec"}, [2.5.2](#efs25778-sec-0027){ref-type="sec"}, [2.5.3](#efs25778-sec-0028){ref-type="sec"}, [2.6](#efs25778-sec-0029){ref-type="sec"}, [2.6.1](#efs25778-sec-0030){ref-type="sec"}, [2.6.1.1](#efs25778-sec-0031){ref-type="sec"}, [2.6.1.2](#efs25778-sec-0032){ref-type="sec"}, [2.6.2](#efs25778-sec-0033){ref-type="sec"}, [2.7](#efs25778-sec-0034){ref-type="sec"}, [3](#efs25778-sec-0035){ref-type="sec"}, [3.1](#efs25778-sec-0036){ref-type="sec"}, [3.2](#efs25778-sec-0037){ref-type="sec"}, [3.2.1](#efs25778-sec-0038){ref-type="sec"}, [3.2.2](#efs25778-sec-0039){ref-type="sec"}, [4](#efs25778-sec-0040){ref-type="sec"}, [4.1](#efs25778-sec-0041){ref-type="sec"}, [4.2](#efs25778-sec-0042){ref-type="sec"}, [4.3](#efs25778-sec-0043){ref-type="sec"}, [5](#efs25778-sec-0044){ref-type="sec"}, [5.1](#efs25778-sec-0045){ref-type="sec"}, [5.2](#efs25778-sec-0046){ref-type="sec"}, [5.2.1](#efs25778-sec-0047){ref-type="sec"}, [5.2.2](#efs25778-sec-0048){ref-type="sec"}, [5.2.3](#efs25778-sec-0049){ref-type="sec"}, [5.2.4](#efs25778-sec-0050){ref-type="sec"}, [5.3](#efs25778-sec-0051){ref-type="sec"}--[5.4](#efs25778-sec-0052){ref-type="sec"} of the draft Scientific Opinion, as well as the draft protocol developed for Sections [5.5](#efs25778-sec-0053){ref-type="sec"} and [6](#efs25778-sec-0075){ref-type="sec"} (Annex [A](#efs25778-sec-2001){ref-type="sec"}), were published for public consultation.[4](#efs25778-note-1009){ref-type="fn"} This was to receive input from stakeholders on the parts of the opinion that have been used to inform the draft protocol, and on the methodology foreseen to inform the parts covered by the protocol. The draft opinion and draft protocol were revised in the light of the comments received. A technical report which addresses the comments received during the consultation has been published (EFSA, [2017b](#efs25778-bib-0081){ref-type="ref"}).

Following the public consultation, the protocol was implemented and the opinion was completed. In April 2019, the draft Scientific Opinion was published for public consultation to collect comments on the new sections that had been integrated (Sections [5.5](#efs25778-sec-0053){ref-type="sec"} and [6](#efs25778-sec-0075){ref-type="sec"}, conclusions and recommendation for research).[5](#efs25778-note-1010){ref-type="fn"} The opinion was then finalised considering the comments received, where appropriate. A technical report which addresses the comments received during the consultation has been published (EFSA, [2019](#efs25778-bib-0082){ref-type="ref"}).

Assessment {#efs25778-sec-0006}
==========

1. Introduction {#efs25778-sec-0007}
===============

In 1993, the SCF adopted an opinion on the nutrient and energy intakes for the European Community. For sodium, an acceptable range of intakes (0.575--3.5 g/day, corresponding to 25‐150 mmol/day) was set for adults. For children, pregnant and lactating women, no value was set.

2. Definition/category {#efs25778-sec-0008}
======================

2.1. Chemistry {#efs25778-sec-0009}
--------------

Sodium (Na^+^) is an alkali metal with an atomic mass of 22.99 Da (Lide, [2009](#efs25778-bib-0189){ref-type="ref"}; Wieser et al., [2013](#efs25778-bib-0326){ref-type="ref"}). Only one sodium isotope (^23^Na) is stable in nature. At normal temperature and pressure, sodium is a solid metal; it is highly reactive in both water and air and is not found naturally in its elemental form. In the Earth\'s crust, there is an abundance of sodium salts such as those with carbonate, nitrate, sulfate, borate, and particularly with halogens, especially chloride (Greenwood and Earnshaw, [1997](#efs25778-bib-0120){ref-type="ref"}; Lide, [2009](#efs25778-bib-0189){ref-type="ref"}).

Sodium chloride (NaCl) is the main constituent of table salt. One gram of sodium chloride provides 0.4 g of sodium and 0.6 g of chloride (17 mmol sodium and chloride).

2.2. Function of the nutrient {#efs25778-sec-0010}
-----------------------------

### 2.2.1. Biochemical functions {#efs25778-sec-0011}

Sodium exists as the electrolyte Na^+^ in body fluids; it is the dominant cation in the extracellular fluid (ECF). Chloride (Cl^--^) is its accompanying extracellular anion and together they contribute the major component of the extracellular osmolality of 275--295 mOsm/kg of water. The principal elements of the corresponding intracellular osmotic activity are contributed by potassium (K^+^), chloride and low molecular organic metabolites. The ECF sodium content approximates to 135--145 mmol/L and that of potassium is 3.5--5.5 mmol/L, whereas within cells sodium and potassium contents approximate 15 mmol/L and 150 mmol/L, respectively (Heer et al., [2000](#efs25778-bib-0133){ref-type="ref"}; Gropper et al., [2009](#efs25778-bib-0123){ref-type="ref"}; Bailey et al., [2014](#efs25778-bib-0027){ref-type="ref"}). The homeostasis of water and sodium, and to an extent that of chloride and potassium, are interdependent and integrated to maintain these conditions (Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}). The functions of sodium lie in: (i) its participation in the control of the volume and systemic distribution of total body water; (ii) enabling the cellular uptake of solutes; and (iii) the generation via interactions with potassium of transmembrane electrochemical potentials.

The systemic control of ECF volume, and the maintenance of osmotic equilibrium between the ECF and the intracellular fluid depends on the mechanisms and transport systems that control the entry of Na^+^ into cells and the energy‐dependent extrusion of Na^+^ out of cells. This function is seen in epithelial polarised cells (e.g. the intestinal and renal tubular epithelia). Such cells have an energy‐dependent sodium pump (Na^+^/K^+^‐ATPase) on their basolateral membrane that exchanges three intracellular molecules of Na^+^ for two extracellular K^+^ molecules entering the cells. This creates a gradient between intracellular and extracellular sodium ionic concentrations and activities, and the passive flow of Na^+^ down this gradient is enabled and regulated by specific cellular membrane pores and carriers that couple the flow of Na^+^ to the entry of water and of solutes (e.g. amino acids, monosaccharides) into the cells (Section [2.3.1](#efs25778-sec-0016){ref-type="sec"}). The link between sodium transport and co‐transport systems underpins cellular uptake and transport of water and solutes in all organs; the energy expended in these processes represents around 25% of the metabolic rate of a human at rest (EFSA, [2005a](#efs25778-bib-0076){ref-type="ref"}).

The differential transmembrane distribution and activity gradients of sodium and potassium induced by carrier proteins and Na^+^/K^+^‐ATPase create a polarised cell membrane potential. This is present in most cells but is particularly evident in muscle (of all types) and in neurones. In these cells, the membranes have ion channels that, in response to stimuli, open to allow the ions to flow across and depolarise the membrane. So, Na^+^ and K^+^ in tandem are fundamental for electrical signalling in the nervous system, muscle and heart; the sodium channels involved are classified as voltage gated channels (Campbell and Reece, [2002](#efs25778-bib-0046){ref-type="ref"}).

### 2.2.2. Health consequences of deficiency and excess {#efs25778-sec-0012}

The health consequences of both chronic and acute deficiencies and excesses of sodium are related to the distribution of total body water and sodium in the extracellular and intracellular fluid compartments. This is more obvious in acute deficiency and excess (Sections [2.2.2.1](#efs25778-sec-0013){ref-type="sec"} and [2.2.2.2](#efs25778-sec-0014){ref-type="sec"}) than it is for long‐term excessive exposure to sodium accompanied by its systemic accumulation in bone, connective tissue, muscle and skin (Titze et al., [2014](#efs25778-bib-0300){ref-type="ref"}) (Section [2.3.3](#efs25778-sec-0018){ref-type="sec"}).

The features of acute sodium excess and deficiency are predominantly neurological and arise from exceeding the homeostatic systems controlling hydration of the central nervous system. Sodium is generally enabled to pass easily across vascular endothelia and, as a result, the sodium concentrations (i.e. activities) of plasma and ECF, including interstitial fluid, are virtually identical. However, in the central nervous system, the capillaries have tight endothelial junctions that block sodium movements. So, changes in plasma and ECF sodium concentrations can create osmotic gradients causing water to move in or out of the cerebral spinal fluid (Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}). This phenomenon affects other tissues and organs. However, organs such as the liver or the kidney can swell, or shrink, to accommodate changes in volume induced by redistribution of water within them, whereas the brain, being encased within the skull, is more susceptible to extreme changes in volume. This is probably why the brain has sensors of plasma osmolality and blood pressure to exercise control of body water, and of intracellular and extracellular tonicity (Section [2.3.4](#efs25778-sec-0019){ref-type="sec"}).

#### 2.2.2.1. Deficiency {#efs25778-sec-0013}

Dietary sodium deficiency is rare in healthy European populations. Sodium chloride and other sodium salts are ubiquitous in the diet (Sections [3.1](#efs25778-sec-0036){ref-type="sec"} and [3.2](#efs25778-sec-0037){ref-type="sec"}), and there are adaptive physiological mechanisms that reduce the losses of sodium in urine, faeces and sweat at low levels of sodium intake (Section [2.3.4](#efs25778-sec-0019){ref-type="sec"}).

Hyponatraemia, defined as a serum sodium concentration less than 135 mmol/L (Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}), is indicative of systemic sodium imbalance but not necessarily of systemic sodium deficiency (Andersson et al., [1982](#efs25778-bib-0016){ref-type="ref"}; Speedy et al., [2000](#efs25778-bib-0283){ref-type="ref"}). The threshold of 135 mmol/L is the lower point of the reference range and, as such, is indicating potential sodium depletion and deficiency. However, because of the systemic interaction of sodium with water balance, the serum sodium concentrations at which symptoms of sodium deficiency become apparent are not well characterised. Severe neurological symptoms are generally associated with serum sodium concentrations \< 120 mmol/L, at which level cerebral oedema develops. Overall, the symptoms progress from malaise, nausea, vomiting and headache to lethargy, impaired consciousness, seizures and coma (Adrogué and Madias, [2000a](#efs25778-bib-0003){ref-type="ref"}; Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}).

#### 2.2.2.2. Excess {#efs25778-sec-0014}

Rapid onset of sodium excess secondary to dietary sodium intake is also uncommon, but acute toxicity may arise from high exposures to sodium, usually as sodium chloride, from ingestion (e.g. self‐poisoning) or from parenteral administration in clinical care. Hypernatraemia, defined as a serum sodium concentration \> 145 mmol/L, is typically a consequence of dehydration rather than of excessive sodium intake. The symptoms of hypernatraemia are similar to those of hyponatraemia and also include non‐specific features such as headache, confusion, fever, nausea and vomiting (Adrogué and Madias, [2000b](#efs25778-bib-0004){ref-type="ref"}; Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}).

In 2005, the NDA Panel explored the relationship between high exposures to sodium (usually as sodium chloride) and hypertension (EFSA, [2005a](#efs25778-bib-0076){ref-type="ref"}, [2005b](#efs25778-bib-0077){ref-type="ref"}). For groups of individuals, there was strong evidence for an exposure‐dependent rise in blood pressure. The Panel noted that this is a continuous relationship that embraces the whole range of habitual sodium intakes and considered that it was not possible to determine a threshold of habitual sodium consumption below which adverse effects on blood pressure were unlikely. The Panel also noted that epidemiological studies indicated a positive association between sodium intake and risk of morbidity and mortality from cardiovascular diseases. Evidence for a direct adverse effect of high sodium intake on heart function (i.e. independent of raised blood pressure) was inconclusive. The Panel concluded that sodium itself was not carcinogenic but that high intakes of sodium chloride could increase susceptibility to carcinogens such as nitrosamines, gastric infection with *Helicobacter pylori*, or give inadequate protection against free radical‐induced damage. Overall, the NDA Panel did not set a tolerable upper intake level (UL) for sodium because of insufficient data. However, the Panel noted that there was strong evidence for the contribution of sodium to high blood pressure in European populations, and that high blood pressure has been directly related to the development of cardiovascular and renal diseases.

2.3. Physiology and metabolism {#efs25778-sec-0015}
------------------------------

As sodium is integral for the homeostasis of total body water, its absorption, distribution and excretion are controlled by systems that monitor and regulate ECF osmolality (tonicity) and volume.

### 2.3.1. Intestinal absorption and secretion {#efs25778-sec-0016}

Sodium is absorbed throughout most of the length of the small and large intestine, with the quantity and mechanism of absorption varying with intestinal sites (Chang and Leung, [2014](#efs25778-bib-0050){ref-type="ref"}). In the small intestine, epithelial uptake of sodium is facilitated by specific co‐transporters on the apex of the enterocytes. These co‐transporters couple the flow of sodium into the enterocytes to facilitate the uptake of low molecular solutes and micronutrients. The flow of sodium is generated by an electrolyte concentration gradient that is created by the extrusion of sodium by Na^+^/K^+^‐ATPase on the basolateral membranes of the cells (Section [2.2.1](#efs25778-sec-0011){ref-type="sec"}). This transfers the solutes out of the gut lumen into the enterocytes on the gut villi and into the portal plasma. The vascular structure creates a countercurrent system dependent on the osmotic activity that results from the localised accumulation of solutes and sodium in the villi. This increased osmotic activity, in turn, draws water into and across the epithelium by paracellular pathways, and the flow drags other luminal solutes across the epithelium (solute drag). Sodium is recycled into the small intestinal lumen via the gastric, intestinal, pancreatic and hepatic secretions that accompany digestion and absorption.

The small intestine is estimated to handle 8--10 L of water in the course of a day. This comprises water from endogenous secretions and from the diet (1--1.5 L/day). More than 98% of the fluid load is absorbed in the gut. About 1--2 L daily enter in the distal ileum and colon, which are the regions where net absorption of sodium and water occurs. These distal processes also include adjustments involved with the homeostasis of potassium, chloride and bicarbonate, as well as the uptake and transfer of intraluminal fermentation products from the colon (Sandle, [1998](#efs25778-bib-0264){ref-type="ref"}; Kato and Romero, [2011](#efs25778-bib-0156){ref-type="ref"}).

In the distal bowel, other carriers are responsible for the uptake of sodium. These include sodium exchange for hydrogen ions (Na^+^/H^+^ exchangers) (Pan et al., [2012](#efs25778-bib-0240){ref-type="ref"}) and/or absorption of anions, chloride and bicarbonate, to maintain electroneutrality (Fordtran et al., [1968](#efs25778-bib-0108){ref-type="ref"}; Turnberg et al., [1970](#efs25778-bib-0303){ref-type="ref"}; Chang and Leung, [2014](#efs25778-bib-0050){ref-type="ref"}). The sodium secretion that accompanies active chloride secretion is a passive process, driven by the transepithelial potential difference resulting from chloride secretion (Kato and Romero, [2011](#efs25778-bib-0156){ref-type="ref"}; Chang and Leung, [2014](#efs25778-bib-0050){ref-type="ref"}). In the rectum, active sodium absorption occurs against large electrochemical gradients through electrogenic sodium channels (Levitan et al., [1962](#efs25778-bib-0187){ref-type="ref"}; Sandle, [1998](#efs25778-bib-0264){ref-type="ref"}; Chang and Leung, [2014](#efs25778-bib-0050){ref-type="ref"}) (Table [1](#efs25778-tbl-0001){ref-type="table"}).

Four 7‐day balance studies spaced seasonally over a year in healthy young adults consuming self‐selected diets, with a mean daily intake of 3.4 g (148 mmol) of sodium, indicated that approximately 98.5% of ingested sodium is absorbed (Holbrook et al., [1984](#efs25778-bib-0137){ref-type="ref"}) (Section [5.2.1](#efs25778-sec-0047){ref-type="sec"}). Shorter balance studies (5--12 days following 2--4 days of adaptation) in Japanese adults with a wider range of intakes showed that the absolute amount of sodium absorbed increases linearly with increasing sodium intake. Mean sodium absorption was 97.8 ± 1.9% for daily intakes of 39--142 mg/kg body weight (bw) or 2.2--6.8 g (95--295 mmol)/day of sodium (Kodama et al., [2005](#efs25778-bib-0165){ref-type="ref"}). Mean 24‐h urinary sodium excretion was 33.2 ± 0.8 g (1,443 ± 35) after 72 h in 14 healthy men consuming 34.5 g (1,500 mmol) of sodium/day, indicating that sodium absorption is maintained at approximately 96% even at very high intake (Luft et al., [1979](#efs25778-bib-0194){ref-type="ref"}).

### 2.3.2. Transport in blood {#efs25778-sec-0017}

Following absorption, sodium ions are distributed by portal and systemic circulations, where their concentrations are maintained within a narrow range by the mechanisms described below (Section [2.3.4](#efs25778-sec-0019){ref-type="sec"}). In healthy adults, serum sodium concentrations are between approximately 135 and 145 mmol/L (Heer et al., [2000](#efs25778-bib-0133){ref-type="ref"}; Gropper et al., [2009](#efs25778-bib-0123){ref-type="ref"}; Bailey et al., [2014](#efs25778-bib-0027){ref-type="ref"}). Reference ranges vary slightly among different laboratories depending on the measurement technique used (Morimatsu et al., [2003](#efs25778-bib-0216){ref-type="ref"}).

### 2.3.3. Distribution to tissues {#efs25778-sec-0018}

Typical total body content of sodium is 1.3--1.5 g (55--65 mmol)/kg bw, equivalent to a total of 85--96 g (3,700--4,200 mmol) for a 70‐kg man (Penney, [2008](#efs25778-bib-0243){ref-type="ref"}; James and Reid et al., [2011](#efs25778-bib-0147){ref-type="ref"}), 95% of which is in the ECF. A large proportion of body sodium is in bone, skin and muscle (Bie, [2018](#efs25778-bib-0036){ref-type="ref"}). Within cells (e.g. myocytes), sodium is present at a lower concentration, approximately 3 mmol/L (Bailey et al., [2014](#efs25778-bib-0027){ref-type="ref"}), with some variation depending on cell types (Yunos et al., [2010](#efs25778-bib-0330){ref-type="ref"}). These pools of sodium have different turnover times, with the most exchangeable pools being ECF and intracellular sodium, and the pool of sodium bound to connective tissue is slower (Titze et al., [2014](#efs25778-bib-0300){ref-type="ref"}; Rakova et al., [2017](#efs25778-bib-0254){ref-type="ref"}; Bie, [2018](#efs25778-bib-0036){ref-type="ref"}).

The pool of sodium in bone, muscle and skin has been proposed to be a sodium depot or reserve, but it could have other roles. Sodium bound to proteoglycans in connective tissue creates a high osmotic force that supports the hydration of these tissues and enables them to withstand high‐pressures. This sodium pool could also have a homeostatic and adaptive role as an extra‐renal clearance depository for handling excessive systemic accumulation of sodium (Titze et al., [2014](#efs25778-bib-0300){ref-type="ref"}; Rakova et al., [2017](#efs25778-bib-0254){ref-type="ref"}; Selvarajah et al., [2017](#efs25778-bib-0274){ref-type="ref"}; Bie, [2018](#efs25778-bib-0036){ref-type="ref"}) which is discussed below.

The deposition of sodium in bone, muscle and skin could explain why an increase in sodium intake is not necessarily associated with a change in body weight, an increase in ECF volume, nor with an increase in plasma sodium concentration or its renal loss (Heer et al., [2000](#efs25778-bib-0133){ref-type="ref"}; Titze et al., [2014](#efs25778-bib-0300){ref-type="ref"}; Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}; Rakova et al., [2017](#efs25778-bib-0254){ref-type="ref"}). A study by Heer et al. ([2000](#efs25778-bib-0133){ref-type="ref"}) found that, compared with a sodium intake of 1.2 g (50 mmol)/day, a daily sodium intake of 12.7 g (550 mmol) was associated with an increase in plasma volume of approximately 300 mL, but with no change in body weight. This implies that there was a redistribution of water from the interstitial ECF to plasma. It is proposed that total body sodium 'fluctuates' independently of sodium intake (Titze et al., [2014](#efs25778-bib-0300){ref-type="ref"}). Long‐term balance studies in men with constant and controlled daily sodium intakes of 2.5 g (110 mmol), 3.6 g (155 mmol) and 4.8 g (210 mmol) demonstrated weekly and half‐weekly cycles of urinary sodium excretion that were inversely related to urine content of aldosterone and its metabolites (as marker of aldosterone production) and directly related to glucocorticoid/cortisol production (Rakova et al., [2013](#efs25778-bib-0253){ref-type="ref"}). This pattern of sodium excretion was accompanied by a monthly cycle of changes in total body sodium content of ± 4.6--9.2 g (200--400 mmol), without parallel changes in total body water content. These studies indicated that osmolyte and water balance are regulated by a rhythmical release of mineralocorticoids and glucocorticoids, the accrual of endogenous water (i.e. water released as a product of systemic metabolism) to adjust ECF osmolality, and by weekly and monthly cyclical excretions of sodium (Titze et al., [2014](#efs25778-bib-0300){ref-type="ref"}; Rakova et al., [2017](#efs25778-bib-0254){ref-type="ref"}).

There is evidence that sodium accumulates in the connective tissue of bone, muscle and skin with age. In a cross‐sectional study, 23Na magnetic resonance of the midcalf showed higher sodium concentrations in the tissues of 57 hypertensive subjects as compared with the 56 normotensive controls. In men (with or without hypertension), but not in women, muscle content of Na increased with age, with no associated increase in muscle water content, whereas water content in the skin increased with that of sodium. Generally, these compositional age‐related changes were larger in men than in women (Kopp et al., [2013](#efs25778-bib-0167){ref-type="ref"}; Titze, [2015](#efs25778-bib-0299){ref-type="ref"}) and have been associated with increased vascular stiffness (Safar et al., [2009](#efs25778-bib-0263){ref-type="ref"}; Olde Engberink et al., [2015](#efs25778-bib-0234){ref-type="ref"}).

Collectively, the above observations contribute to the biological mechanistic plausibility of the positive association of sodium intakes/exposure with systemic blood pressure. Also, cyclic hormonal regulatory processes may contribute to the inherent within‐person variability in 24‐h urine sodium excretion, beyond daily variations in intake.

### 2.3.4. Elimination {#efs25778-sec-0019}

The excretion and retention (i.e. homeostasis) of sodium and water are effected by an integrated neurohormonal control from centres located in the hypothalamus (Lowell, [2019](#efs25778-bib-0192){ref-type="ref"}). Plasma osmolality and volume are sensed by four interdependent sensor systems. These comprise a group that detects plasma osmolality, and a system of pressure‐sensitive receptors (baroreceptors).

ECF osmolality is sensed by the circumventricular organs (CVOs), which are highly vascularised areas in the hypothalamus. Neuronal osmoreceptors in CVOs have direct exposure to the ECF through gaps in the blood--brain barrier. The osmoreceptors shrink when exposed to increased ECF osmolality, e.g. as would result from a decrease in total body water. This shrinkage is relayed to the hypothalamic supraoptic nucleus, which stimulates thirst and the release of antidiuretic hormone (ADH) by the pituitary gland. ADH enables water retention by increasing the number of water permeable channels (aquaporins) in the luminal cell membranes of the renal collecting ducts. ADH has a half‐life of 20 min and it is continuously secreted to maintain the physiological range of osmolality. So, the supraoptic nucleus reacts to increased osmolality by increasing water intake and by reducing renal water excretion (Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}). When serum sodium concentration falls below 135 mmol/L, ADH secretion and thirst are inhibited.

Plasma volume is sensed by two types of pressure‐sensitive receptors (or baroreceptors) that respond to either high or low vascular pressure. 'High‐pressure' baroreceptors are located in the cerebral and carotid arteries, aortic arch and the juxta glomerular apparatus of renal glomeruli, whereas 'low‐pressure' baroreceptors lie in the thoracic veins, the cardiac atria and right ventricle, and the pulmonary (thoracic) veins.

Collectively, these sensors regulate the neurohumoral control of total body water and ECF. The osmosensors operate by mediating changes in water intake and renal distal tubule retention or loss of water through aquapores. The baroreceptors induce changes in renal retention or loss of sodium to mediate water homeostasis. The mediators include the sympathetic nervous system (SNS) and catecholamines; atrial natriuretic peptide; and the renin--angiotensin--aldosterone system (RAAS).

The renin--angiotensin--aldosterone pathway is active in several different tissues, but most notably the kidney (Penney, [2008](#efs25778-bib-0243){ref-type="ref"}; Hamlyn, [2014](#efs25778-bib-0127){ref-type="ref"}; Lowell, [2019](#efs25778-bib-0192){ref-type="ref"}). Renin is released from the juxtaglomerular apparatus in response to reduced pressure in the afferent renal arterioles, increased sympathetic nerve activity and decreased sodium and chloride concentrations in the distal tubular fluid. Renin hydrolyses angiotensinogen into angiotensin I that is converted by the angiotensin‐converting enzyme into angiotensin II. Angiotensin II stimulates: (i) sodium, and therefore water, reabsorption in the proximal tubule; (ii) constriction of the arterioles; and (iii) the release of aldosterone from the adrenal cortex. Aldosterone stimulates renal recovery of sodium in exchange for excreted potassium in the epithelia of the distal tubule and collecting ducts, and in the distal colon. Aldosterone also facilitates the simultaneous reabsorption of water with that of sodium by stimulating the release of ADH (which increases the number of aquaporins in the distal tubules) and stimulates sodium intake via neuronal control of salt appetite (Lowell, [2019](#efs25778-bib-0192){ref-type="ref"}).

As with sodium kinetics (Section [2.3.3](#efs25778-sec-0018){ref-type="sec"}), the regulation of electrolyte and water homeostasis exhibits a circadian rhythm affecting blood pressure, glomerular perfusion and filtration rate, which results in a variable rate of urinary excretion of sodium and potassium. This biological clock is mediated by regulation of the expression of genes responsible for the neuroendocrine control of the renal handling of sodium (Gumz et al., [2015](#efs25778-bib-0126){ref-type="ref"}; Solocinski and Gumz, [2015](#efs25778-bib-0282){ref-type="ref"}).

#### 2.3.4.1. Urine {#efs25778-sec-0020}

The kidney is the main organ mediating the excretion and retention of sodium and, so, water homeostasis, as outlined above. It efficiently excretes sodium in response to high dietary intakes, and salvages sodium when dietary intake is low (Section [5.2](#efs25778-sec-0046){ref-type="sec"}).

In experiments in which subjects at a steady state were shifted to a lower level of sodium intake, the half‐life for the reduction in renal sodium excretion was about 24 h (Strauss et al., [1958](#efs25778-bib-0287){ref-type="ref"}; Epstein and Hollenberg, [1976](#efs25778-bib-0094){ref-type="ref"}) and, consequently, a steady state between sodium intake and urinary sodium excretion is considered to be achieved within a few days (Cogswell et al., [2013](#efs25778-bib-0057){ref-type="ref"}).

A meta‐analysis investigating urinary sodium excretion relative to sodium intake included 35 studies in which a constant quantity of dietary sodium was provided to participants for a minimum of 3 days (Lucko et al., [2018](#efs25778-bib-0193){ref-type="ref"}). This was considered to be the minimum duration to ensure that participants were at a steady state of urine sodium excretion relative to sodium intake. In a subgroup analysis, the length of this stabilisation period (categorised as a minimum 3, 5 or 7 days) was not found to alter the percentage of dietary sodium excreted. On average, 92.8% of daily dietary sodium was excreted in 24‐h urine (95% CI 90.7, 95.0; I^2^ 95.1%, p \< 0.001). The average excretion of ingested sodium varied from 76% to 122% across studies. The pooled estimate was similar when the analysis was restricted to studies conducted in healthy people (93.7%, 95% CI 90.5, 96.8; I^2^ 97.1%, p \< 0.001). Comparable excretion rates have been reported in studies in which people consumed their usual diet: 86% of the sodium ingested over 4 weeks (1 week per season over a year, to cover variability) was excreted in 24‐h urine samples collected during the same period (Holbrook et al., [1984](#efs25778-bib-0137){ref-type="ref"}) and 98% of dietary sodium was excreted in 24‐h urine in another 3‐day study (Schachter et al., [1980](#efs25778-bib-0270){ref-type="ref"}).

The nephron, under the neurohormonal control systems described above, is the key organ regulating sodium excretion and maintaining normal ECF and plasma volumes. Glomerular filtration allows a filtrate free of cells and macromolecules (the electrolyte content of which resembles that of plasma) to pass into the proximal tubules. The glomerular filtration rate (measured as creatinine clearance, with a usual value of around 125 mL/min) decreases with age.

The kidney has the capacity to filter large amounts of sodium, more than 99% of which is then reabsorbed in the renal tubules via co‐transporters driven by the basolateral Na^+^/K^+^‐ATPase. Approximately 60--70% of sodium reabsorption occurs via co‐transporters in the proximal tubule, along with organic molecules (amino acids, glucose and organic acids), mediated by membrane Na^+^/H^+^ exchange (Greger, [2000](#efs25778-bib-0121){ref-type="ref"}). Water follows this movement of solutes. In the ascending limb of the loop of Henle, 20--30% of the filtered sodium chloride is absorbed via the Na^+^/2Cl^--^/K^+^ co‐transport system. However, this loop is impermeable to water and the filtrate becomes less concentrated. In the early distal tubule, another 6% of the filtered sodium is recovered, and this further dilutes the fluid. About 5--10% of sodium reabsorption occurs in the distal tubule, through active sodium transport via the Na^+^‐Cl^--^ co‐transporter (Greger, [2000](#efs25778-bib-0121){ref-type="ref"}). In the distal tubule of the nephron, aldosterone enhances sodium reabsorption and potassium excretion.

###### 

Regulation of sodium excretion in the kidney and distal bowel

+-----------------------+-------------------+-------------------------------------------------------------------+------------------------------------------+----------------------------+
| Site                  | Na reabsorbed (%) | Mechanism                                                         | Water transfer                           | Regulating factors         |
+=======================+===================+===================================================================+==========================================+============================+
| Proximal renal tubule | 60--70            | Co‐transporters with solutes. Active Na^+^/K^+^ ATP‐ase dependent | Principal site for water reabsorption    | Angiotensin II             |
|                       |                   |                                                                   |                                          |                            |
|                       |                   | Some Na/H^+^                                                      | Highly permeable driven by osmolality    | SNS catecholamines         |
+-----------------------+-------------------+-------------------------------------------------------------------+------------------------------------------+----------------------------+
| Loop of Henle         | 20--30            | Na^+^/K^+^/2Cl^--^ co‐transport                                   | Impermeable to water                     | Flow dependent             |
|                       |                   |                                                                   |                                          |                            |
|                       |                   |                                                                   |                                          | Pressure                   |
|                       |                   |                                                                   |                                          |                            |
|                       |                   |                                                                   |                                          | Natriuresis                |
+-----------------------+-------------------+-------------------------------------------------------------------+------------------------------------------+----------------------------+
| Distal tubule         | 5--10             | Na^+^‐Cl^--^ co‐transport                                         | Impermeable to water                     | Aldosterone                |
|                       |                   |                                                                   |                                          |                            |
|                       |                   |                                                                   |                                          | Flow dependent             |
+-----------------------+-------------------+-------------------------------------------------------------------+------------------------------------------+----------------------------+
| Collecting ducts      | 5                 | Na^+^ exchange K^+^ channels                                      | ADH‐mediated permeability via aquaporins | Aldosterone                |
|                       |                   |                                                                   |                                          |                            |
|                       |                   |                                                                   |                                          | Atrial natriuretic peptide |
+-----------------------+-------------------+-------------------------------------------------------------------+------------------------------------------+----------------------------+
| Distal bowel          |                   | Na^+^ channels                                                    | Aquaporins                               | Aldosterone                |
+-----------------------+-------------------+-------------------------------------------------------------------+------------------------------------------+----------------------------+

ADH: antidiuretic hormone; Cl: chloride; K: potassium; Na: sodium; SNS: sympathetic nervous system.
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#### 2.3.4.2. Faeces {#efs25778-sec-0021}

The efficiency of distal intestinal absorption of intraluminal sodium is responsive to aldosterone (Sandle, [1998](#efs25778-bib-0264){ref-type="ref"}) and has been described in Section [2.3.1](#efs25778-sec-0016){ref-type="sec"}.

Balance studies have shown that sodium losses in the faeces were relatively stable and limited to a few mmol/day for sodium intakes over a range between 1.2 and 12.7 g/day (50 and 550 mmol/day) (Holbrook et al., [1984](#efs25778-bib-0137){ref-type="ref"}; Heer et al., [2000](#efs25778-bib-0133){ref-type="ref"}; Palacios et al., [2004](#efs25778-bib-0239){ref-type="ref"}). For example, in the balance study by Holbrook et al. ([1984](#efs25778-bib-0137){ref-type="ref"}) in which sodium losses were estimated for four periods of 7 days in 28 US men and women consuming their usual diet (Section [5.2](#efs25778-sec-0046){ref-type="sec"}), mean (± SD) sodium losses in faeces were 56 ± 26 mg/day (2.4 ± 1.1 mmol/day), representing less than 2% of sodium intake.

#### 2.3.4.3. Dermal losses {#efs25778-sec-0022}

Sodium concentration in sweat varies widely. Values between 10 mmol/L (0.23 g/L) and 180 mmol/L (4.20 g/L) have been reported in adults (IOM, [2005](#efs25778-bib-0144){ref-type="ref"}; Bates and Miller, [2008](#efs25778-bib-0030){ref-type="ref"}; Kaptein et al., [2016](#efs25778-bib-0154){ref-type="ref"}). Influencing factors include levels of sodium intake, sweat rate, hydration status and degree of heat acclimation (Allan and Wilson, [1971](#efs25778-bib-0010){ref-type="ref"}; Allsopp et al., [1998](#efs25778-bib-0013){ref-type="ref"}; Bates and Miller, [2008](#efs25778-bib-0030){ref-type="ref"}). Interindividual variability may also be influenced by physiological determinants of sodium reabsorption in the sweat gland (Brown et al., [2011](#efs25778-bib-0041){ref-type="ref"}). Sodium concentration in sweat decreases following heat acclimation (Consolazio et al., [1963](#efs25778-bib-0059){ref-type="ref"}; Allsopp et al., [1998](#efs25778-bib-0013){ref-type="ref"}; Buono et al., [2007](#efs25778-bib-0043){ref-type="ref"}; Bates and Miller, [2008](#efs25778-bib-0030){ref-type="ref"}), contributing to the maintenance of sodium balance under conditions of high sweat excretion (Consolazio et al., [1963](#efs25778-bib-0059){ref-type="ref"}; Allsopp et al., [1998](#efs25778-bib-0013){ref-type="ref"}) (Section [5.2](#efs25778-sec-0046){ref-type="sec"}).

Studies conducted under conditions of moderate temperature and exercise levels indicate small sodium losses via sweat across a wide range of sodium intake levels (Barr et al., [1991](#efs25778-bib-0029){ref-type="ref"}; Heer et al., [2000](#efs25778-bib-0133){ref-type="ref"}; Palacios et al., [2004](#efs25778-bib-0239){ref-type="ref"}). In the balance study by Palacios et al. ([2004](#efs25778-bib-0239){ref-type="ref"}) in 36 female adolescents under sedentary conditions (see Section [5.2](#efs25778-sec-0046){ref-type="sec"}), sweat losses represented ca. 3% of total sodium losses under the 'high' sodium diet (4 g (174 mmol)/day) and 10% under the 'low' sodium diet (1.3 g (56 mmol)/day). Sodium losses via sweat can be considerably higher in situations of exercise and heat (Sharp, [2006](#efs25778-bib-0275){ref-type="ref"}; Bates and Miller, [2008](#efs25778-bib-0030){ref-type="ref"}; Cogswell et al., [2015](#efs25778-bib-0058){ref-type="ref"}).

#### 2.3.4.4. Breast milk {#efs25778-sec-0023}

Colostrum has higher concentrations of sodium than mature milk (Koo and Gupta, [1982](#efs25778-bib-0166){ref-type="ref"}; Atkinson et al., [1995](#efs25778-bib-0024){ref-type="ref"}). The sodium content of breast milk decreased rapidly in the first days post‐partum, as the mammary gland undergoes the transition between pregnancy and lactation (i.e. closure of the intercellular junctions) (Atkinson et al., [1995](#efs25778-bib-0024){ref-type="ref"}). This is followed by a gradual decline in the sodium concentration of mature milk.

The concentration of electrolytes, including sodium, in human milk is lower than in plasma. It is determined by an electrical potential gradient in the mammary epithelial cells regulated through membrane transport pathways (Wack et al., [1997](#efs25778-bib-0309){ref-type="ref"}; Truchet and Honvo‐Houeto, [2017](#efs25778-bib-0301){ref-type="ref"}). It is not influenced by maternal sodium intake (Filippi et al., [1981](#efs25778-bib-0103){ref-type="ref"}; Keenan et al., [1982](#efs25778-bib-0159){ref-type="ref"}; Ereman et al., [1987](#efs25778-bib-0095){ref-type="ref"}). Diurnal variations in breast milk sodium concentration, reciprocal to potassium concentration, have been reported (Keenan et al., [1982](#efs25778-bib-0159){ref-type="ref"}, [1983](#efs25778-bib-0160){ref-type="ref"}). Factors that have been associated with increased sodium concentration in breast milk include pathological processes such as mastitis or localised inflammation of breast tissue (Morton, [1994](#efs25778-bib-0217){ref-type="ref"}), premature birth (Gross et al., [1980](#efs25778-bib-0124){ref-type="ref"}) and manual compared with mechanical (pump) expression (Lang et al., [1994](#efs25778-bib-0178){ref-type="ref"}).

Based on 11 studies on sodium concentration in breast milk from 511 women in the USA, the UK and Canada, Atkinson et al. ([1995](#efs25778-bib-0024){ref-type="ref"}) reported mean sodium concentrations across studies between 17.1 and 22.3 mmol/L (393 and 513 mg/L) at day 3 (colostrum), 9.4 and 13.1 mmol/L (216 and 301 mg/L) at day 14 (transitional milk), 5.9 and 17.1 mmol/L (136 and 393 mg/L), 4.7 and 8.0 mmol/L (108 and 184 mg/L), and 3.6 and 6.0 mmol/L (83 and 138 mg/L) at days 30, 90 and 180 of lactation (mature milk), respectively.

Appendix [A](#efs25778-sec-1001){ref-type="sec"} reports data on sodium concentration in breast milk from additional studies that involved mothers of term infants in Western populations. Mean sodium concentrations are between 3.0 and 10.6 mmol/L (70 and 244 mg/L) from eight studies that analysed mature breast milk (Keenan et al., [1982](#efs25778-bib-0159){ref-type="ref"}; Koo and Gupta, [1982](#efs25778-bib-0166){ref-type="ref"}; Parr et al., [1991](#efs25778-bib-0242){ref-type="ref"}; Holt, [1993](#efs25778-bib-0138){ref-type="ref"}; Motil et al., [1997](#efs25778-bib-0218){ref-type="ref"}; Wack et al., [1997](#efs25778-bib-0309){ref-type="ref"}; Fly et al., [1998](#efs25778-bib-0104){ref-type="ref"}; Bjorklund et al., [2012](#efs25778-bib-0037){ref-type="ref"}) and 11.2 mmol/L (257 mg/L) in one study that used mixed samples (collected between 1 and 8 weeks post‐partum) (Bauer and Gerss, [2011](#efs25778-bib-0031){ref-type="ref"}).

Based on the data presented in Appendix [A](#efs25778-sec-1001){ref-type="sec"}, the Panel considers an approximate midpoint of sodium concentration in mature breast milk of women from Western countries as 150 mg/L (6.5 mmol)/L. Based on a mean milk transfer of 0.8 L/day (Butte et al., [2002](#efs25778-bib-0044){ref-type="ref"}; FAO/WHO/UNU, [2004](#efs25778-bib-0100){ref-type="ref"}; EFSA NDA Panel, [2009](#efs25778-bib-0083){ref-type="ref"}) during the first 6 months of lactation in exclusively breastfeeding women, the Panel estimates the maternal loss of sodium through breast milk to be 120 mg (5.2 mmol)/day.

2.4. Modification of sodium metabolism during pregnancy {#efs25778-sec-0024}
-------------------------------------------------------

During pregnancy, there is an expansion of the ECF, including the plasma volume, starting within 2 weeks of conception. Expansion of the plasma volume is between 1 and 1.6 L. These changes occur irrespective of the mother\'s size, are usually larger in multigravida, and are accompanied by a fall in both plasma osmolality and plasma sodium concentrations (Davidson and Repke et al., [1998](#efs25778-bib-0066){ref-type="ref"}). The expansion of the ECF represents a change in the homeostasis of total body water that is accompanied by increased cardiac output, increased vascular perfusion of organs and tissues, and reduced SBP in the first half of pregnancy. As a consequence, the volume of the kidneys increases by around 30%. The renal blood flow almost doubles, the glomerular filtration rate is increased by 50%, and these changes are accompanied by an increased tubular reabsorption of sodium. Simultaneously, there is an increased renal clearance of low‐molecular‐weight solutes such as proteins, amino acids and glucose. Creatinine clearance is increased by 25% in the fourth week of gestation and by 45% in the ninth week (Cheung and Lafayette, [2013](#efs25778-bib-0052){ref-type="ref"}).

Progesterone has a major influence on these changes. This hormone induces smooth muscle relaxation and vasodilation and it reduces the response of the distal tubules to aldosterone, even though aldosterone production is also increased early in pregnancy. However, there are other adaptations, which have been poorly characterised, namely the production of hormones involved in the regulation of body water and a reduced responsiveness of receptors, particularly the RAAS, to these hormones (Brown, [1989](#efs25778-bib-0040){ref-type="ref"}; Wintour, [1998](#efs25778-bib-0327){ref-type="ref"}; Cheung and Lafayette, [2013](#efs25778-bib-0052){ref-type="ref"}). The ECF changes disappear by 1 month after delivery but the reversal of the renal adaptations may take up to 6 months post‐partum.

2.5. Interaction with other nutrients {#efs25778-sec-0025}
-------------------------------------

### 2.5.1. Potassium {#efs25778-sec-0026}

The metabolism of potassium and sodium are strongly interrelated, in part due to Na^+^/K^+^‐ATPase exchange mechanisms (Adrogué and Madias, [2014](#efs25778-bib-0005){ref-type="ref"}) (Section [2.2.1](#efs25778-sec-0011){ref-type="sec"}). Additionally, and importantly, the efficiency of sodium homeostasis, particularly its renal regulation, is related to that of potassium.

In its previous assessment of DRVs for potassium, the Panel concluded that dietary potassium intake modulates the influence of sodium on blood pressure (EFSA NDA Panel, [2016](#efs25778-bib-0090){ref-type="ref"}). There is also evidence that the effect of potassium intake on blood pressure may be higher in individuals with high sodium chloride intake compared with those with low sodium chloride intake. In a meta‐analysis of randomised controlled trials (RCTs) on the effect of potassium intake on blood pressure, Aburto et al. ([2013](#efs25778-bib-0001){ref-type="ref"}) conducted subgroup analyses according to levels of sodium intake, as assessed through baseline urinary sodium excretion. The largest blood pressure‐lowering effect of potassium was associated with the highest category of sodium intake (greater than 4 g (174 mmol)/day) compared with the lower categories (\< 2 g (87 mmol)/day and 2--4 g (87--174 mmol)/day).

In its opinion on DRVs for potassium (EFSA NDA Panel, [2016](#efs25778-bib-0090){ref-type="ref"}), the Panel considered whether the sodium‐to‐potassium intake ratio could influence blood pressure outcomes more than either potassium or sodium intakes alone. According to the systematic review by Perez and Chang ([2014](#efs25778-bib-0244){ref-type="ref"}), evidence from RCTs carried out in hypertensive subjects suggests that the sodium‐to‐potassium excretion ratio, on a molar basis, is more strongly associated with blood pressure outcomes than either sodium or potassium alone. Only four RCTs were conducted in normotensive subjects. The Panel notes, however, that none of the RCTs included in the review was designed to assess the effect of a change in the sodium‐to‐potassium ratio vs a change in either nutrient alone on blood pressure outcomes. This systematic review also included one prospective cohort study that reported that the sodium‐to‐potassium ratio, on a weight basis (assessed through 3‐day weighed records), was more strongly associated with hypertension and/or systolic and diastolic blood pressure levels than either sodium or potassium alone (Du et al., [2014](#efs25778-bib-0075){ref-type="ref"}). The Panel notes that additional prospective cohort studies have investigated the association between the sodium‐to‐potassium intake or excretion ratio, assessed through variable methods (dietary questionnaire, spot or 24‐h urine excretion), and blood pressure and CVD outcomes with inconsistent results (Chien et al., [2008](#efs25778-bib-0054){ref-type="ref"}; Kieneker et al., [2014](#efs25778-bib-0162){ref-type="ref"}; Okayama et al., [2016](#efs25778-bib-0233){ref-type="ref"}; Tabara et al., [2017](#efs25778-bib-0293){ref-type="ref"}; O\'Donnell et al., [2019](#efs25778-bib-0800){ref-type="ref"}).

A possible moderating effect of potassium intake on the relationship between sodium and blood pressure was explored in the meta‐analyses of RCTs conducted for the present opinion (Section [5.5.1.2](#efs25778-sec-0059){ref-type="sec"} and Appendix [I](#efs25778-sec-1009){ref-type="sec"}). Stratified analysis by levels of potassium intake/excretion are presented in Tables [I.1](#efs25778-tbl-0015){ref-type="table"} and [I.2](#efs25778-tbl-0016){ref-type="table"}. When building the meta‐regression models, potassium intake was not retained as it did not explain a significant proportion of the heterogeneity. Such analyses were, in addition, limited by the number of studies for which information on potassium intake/excretion was missing (13 out of 35 studies).

The Panel concludes that the interrelationship between sodium, potassium and blood pressure or CVD outcomes has not been sufficiently characterised to inform the DRVs for sodium.

### 2.5.2. Chloride {#efs25778-sec-0027}

The interaction between sodium and chloride is biologically crucial in that they, with potassium, diffuse freely in aqueous medium. In biological systems the three ions are compartmentalised by lipid membranes in such a way that their individual physicochemical properties maintain osmotic balance, electroneutrality, and acid--base balance between intracellular compartments and the cytoplasm, and between the cytoplasm and ECF. Regulated changes in the transmembrane balance for these ions in particular are fundamental for the transport of solutes across membranes (e.g. in intestinal absorption), and the generation of electrical signals in the muscle, and in the peripheral and central nervous systems (Berend et al., [2012](#efs25778-bib-0034){ref-type="ref"}; Imbrici et al., [2015](#efs25778-bib-0142){ref-type="ref"}). So, the functions of sodium depend on the availability of chloride as a counter‐ion (Section [2.2.1](#efs25778-sec-0011){ref-type="sec"}).

Chloride is rate limiting for the transport of sodium and chloride in the thin ascending loop of Henle, because of the differences in the affinities of sodium and chloride for the co‐transporters. Therefore, the availability of chloride has a determinant effect on the release of renin (Kotchen et al., [1987](#efs25778-bib-0169){ref-type="ref"}). Although chloride has biological functions independent of sodium, any direct role, independent of sodium or potassium, in modulating blood pressure has not been established (McCallum et al., [2015](#efs25778-bib-0203){ref-type="ref"}; EFSA NDA Panel, [2019](#efs25778-bib-0091){ref-type="ref"}).

Data from studies on hypertensive rats, a limited number of clinical observations, and accumulating reports on putative mechanisms suggest that the full‐expression of sodium chloride‐dependent elevation in blood pressure relies on the concomitant presence of both sodium and chloride (Kurtz et al., [1987](#efs25778-bib-0176){ref-type="ref"}; Shore et al., [1988](#efs25778-bib-0277){ref-type="ref"}; Luft et al., [1990](#efs25778-bib-0196){ref-type="ref"}; Kotchen and Kotchen, [1997](#efs25778-bib-0170){ref-type="ref"}; McCallum et al., [2015](#efs25778-bib-0203){ref-type="ref"}). It is noteworthy that dietary sodium chloride causes a greater rise of mean blood pressure, in both normotensive and hypertensive subjects, than does sodium combined with other anions (e.g. citrate, phosphate, bicarbonate) (Shore et al., [1988](#efs25778-bib-0277){ref-type="ref"}; McCallum et al., [2015](#efs25778-bib-0203){ref-type="ref"}; EFSA NDA Panel, [2019](#efs25778-bib-0091){ref-type="ref"}).

The Panel notes that there is evidence that chloride can contribute to the effect of sodium chloride on blood pressure.

### 2.5.3. Calcium {#efs25778-sec-0028}

Calcium and sodium share common transport mechanisms in the kidney; the reabsorption of calcium parallels the reabsorption of sodium at the renal tubular level (Yu, [2015](#efs25778-bib-0329){ref-type="ref"}; Moor and Bonny, [2016](#efs25778-bib-0213){ref-type="ref"}). There is consistent evidence that an increase in sodium intake increases urinary calcium excretion, while a reduction in sodium intake lowers urinary calcium excretion (Afssa, [2001](#efs25778-bib-0006){ref-type="ref"}; EFSA, [2005a](#efs25778-bib-0076){ref-type="ref"}; IOM, [2005](#efs25778-bib-0144){ref-type="ref"}).

In a cross‐sectional study of 484 post‐menopausal women, Nordin and Polley ([1987](#efs25778-bib-0229){ref-type="ref"}) reported that urinary calcium excretion was positively and independently related to calculated 24‐h urinary sodium excretion. The correlation between urinary calcium and urinary sodium was stronger in those on lower dietary calcium intakes (less than 1,250 mg/day), as assessed by food frequency questionnaires (FFQs).

Subsequently, two RCTs have assessed whether the quantitative relationship between sodium intake and calcium excretion, and the effect of increasing calcium excretion on calcium balance, depend on background calcium intake (Lin et al., [2003](#efs25778-bib-0190){ref-type="ref"}; Teucher et al., [2008](#efs25778-bib-0296){ref-type="ref"}). In a 2 × 3 factorial design, Lin et al. ([2003](#efs25778-bib-0190){ref-type="ref"}) randomised 186 adult men and women to a control diet, supplying 450 mg calcium/day, or the Dietary Approaches to Stop Hypertension (DASH) diet, supplying 1,250 mg calcium/day, and to three sodium intake levels of 1.1 g (50 mmol), 2.3 g (100 mmol) and 3.4 g (150 mmol)/day for 30 days. In a crossover design, Teucher et al. ([2008](#efs25778-bib-0296){ref-type="ref"}) assigned 11 postmenopausal women to dietary interventions characterised by calcium intakes of 518 versus 1,284 mg/day and by sodium chloride intakes of 3.9 g (170 mmol) vs 11.2 g (487 mmol)/day) for four 5‐week periods. The two studies provided consistent evidence that sodium intake affects urinary calcium excretion both at 'low' and 'high'‐calcium intake. Teucher et al. ([2008](#efs25778-bib-0296){ref-type="ref"}) estimated bone calcium balances using a compartmental model. With the 'low'‐calcium diets, negative bone calcium balances were estimated at both levels of sodium intakes. A negative bone sodium balance was also estimated on the 'high'‐calcium/'high'‐sodium chloride diet, while bone calcium balance was positive on the 'high'‐calcium/'low'‐sodium chloride diet. The only kinetic parameter significantly affected by sodium chloride intake was urinary calcium excretion.

The Panel notes that increasing sodium intake induces an increase in urinary calcium excretion that may negatively affect bone calcium balance, even when dietary calcium intake is above the PRI for calcium (EFSA NDA Panel, [2015](#efs25778-bib-0089){ref-type="ref"}).

2.6. Biomarkers {#efs25778-sec-0029}
---------------

### 2.6.1. Biomarkers of intake {#efs25778-sec-0030}

In healthy people, almost all dietary sodium is absorbed (Section [2.3.1](#efs25778-sec-0016){ref-type="sec"}) and urine is the major route of sodium excretion (Section [2.3.4.1](#efs25778-sec-0020){ref-type="sec"}). Urinary sodium excretion has traditionally been used as a biomarker of sodium intake, as it is considered to be more reliable than estimates of intake based on dietary assessments (Section [3.2](#efs25778-sec-0037){ref-type="sec"}).

#### 2.6.1.1. Measurements in 24‐h urine collection {#efs25778-sec-0031}

Twenty‐four‐hour urinary sodium excretion is used as a measure of average sodium intake at the population level (WHO, [2011](#efs25778-bib-0319){ref-type="ref"}). In a recent meta‐analysis of 35 studies (Lucko et al., [2018](#efs25778-bib-0193){ref-type="ref"}), mean 24‐h urine sodium was a close (93% on average) estimate of mean 24‐h dietary intake of sodium (Section [2.3.4.1](#efs25778-sec-0020){ref-type="sec"}). Adjustments to account for sodium excretion through sweat or in stools have been made only in a few studies, and in most cases, 24‐h urinary sodium excretion is used as a marker of daily sodium intake, without correction for other routes of sodium losses (Cogswell et al., [2015](#efs25778-bib-0058){ref-type="ref"}).

Incomplete collections of 24‐h urine samples can, however, introduce bias in measuring daily sodium excretion, and investigators need to implement quality control procedures (Cobb et al., [2014](#efs25778-bib-0055){ref-type="ref"}; Lucko et al., [2018](#efs25778-bib-0193){ref-type="ref"}). Several markers exist to assess and ensure complete collections, including: (i) urinary recovery of ingested *para*‐aminobenzoic acid (PABA) (usual criterion ≥ 85%), which is considered as the reference method; (ii) 24‐h urinary creatinine excretion; (iii) self‐report of missed voids; (iv) total urine volume (less than a specific threshold); and (v) duration of collection time (typically accepted range between 20 and 28 h); or (vi) combinations of the above (e.g. ratio of urinary to predicted creatinine excretion with total urine volume).

In eight studies using PABA, the percentage of incomplete collections ranged between 6% and 47% (John et al., [2016](#efs25778-bib-0151){ref-type="ref"}). Based on 24‐h urinary samples from 507 subjects, Wielgosz et al. ([2016](#efs25778-bib-0325){ref-type="ref"}) assessed the impact of different methods of assessing completeness of collection on sodium intake estimates. Methods such as exclusion of individuals who collected urine for more than or less than 24 h, time‐adjustment of urine collections that varied from 24 h and creatinine‐based exclusion criteria were assessed. Estimated mean daily sodium intake varied between 3.6 g (156 mmol) and 7.3 g (317 mmol) in the same set of urine samples depending on the method used to exclude or correct incomplete 24‐h urine collections.

John et al. ([2016](#efs25778-bib-0151){ref-type="ref"}) reviewed the literature to evaluate the validity of various methods using PABA recovery as the referent marker. The indices that were based on creatinine excretions had a moderate sensitivity (6--63% in four studies), but higher specificity (57--99.7%) to identify incomplete collection. Taking PABA recovery as the reference, the most valid method for identifying incomplete collections was the ratio of observed to predicted creatinine excretion (ratio \< 0.7). The Panel acknowledges the risk that incomplete collection of 24‐h urine can lead to underestimated urinary sodium excretions. The Panel notes that assessments of the reliability of daily sodium intake estimates based on urinary excretion need to take into account the quality control measures that were applied by the researchers to ensure and assess the completeness of urine collections.

Sodium levels in 24‐h urine collections are inherently variable. This variation is usually assumed to reflect daily variations in intake, although considerable day‐to‐day variability has also been observed in 24‐h sodium excretion of individuals under conditions of well controlled, fixed sodium intakes (Rakova et al., [2013](#efs25778-bib-0253){ref-type="ref"}; Weaver et al., [2016](#efs25778-bib-0313){ref-type="ref"}; Lucko et al., [2018](#efs25778-bib-0193){ref-type="ref"}) (Section [2.3.3](#efs25778-sec-0018){ref-type="sec"}).

The number of 24‐h urine collections needed to cover intraindividual variability range between 5 and 10 (Luft et al., [1982](#efs25778-bib-0195){ref-type="ref"}; Siani et al., [1989](#efs25778-bib-0278){ref-type="ref"}; Lerchl et al., [2015](#efs25778-bib-0186){ref-type="ref"}; Weaver et al., [2016](#efs25778-bib-0313){ref-type="ref"}). Luft et al. ([1982](#efs25778-bib-0195){ref-type="ref"}) conducted a study among 43 free‐living individuals to examine the utility of 24‐h urine collections in capturing variations in sodium intake. They reported that nine 24‐h collections were optimal to predict usual intake (r = 0.75). According to two prolonged balance studies (105 and 250 days) that involved 10 healthy young men, Lerchl et al. ([2015](#efs25778-bib-0186){ref-type="ref"}) concluded that a single, accurately collected, 24‐h urine sample was not able to detect a 3 g difference in the individual sodium chloride intake (corresponding to a difference of 1.2 g of sodium) among men with sodium chloride intakes of 6, 9 or 12 g/day (corresponding to 2.5 (110 mmol), 3.6 (155 mmol) and 4.8 g (210 mmol) of sodium). This resulted in a misclassification of half of the study participants with respect to their usual sodium intake. A collection of three consecutive 24‐h urine samples reduced the number of misclassified individuals to 25%, and a collection of seven samples to 8%. In the study by Weaver et al. ([2016](#efs25778-bib-0313){ref-type="ref"}), at least 10 repeated 24‐h samples were required on an average sodium intake of about 4 g (175 mmol)/day to reach a level of 75% reliability in the estimation of individual levels of sodium excretion.

In their review of observational cohort studies evaluating the association between sodium intake and health‐related outcomes, Cobb et al. ([2014](#efs25778-bib-0055){ref-type="ref"}) noted that the error introduced by the high day‐to‐day variability in sodium intake appears to be random and does not lead to biased estimates of the overall mean intake, when a single 24‐h urine collection is used. It limits, however, the accurate classification of study participants on the basis of their individual usual sodium intakes, which additionally leads to an overestimation of the proportion of individuals being classified in the tails of the intake distribution (Cogswell et al., [2015](#efs25778-bib-0058){ref-type="ref"}). In an analysis based on follow‐up data from the US Trials of Hypertension Prevention that included multiple 24‐h urine collections per subject, the use of the single (first) measured 24‐h urinary sodium collection flattened the relationship between sodium intake and overall mortality compared with the average of multiple (three to seven) measured 24‐h collections (He et al., [2018](#efs25778-bib-0131){ref-type="ref"}). The Panel notes that a single 24‐h urine collection does not reliably reflect an individual\'s usual intake, primarily due to within‐person day‐to‐day variability in sodium intake and excretion.

The Panel therefore considers that a single 24‐h collection can be used to estimate average group sodium daily intakes, but a single 24‐h urine collection can lead to random misclassification of study participants in relation to their usual sodium intake. In addition, the Panel notes that incomplete 24‐h urine collections can introduce bias in intake estimates.

#### 2.6.1.2. Casual spot urine collections and timed spot collections {#efs25778-sec-0032}

Other methods such as casual spot and timed spot urine collections (i.e. collection during the day, evening, or overnight) have also been used as indicators of sodium intake. Day‐to‐day and diurnal variations in sodium excretion render these measures highly variable at the individual level; hence, these methods are subject to greater within‐person variability in sodium excretion than 24‐h urine collections (Ji et al., [2012](#efs25778-bib-0148){ref-type="ref"}; Wang et al., [2013](#efs25778-bib-0310){ref-type="ref"}). Predictive equations have been developed to estimate 24‐h urinary sodium excretion from spot urine samples (Kawasaki et al., [1993](#efs25778-bib-0157){ref-type="ref"}; Tanaka et al., [2002](#efs25778-bib-0294){ref-type="ref"}; Brown et al., [2013](#efs25778-bib-0042){ref-type="ref"}). Their validity has been assessed in a number of studies (Kawasaki et al., [1993](#efs25778-bib-0157){ref-type="ref"}; Tanaka et al., [2002](#efs25778-bib-0294){ref-type="ref"}; Brown et al., [2013](#efs25778-bib-0042){ref-type="ref"}; Cogswell et al., [2013](#efs25778-bib-0057){ref-type="ref"}; Ji et al., [2014](#efs25778-bib-0149){ref-type="ref"}; Mente et al., [2014](#efs25778-bib-0210){ref-type="ref"}; Pfister et al., [2014](#efs25778-bib-0245){ref-type="ref"}; Polonia et al., [2017](#efs25778-bib-0248){ref-type="ref"}; Zhou et al., [2017](#efs25778-bib-0331){ref-type="ref"}) (Appendix [B](#efs25778-sec-1002){ref-type="sec"}). Associations between these estimates and 24‐h urinary excretions have primarily been assessed through correlation coefficients, which ranged between +0.33 (one timed morning urine collection in a sample of 297 white women in the UK and application of the Tanaka formula (Ji et al., [2014](#efs25778-bib-0149){ref-type="ref"})) and + 0.53 (one morning urine collection in a sample of 159 men and women in Japan and application of the Kawasaki formula (Kawasaki et al., [1993](#efs25778-bib-0157){ref-type="ref"})). In more recent studies, agreement between predicted and observed excretions has also been assessed through Bland--Altman plots, which indicate overestimation of predicted 24‐h excretions at lower levels and underestimation at higher levels of observed 24‐h urinary excretions for both men and women (Brown et al., [2013](#efs25778-bib-0042){ref-type="ref"}; Cogswell et al., [2013](#efs25778-bib-0057){ref-type="ref"}; Ji et al., [2014](#efs25778-bib-0149){ref-type="ref"}; Mente et al., [2014](#efs25778-bib-0210){ref-type="ref"}; Polonia et al., [2017](#efs25778-bib-0248){ref-type="ref"}).

Cogswell et al. ([2013](#efs25778-bib-0057){ref-type="ref"}) undertook a study to assess the validity of various equations predicting 24‐h urinary sodium excretion based on spot urine concentrations (Appendix [B](#efs25778-sec-1002){ref-type="sec"}). A sample of 407 adults aged 18--39 years provided one sample of 24‐h urine collection, from which four timed voids (morning, afternoon, evening and overnight) were selected. The published Kawasaki, Tanaka and INTERSALT equations were used to predict 24‐h sodium excretion with spot urine by specimen timing and race--sex subgroups. Bias was assessed through calculating the mean differences between estimated and measured 24‐h sodium excretion and with the use of Bland--Altman plots. The authors concluded that the INTERSALT equation when applied to sodium concentration in morning, afternoon and evening (but not overnight) samples provided the least biased estimates of population mean sodium intakes. The Tanaka equation was more reliable for mean population estimates when applied to overnight samples. However, the authors observed significant overestimation and underestimation among individuals and concluded that none of the equations provided unbiased estimates of individual 24‐h sodium excretion. The use of spot vs 24‐h urine samples for measuring differences in mean sodium excretion between population samples was assessed in the China Salt Substitute and Stroke Study (Huang et al., [2018](#efs25778-bib-0139){ref-type="ref"}). The Tanaka, Kawasaki and INTERSALT equations provided substantially underestimated differences between intervention and control groups compared with the values obtained using 24‐h urine samples.

Spot urine collections are, however, considered useful for trend analysis at group/population level (WHO, [2011](#efs25778-bib-0319){ref-type="ref"}; Ji et al., [2012](#efs25778-bib-0148){ref-type="ref"}; Cogswell et al., [2013](#efs25778-bib-0057){ref-type="ref"}).

The Panel notes that the reliability of both overnight and spot urine collections to estimate daily sodium intake is largely affected by circadian variations in individual sodium excretion. The Panel further notes that estimates of individual daily intakes from predictive equations based on spot urine samples can be biased, particularly at the lower and higher ends of the distribution and can therefore substantially misclassify exposure.

### 2.6.2. Biomarkers of status {#efs25778-sec-0033}

Homeostatic mechanisms maintain plasma sodium concentration of healthy individuals within a narrow range (Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}) (Section [2.3.2](#efs25778-sec-0017){ref-type="sec"}). Red blood cells concentrations are around 11 mmol/L (Cox, [1995](#efs25778-bib-0062){ref-type="ref"}; Penney, [2008](#efs25778-bib-0243){ref-type="ref"}). Differences by sex have been observed (Beilin et al., [1966](#efs25778-bib-0032){ref-type="ref"}). Slightly elevated plasma sodium concentration (by about 1--3 mmol/L) is often observed in hypertensive subjects (de Wardener et al., [2004](#efs25778-bib-0068){ref-type="ref"}; Blaustein et al., [2012](#efs25778-bib-0038){ref-type="ref"}).

The plasma sodium concentration is closely related to overall sodium balance, as well as potassium and water homeostasis. So, changes in plasma sodium concentration are related to the overall osmolarity of the diet, blood and gastrointestinal fluids, sweat and urine (Sterns, [2015](#efs25778-bib-0285){ref-type="ref"}). Hyponatraemia and hypernatraemia are typically related to disorders affecting water and electrolyte balances, and are seldom due to inappropriate sodium intake (Section [2.2.2](#efs25778-sec-0012){ref-type="sec"}). Plasma sodium concentration does not accurately reflect sodium body content.

The Panel considers that there is no biomarker of sodium status that can be used for setting DRVs for sodium in the general population.

2.7. Effects of genotype {#efs25778-sec-0034}
------------------------

There is heterogeneity in sodium‐dependent trafficking systems, much of which is not noticed because of the redundancy in many metabolic pathways that enable compensatory systems. Nonetheless, many genotypic variants that affect sodium‐dependent solute carriers for amino acids, monosaccharides, vitamins, potassium, calcium and bile acid, for example, have been reported. Additionally, there are monogenic defects affecting voltage‐gated sodium channels in neurons, and all types of muscle. Depending on the channel affected, the clinical features embrace cardiac conductivity defects, myopathies, increased sensitivity to pain, paroxysmal extreme pain, neuropathies, epilepsy and autonomic dysfunction (OMIM on line[6](#efs25778-note-1011){ref-type="fn"}).

Many monogenic changes affecting the renal excretion and salvage of sodium, chloride and water have also been identified, and these constitute a spectrum of defects involving both hypotension and hypertension (Schafer, [2002](#efs25778-bib-0271){ref-type="ref"}; Padmanabhan et al., [2015](#efs25778-bib-0238){ref-type="ref"}). Inherited defects in sodium reabsorption in the loop of Henle are associated with increased loss of sodium and chloride (salt‐losing tubulopathies) accompanied by hypokalaemia and alkalosis (e.g. Bartter\'s syndrome, Gitelman\'s syndrome). These genotypes are usually associated with normal or reduced blood pressure (Schafer, [2002](#efs25778-bib-0271){ref-type="ref"}; Padmanabhan et al., [2015](#efs25778-bib-0238){ref-type="ref"}). Other genotypes are associated with increased epithelial Na channel (ENaC) function causing syndromes involving excess aldosterone and mineralocorticoid activity leading to volume expansion and hypertension, hypokalaemia and, occasionally, alkalosis (e.g. Liddle\'s syndrome). In some instances, these syndromes include increased mucus viscosity and bronchiectasis. Other syndromes involve loss of ENaC activity resulting in a syndrome of pseudohypoaldosteronism with reduced ECF volume, sodium loss with hyperkalaemia and hypotension (Schafer, [2002](#efs25778-bib-0271){ref-type="ref"}; Padmanabhan et al., [2015](#efs25778-bib-0238){ref-type="ref"}).

'Salt sensitivity' is defined as a trait present in humans, by which the blood pressure of some members of the population exhibits changes parallel to changes in salt intake (Elijovich et al., [2016](#efs25778-bib-0092){ref-type="ref"}). As a response to 'high' exposure to sodium or sodium chloride in the population at large is a rise in blood pressure levels, the distinctiveness of a 'salt‐sensitive' individual lies in the immediacy of the observed changes in blood pressure levels induced by alterations in sodium chloride intake. 'Salt sensitivity' can be regarded as one end of a Gaussian distribution of blood pressure responses to change in dietary sodium chloride, while the other extreme has been termed 'salt resistant' (Weinberger, [1996](#efs25778-bib-0315){ref-type="ref"}; Strazzullo et al., [2000](#efs25778-bib-0288){ref-type="ref"}; He et al., [2009](#efs25778-bib-0128){ref-type="ref"}). The range of responses depends on the balance of environmental, dietary, for example potassium intake, and lifestyle factors with individuals' physiological characteristics and genetic profiles (Lupoli et al., [2013](#efs25778-bib-0197){ref-type="ref"}; Luzardo et al., [2015](#efs25778-bib-0198){ref-type="ref"}; Padmanabhan et al., [2015](#efs25778-bib-0238){ref-type="ref"}; Elijovich et al., [2016](#efs25778-bib-0092){ref-type="ref"}). Although there is evidence for a genetic basis of 'salt sensitivity', the identification of genetic variants associated with 'salt sensitivity' is challenging (Elijovich et al., [2016](#efs25778-bib-0092){ref-type="ref"}). The Panel notes that, as yet, there is no consensus on the characterisation of 'salt sensitivity' (Luzardo et al., [2015](#efs25778-bib-0198){ref-type="ref"}; Elijovich et al., [2016](#efs25778-bib-0092){ref-type="ref"}).

The Panel considers that as yet no genotype has been characterised sufficiently to merit consideration about the estimation of DRVs for sodium in the general population.

3. Dietary sources and intake data {#efs25778-sec-0035}
==================================

3.1. Dietary sources {#efs25778-sec-0036}
--------------------

All unprocessed foods contain sodium, although at low levels. The sodium content of unprocessed, raw meat and fish is typically between 30 and 150 mg (1.3 and 6.5 mmol)/100 g, and fruits and vegetables generally contain less than 50 mg (2.2 mmol)/100 g (UK Food Standards Agency, [2002](#efs25778-bib-0305){ref-type="ref"}; Anses, [2016c](#efs25778-bib-0022){ref-type="ref"}; National Institute for Health and Welfare, [2016](#efs25778-bib-0221){ref-type="ref"}).

Sodium is present in variable amounts in water, with mineral deposits, seawater spray, sewage effluents, and salt used in road de‐icing contributing significant quantities of sodium to water (WHO, [2003](#efs25778-bib-0318){ref-type="ref"}). Water treatment chemicals, such as sodium fluoride, sodium bicarbonate and sodium hypochlorite, can also increase the sodium content of water. Median (25--75th) sodium concentrations in tap water sampled in 30 European countries was 0.4 (0.2--0.9) mmol/L (9.5 (4.3--20.0) mg/L) (n = 579 samples) (Banks et al., [2015](#efs25778-bib-0028){ref-type="ref"}). High variability was found in European samples of bottled mineral water, from 0.04 mmol (1 mg) to 61.7 mmol (1,419 mg)/L (n = 73) (Azoulay et al., [2001](#efs25778-bib-0025){ref-type="ref"}). So, the contribution of drinking water to dietary sodium intake may vary substantially depending on the source and quantity of the water that is consumed.

Sodium is added to food mostly as sodium chloride during processing. In addition, sodium may be added in the form of sodium‐containing food additives, such as sodium bicarbonate in fine bakery wares or sodium nitrate in processed meat. Authorised sodium‐containing food additives include riboflavin 5′‐phosphate sodium, [d]{.smallcaps}‐pantothenate sodium, sodium‐[l]{.smallcaps}‐ascorbate, ferric sodium diphosphate, ferric sodium ethylenediaminetetraacetate (EDTA), sodium iodide, sodium iodate, sodium bicarbonate, sodium carbonate, sodium citrate, sodium gluconate, sodium lactate, sodium hydroxide, sodium salts of orthophosphoric acid, sodium selenate, sodium selenite, sodium hydrogen selenite, sodium fluoride, sodium molybdate and sodium borate, which can be added to both foods[7](#efs25778-note-1012){ref-type="fn"} and food supplements.[8](#efs25778-note-1013){ref-type="fn"} Sodium sulfate and sodium monofluorophosphate are authorised for use in food supplements only.^7^ The sodium content of infant and follow‐on formulae[9](#efs25778-note-1014){ref-type="fn"} and processed cereal‐based foods and baby foods for infants and young children[10](#efs25778-note-1015){ref-type="fn"} is regulated.

The sodium content of processed foods can vary substantially between countries, reflecting dietary habits and taste preferences. In addition, large variations have been observed in the sodium content of food items belonging to the same food group. Studies conducted in the Netherlands, Australia and the UK agree on the wide range of sodium content among similar food items. Based on these estimations, food groups with the highest sodium content are sauces (particularly Asian ones), processed meat, cheese and canned fish, whereas food groups with the lowest sodium content are rice, pasta, cereal products (excluding bread) and processed fruits and vegetables (Webster et al., [2010](#efs25778-bib-0314){ref-type="ref"}; Ni Mhurchu et al., [2011](#efs25778-bib-0223){ref-type="ref"}; Capuano et al., [2013](#efs25778-bib-0048){ref-type="ref"}; Eyles et al., [2013](#efs25778-bib-0098){ref-type="ref"}). In European populations, the main contributors to sodium intake are bread, meat and meat products, and cheese and dairy products (European Commission, [2012](#efs25778-bib-0097){ref-type="ref"}; Kloss et al., [2015](#efs25778-bib-0164){ref-type="ref"}).

The relative contributions of different sodium sources (inherently food‐borne, processing‐added, table salt, cooking salt) to intake is variable, as illustrated by studies conducted in the UK (Farrimond et al., [1995](#efs25778-bib-0102){ref-type="ref"}; Henderson et al., [2003](#efs25778-bib-0801){ref-type="ref"}), Denmark (Andersen et al., [2009](#efs25778-bib-0015){ref-type="ref"}) and Italy (Leclercq and Ferro‐Luzzi, [1991](#efs25778-bib-0184){ref-type="ref"}). Estimates of the mean contribution of discretionary sodium chloride (i.e. added during the preparation of the meals or at the table) vary from 10% in the study in Denmark to more than one third of the total intake in the study in Italy. The Panel however notes the substantial uncertainty associated with these estimates.

The Panel notes that sodium chloride added during industrial food processing, discretionary use or food preservation is the major source of dietary sodium in Western diets. Other sources of sodium include inherently native sources, and sodium‐containing food additives, in which sodium may be associated with anions other than chloride.

3.2. Dietary intake {#efs25778-sec-0037}
-------------------

### 3.2.1. Methodological considerations {#efs25778-sec-0038}

In dietary surveys, sodium intake is estimated through recalls (of recent or usual diet) or food diaries capturing intakes in real‐time. In addition to the limitations inherent to the use of dietary questionnaires, i.e. the inaccurate reporting of participants and the use of incomplete or outdated food composition tables to determine the sodium content of food, errors in estimating sodium intake can be introduced by the failure to capture the sodium chloride added at the table and/or during cooking. These errors can result in biased estimates of sodium intake, which if they differ by exposure or disease status (i.e. high consumers or hypertensive subjects may misreport more often than individuals with lower intakes or normal blood pressure, respectively), can have an unpredictable impact on the estimated association between sodium intake and disease risk.

In a pooled analysis of data collected in five large validation studies conducted in the USA, Freedman et al. ([2015](#efs25778-bib-0111){ref-type="ref"}) assessed the relative validity of FFQs and 24‐h dietary recalls (DRs) in capturing sodium intake through comparisons with 24‐h urinary sodium levels. On average, weighted by the inverse of the variance, underreporting was 28% (men) and 39% (women) with a FFQ and 4% (men) and 13% (women) with a single 24‐h DR. Underreporting of sodium was strongly associated with higher body mass index (BMI) for both instruments and also with being black, male, and having a high school education versus a college education or higher for FFQs. Correlation coefficients between self‐reported questionnaires and 24‐h urinary estimates improved when sodium intake was expressed in relation to total energy intake (i.e. as sodium density) and when multiple 24‐h DRs were collected as compared with a single 24‐h DR.

Two recent reviews of validation studies compared estimates of sodium intakes based on dietary questionnaires (24‐h dietary recalls, food diaries or FFQs) with 24‐h urinary sodium excretion (McLean et al., [2017](#efs25778-bib-0206){ref-type="ref"}, [2018](#efs25778-bib-0207){ref-type="ref"}). Studies were quite heterogeneous in the period covered, i.e. number of days covered by 24‐h DRs or records, of months captured by FFQs and the number of 24‐h urine samples collected; in whether sodium chloride used for preparation or added at the table was taken into consideration; in considering participants' characteristics in the analysis; and in the way the data were analysed. In most studies, correlation coefficients were estimated and ranged from 0.11 to 0.49 for food diaries (six studies) and from 0.16 to 0.72 for 24‐h DRs (10 studies) (McLean et al., [2018](#efs25778-bib-0207){ref-type="ref"}). The results of Bland--Altman analysis performed in two studies generally point to poor agreement between estimations based on 24‐h DRs and urine collections. In particular, one study reported a negative association (increasing urinary sodium excretion was associated with increasing underestimation by dietary method) but the limits of agreement were not reported. The second study reported a mean difference of 0.087 g/day, but with 95% limits of agreement ranging from −3.1 to +3.3 g/day, indicating a wide range of bias in the estimations. The correlation coefficients between intakes assessed through FFQs and 24‐h urines ranged from 0.07 to 0.36 across 16 eligible validation studies (McLean et al., [2017](#efs25778-bib-0206){ref-type="ref"}). Concurrent urine collections did not substantially improve the correlations. One eligible study indicated poor agreement between estimates from a FFQ and 24‐h urine collection based on the Bland--Altman method. There was no obvious bias at low or high sodium intakes in that study.

The Panel notes that there is generally poor agreement between sodium intake estimates based on dietary questionnaires and 24‐h urine collections. The Panel considers that estimates of sodium intake based on 24‐h urinary excretion are more accurate than estimates of intake based on dietary questionnaires (Section [2.5.1](#efs25778-sec-0026){ref-type="sec"}). Twenty four‐hour urine collection is the recommended method for assessing population mean sodium intake. There are limitations, however, in the use of this method, including potential bias due to inaccurate collection. The Panel additionally considers that when estimates of individual intakes are based on single measurements or the average of a small number of urine collections, they may be prone to random errors due to within‐individual day‐to‐day variability in sodium excretion, which may result in the estimation of inaccurate percentiles of sodium intake.

### 3.2.2. Sodium urinary excretion in European populations and abroad {#efs25778-sec-0039}

In 2016, an overview of sodium intake in European populations was prepared based on data on sodium urinary excretion in European populations collected through EFSA focal points and the members of the EFSA Food Consumption Network.[11](#efs25778-note-1016){ref-type="fn"} Data were collected from 18 countries, and the most recent surveys, conducted between 2002 and 2014, were selected. Appendix [C](#efs25778-sec-1003){ref-type="sec"} provides urinary sodium excretion data in children in four countries (Austria, Iceland, Italy, Spain). Appendices [D](#efs25778-sec-1004){ref-type="sec"} and [E](#efs25778-sec-1005){ref-type="sec"} provide urinary sodium excretion data of adult men and women in 17 countries (Austria, Belgium, Croatia, the Czech Republic, Finland, Germany, Greece, Hungary, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland, the Netherlands and the United Kingdom). Most countries used 24‐h urine collection, while three countries collected spot or timed urine collection and estimated daily sodium excretion through arithmetic extrapolation. Studies using 24‐h urine collection were heterogeneous with respect to the methods and criteria applied for the assessment and exclusion of incomplete or unreliable urine collections (e.g. PABA recovery, creatinine excretion levels, urinary volume, self‐reporting of incomplete samples). Some studies were designed as national monitoring surveys, while others were conducted as part of broader observational studies. Sample sizes also varied widely, from tens to thousands of people.

Mean sodium urinary excretion levels across countries ranged between 3.2 and 6.1 g/day (141 and 266 mmol/day) in adult men, and between 2.6 and 4.2 g/day (112 and 182 mmol/day) in adult women. Across all countries, mean sodium excretion levels were higher in men than in women. In children, values ranged between 1.7 g/day (72 mmol/day) in 6‐year‐old boys and girls in Iceland and 2.8 and 3.5 g/day (122 and 154 mmol/day) in Austrian boys and girls aged 13--14 years old.

Powles et al. ([2013](#efs25778-bib-0249){ref-type="ref"}) combined data from national and subnational adult population surveys of 24‐h urinary sodium excretion and dietary sodium intake, conducted in 187 countries (21 regions) between 1980 and 2010. Dietary estimates were converted into urine equivalents based on surveys having data for both measurements from the same individuals, and mean sodium intake was estimated through Bayesian hierarchical modelling. Across European countries, mean (95% uncertainty interval) sodium intake estimates ranged from 3.27 (2.98--3.58) g/day (Denmark) to 4.42 (4.22--4.61) g/day (Italy) for men and women combined. World‐wide, sodium intakes were the highest in East and Central Asia and Eastern Europe (mean \> 4.2 g/day), and in Central Europe and Middle East/North Africa sodium intake ranged between 3.9 and 4.2 g/day. Regional mean intakes in North America, Western Europe and Australia/New Zealand ranged between 3.4 and 3.8 g/day. Intakes were lower (\< 3.3 g/day) in sub‐Saharan Africa and Latin America, but more uncertain due to the few data sources available.

In the INTERSALT study, an international study undertaken in 1982--1985 in which 52 centres from 32 countries participated, 200 men and women (aged 20--59 years) equally distributed in age and sex groups were recruited in each centre. Participants were asked to provide a 24‐h urine collection, following a standardised protocol. Urine analyses were conducted in the same laboratory. The study pointed to a large variation in the sodium intake of free‐living healthy individuals, with median urinary sodium excretion ranging between 0.005 g (0.2 mmol)/day in Yanomamo Indians in Brazil and 5.6 g (242.1 mmol)/day in China (Intersalt Cooperative Research Group, [1988](#efs25778-bib-0143){ref-type="ref"}).

4. Overview of dietary reference values and recommendations {#efs25778-sec-0040}
===========================================================

4.1. Adults {#efs25778-sec-0041}
-----------

For adults aged 19 and older, the US National Academies of Sciences, Engineering, and Medicine (NASEM) set an adequate intake (AI) of 1.5 g/day (NASEM, [2019](#efs25778-bib-0220){ref-type="ref"}). The lowest levels of sodium intake evaluated in randomised trials conducted among adults (DASH‐sodium trial and eight other trials) and the balance study from Allsopp et al. ([1998](#efs25778-bib-0013){ref-type="ref"}) which indicated neutral balance with heat stress at this level of intake were considered in setting the AI. The NASEM concluded that evidence of harmful effects of low sodium intake on type 2 diabetes, glucose tolerance, and insulin sensitivity, blood pressure, plasma lipid concentrations, cardiovascular disease and all‐cause mortality was insufficient and inconsistent. The NASEM also established a Chronic Disease Risk Reduction Intake (CDRR) for sodium, defined as the lowest level of intake for which there was sufficient strength of evidence to characterise a chronic disease risk reduction. In the sodium intake range of 2.3--4.1 g/day (100--178 mmol/day), the strength of evidence was considered high that reducing sodium intake reduces chronic disease risk, based on evidence of reduction in cardiovascular disease incidence, reduction in hypertension incidence, and lowering of systolic and diastolic blood pressure. A sodium CDRR of reducing intakes if above 2.3 g/day (100 mmol/day) was proposed, which is applicable to adults with and without hypertension, irrespective of sex, age or race/ethnicity. The 2015--2020 Dietary Guidelines for Americans recommended that adults limit sodium intake to less than 2.3 g/day (HHS/USDA, [2015](#efs25778-bib-0136){ref-type="ref"}).

The German‐speaking countries (D--A--CH, [2016](#efs25778-bib-0065){ref-type="ref"}; Strohm et al., [2018](#efs25778-bib-0290){ref-type="ref"}) based their DRVs on data from the balance study by Allsopp et al. ([1998](#efs25778-bib-0013){ref-type="ref"}) in which male subjects achieved a positive sodium balance with sodium intake of 1.5 g/day after 8 days, under conditions of moderate physical activity and heat exposure. In addition, it was noted that the requirements of other nutrients, with the exception of iodine and fluoride, can be achieved with a diet providing 1.5 g sodium/day (Deutsche Gesellschaft für Ernährung, [2015](#efs25778-bib-0069){ref-type="ref"}). An AI of 1.5 g/day was set for all adults. In a separate statement, the German Nutrition Society (DGE) emphasised the relationship between sodium chloride intake and blood pressure, and that a high consumption of sodium chloride is associated with an elevated or 'suboptimal' blood pressure while a low consumption is associated with blood pressure in the normal or 'optimal' range (Strohm et al., [2016](#efs25778-bib-0289){ref-type="ref"}). This association was considered a convincing proof of an indirect effect of high sodium chloride intake via hypertension on the risk of CVD, while the evidence for a direct effect of sodium chloride intake on CVD risk was considered inconsistent. A target value for dietary sodium chloride of 6 g/day (2.4 g sodium) for adults was recommended.

The Nordic countries (Nordic Council of Ministers, [2014](#efs25778-bib-0228){ref-type="ref"}) acknowledged that trials showed a decrease in blood pressure when sodium intake was reduced, and that blood pressure is a risk factor for CVD (Bibbins‐Domingo et al., [2010](#efs25778-bib-0035){ref-type="ref"}). It was stated that recommended intakes for sodium should be based on public health considerations rather than actual requirements. A sodium chloride intake of less than 6 g/day or a sodium intake of less than 2.4 g/day was considered a population goal.

In 2014, the Italian Society of Nutrition (SINU) set an AI of 1.5 g sodium/day for adults aged 18--59 years, in line with IOM\'s conclusions (IOM, [2005](#efs25778-bib-0144){ref-type="ref"}). A suggested dietary target (SDT) of 2 g sodium/day was proposed for this age group for the prevention of cardiovascular and other chronic diseases, consistent with the recommendation from the WHO ([2012b](#efs25778-bib-0321){ref-type="ref"}). It was stated that the target for the population is a sodium intake below the SDT. For older adults (≥ 60 years), SINU proposed a decrease in the AI and SDT compared with younger adults, in proportion with the requirement for energy. This was taking into consideration the fact that the sensitivity of blood pressure to sodium chloride intake increases with age (Khaw and Barrett‐Connor, [1990](#efs25778-bib-0161){ref-type="ref"}; Vollmer et al., [2001](#efs25778-bib-0308){ref-type="ref"}), and also accounted for reduced renal and cardiovascular functions in older adults.

The WHO ([2012b](#efs25778-bib-0321){ref-type="ref"}) has not set DRVs for sodium but recommends a reduction in sodium intake to \< 2 g/day sodium (5 g/day sodium chloride) in adults (≥ 16 years of age) (strong recommendation[12](#efs25778-note-1017){ref-type="fn"}). This was based on evidence from systematic reviews on the relationship between sodium and blood pressure and risk of cardiovascular disease, stroke and coronary heart disease in adults (WHO, [2012a](#efs25778-bib-0320){ref-type="ref"},[c](#efs25778-bib-0322){ref-type="ref"}).

The Health Council of the Netherlands concluded that, in a large number of RCTs, lowering sodium intake reduces blood pressure, which is a causal risk factor of cardiovascular diseases (Kromhout et al., [2016](#efs25778-bib-0172){ref-type="ref"}). The Committee observed that the protective effect of a low intake of sodium was stronger in hypertensive than in normotensive people (Graudal et al., [2011](#efs25778-bib-0118){ref-type="ref"}; Aburto et al., [2013](#efs25778-bib-0001){ref-type="ref"}; He et al., [2013](#efs25778-bib-0129){ref-type="ref"}). The guideline could not be quantified because of insufficient data from high‐quality cohort studies on sodium intake and cardiovascular risk. Therefore, the Committee decided to maintain its previous guideline to limit salt intake to 6 g/day (2.4 g sodium) (Health Council of the Netherlands, [2006](#efs25778-bib-0132){ref-type="ref"}).

Afssa ([2001](#efs25778-bib-0006){ref-type="ref"}) did not set a PRI for sodium because of a lack of intervention studies (in particular on cardiovascular morbidity and mortality) to define a PRI. A lack of consensus was noted on the relationship between sodium intake and blood pressure (Alderman et al., [1997](#efs25778-bib-0009){ref-type="ref"}; Stamler et al., [1997](#efs25778-bib-0284){ref-type="ref"}; Weinberger, [1997](#efs25778-bib-0316){ref-type="ref"}; McCarron, [1998](#efs25778-bib-0205){ref-type="ref"}; Taubes, [1998](#efs25778-bib-0295){ref-type="ref"}; MacGregor and de Wardener, [1999](#efs25778-bib-0201){ref-type="ref"}; Swales, [1999](#efs25778-bib-0291){ref-type="ref"}). Afssa ([2001](#efs25778-bib-0006){ref-type="ref"}) suggested that healthy adults should not consume more than 12 g/day and not less than 5 g/day of sodium chloride (corresponding to 4.8 and 2.0 g/day of sodium). In 2016, Anses considered recent literature on the relationship between sodium intake and blood pressure (Mente et al., [2014](#efs25778-bib-0210){ref-type="ref"}) and cardiovascular risk (IOM, [2013](#efs25778-bib-0145){ref-type="ref"}; Adler et al., [2014](#efs25778-bib-0002){ref-type="ref"}; Graudal et al., [2014](#efs25778-bib-0119){ref-type="ref"}; O\'Donnell et al., [2014](#efs25778-bib-0231){ref-type="ref"}; Pfister et al., [2014](#efs25778-bib-0245){ref-type="ref"}) and noted a lack of consensus; the experts concluded that current data were insufficient to set a UL, a PRI or an AI for sodium (Anses, [2016b](#efs25778-bib-0021){ref-type="ref"}). In its update of the food‐based dietary guidelines for the French population, Anses selected the median consumption of sodium as the maximum value not to be exceeded, which amounts to reducing intake in the half of the population with higher intake levels, in agreement with public health policies. The French consumption survey INCA2 reported median daily intakes of sodium of 2,273 mg for women and 2,994 mg for men (excluding sodium from salt added at the table) (Anses, [2016a](#efs25778-bib-0020){ref-type="ref"}).

The SCF ([1993](#efs25778-bib-0267){ref-type="ref"}) did not set a PRI for sodium but an acceptable range of intakes of 0.575--3.5 g sodium/day. The lower intake took into account reports on maintenance of sodium balances at intakes as low as 0.069--0.46 g/day, and observed habitual intakes in some populations of 0.23--0.92 g/day (Glieberman, [1973](#efs25778-bib-0117){ref-type="ref"}; INTERSALT Cooperative Research Group, [1988](#efs25778-bib-0143){ref-type="ref"}; Law et al., [1991a](#efs25778-bib-0182){ref-type="ref"}), allowing for changes in physical activity and ambient temperature. The upper intake was based on evidence that an intake higher than 4.6 g/day may be associated with increased risk of hypertension, especially in older adults (Frost et al., [1991](#efs25778-bib-0113){ref-type="ref"}; Law et al., [1991a](#efs25778-bib-0182){ref-type="ref"},[b](#efs25778-bib-0183){ref-type="ref"}), and the public health consideration that intakes should be lower than this amount to reduce the risk of hypertension and CVD.

The UK COMA (DH, [1991](#efs25778-bib-0071){ref-type="ref"}) set DRVs based on the balance of 'risks and benefits' of sodium intakes. The COMA was unable to derive an estimated average requirement (EAR) but set a lower reference nutrient intake (LRNI) for sodium at 25 mmol/day (0.575 g/day) and a reference nutrient intake (RNI) at 70 mmol/day (1.6 g/day). It was noted that a reduction in sodium intake decreases blood pressure in people with established hypertension, but this may not be seen in people with normal blood pressure. The COMA was unable to determine a potentially toxic threshold for sodium intake. It was noted that 10% of the population may be affected by a genetic susceptibility to sodium‐related hypertension apparent at sodium intakes of 3.2--4.7 g/day. In 2003, the UK Scientific Advisory Committee on Nutrition (SACN) endorsed the RNI of 70 mmol/day (1.6 g/day) and recommended a target sodium chloride intake of less than 6 g/day (2.4 g (100 mmol) sodium)) for the adult population by multiplying the RNI by a factor of 1.5 (SACN, [2003](#efs25778-bib-0261){ref-type="ref"}). The Committee noted that this is higher than the RNI and substantially greater than the sodium chloride intake required to maintain the sodium content of the body. It noted that the target salt intakes set for adults do not represent ideal or optimum consumption levels, but an achievable population goal as part of a public health strategy.

###### 

Overview of dietary reference values (adequate intakes) for sodium for adults

+---------------+----------------------------------------------------+-------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+----------------------------------------------------------------------------------------------------+
|               | NASEM ([2019](#efs25778-bib-0220){ref-type="ref"}) | D--A--CH ([2016](#efs25778-bib-0065){ref-type="ref"}) | SINU ([2014](#efs25778-bib-0281){ref-type="ref"}) | SCF ([1993](#efs25778-bib-0267){ref-type="ref"})  | DH ([1991](#efs25778-bib-0071){ref-type="ref"}); SACN ([2003](#efs25778-bib-0261){ref-type="ref"}) |
+===============+====================================================+=======================================================+===================================================+===================================================+====================================================================================================+
| Age (years)   | ≥ 19                                               | ≥ 19                                                  | ≥ 19                                              | ≥ 18                                              | ≥ 19                                                                                               |
+---------------+----------------------------------------------------+-------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+----------------------------------------------------------------------------------------------------+
| AI            | 1.5                                                | 1.5                                                   | 1.5                                               | 0.575--3.5[a](#efs25778-note-0008){ref-type="fn"} | 1.6                                                                                                |
|               |                                                    |                                                       |                                                   |                                                   |                                                                                                    |
| Men (g/day)   | 1.5                                                | 1.5                                                   | 1.5                                               | 0.575--3.5[a](#efs25778-note-0008){ref-type="fn"} | 1.6                                                                                                |
|               |                                                    |                                                       |                                                   |                                                   |                                                                                                    |
| Women (g/day) |                                                    |                                                       |                                                   |                                                   |                                                                                                    |
+---------------+----------------------------------------------------+-------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+----------------------------------------------------------------------------------------------------+
| Age (years)   |                                                    |                                                       | ≥ 60                                              |                                                   |                                                                                                    |
+---------------+----------------------------------------------------+-------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+----------------------------------------------------------------------------------------------------+
| AI            |                                                    |                                                       | 1.2                                               |                                                   |                                                                                                    |
|               |                                                    |                                                       |                                                   |                                                   |                                                                                                    |
| Men (g/day)   |                                                    |                                                       | 1.2                                               |                                                   |                                                                                                    |
|               |                                                    |                                                       |                                                   |                                                   |                                                                                                    |
| Women (g/day) |                                                    |                                                       |                                                   |                                                   |                                                                                                    |
+---------------+----------------------------------------------------+-------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+----------------------------------------------------------------------------------------------------+

AI: adequate intake; D--A--CH: Deutschland--Austria--Confoederatio Helvetica; DH: Department of Health; NASEM: National Academies of Sciences, Engineering, and Medicine; SACN: Scientific Advisory Committee on Nutrition; SCF: Scientific Committee for Food; SINU: Italian Society of Nutrition.

Acceptable range of intakes.

John Wiley & Sons, Ltd

###### 

Overview of population goal/target for sodium and sodium chloride intake for adults

+-------------------------+------------------------------------------------------------------+-----------------------------------------------------+-------------------------------------------------------+--------------------------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+--------------------------------------------------------------------------------+---------------------------------------------------+
|                         | Strohm et al. ([2016](#efs25778-bib-0289){ref-type="ref"}) (DGE) | Anses ([2016a](#efs25778-bib-0020){ref-type="ref"}) | HHS/USDA ([2015](#efs25778-bib-0136){ref-type="ref"}) | Nordic Council of Ministers ([2014](#efs25778-bib-0228){ref-type="ref"}) | SINU ([2014](#efs25778-bib-0281){ref-type="ref"}) | WHO ([2012b](#efs25778-bib-0321){ref-type="ref"}) | Health Council of the Netherlands ([2006](#efs25778-bib-0132){ref-type="ref"}) | SACN ([2003](#efs25778-bib-0261){ref-type="ref"}) |
+=========================+==================================================================+=====================================================+=======================================================+==========================================================================+===================================================+===================================================+================================================================================+===================================================+
| Age (years)             |                                                                  | ≥ 18                                                | ≥ 19                                                  | ≥ 18                                                                     | ≥ 18                                              | ≥ 16                                              | ≥ 18                                                                           | ≥ 19                                              |
+-------------------------+------------------------------------------------------------------+-----------------------------------------------------+-------------------------------------------------------+--------------------------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+--------------------------------------------------------------------------------+---------------------------------------------------+
| Sodium chloride (g/day) | 6                                                                | --                                                  | 5.75                                                  | 6                                                                        | 5                                                 | 5                                                 | 6                                                                              | 6                                                 |
+-------------------------+------------------------------------------------------------------+-----------------------------------------------------+-------------------------------------------------------+--------------------------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+--------------------------------------------------------------------------------+---------------------------------------------------+
| Sodium (g/day)          | 2.4                                                              | M: ≤ 2,994 mg/day                                   | 2.3                                                   | 2.4                                                                      | 2.0                                               | 2.0                                               | 2.4                                                                            | 2.4                                               |
|                         |                                                                  |                                                     |                                                       |                                                                          |                                                   |                                                   |                                                                                |                                                   |
|                         |                                                                  | W: ≤ 2,273 mg/day                                   |                                                       |                                                                          |                                                   |                                                   |                                                                                |                                                   |
+-------------------------+------------------------------------------------------------------+-----------------------------------------------------+-------------------------------------------------------+--------------------------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+--------------------------------------------------------------------------------+---------------------------------------------------+
| Age (years)             |                                                                  |                                                     |                                                       |                                                                          | ≥ 60                                              |                                                   |                                                                                |                                                   |
+-------------------------+------------------------------------------------------------------+-----------------------------------------------------+-------------------------------------------------------+--------------------------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+--------------------------------------------------------------------------------+---------------------------------------------------+
| Sodium chloride (g/day) |                                                                  |                                                     |                                                       |                                                                          | 4                                                 |                                                   |                                                                                |                                                   |
+-------------------------+------------------------------------------------------------------+-----------------------------------------------------+-------------------------------------------------------+--------------------------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+--------------------------------------------------------------------------------+---------------------------------------------------+
| Sodium (g/day)          |                                                                  |                                                     |                                                       |                                                                          | 1.6                                               |                                                   |                                                                                |                                                   |
+-------------------------+------------------------------------------------------------------+-----------------------------------------------------+-------------------------------------------------------+--------------------------------------------------------------------------+---------------------------------------------------+---------------------------------------------------+--------------------------------------------------------------------------------+---------------------------------------------------+

Anses: French Agency for Food, Environmental and Occupational Health and Safety; DGE: German Society of Nutrition; HHS/USDA: Health and Human Services/United States Department of Agriculture; M: men; SACN: Scientific Advisory Committee on Nutrition; SINU: Italian Society of Nutrition; W: women; WHO: World Health Organization.

John Wiley & Sons, Ltd

4.2. Infants and children {#efs25778-sec-0042}
-------------------------

For infants aged 7--12 months, the NASEM ([2019](#efs25778-bib-0220){ref-type="ref"}) set an AI of 370 mg/day (16.1 mmol/day) based on the sodium intake from breast milk (approximately 70 mg/day (3.0 mmol/day)) and from complementary foods (300 mg/day (13.0 mmol/day)). For children and adolescents 1--18 years of age, the AIs were derived by extrapolating from the sodium AI for adults based on average Estimated Energy Requirements for sedentary children, as compared to an Estimated Energy Requirement for adults. Regarding CDRR intake, the NASEM noted that evidence to assess the relationship between sodium intake and chronic disease in children and adolescents was insufficient and the uncertainties about the long‐term chronic disease benefits of reduced sodium intake beginning in childhood. However, the committee considered that the risk of not setting a CDRR for children outweighed the risk of setting a sodium CDRR intake for children based on evidence of blood pressure tracking to adulthood, the public health importance, and consideration of salt‐taste sensitivity and preferences starting to develop as early as 3--4 months of age. The sodium CDRRs for children were extrapolated from the adult sodium CDRR, based on energy requirements, and were set as follows: 1.2 g/day for children aged 1--3 years, 1.5 g/day for children aged 4--8 years, and 1.8 g/day for children aged 9--13 years and 2.3 g/day for children aged 14--17 years. The 2015--2020 Dietary Guidelines for Americans (HHS/USDA, [2015](#efs25778-bib-0136){ref-type="ref"}) recommended that children limit sodium intake to less than the ULs established by the IOM in 2005.

For infants aged 4--11 months, the German‐speaking countries (D--A--CH, [2016](#efs25778-bib-0065){ref-type="ref"}) derived an AI of 0.2 g/day. This was based on an estimated sodium intake from breast milk of 0.13 g/day for infants aged 0--4 months (considering a sodium content of breast milk of 0.170 g/L and assuming an average breast milk intake of 0.75 L/day) and upward extrapolation considering differences in body weight. AIs for children were extrapolated down from the AI of adults, based on difference in body weight and applying a growth factor.

For children, Nordic countries stated that data suggest that a reduction in sodium intake at an early age is associated with a lower blood pressure in later life. For children below 2 years of age, it was recommended to limit sodium chloride intake to below 0.5 g/MJ (equivalent to 0.2 g/MJ of sodium), to avoid developing a preference for a diet with a high sodium chloride level. From 2--9 years, it was recommended not to exceed a sodium chloride intake of about 3--4 g/day (Nordic Council of Ministers, [2014](#efs25778-bib-0228){ref-type="ref"}).

For infants aged 7--12 months, SINU ([2014](#efs25778-bib-0281){ref-type="ref"}) set an AI based on the sodium intake from breast milk and from complementary foods, in line with the approach taken by IOM ([2005](#efs25778-bib-0144){ref-type="ref"}). For children aged 1--10 years, AIs and SDTs were extrapolated down from the AI for adults in proportion of the energy requirement of the respective age groups. For children and adolescents aged 11--18 years, the same AI and SDT as for adults were proposed.

The WHO ([2012b](#efs25778-bib-0321){ref-type="ref"}) has not set DRVs for sodium but recommends a reduction in sodium intake to control blood pressure in children aged 2--15 years of age (strong recommendation). The recommended maximum level of intake of 2 g/day sodium in adults should be adjusted downward based on the energy requirements of children relative to those of adults.

Afssa ([2001](#efs25778-bib-0006){ref-type="ref"}) and the SCF ([1993](#efs25778-bib-0267){ref-type="ref"}) did not set DRVs for sodium in infants and children due to insufficient evidence.

The UK COMA (DH, [1991](#efs25778-bib-0071){ref-type="ref"}) set LRNIs and RNIs for infants and children. For infants and children above 6 months, RNIs were derived factorially by calculating the daily increase in total body sodium content allowing for the declining proportion with age of ECF in body mass (Friis‐Hansen, [1961](#efs25778-bib-0112){ref-type="ref"}), with an allowance for dermal, faecal and urinary losses. So, LRNIs between 0.2 g sodium/day (7 months to 3 years) and 0.575 g sodium/day (15 to 18 years) were set. In 2003, the UK Scientific Advisory Committee on Nutrition endorsed the RNI proposed by COMA and multiplied them by a factor of 1.5 to set daily target average sodium chloride intake (SACN, [2003](#efs25778-bib-0261){ref-type="ref"}). The Committee noted that target sodium chloride intakes do not represent ideal or optimum consumption levels, but an achievable population goal.

###### 

Overview of dietary reference values (adequate intakes) for sodium for infants and children

                 NASEM ([2019](#efs25778-bib-0220){ref-type="ref"})   D--A--CH ([2016](#efs25778-bib-0065){ref-type="ref"})   SINU ([2014](#efs25778-bib-0281){ref-type="ref"})   DH ([1991](#efs25778-bib-0071){ref-type="ref"})
  -------------- ---------------------------------------------------- ------------------------------------------------------- --------------------------------------------------- -------------------------------------------------
  Age (months)   0--6                                                 4--11                                                                                                       4--6
  AI (g/day)     0.11                                                 0.2                                                                                                         0.28[a](#efs25778-note-0011){ref-type="fn"}
  Age (months)   7--12                                                                                                        6--12                                               7--9
  AI (g/day)     0.37                                                                                                         0.4                                                 0.32[a](#efs25778-note-0011){ref-type="fn"}
  Age (months)                                                                                                                                                                    10--12
  AI (g/day)                                                                                                                                                                      0.35[a](#efs25778-note-0011){ref-type="fn"}
  Age (years)    1--3                                                 1--3                                                    1--3                                                1--3
  AI (g/day)     0.8                                                  0.4                                                     0.7                                                 0.5[a](#efs25778-note-0011){ref-type="fn"}
  Age (years)    4--8                                                 4--6                                                    4--6                                                4--6
  AI (g/day)     1.0                                                  0.5                                                     0.9                                                 0.7[a](#efs25778-note-0011){ref-type="fn"}
  Age (years)                                                         7--9                                                    7--10                                               7--10
  AI (g/day)                                                          0.75                                                    1.1                                                 1.2[a](#efs25778-note-0011){ref-type="fn"}
  Age (years)    9--13                                                10--12                                                  11--14                                              11--14
  AI (g/day)     1.2                                                  1.1                                                     1.5                                                 1.6[a](#efs25778-note-0011){ref-type="fn"}
  Age (years)    14--18                                               13--14                                                  15--17                                              15--18
  AI (g/day)     1.5                                                  1.4                                                     1.5                                                 1.6[a](#efs25778-note-0011){ref-type="fn"}
  Age (years)                                                         15--18                                                                                                      
  AI (g/day)                                                          1.5                                                                                                         

AI: adequate intake; D--A--CH: Deutschland--Austria--Confoederatio Helvetica; DH: Department of Health; NASEM: National Academies of Sciences, Engineering, and Medicine; SINU: Italian Society of Nutrition.

Reference nutrient intake (RNI).
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###### 

Overview of population goal/target for sodium and sodium chloride intake for children

                            HHS/USDA ([2015](#efs25778-bib-0136){ref-type="ref"})   Nordic Council of Ministers ([2014](#efs25778-bib-0228){ref-type="ref"})   SINU ([2014](#efs25778-bib-0281){ref-type="ref"})   SACN ([2003](#efs25778-bib-0261){ref-type="ref"})
  ------------------------- ------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------
  Age (months)                                                                                                                                                                                                     0--6
  Sodium chloride (g/day)                                                                                                                                                                                          1
  Sodium (g/day)                                                                                                                                                                                                   0.4
  Age (months)                                                                      0--24                                                                                                                          7--12
  Sodium chloride (g/day)                                                           0.5[a](#efs25778-note-0013){ref-type="fn"}                                                                                     1
  Sodium (g/day)                                                                    0.2[a](#efs25778-note-0013){ref-type="fn"}                                                                                     0.4
  Age (years)               1--3                                                    2--9                                                                       1--3                                                1--3
  Sodium chloride (g/day)   3.75                                                    3--4                                                                       2.25                                                2
  Sodium (g/day)            1.5                                                     1.2--1.6                                                                   0.9                                                 0.8
  Age (years)               4--8                                                    10--18                                                                     4--6                                                4--6
  Sodium chloride (g/day)   4.75                                                    6                                                                          3                                                   3
  Sodium (g/day)            1.9                                                     2.4                                                                        1.2                                                 1.2
  Age (years)               9--13                                                                                                                              7--10                                               7--10
  Sodium chloride (g/day)   5.5                                                                                                                                3.75                                                5
  Sodium (g/day)            2.2                                                                                                                                1.5                                                 2.0
  Age (years)               14--18                                                                                                                             11--17                                              11--18
  Sodium chloride (g/day)   5.75                                                                                                                               5.0                                                 6
  Sodium (g/day)            2.3                                                                                                                                2.0                                                 2.4

HHS/USDA: Health and Human Services/ United States Department of Agriculture; SACN: Scientific Advisory Committee on Nutrition; SINU: Italian Society of Nutrition.

Expressed as nutrient density, i.e. g of sodium/MJ of energy intake.
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4.3. Pregnancy and lactation {#efs25778-sec-0043}
----------------------------

The NASEM considered that there was a lack of evidence to suggest that sodium requirements of pregnant women differ from that of non‐pregnant women and proposed a sodium AI for pregnant women of 1.5 g/day (65 mmol/day) (NASEM, [2019](#efs25778-bib-0220){ref-type="ref"}). Regarding lactating women, the NASEM noted that sodium is excreted in breast milk but the concentrations are determined by an electrical potential gradient, rather than by maternal dietary intake. The sodium requirements for lactating women does not appear to differ from that of non‐pregnant, non‐lactating women and the same AI of 1.5 g/day (65 mmol/day) was set for this group. The NASEM considered that there was insufficient evidence that a different sodium CDRR is needed for pregnant or lactating females compared to their non‐pregnant, non‐lactating age group counterparts. The same sodium CDRR of 2.3 g/day was proposed for these groups.

D--A--CH ([2016](#efs25778-bib-0065){ref-type="ref"}) considered that the extra sodium requirement of 0.07 g/day (3 mmol/day) during pregnancy, due to the expansion of ECF volume, can be covered by homeostatic mechanisms. The same was considered to be true for the additional requirement of 0.13 g/day (6 mmol/day) during lactation due to sodium losses with breast milk.

SINU ([2014](#efs25778-bib-0281){ref-type="ref"}) considered that the AI for non‐pregnant non‐lactating women was sufficient to cover the increase in sodium requirement during pregnancy and lactation; the same AI as for other adults (1.5 sodium/day) was maintained for these population groups. SINU recommended that the SDT for other adults (2 g sodium/day) also applies to pregnant and lactating women.

The Nordic countries (Nordic Council of Ministers, [2014](#efs25778-bib-0228){ref-type="ref"}) concluded that there was a lack of evidence to suggest that the sodium requirement during pregnancy and lactation differs significantly from that of non‐pregnant women; no DRVs for sodium were set for these population groups. Likewise, the SCF ([1993](#efs25778-bib-0267){ref-type="ref"}) and the UK COMA (DH, [1991](#efs25778-bib-0071){ref-type="ref"}) did not set specific DRVs for sodium for pregnant and lactating women.

###### 

Overview of dietary reference values (adequate intakes) for sodium for pregnant and lactating women

                         NASEM ([2019](#efs25778-bib-0220){ref-type="ref"})   D--A--CH ([2016](#efs25778-bib-0065){ref-type="ref"})   SINU ([2014](#efs25778-bib-0281){ref-type="ref"})
  ---------------------- ---------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------
  Age (years)            14--50                                                                                                       
  AI pregnancy (g/day)   1.5                                                  1.5                                                     1.5
  AI lactation (g/day)   1.5                                                  1.5                                                     1.5

AI: adequate intake; D--A--CH: Deutschland--Austria--Confoederatio Helvetica; g: gram; NASEM: National Academies of Sciences, Engineering, and Medicine; SINU: Italian Society of Nutrition.

John Wiley & Sons, Ltd

5. Criteria (endpoints) on which to base dietary reference values {#efs25778-sec-0044}
=================================================================

5.1. Biomarkers as indicators of sodium requirement {#efs25778-sec-0045}
---------------------------------------------------

As stated in Section [2.4](#efs25778-sec-0024){ref-type="sec"}, the Panel considers that there are no appropriate biomarkers of sodium status that can be used for deriving DRVs for sodium.

5.2. Balance studies {#efs25778-sec-0046}
--------------------

Balance studies are based on the assumption that a healthy subject on an adequate diet maintains equilibrium or a null balance, between nutrient intakes and nutrient losses. At this null balance, the intake matches the requirement determined by the physiological state of the individual. When intakes exceed losses (positive balance), there is nutrient accretion that may be attributable to growth or weight gain, anabolism, or repletion of stores; when losses exceed intakes (negative balance), nutrient stores are progressively depleted, resulting in clinical symptoms of deficiency in the long term. In addition to numerous methodological concerns about accuracy and precision in the determination of nutrient intakes and losses (Baer et al., [1999](#efs25778-bib-0026){ref-type="ref"}), the validity of balance studies to calculate nutrient requirements has been questioned. Differences between intakes and losses of a nutrient may only reflect adaptive changes before a new steady state is reached (Young, [1986](#efs25778-bib-0328){ref-type="ref"}), or the conditions for the maintenance of nutrient 'stores' in the context of a given diet, whereas the health relevance of the size of body pools still needs to be established for each nutrient (Mertz, [1987](#efs25778-bib-0211){ref-type="ref"}).

Although the term 'balance studies' is used in this section, the Panel considered studies that describe comparative assessments between sodium intake and sodium excretion provided that their designs allowed for an adaptation period (see Section [2.3.4.1](#efs25778-sec-0020){ref-type="sec"}). The key characteristics and results of eligible balance studies are tabulated in Appendix [F.1](#efs25778-sec-0092){ref-type="sec"} and summarised below.

### 5.2.1. Balance studies in adults {#efs25778-sec-0047}

Holbrook et al. ([1984](#efs25778-bib-0137){ref-type="ref"}) aimed to assess sodium 'balance' in 28 United States healthy (20--53 years), free‐living men and women consuming self‐selected diets. For 1 week in each season of the year (four 7‐day periods), participants collected duplicate samples of food and beverages consumed and 24‐h urine and faecal samples for sodium content analysis. Sodium 'balance' was calculated as the difference between sodium intake (including salt added during preparation and at the table) and sodium excretion through urine and faeces. Dermal losses were not measured. Results are given for the four 7‐day periods combined (28 days). Most participants decreased their energy intake, as assessed by dietary records (mean decrease of about 17% for men and 13% for women), during the collection periods. Mean sodium intake was 3.4 g (148 mmol)/day. Mean ± SD difference between sodium intake and excretion was +0.47 ± 0.32 g (+20 ± 14 mmol)/day. The 95% CI of the mean did not include zero. The mean difference between sodium intake and excretion was more positive during the summer (+0.6 g (26 mmol)/day versus +0.4 g (17 mmol)/day in other periods). The Panel notes the positive difference between sodium intake and excretion in these free‐living individuals with a mean sodium intake of 3.4 g (148 mmol)/day. The Panel also notes that dermal losses were not assessed, which may have contributed to the positive difference.

One study (Allsopp, [1997](#efs25778-bib-0012){ref-type="ref"}; Allsopp et al., [1998](#efs25778-bib-0013){ref-type="ref"}) investigated sodium balance in 25 men (18--40 years, BMI 20--34 kg/m^2^, not on regular strenuous physical training), who were confined to an experimental chamber at 25°C for 3 days (days 1--3), followed by 5 days at 40°C from 08:00 to 18:00 h and then at 25°C from 18:00 to 08:00 h (days 4--8). Relative humidity and air velocity were kept constant. Sodium intake was controlled and kept constant throughout the study at doses of 1.5 g (65 mmol)/day (n = 9), 4 g (174 mmol)/day (n = 9) or 8 g (348 mmol)/day (n = 7). Sodium losses were estimated from daily 24‐h urine collections, faecal samples and whole‐body wash‐downs on days 3, 4 and 8. Plasma aldosterone concentration was measured from morning blood samples. On day 8, mean ± SD sodium balance was +0.04 ± 0.35 g/day, +0.79 ± 0.64 g/day and +0.67 ± 1.19 g/day in the groups of men consuming 1.5, 4 and 8 g sodium/day, respectively. On day 8, no two groups were dissimilar with respect to net sodium balance. In the group consuming 1.5 g of sodium/day, mean plasma levels of aldosterone had increased by day 3 (vs no increase in the other two groups). During the heat exposure period, such an increase was observed in all groups, but it was more apparent in the group consuming 1.5 g of sodium/day.

The Panel notes that men with low physical activity and a daily exposure to prolonged heat were on average in balance, partly mediated by changes in aldosterone secretion, after 8 days of a controlled diet that provided 1.5 g (65 mmol) of sodium/day.

A series of studies addressing Na, K, Ca, Mg, P, Fe, Zn, Cu and Mn was conducted in Japan and have been collectively analysed on several occasions (Kodama et al., [2005](#efs25778-bib-0165){ref-type="ref"}; Nishimuta et al., [2005](#efs25778-bib-0224){ref-type="ref"}, [2006](#efs25778-bib-0225){ref-type="ref"}, [2012](#efs25778-bib-0226){ref-type="ref"}, [2018](#efs25778-bib-0227){ref-type="ref"}). Nishimuta et al. ([2012](#efs25778-bib-0226){ref-type="ref"}) calculated the 'estimated equilibrated dietary intakes (EEDI)' for sodium (the intercept of a linear regression equation between intake and balance) using data from 13 'balance' studies conducted in young Japanese women (n = 131, 18--26 years). Daily sodium intake, assessed through duplicate diet samples, ranged between 2.5 g (107 mmol) and 4.8 g (209 mmol). Each study included an adaptation period of 2--4 days. Sodium concentration in urine and faeces were measured. Sodium losses in sweat during exercise were measured in five studies by collecting sweat from the arm. The duration of the balance periods ranged from 8 to 12 days. Notwithstanding the uncertainty induced by measurements of sweat losses, the Panel notes that, in this collective analysis of primary studies among Japanese women, mean sodium 'balance' was 'positive' (+6.07 ± 4.06 mg/kg bw) with sodium intakes above 2.5 g (107 mmol).

Other sodium balance studies or experiments assessing sodium excretion in different circumstances are also available in the literature (McCance, [1936](#efs25778-bib-0204){ref-type="ref"}; Falconer and Lyall, [1937](#efs25778-bib-0099){ref-type="ref"}; Dole et al., [1950](#efs25778-bib-0074){ref-type="ref"}; Heer et al., [2000](#efs25778-bib-0133){ref-type="ref"}, [2009](#efs25778-bib-0134){ref-type="ref"}; Rakova et al., [2013](#efs25778-bib-0253){ref-type="ref"}). The Panel considers that these 'balance studies' cannot be used for setting DRVs for sodium due to the very small number of study participants (two in McCance ([1936](#efs25778-bib-0204){ref-type="ref"}); three in Falconer and Lyall ([1937](#efs25778-bib-0099){ref-type="ref"})), the inclusion of participants with pre‐existing medical conditions (Dole et al., [1950](#efs25778-bib-0074){ref-type="ref"}), the absence of adaptation periods (Heer et al., [2000](#efs25778-bib-0133){ref-type="ref"}, [2009](#efs25778-bib-0134){ref-type="ref"}), or the lack of measurements of both faecal and dermal losses (Rakova et al., [2013](#efs25778-bib-0253){ref-type="ref"}).

### 5.2.2. Balance studies in children {#efs25778-sec-0048}

Using a randomised cross‐over design, Palacios et al. ([2004](#efs25778-bib-0239){ref-type="ref"}) assessed sodium retention in 14 white and 22 black US girls (11--15 years) during 3 weeks on a 'low' (mean ± SEM: 1.31 ± 0.04 g (57 ± 2 mmol)/day) and 3 weeks on a 'high' (3.95 ± 0.05 g (172 ± 2 mmol)/day)) sodium intake, separated by a 2‐week wash‐out in which participants consumed self‐selected diets. The first week of each period served as an equilibration period. The study was conducted in summer time. Eight white and 15 black girls completed both periods, while six white and seven black girls completed one of the two periods only. Before the study initiation, subjects completed six 24‐h dietary recalls. Dietary intakes of protein, fat, fibre, potassium, calcium and phosphorus were controlled, at levels representative of usual intakes in this population. Faecal and 24‐h urine samples were collected daily for 20 days during each study period. Corrections for incomplete samples were applied based on the excretion of creatinine in urine and polyethylene glycol in faeces ('normalised' 24‐h pools). Whole‐body sweat was collected after 2 weeks of acclimatisation to the diet for 24 h by a whole‐body scrub‐down procedure, taking measures to minimise the contribution of exfoliated skin to the estimate. Mean sodium balance over the last 2 weeks of each period was calculated including sodium losses in sweat. Aldosterone concentration and renin activity were measured in plasma sampled upon awakening ('resting' samples) and 2 h later ('stimulated' samples).

Mean (± SD) sodium balance was positive during 'low' and 'high' sodium intakes (+0.4 ± 0.31 g/day among blacks (n = 19) and +0.2 ± 0.14 g/day among whites (n = 12) on 'low' intake and +1.0 ± 0.61 g/day among blacks (n = 19) and +0.3 ± 0.28 g/day among whites (n = 10) on 'high' intake). Results were similar when urine and faecal samples were not normalised and when only subjects completing both dietary periods were analysed. The Panel notes that this study in adolescent girls reports positive mean sodium balances with a daily sodium intake of 1.31 g (57 mmol). Plasma aldosterone concentrations were elevated at the end of the 'low' sodium period compared with the 'high' sodium period (Appendix [F.1](#efs25778-sec-0092){ref-type="sec"}).

### 5.2.3. Mechanistic considerations {#efs25778-sec-0049}

In daily life, the body constantly adapts to maintain sodium (and water) homeostasis in response to changing environmental conditions. Sodium balance is tightly regulated through neural and hormonal mechanisms (including the SNS and the RAAS) affecting its renal reabsorption and intake ('salt appetite') (Section [2.3.4](#efs25778-sec-0019){ref-type="sec"}). Several meta‐analyses of human intervention studies have investigated the effect of a reduction in sodium intake on these systems (Graudal et al., [2011](#efs25778-bib-0118){ref-type="ref"}; WHO, [2012c](#efs25778-bib-0322){ref-type="ref"}; He et al., [2013](#efs25778-bib-0129){ref-type="ref"}) (Table [F.1](#efs25778-tbl-0013){ref-type="table"} in Appendix [F.2](#efs25778-sec-0093){ref-type="sec"}). In the meta‐analysis from He et al. ([2013](#efs25778-bib-0129){ref-type="ref"}), which included most of the studies that were also considered in the other two meta‐analyses, a reduction in sodium intake, resulting in 24‐h urinary sodium excretion in the range of 50--100 mmol (1.2--2.3 g)/day, was associated with mean increases in plasma renin activity of 0.26 (95% CI 0.17, 0.36) ng/mL per h, plasma aldosterone concentration of 73.20 (95% CI 44.92, 101.48) pmol/L and plasma noradrenaline concentration of 31.67 (95% CI 6.57, 56.77) pg/mL). The effect estimate on plasma adrenaline concentration was 6.70 (95% CI --0.25, 13.64) pg/mL (He et al., [2013](#efs25778-bib-0129){ref-type="ref"}). The trials included in these analyses lasted from 4 to 11 weeks.

Cross‐sectional analyses of data from subjects with different levels of sodium intake indicate curvilinear relationships between sodium intake, plasma renin activity and urinary aldosterone excretion; both increased sharply with 24‐h urinary sodium excretion \< 50 to 100 mmol/day (1.2 to 2.3 g/day) (Laragh et al., [1972](#efs25778-bib-0179){ref-type="ref"}; Laragh and Sealey, [2011](#efs25778-bib-0180){ref-type="ref"}).

In a study of sodium metabolism in young men consuming controlled amounts of sodium for several weeks (Rakova et al., [2013](#efs25778-bib-0253){ref-type="ref"}), average daily urinary excretion of aldosterone increased with gradual sodium restriction from 4.9 g/day to 2.5 g/day, each level maintained constant for \> 29 days (Table [F.2](#efs25778-tbl-0014){ref-type="table"} in Appendix [F.2](#efs25778-sec-0093){ref-type="sec"}). In contrast, a decrease in urinary levels of glucocorticoids in urine was observed. On average, 95% of dietary sodium was recovered in urine over each dietary phase, which suggests that sodium balance was achieved at each level of sodium intake, through the activation of hormonal regulatory mechanisms. A high day‐to‐day variability in urinary excretion of sodium was also observed, as well as weekly and monthly rhythms of fluctuations in aldosterone and glucocorticoids that correlated with body sodium accumulation (apparent positive balance) and release (apparent negative balance), independent of sodium intake.

### 5.2.4. Conclusions {#efs25778-sec-0050}

Mean sodium intake assessed in eligible balance studies ranged between 1.5 g and 4.9 g/day in adults (three studies) and between 1.31 and 3.95 g/day in adolescents (one study). No data are available for sodium intakes below 1.3 g/day (adolescents) and 1.5 g/day (adults).

The Panel notes that adaptation mechanisms triggered by neural and hormonal signals enable the maintenance of sodium balance over a wide range of sodium intakes. The concerns about using balance studies to establish nutrient requirements are particularly relevant for sodium. Recent data from a long‐term study of sodium metabolism suggest that rhythmical variations in the sodium body pools independent of sodium intake may occur. This complicates the interpretation of balance studies. Overall, the Panel considers that balance studies cannot be used to determine sodium requirements, but could be used to inform about the levels of sodium intake that are adequate to maintain a null sodium balance. The Panel also notes the lack of data on the health effects of a sustained activation of the SNS and the RAAS system in the general population.

5.3. Indicators of sodium requirement in pregnancy and lactation {#efs25778-sec-0051}
----------------------------------------------------------------

Total body sodium is estimated to increase by 23 g (1,000 mmol) during pregnancy, and has been assumed to represent an additional daily requirement of 70--90 mg (3--4 mmol) of sodium (Pitkin et al., [1972](#efs25778-bib-0246){ref-type="ref"}). However, the increase is not evenly distributed throughout pregnancy. The need arises from the expansion of the maternal ECF volume (approximating 3.0 L) that comprises 60% of the extra requirement, and the remaining 40% meets the compositional requirements of the fetus, placenta and the amniotic fluid. The changes in the volume and distribution of body water start early in pregnancy and are associated with the initial endocrine response to pregnancy that, among other things, increases the homeostatic retention of sodium (Section [2.4](#efs25778-sec-0024){ref-type="sec"}).

Oliver et al. ([1981](#efs25778-bib-0235){ref-type="ref"}) undertook a comparative study among women of two South American tribes to understand how hormonal adaptation impacts on sodium balance during pregnancy and lactation. The first group consisted of pregnant (n = 4), non‐pregnant/lactating (n = 16) and non‐pregnant/non‐lactating (n = 16) Yanomamo Indian women living in villages in northern Brazil and southern Venezuela with no access to sodium chloride. The second group included pregnant (n = 7) and non‐pregnant (n = 9) Guaymi Indian women of Panama, who had free access to sodium chloride and used it to cook vegetables and preserve meat. The second (control) group was included to address concerns about genetic susceptibility. In both groups, measurements of arterial blood pressure, blood and spot urine samples were collected between 08:00 and 10:00 h in the morning. Breast milk samples were collected only among the Yanomamo women. Urinary sodium concentrations among Yanomamo women ranged between 0.7 mmol/L (pregnant) and 1.4 mmol/L (non‐pregnant/non‐lactating women) and between 77.8 mmol/L (pregnant) and 119.0 mmol/L (non‐pregnant) among Guaymi women. In breast milk, the concentrations of sodium ranged between 5 and 9 mmol/L (0.1--0.2 g/L) meaning that it was comparable to the sodium concentration in sodium‐affluent regions. The pregnant Yanomamo had high urinary concentrations of aldosterone, associated with higher plasma renin activities and serum aldosterone concentrations than in all other subjects. Pregnant Guaymi also had elevated serum and urinary aldosterone concentrations, but significantly lower (p \< 0.001) than in Yanomamo women. Prolonged lactation in the Yanomamo was associated with elevation of plasma renin activity, serum and urinary aldosterone concentration compared with the Guaymi, but was not higher than in non‐lactating Yanomamo women. Based on evidence from two Indian tribes living in South America, the Panel notes that pregnancy in a salt‐poor environment is associated with hormonal adaptation associated with sodium retention, similar to non‐pregnant adults (Allsopp et al., [1998](#efs25778-bib-0013){ref-type="ref"}).

The Panel considers that the requirement for the daily accretion rate of sodium in fetal and maternal tissues can be met by the adaptive changes that maintain sodium homeostasis during pregnancy.

Sodium losses in human milk are relatively small (a few mmol/day). The concentration of sodium in human milk is not influenced by maternal sodium intake (Section [2.3.4.4](#efs25778-sec-0023){ref-type="sec"}). The Panel notes that there is no evidence that sodium requirement of lactating women differs from the requirement of non‐lactating women.

5.4. Indicators of sodium requirement in infants and children {#efs25778-sec-0052}
-------------------------------------------------------------

Sodium is retained with growth of tissues during child development (Section [5.2.2](#efs25778-sec-0048){ref-type="sec"}).

The neonate is in a state of relative total body water and ECF excess, and the typical diuresis accompanied by sodium loss, which occurs immediately after birth, is considered physiological. During the first days of postnatal life, fractional excretion of sodium decreases progressively, and a state of positive balance is reached (Ross et al., [1977](#efs25778-bib-0258){ref-type="ref"}; Al‐Dahhan et al., [1984](#efs25778-bib-0008){ref-type="ref"}). Multiple endocrine systems are integrated with the renal regulatory mechanisms to enhance sodium retention in infants, in part through an activation of the RAAS (Al‐Dahhan et al., [1983](#efs25778-bib-0007){ref-type="ref"}; Chevalier, [2001](#efs25778-bib-0053){ref-type="ref"}).

As few data were available to calculate reference values for infants, the UK COMA Panel on Dietary Reference Values (1991) used a factorial approach based on intracellular and ECF concentrations of sodium with allowances for growth‐related changes in the volumes of these compartments according to body compositional reference data (Widdowson, [1980](#efs25778-bib-0323){ref-type="ref"}). Values for the first 6 months of life were also based on reference values for the composition of breast milk and a presumed intake of 850 mL/day. As there was appreciable uncertainty in these data, the derived values were regarded as LNRIs rather than ARs. The SCF ([1993](#efs25778-bib-0267){ref-type="ref"}) considered these data as too uncertain to set reference intakes for sodium in infants and young children.

Fomon ([1993](#efs25778-bib-0106){ref-type="ref"}) also attempted to estimate the physiological requirement for sodium of infants via a factorial approach by adding requirements for growth to obligatory losses. Sodium accretion with growth was estimated from data on sodium content of the whole body and of cellular and extracellular water, taking into account the quantities of these fluids at different ages of reference infants, and from the amount of sodium in osseous mineral at different ages (Pitts, [1974](#efs25778-bib-0247){ref-type="ref"}; Forbes, [1975](#efs25778-bib-0107){ref-type="ref"}; Fomon et al., [1982](#efs25778-bib-0105){ref-type="ref"}; Widdowson, [1982](#efs25778-bib-0324){ref-type="ref"}; Boskey, [1988](#efs25778-bib-0039){ref-type="ref"}). It resulted in a sodium requirement for growth of 27 mg (1.2 mmol)/day for infants aged 0--4 months and 16 mg (0.7 mmol)/day for infants aged 4--12 months, respectively. Sodium losses via the skin, dependent on the body surface area, were estimated to be 24 mg (1.0 mmol) from 0 to 4 months and 30 mg (1.3 mmol)/day from 4 to 12 months, respectively (Forbes, [1975](#efs25778-bib-0107){ref-type="ref"}). Assuming an absorption of 95%, 54 mg (2.3 mmol) of dietary sodium/day were calculated to be needed at the age of 0--4 months, to account for growth demands and replace losses, and 48 mg (2.1 mmol)/day for the age 4--12 months. Fomon ([1993](#efs25778-bib-0106){ref-type="ref"}) proposed a daily recommended intake of 80 mg (3.5 mmol) of sodium for infants throughout the first year of life in consideration of both the uncertainty created by the limited data available and the need for assumptions to be made, and the necessity to provide for individual variability in requirements. The Panel notes that the quantity of sodium provided by human milk during the first 6 months of life (i.e. 120 mg/day assuming a volume of 0.8 L/day and a sodium concentration of 150 mg/L (see Section [2.3.4.4](#efs25778-sec-0023){ref-type="sec"})) is higher than this calculated physiological requirement.

5.5. Sodium intake and health consequences {#efs25778-sec-0053}
------------------------------------------

Three categories of health outcomes were selected as the most suitable to inform the setting of DRVs: blood pressure, cardiovascular disease‐related endpoints and bone health. They were selected on the basis of their biological relevance for the general healthy population, the biological plausibility of their relationship with sodium intake, and the type of evidence (i.e. RCTs and/or prospective observational studies) (see protocol, Annex [A](#efs25778-sec-2001){ref-type="sec"}). Systematic reviews of the literature were conducted to characterise the relationship between sodium intake and these outcomes. The subquestions addressed by the systematic reviews are reported in Table [7](#efs25778-tbl-0007){ref-type="table"}.

###### 

Subquestions addressed by the systematic reviews on sodium

  No      Subquestion
  ------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1**   What is the relationship between sodium intake and blood pressure in humans?
  **2**   What is the relationship between sodium intake and cardiovascular disease‐related outcomes in humans?
  **3**   What is the relationship in children[a](#efs25778-note-0015){ref-type="fn"} between sodium intake and bone mineral density (BMD) and/or bone mineral content (BMC)?
  **4**   What is the relationship in adults[b](#efs25778-note-0016){ref-type="fn"} between sodium intake and BMD?
  **5**   What is the relationship in adults[b](#efs25778-note-0016){ref-type="fn"} between sodium intake and the risk of osteoporotic fractures?

6 months to \< 18 years.

≥ 18 years.

John Wiley & Sons, Ltd

Eligible study design included randomised controlled parallel (RCTs) or crossover trials (with a wash‐out period of any duration) and prospective studies including cohort studies, nested case--control and case--cohort studies. Trials were eligible if the intervention consisted in a change in sodium intake compared with usual diet or placebo.

In relation to blood pressure and CVD‐related outcomes, trials with concomitant interventions deemed to affect the outcome of interest were excluded. For bone‐related outcomes, trials in which the same concomitant intervention was applied to all study groups were included. On study duration, trials on blood pressure with a minimum duration of 4 weeks and trials on CVD outcomes with a minimum duration of 6 months were eligible. Trials on BMD or risk of osteoporotic fractures in adults had to last at least 1 year.

On subject characteristics, eligible studies involved adults (≥ 18 years) and children (6 months to \< 18 years) from the general population. Trials including diseased individuals, individuals on a therapeutic diet (including weight loss diet), hypertensive subjects on blood pressure‐lowering medications, trials in pregnant women and trials with specialised exercise (e.g. athletes, militaries) and extreme environmental conditions (e.g. prolonged exposure to unusually high temperature) were excluded. Observational studies that did not explicitly exclude prevalent (i.e. pre‐existing) cases of the outcome of interest at baseline were excluded.

Studies were eligible if sodium intake was assessed based on urinary sodium excretion calculated from single or multiple 24‐h urine collection(s). Other types of sodium intake measurements were excluded.

The literature searches were conducted in three electronic bibliographic databases (Cochrane library, Embase, PubMed) and two resources indexing PhD theses (DART, PQDT Open) in February 2018, and updated in October 2018. Search strings are described in the protocol (Annex [A](#efs25778-sec-2001){ref-type="sec"}). Two separate searches were performed to address subquestions 1 and 2 (Appendix [G.1](#efs25778-sec-0094){ref-type="sec"}) and subquestions 3--5 (Appendix [G.2](#efs25778-sec-0098){ref-type="sec"}). Two independent reviewers screened the literature identified through the searches.

In relation to subquestions 1 and 2 (blood pressure, hypertension and CVD outcomes), 7,141 unique references were identified after removing duplicates (see PRISMA Chart, Appendix [G.1.1](#efs25778-sec-0095){ref-type="sec"}). The title and abstract screening left 402 relevant articles that underwent a full‐text review. Of those, 357 were excluded (Appendix [G.1.2](#efs25778-sec-0096){ref-type="sec"}). A total of 45 publications reporting on 36 RCTs and 9 prospective observational studies were included. Screening of the reference lists of these publications (877 references) did not yield additional eligible studies. Also, no additional eligible studies were identified among the studies included in similar systematic reviews (Appendix [G.1.3](#efs25778-sec-0097){ref-type="sec"}).

In relation to subquestions 3--5 (bone health), 1,732 unique references were identified after removing duplicates (see PRISMA Chart, Appendix [G.2.1](#efs25778-sec-0099){ref-type="sec"}). The title and abstract screening identified 40 articles that underwent a full‐text review. In total, 38 articles were excluded (Appendix [G.2.2](#efs25778-sec-0100){ref-type="sec"}). A final two articles were included (Devine et al., [1995](#efs25778-bib-0070){ref-type="ref"}; Ilich et al., [2010](#efs25778-bib-0141){ref-type="ref"}). No additional eligible study was found from the reference lists of the two eligible articles or from the list of articles included in a systematic review with a similar research question identified through the search (Appendix [G.2.3](#efs25778-sec-0101){ref-type="sec"}).

Risk of bias (RoB) in eligible studies was appraised using tailored versions of the OHAT‐NTP RoB tool (OHAT/NTP, [2015](#efs25778-bib-0232){ref-type="ref"}) and studies were classified as being at low (tier 1), moderate (tier 2) or high (tier 3) RoB (Appendix [G.3](#efs25778-sec-0102){ref-type="sec"}).

### 5.5.1. Blood pressure and hypertension {#efs25778-sec-0054}

#### 5.5.1.1. Office blood pressure in children {#efs25778-sec-0055}

The characteristics of eligible studies and the outcome of the RoB appraisal are presented in Appendices [H.1](#efs25778-sec-0106){ref-type="sec"} and [H.2](#efs25778-sec-0107){ref-type="sec"}, respectively.

##### Experimental studies {#efs25778-sec-0056}

Two RCTs met the eligibility criteria described in the review protocol (Miller et al., [1988](#efs25778-bib-0212){ref-type="ref"}; He et al., [2015](#efs25778-bib-0130){ref-type="ref"}).

In a 12‐week trial in the UK, school‐age identical pairs of twins and their families received instructions to restrict their sodium intake (Miller et al., [1988](#efs25778-bib-0212){ref-type="ref"}). During the middle 4‐week period, one member of each twin pair, chosen at random, received a daily NaCl supplement designed to return sodium intake to baseline levels. In total, 88 twins completed the study. During the supplement period, higher UNa was observed in the sodium‐supplemented group (72.1 mmol/24 h) compared with the control group (44.4 mmol/24 h), while there were no between‐group differences in SBP (mean (SEM) 0.3 (0.6) mm Hg) and DBP (−0.2 (0.7) mm Hg). Overall, this study was judged to be at low RoB (tier 1).

In a cluster‐randomised controlled study, 28 primary schools in China were randomly assigned to an intervention consisting of a 'low‐salt' education programme for 3.5 months (n = 141 children, mean (SD) age: 10.2 (0.5) years) or to their usual nutrition education programme with no particular reference to sodium chloride intake (n = 138 children, 10.0 (0.5) years) (He et al., [2015](#efs25778-bib-0130){ref-type="ref"}). Baseline mean (SE) UNa were 116.7 (5.2) mmol/day and 124.2 (5.1) mmol/day in the control and intervention group, respectively. A reduction in UNa was observed in the intervention group (−12.1 (95% CI −19.9, −4.2) mmol/24 h), whereas sodium excretion increased in the control group (+20.5 (12.6, 28.4) mmol/24 h). The adjusted difference between the two groups in the change of sodium excretion was −33.3 (−44.2, −22.3) mmol/24 h (p \< 0.001). In both groups, SBP and DBP increased between baseline and the end of intervention. The adjusted difference between the two groups in the blood pressure change from baseline (intervention vs control) was −0.8 (−3.0, 1.5) mm Hg for SBP (p = 0.51) and −1.2 (−3.7, 1.2) mm Hg for DBP (p = 0.33). This study was judged to be at moderate RoB (tier 2), in particular due to a potential RoB in relation to the outcome assessment (unblinded outcome assessors).

##### Observational studies {#efs25778-sec-0057}

Two publications from the DONALD prospective cohort study met the eligibility criteria set out in the review protocol (Shi et al., [2014](#efs25778-bib-0276){ref-type="ref"}; Krupp et al., [2015](#efs25778-bib-0173){ref-type="ref"}). DONALD is an open cohort study implemented in Germany since 1985. Examinations are conducted at ages 3, 6, 9, 12, 18 and 24 months and then annually until young adulthood and comprise anthropometry, a 3‐day weighed dietary record, a 24‐h urine sample (from age 3--4 years onwards), medical examinations and parental interviews.

Shi et al. ([2014](#efs25778-bib-0276){ref-type="ref"}) analysed data from 435 healthy participants, for whom at least three repeated measurements of blood pressure had been taken and who had provided three parallel 24‐h urine samples. The median age was 6 years at baseline and 16 years during the last assessment. In boys, the median (25--75th percentile) UNa was 67.4 (50.6--89.9) mmol/day and 131 (96.9--176) mmol/day during the first and last assessment, respectively. Corresponding values in girls were 58.7 (45.9--74.5) mmol/day and 108 (81.7--133) mmol/day. In the prepubertal stage, no association between changes in UNa and SBP or DBP was observed. In the pubertal stage, the association (β (95% CI)) between intraindividual changes in UNa and blood pressure was 0.1 (−0.004, 0.2) mm Hg for SBP (p = 0.06) and 0.1 (−0.02, 0.2) mm Hg for DBP (p = 0.09) by 1 mmol/MJ per day increase in UNa. When analysing differences in UNa and mean blood pressure between the subjects, the associations were 0.1 (−0.1, 0.4) mm Hg for SBP (p = 0.3) and 0.2 (−0.4, 0.04) mm Hg for DBP (p = 0.1). This study was judged to be at low RoB (tier 1).

Among the DONALD participants who had already reached adult age, Krupp et al. ([2015](#efs25778-bib-0173){ref-type="ref"}) selected 206 participants who had three repeated urinary, dietary and blood pressure measurements during adolescence (11--16 years) and one blood pressure measurement in young adulthood (18--25 years). The estimated mean (SD) sodium chloride excretion was 116 (27) and 105 (32) mmol/day in boys and girls, respectively. In multivariable linear regression models, there was a positive association between UNa (per 1 mmol/day increase) and adult SBP in boys (β (95% CI) = 0.10 (0.03, 0.18), p = 0.01) but not in girls (−0.05 (−0.11, 0.02), p = 0.1). No association was found between UNa during adolescence and adult DBP (boys: 0.02 (−0.08, 0.04), p = 0.6; girls: 0.02 (−0.03, 0.08), p = 0.4). This study was judged to be at low RoB (tier 1).

##### Conclusion {#efs25778-sec-0058}

The Panel notes that two RCTs (tiers 1 and 2) did not provide evidence for an effect of sodium reduction on blood pressure in school‐age children. The observational study (tier 1) showed no significant association between UNa and blood pressure in pre‐pubertal and pubertal children and provided weak evidence for a positive association between UNa during adolescence and SBP in adulthood.

#### 5.5.1.2. Office blood pressure in adults {#efs25778-sec-0059}

The characteristics of eligible studies and the outcome of the RoB appraisal are presented in Appendices [H.1](#efs25778-sec-0108){ref-type="sec"} and [H.2](#efs25778-sec-0111){ref-type="sec"}, respectively.

##### Experimental evidence {#efs25778-sec-0060}

In line with the protocol (Annex [A](#efs25778-sec-2001){ref-type="sec"}), eligible RCTs were used to conduct quantitative analyses with the aim to characterise the dose--response relationship between sodium intake and blood pressure. The analysis report is provided in Annex [B](#efs25778-sec-2002){ref-type="sec"}. The main results are outlined below and Appendices [I.3](#efs25778-sec-0114){ref-type="sec"} and [I.4](#efs25778-sec-0115){ref-type="sec"}.

In total, 32 RCTs, providing 35 comparisons, met the eligibility criteria. Seven were parallel RCTs, including one cluster‐randomised trial and 25 were crossover RCTs. In total, 25 trials modified sodium intake by providing subjects with NaCl or placebo tablets or a controlled diet with various amounts of Na ('feeding trials'), while seven trials used sodium reduction counselling ('counselling trials'). The between‐group differences in mean UNa ranged from 13.3 to 285 mmol/day, with a median mean value of 72 mmol/day. The study size ranged from 11 to 1,159 participants and the duration of the intervention lasted from 4 weeks to 36 months. In total, 17 studies involved hypertensive individuals, eight studies involved normotensive individuals and seven studies involved mixed populations. In total, 27 studies were classified in tier 1 and five studies in tier 2.

Meta‐analyses at study level

The results of the random‐effects meta‐analyses of trials of effects of sodium reduction on blood pressure are presented in Appendix [I.3](#efs25778-sec-0114){ref-type="sec"} and Annex [B](#efs25778-sec-2002){ref-type="sec"}.

A random‐effects meta‐analysis of the 32 eligible RCTs showed significant effects of sodium reduction on SBP (−3.9 (95% CI −5.1, −2.8) mm Hg; I^2^ 61.9%, p \< 0.001) and DBP (−2.0 (−2.8, −1.2) mm Hg; I^2^ 60.6%, p \< 0.001) (Figures [I.1](#efs25778-fig-0004){ref-type="fig"} and [I.5](#efs25778-fig-0008){ref-type="fig"}).

Contextual sources of heterogeneity were explored in subgroup analyses. A larger effect was found in hypertensive than normotensive individuals, for both SBP (hypertensive: −5.6 (−8.1, −3.1) mm Hg vs normotensive: −2.0 (−3.3, −0.7) mm Hg) and DBP (hypertensive: −2.9 (−4.2, −1.6) mm Hg vs normotensive: −0.9 (−1.6, −0.2) mm Hg) (Figures [I.2](#efs25778-fig-0005){ref-type="fig"} and [I.6](#efs25778-fig-0009){ref-type="fig"}). The effect of reduction in sodium intake was higher among subjects aged 50 years or more (SBP −6.1 (−8.2, −4.1) mm Hg; DBP −2.9 (−4.0, −1.9) mm Hg) than among subjects younger than 50 years (SBP −2.2 (−3.3, −1.1) mm Hg; DBP −1.0 (−2.0, 0.0) (Figures [I.3](#efs25778-fig-0006){ref-type="fig"} and [I.7](#efs25778-fig-0010){ref-type="fig"}). With respect to sex, a higher effect was found in studies which consisted mostly of men (i.e. \> 55% of total sample) than in studies which consisted mostly of women. The exploration of the potential moderating effects of ethnicity, BMI or potassium intake was limited by the small number of studies for which information on these factors was available (Tables [I.1](#efs25778-tbl-0015){ref-type="table"} and [I.2](#efs25778-tbl-0016){ref-type="table"} in Appendix [I.3](#efs25778-sec-0114){ref-type="sec"}).

On the identified methodological sources of heterogeneity, larger effects were found in crossover compared with parallel trials, when measuring blood pressure in supine position compared with sitting position, (Tables [I.1](#efs25778-tbl-0015){ref-type="table"} and [I.2](#efs25778-tbl-0016){ref-type="table"}). The effect of sodium reduction was smaller in trials of longer duration (≥ 1 year) compared with trials of shorter duration (4 weeks) (Figures [I.4](#efs25778-fig-0007){ref-type="fig"} and [I.8](#efs25778-fig-0011){ref-type="fig"}). After exclusion of the van Berge‐Landry and James ([2004](#efs25778-bib-0306){ref-type="ref"}) study as an outlier, the effect of sodium reduction on SBP was −1.8 (−2.9, −0.8) mm Hg in 'counselling' trials and −4.0 (−5.3, −2.7) mm Hg in 'feeding' trials. The respective values for DBP were −1.7 (−2.6, −0.9) mm Hg and −1.8 (−3.2, −0.5) mm Hg.

Meta‐analyses, meta‐regression and dose--response modelling at arm level

The results of the mixed‐effects meta‐regression models of the relationship between 24‐h urinary sodium excretion and absolute blood pressure levels are presented in Appendix [I.4](#efs25778-sec-0115){ref-type="sec"} and Annex [B](#efs25778-sec-2002){ref-type="sec"}.

To investigate the dose--response association between mean absolute values of 24‐h urinary sodium excretion and mean absolute values of blood pressure, all arms (68) from the eligible RCTs (32) were subjected to meta‐analysis assuming a random‐effects model.

The pooled mean estimate across arms was 137.1 (134.2--140.1) mm Hg for SBP and 84.0 (82.0--85.9) mm Hg for DBP; subgroup analyses were repeated at the arm level applying the same *a priori* categorisations of relevant potential modifiers to identify candidate moderators to be included in the multivariable models, producing comparable results to those from the meta‐analyses at study level.

In total, 60 points (arms as unit of analysis) from 28 RCTs were included in the final dose--response models. Two RCTs were excluded from the meta‐analysis pool because of missing information on age (Puska et al., [1983](#efs25778-bib-0252){ref-type="ref"}; Richards et al., [1984](#efs25778-bib-0257){ref-type="ref"}). One (Alli et al., [1992](#efs25778-bib-0011){ref-type="ref"}) was excluded after thorough consideration of some inconsistencies in the design and results of the study. Van Berge‐Landry and James ([2004](#efs25778-bib-0306){ref-type="ref"}) were selected only for sensitivity analysis, given the fact that it was the only study with UNa values in the control and intervention arms well beyond the range covered by all other trials (achieved urinary excretion: 309 and 24 mmol/day at the end of the 'high' and 'low' sodium interventions, respectively). Two arms were included from all trials except for MacGregor et al. ([1989](#efs25778-bib-0200){ref-type="ref"}) (three arms), Sacks et al. ([2001](#efs25778-bib-0260){ref-type="ref"}) (three arms) and Watt et al. ([1985](#efs25778-bib-0312){ref-type="ref"}) (four arms). After the exclusion of the eight arms, 14 were from parallel RCTs, 46 were from crossover RCTs and none from cluster‐randomised trials.

Fifty‐two arms were from 'feeding trials' and eight arms from 'counselling trials'. Mean 24‐h sodium excretion, once van Berge‐Landry was excluded, ranged from 49.0 to 202.9 mmol/day, with a median of 126.7 mmol/day. The arm size ranged from 10 to 515 participants, who were hypertensive in 33 out of the 60 arms.

Mixed‐effects meta‐regression models were fitted to account for the multilevel structure in the data, with arms nested within studies; two random effects (intercepts) on arm and study were specified and five fixed effects were included from the list of potential moderators tested in univariate meta‐regressions.

Different functional forms were explored for the shape of the dose--response relationship; non‐linearities as tested by fitting restricted cubic and linear splines were not statistically significant once both random effects were specified in the models.

The final set of moderators included in both SBP and DBP models was: age at baseline (\< 40 years old (reference), 40--49, 50--59, ≥ 60 years old); blood pressure status at baseline (normotensive (reference) hypertensive); blood pressure measurement method (supine (reference), sitting); mean urinary sodium excretion at baseline (\< 100 mmol/day (reference), 100--149, ≥ 150 mmol/day); and specific trial design (no run‐in (reference), run‐in normal diet, run‐in low‐sodium diet) (Tables [I.3](#efs25778-tbl-0017){ref-type="table"} and [I.4](#efs25778-tbl-0018){ref-type="table"} in Appendix [I.4](#efs25778-sec-0115){ref-type="sec"}).

Other variables, including potassium intake, BMI and ethnicity, did not explain a significant proportion of heterogeneity in a consistent manner in both SBP and DBP analyses and/or suffered from a high proportion of missing data, so they were not retained in the final models.

For each 100 mmol (2.3 g)/24‐h increase in mean UNa, holding all other covariates constant, mean SBP increased by 5.3 mm Hg (95% CI: 3.6--6.9 mm Hg) and mean DBP increased by 2.6 mm Hg (95% CI: 1.6--3.7 mm Hg) (Figures [I.9](#efs25778-fig-0012){ref-type="fig"} and [I.10](#efs25778-fig-0013){ref-type="fig"} in Appendix [I.4](#efs25778-sec-0115){ref-type="sec"}). Similar effects were estimated in crude models (with no other covariates than mean sodium excretion).

Mean sodium excretion explained only 4% of the heterogeneity across trials in the SBP model and 3% in the DBP model. However, in both models the set of moderators explained more than 85% of the between‐study heterogeneity.

Moderating effects of age and hypertensive status were explored in stratified analyses. A larger association was found in hypertensive than normotensive individuals, for both SBP (hypertensive: 6.4 (4.3, 8.6) mm Hg vs normotensive: 4.4 (2.1, 6.6) mm Hg) and DBP (hypertensive: 3.7 (2.5, 5.0) mm Hg vs normotensive: 1.7 (0.1, 3.3) mm Hg) (Annex [B](#efs25778-sec-2002){ref-type="sec"}). The effect of sodium was higher among subjects aged 50 years or more (SBP 7.1 (5.0, 9.2) mm Hg; DBP 3.8 (2.6, 5.0) mm Hg) than among subjects younger than 50 years (SBP 3.5 (1.5, 7.4) mm Hg; DBP 1.2 (−0.4, 2.9) (Annex [B](#efs25778-sec-2002){ref-type="sec"}).

Limitations of the models

Sources of uncertainty specific to the statistical analysis and their potential impact on the final estimates, where possible, were identified and described (see Annex [B](#efs25778-sec-2002){ref-type="sec"}).

Using arms' absolute values generated in controlled settings was expected to allow a better characterisation of the dose--response relationship between sodium intake and blood pressure levels than using data from observational studies (potential confounding). Still, relationships described via meta‐regression are observational in nature as they do not have the benefit of randomisation to support a causal interpretation (Thompson and Higgins, [2002](#efs25778-bib-0298){ref-type="ref"}). The models are representations of the relationship between mean UNa and mean SBP or DBP at 'group' level (potential aggregation bias). Also, some potential moderators could not be explored (e.g. BMI, ethnicity, potassium intake and energy intake[13](#efs25778-note-1018){ref-type="fn"}) due to missing information.

Given the influence of the design of the trials on data structure and incompleteness of information there was a strong 'methodological' component (covariates that are linked to the experimental setting) specified in the models to reach a good fitting and contributing to explain a large part of the heterogeneity between studies (random effects). This added challenges on the interpretation of the models. Constants (intercepts) and predictions were substantially influenced by experimental factors and were difficult to reconcile with 'populations' values. So, the model cannot be used to make predictions at population level, but it provides evidence for a positive linear relationship between mean sodium excretion and mean levels of SBP and DBP.

##### Observational studies {#efs25778-sec-0061}

One prospective cohort study met the inclusion criteria (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}). The analysis combined data from 1,499 participants aged ≥ 20 years from Belgium, the Czech Republic, Italy, Poland and the Russian Federation of the European EPOGH and FLEMENGHO cohorts, without antihypertensive treatment and CVD history at baseline. During a follow‐up of 6.1 years, a 100 mmol increase in sodium excretion was associated with a 1.71 mm Hg (95% CI 0.79, 2.64) increase in SBP. The value for DBP was 0.38 mm Hg (95% CI --0.31, 1.07). This study was judged to be at moderate RoB (tier 2), in particular due to the lack of adjustment for significant confounders (energy intake, smoking and physical activity), potential misclassification of participants in the lowest category of sodium excretion related to the apparent undercollection of urine samples compared with the other categories (i.e. lower urinary volume and creatinine excretion) and substantial attrition during follow‐up.

##### Conclusion {#efs25778-sec-0062}

Based on data from RCTs, the Panel considers that there is strong evidence for a positive relationship between UNa and SBP and DBP over the range of mean UNa observed in the studies (between 49 and 209 mmol/24 h (1.3 to 4.8 g/day)). One eligible prospective observational study (tier 2) investigating the long‐term relationship between UNa and blood pressure levels supports such relationship.

#### 5.5.1.3. Hypertension {#efs25778-sec-0063}

The characteristics of eligible studies, the outcome of the RoB appraisal and descriptive forest plots are presented in Appendices [J.1](#efs25778-sec-0116){ref-type="sec"}, [J.2](#efs25778-sec-0119){ref-type="sec"} and [J.3](#efs25778-sec-0122){ref-type="sec"}, respectively.

##### Experimental studies {#efs25778-sec-0064}

Two RCTs assessed the effect of sodium reduction on the incidence of hypertension, namely the Trials of Hypertension Prevention (TOPH), phases I and II (The Trials of Hypertension Collaborative Research Group, [1997](#efs25778-bib-0297){ref-type="ref"}; Whelton et al., [1997](#efs25778-bib-0317){ref-type="ref"}). Both trials were conducted in the USA and involved individuals aged 35 to 54 years with 'high‐normal' blood pressure at baseline (DBP of 80--89 mm Hg in TOPH I; DBP of 83--89 mm Hg and SBP \< 140 mm Hg in TOPH II), not taking antihypertensive treatment. TOPH II selected overweight individuals (BMI 110--165% of desirable body weight). Participants were randomised to a dietary sodium reduction counselling programme or a usual care group. TOPH I lasted 18 months, while TOPH II lasted 36--48 months. The incidence of hypertension in the intervention group vs control group during follow‐up was compared. In TOPH I, baseline mean (SD) UNa was 154.6 (77.9) and 156.4 (60.5) mmol in the sodium reduction group (n = 326) and usual care group (n = 417), respectively, while values were 186.1 (80.7) mmol and 188.0 (80.9) mmol/day in the sodium reduction group (n = 581) and usual care group (n = 576) in TOPH II.

In TOPH I (Whelton et al., [1997](#efs25778-bib-0317){ref-type="ref"}), UNa decreased to 99.4 (60.0) mmol/day in the intervention group compared with 146.5 (79.2) mmol/day in the control group after 18 months, corresponding to a net (between groups) difference of 47.2 mmol (p \< 0.0001). During follow‐up, the incidence of hypertension was 8.6% in the sodium reduction group compared with 11.3% in the usual care group (RR (95% CI) = 0.76 (0.49, 1.18)). This study was judged to be at low RoB (tier 1).

In TOPH II (The Trials of Hypertension Collaborative Research Group, [1997](#efs25778-bib-0297){ref-type="ref"}), the estimated net reduction in UNa was 40 mmol/day (p \< 0.001) after 36 months. Through 48 months, the incidence of hypertension was 38.1% in the intervention group compared with 44.4% in the usual care group (RR = 0.82, p = 0.05). This study was judged to be at low RoB (tier 1).

##### Observational studies {#efs25778-sec-0065}

Two prospective cohort studies assessed the association between UNa and the incidence of hypertension (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}; Forman et al., [2012](#efs25778-bib-0109){ref-type="ref"}). The EPOGH/FLEMENGHO 'hypertension cohort' followed up individuals aged ≥ 20 years from Belgium, the Czech Republic, Italy, Poland and the Russian Federation (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}). The PREVEND cohort investigated the natural course of albuminuria and its relationship with renal and cardiovascular diseases in Dutch subjects aged 25--75 years and was characterised by an oversampling of participants with elevated albumin excretion at baseline (\> 10 mg/L) (Forman et al., [2012](#efs25778-bib-0109){ref-type="ref"}). At baseline, mean (SD) 24‐h sodium excretion was 174.2 (74.1) mmol in the EPOGH/FLEMENGHO cohort, while median (interquartile range (IQR)) sodium excretion was 137 (106--171) mmol/day in the PREVEND cohort.

In the PREVEND cohort (Forman et al., [2012](#efs25778-bib-0109){ref-type="ref"}), hazard ratio (HR) (95% CI) for incident hypertension was 1.05 (1.00--1.10) for each 43 mmol (1 g) higher UNa (5,556 men and women; 878 cases; median follow‐up 6.4 years). The HR was 1.21 (0.98--1.51) comparing the highest (median (IQR) UNa: 271 (242--316) mmol) to the lowest quartile (97 (79--110) mmol) of UNa. The association of UNa with incident hypertension was modified by serum uric acid (SUA) and albumin urine excretion (UAlbumin). The adjusted HRs were 0.98 (0.89--1.08), 1.05 (0.96--1.15) and 1.09 (1.02--1.16) per each 1 g (43 mmol) increase in UNa in the lowest, middle and highest tertiles of SUA, respectively. Corresponding HRs were 0.99 (0.93--1.06), 1.02 (0.92--1.12) and 1.18 (1.07--1.29) per each 1 g (43 mmol) increase in UNa among those with UAlbumin \< 10 mg/day, between 10 and 15 mg/day, and \> 15 mg/day, respectively. This study was judged to be at low RoB (tier 1).

In the EPOGH/FLEMENGHO cohort (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}) HRs (95% CI) for the incidence of hypertension were 1.00 (0.87--1.16), 1.02 (0.89--1.16) and 0.98 (0.86--1.12) in the low (mean (SD) UNa: women 94.4 (21.5) mmol; men 121.3 (27.9) mmol), medium (women 147.4 (14.3) mmol; 185.3 (16.1) mmol) and high (women 222.1 (47.2) mmol; men 282.2 (56.4) mmol) sex‐specific tertiles of sodium excretion, respectively, compared with the whole population (2,096 men and women; 552 events; median follow‐up 6.5 years). This study was judged to be at moderate RoB (tier 2), in particular due to the overadjustment for SBP, potential misclassification of participants in the lowest category of sodium excretion related to the apparent undercollection of urine samples compared with the other categories (i.e. lower urinary volume and creatinine excretion) and substantial attrition during follow‐up.

##### Conclusion {#efs25778-sec-0066}

A small number of studies, two RCTs (tier 1) and two prospective observational studies (tiers 1 and 2) investigating the relationship between UNa and risk of hypertension were eligible for the assessment. Overall, the Panel considers that these studies support a positive relationship between UNa and blood pressure.

### 5.5.2. Cardiovascular disease {#efs25778-sec-0067}

Six publications, pertaining to five different cohort studies, were eligible (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}; Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}; Cook et al., [2014](#efs25778-bib-0060){ref-type="ref"}; Joosten et al., [2014](#efs25778-bib-0153){ref-type="ref"}; Kieneker et al., [2018](#efs25778-bib-0163){ref-type="ref"}; Lelli et al., [2018](#efs25778-bib-0185){ref-type="ref"}). Three cohorts were based on random samples of adult populations: (i) the EPOGH/FLEMENGHO 'outcome cohort' involved individuals aged ≥ 20 years from Belgium, the Czech Republic, Italy, Poland and the Russian Federation (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}); (ii) the 'Finnish cohort' involved individuals aged 25--64 years (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}); and (iii) the InCHIANTI cohort involved individuals aged ≥ 65 years in Italy (Lelli et al., [2018](#efs25778-bib-0185){ref-type="ref"}). Another cohort was constituted of the control groups of the TOPH I and TOPH II sodium reduction trials that involved United States individuals aged 30--54 years with 'high‐normal' blood pressure at baseline (post‐trials follow‐up) (Cook et al., [2014](#efs25778-bib-0060){ref-type="ref"}). Finally, the PREVEND cohort involved subjects aged 25--75 years and was characterised by an oversampling of participants with elevated albumin excretion at baseline (\> 10 mg/L) (Joosten et al., [2014](#efs25778-bib-0153){ref-type="ref"}; Kieneker et al., [2018](#efs25778-bib-0163){ref-type="ref"}).

These publications addressed the association between sodium intake and risk of stroke (three papers), risk of CHD (three papers) and risk of total CVD (three papers) (Table [8](#efs25778-tbl-0008){ref-type="table"}). As per the protocol eligibility criteria, only analyses that excluded prevalent cases at baseline were considered. Two publications reported HRs for sodium excretion expressed as a continuous variable, one publication reported HRs by categories of sodium excretion, and three publications reported both. One publication used the whole study population as reference group to calculate HR in each sodium excretion category, which hindered its inclusion in pooled analyses. Because of the small number of eligible studies available for pooling for each outcome type, meta‐analyses were not conducted.

The study characteristics, the outcome of the RoB appraisal and descriptive forest plots, are presented in Appendices [K.1](#efs25778-sec-0123){ref-type="sec"}, [K.2](#efs25778-sec-0124){ref-type="sec"} and [K.3](#efs25778-sec-0126){ref-type="sec"}.

In relation to sodium exposure measurement, multiple 24‐h urine samples were collected in the PREVEND and TOPH cohorts, while single 24‐h urine collections were available in the other three cohorts. In four publications, quality measures have been applied to deal with inaccurate urine collections. Two papers excluded samples deemed to be incomplete from their analyses *a priori* (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}), based on sex‐specific creatinine cut‐offs and urine volume; (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}), based on self‐reporting); two papers excluded samples in sensitivity analyses (Cook et al., [2014](#efs25778-bib-0060){ref-type="ref"}), based on intraindividual variability in creatinine/body weight ratio; (Joosten et al., [2014](#efs25778-bib-0153){ref-type="ref"}) based on estimated urine volume vs actual).

The overall RoB was judged to be low for four publications (tier 1), and moderate for three publications (tier 2). For the three papers for which the overall RoB was judged moderate (tier 2), the main concerns related to: (i) overadjustment for blood pressure (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}; Lelli et al., [2018](#efs25778-bib-0185){ref-type="ref"}); (ii) potential for reverse causality due to the inclusion of hypertensive subjects in the sample (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}; Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}; Lelli et al., [2018](#efs25778-bib-0185){ref-type="ref"}); (iii) potential misclassification of participants in the lowest category of sodium intake related to the apparent undercollection of urine samples compared with the other categories (i.e. lower creatinine excretion relative to body weight) (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}); and (iv) higher attrition rate in the highest category of sodium intake compared with the other categories (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}).

At baseline, median (IQR) UNa was 137 (106--171) mmol (min--max: 50--315 mmol) in the PREVEND cohort, 205 mmol in men (IQR Not Reported (NR); min--max: 25--552) and 154 mmol in women (IQR NR; min--max: 12 to 512 mmol) in the Finnish cohort, 236 (160--306) mmol in the InCHIANTI cohort, and 158 (127--194) mmol in the TOPHI/II cohort (min--max: NR). The mean (SD) UNa was 178.0 (74.8) mmol (min--max: 50--400 mmol) in the EPOGH/FLEMENGHO cohort.

###### 

Outcomes and references of prospective cohort studies on CVD

+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+
| Outcome type        | No. publications | References (cohort name)                                                               |                                                                                        |
+=====================+==================+========================================================================================+========================================================================================+
| Stroke              | Non‐fatal        | 1                                                                                      | Tuomilehto et al. ([2001](#efs25778-bib-0302){ref-type="ref"}) (Finnish cohort)        |
+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+
| Fatal and non‐fatal | 2                | Stolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"}) (EPOGH/FLEMENGHO) |                                                                                        |
|                     |                  |                                                                                        |                                                                                        |
|                     |                  | Kieneker et al. ([2018](#efs25778-bib-0163){ref-type="ref"}) (PREVEND)                 |                                                                                        |
+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+
| CHD                 | Non‐fatal        | 1                                                                                      | Tuomilehto et al. ([2001](#efs25778-bib-0302){ref-type="ref"}) (Finnish cohort)        |
+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+
| Fatal and non‐fatal | 2                | Stolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"}) (EPOGH/FLEMENGHO) |                                                                                        |
|                     |                  |                                                                                        |                                                                                        |
|                     |                  | Joosten et al. ([2014](#efs25778-bib-0153){ref-type="ref"}) (PREVEND)                  |                                                                                        |
+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+
| CVD (total)         | Fatal            | 1                                                                                      | Stolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"}) (EPOGH/FLEMENGHO) |
+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+
| Non‐fatal           | 1                | Lelli et al. ([2018](#efs25778-bib-0185){ref-type="ref"}) (InCHIANTI)                  |                                                                                        |
+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+
| Fatal and non‐fatal | 2                | Cook et al. ([2014](#efs25778-bib-0060){ref-type="ref"}) (TOPH I/TOPH II)              |                                                                                        |
|                     |                  |                                                                                        |                                                                                        |
|                     |                  | Stolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"}) (EPOGH/FLEMENGHO) |                                                                                        |
+---------------------+------------------+----------------------------------------------------------------------------------------+----------------------------------------------------------------------------------------+

CHD: coronary heart disease; CVD: cardiovascular disease; EPOGH/FLEMENGHO: European Project on Genes in Hypertension/Flemish Study on Genes and Health Outcomes; InCHIANTI: Invecchiare in Chianti; PREVEND: Prevention of Renal and Vascular End‐stage Disease; TOPH: Trials of Hypertension Prevention

John Wiley & Sons, Ltd

#### 5.5.2.1. Stroke {#efs25778-sec-0068}

In the PREVEND cohort (7,330 men and women), 183 fatal and non‐fatal stroke events occurred during a median follow‐up of 12.5 years (Kieneker et al., [2018](#efs25778-bib-0163){ref-type="ref"}). The HR (95% CI) was 1.44 (1.14--1.82) per 51 mmol/24 h decrement in UNa. By sex‐specific quintiles of UNa, HRs were 1.45 (0.92--2.29) (57 cases, 16,272 person‐years) in Q1, 1.13 (0.71--1.79) (49 cases, 16,515 person‐years) in Q2, 1.04 (0.64--1.71) (25 cases, 16,720 person‐years) in Q4 and 0.81 (0.46--1.41) in Q5 (19 cases, 16,908 person‐years), with Q3 taken as the reference category (33 cases, 16,774 person‐years). Similar HRs for the risk of fatal and non‐fatal stroke were estimated after adjustment for potential mediators, i.e. SBP and antihypertensive medication (1.44 (1.14--1.82)), plasma renin (1.50 (1.18--1.90)), aldosterone (1.54 (1.21--1.97)), and sodium levels (1.49 (1.17--1.90)), respectively. In sensitivity analyses, the association did not change after exclusion of individuals who were taking antihypertensive drugs at baseline (6,388 subjects (126 events)) and those with malignancies, type 2 diabetes, or chronic kidney disease at baseline (6,054 subjects (112 events)). In a weighted analysis, that accounted for the sampling design of the study, the HR was 1.68 (1.12--2.50) per 51 mmol/24 h decrement in UNa. This study was judged to be at low RoB (tier 1).

In the Finnish cohort (2,420 men and women), 84 non‐fatal stroke events occurred during 8 to 13 years follow‐up (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}). The HR (95% CI) was 1.13 (0.84--1.51) per 100 mmol/24 h increase in UNa. This study was judged to be at moderate RoB (tier 2).

In the EPOGH/FLEMENGHO cohort (3,681 men and women), 33 fatal and non‐fatal stroke events occurred during a median follow‐up of 7.9 years (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}). The HRs (95% CI) were 1.05 (0.56--1.96) (13 events), 1.28 (0.75--2.17) (13 events) and 0.78 (0.46--1.33) (7 events) in the low, medium and high sex‐specific tertiles of UNa, respectively, compared with the overall risk in the entire cohort. This study was judged to be at moderate RoB (tier 2).

#### 5.5.2.2. Coronary heart disease {#efs25778-sec-0069}

In the PREVEND cohort (7,543 men and women), 452 fatal and non‐fatal CHD events occurred during a median follow‐up of 10.5 years (Joosten et al., [2014](#efs25778-bib-0153){ref-type="ref"}). The HR was 1.07 (0.98--1.18) for each 1 g/day (43 mmol/24 h) increment in UNa. In stratified analysis, each 1 g/day increment in UNa was associated with an increased risk for CHD in subjects with hypertension (1.14 (1.01--1.28); n = 2,363) and in subjects with plasma N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) concentrations above the sex‐specific median (1.16 (1.03--1.30); 320 events; n = 3,771). This study was judged to be at low RoB (tier 1).

In the Finnish cohort (2,402 men and women), 128 non‐fatal CHD events occurred during 8 to 13 years follow‐up (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}). The HR (95% CI) was 1.34 (1.08--1.67) per 100 mmol/24 h increase in UNa. This study was judged to be at moderate RoB (tier 2).

In the EPOGH/FLEMENGHO cohort (3,681 men and women), 98 fatal and non‐fatal CHD events occurred during a median follow‐up of 7.9 years (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}). HRs (95% CI) were 1.41 (0.99--2.01) (45 events), 1.15 (0.87--1.52) (34 events) and 0.87 (0.66--1.15) (19 events) in the low, medium and high sex‐specific tertiles of UNa, respectively, compared with the overall risk in the entire cohort. This study was judged to be at moderate RoB (tier 2).

#### 5.5.2.3. Cardiovascular disease (composite outcome) {#efs25778-sec-0070}

In a 10--15 years post‐trial follow‐up, the association between UNa and risk of fatal and non‐fatal CVD events was assessed among subjects who had not been assigned to an active sodium reduction intervention group in the TOPH I and TOPH II trials (Cook et al., [2014](#efs25778-bib-0060){ref-type="ref"}). In total, 193 events occurred (68 myocardial infarctions, 77 coronary revascularisations, 22 strokes (1 participant reported both myocardial infarction and stroke), and 27 CVD deaths). Four categories of UNa were defined as follows: \< 100 mmol (\< 2.3 g), 100 to \< 157 mmol (2.3 to \< 3.6 g), 157 to \< 209 mmol (3.6 to \< 4.8 g) (reference category), and ≥ 209 mmol (≥ 4.8 g) sodium/24 h. HRs were 0.68 (0.34--1.37; 15 events/189 total) and 0.75 (0.50--1.11; 48/590) for the two lowest categories compared with the reference category (40/427), while it was 1.05 (0.68--1.62; 23/191) for the highest category compared with the reference category (p for trend = 0.13). There was a linear 17% increase in risk per 43 mmol (1 g)/24 h increase in UNa (p = 0.054). Spline curves supported a linear association of UNa with CVD events (p value for linearity = 0.044; p value for nonlinearity = 0.76). This study was judged to be at low RoB (tier 1).

In the InCHIANTI cohort (514 men and women), 169 non‐fatal CVD events (CVD types no reported) occurred during a median follow‐up of 9 years (Lelli et al., [2018](#efs25778-bib-0185){ref-type="ref"}). A RR (95% CI) of 0.96 (0.90--1.02) was reported (reference unit of UNa not reported). This study was judged to be at moderate RoB (tier 2).

In the EPOGH/FLEMENGHO cohort, 232 fatal and non‐fatal CVD events occurred during a median follow‐up of 7.9 years (non‐fatal events included: 43 heart failures, 33 coronary revascularisations, 27 myocardial infarctions (MI), 14 pulmonary heart diseases, 13 strokes, 9 pulmonary embolisms, 4 coronary syndrome, 3 ischaemic heart diseases (IHD) and 2 aortic aneurysms; fatal events included: 29 heart failure, 20 stroke, 19 MI, 6 IHD, 6 sudden deaths, 2 pulmonary embolisms, 1 arterial embolism and 1 aortic aneurysm) (Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}). HRs (95% CI) were 1.12 (0.90--1.41) (100 events), 1.09 (0.88--1.34) (79 events) and 0.92 (0.74--1.13) (53 events) in the low, medium and high sex‐specific tertiles of UNa, respectively, compared with the overall risk in the entire cohort (3,681 men and women). The adjusted HRs for fatal CVD events only were 1.41 (0.94--2.12) (50 events), 0.98 (0.69--1.40) (24 events) and 1.02 (0.71--1.45) (10 events), respectively. This study was judged to be at moderate RoB (tier 2).

#### 5.5.2.4. Mechanistic considerations {#efs25778-sec-0071}

There is a positive relationship between sodium intake and blood pressure (Section [5.5.1](#efs25778-sec-0054){ref-type="sec"}), which, in turn, is an established independent risk factor for CVD, mostly CHD and stroke.

Other mechanisms have been proposed by which sodium intake may affect CVD risk (reviewed by Farquhar et al. ([2015](#efs25778-bib-0101){ref-type="ref"})), including through an effect on endothelial function, arterial stiffness and left ventricular mass. In a meta‐analysis of trials investigating the effect of sodium intake on carotid‐femoral pulse wave velocity (PWV), as a marker of arterial stiffness, D\'Elia et al. ([2018](#efs25778-bib-0064){ref-type="ref"}) reported that an average reduction in sodium intake of 89.3 mmol/day was associated with a pooled effect of 2.84% (95% CI: 0.51--5.08, I^2^ 14%; pooling data of 14 cohorts from 11 studies) reduction in PWV. There is some evidence that the effect of sodium reduction on PWV could, at least in part, be independent of the changes in blood pressure (D\'Elia et al., [2018](#efs25778-bib-0064){ref-type="ref"}).

There is uncertainty on the health effects of changes in regulatory hormones associated with sodium reduction (Section [5.2.3](#efs25778-sec-0049){ref-type="sec"}), including how they might affect the risk of stroke at low UNa, beyond the well‐established effect of blood pressure on stroke risk.

#### 5.5.2.5. Conclusions {#efs25778-sec-0072}

A small number of observational prospective studies was eligible for the assessment. Three cohorts (PREVEND, EPOGH/FLEMENGHO and the Finnish cohort) investigated the association between UNa and risk of stroke (1 in tier 1; 2 in tier 2) and risk of CHD (1 in tier 1; 2 in tier 2). Three cohorts (EPOGH/FLEMENGHO, InCHIANTI and TOPHI/II) investigated the association between UNa and risk of CVD (1 in tier 1; 2 in tier 2).

Overall, limited conclusions can be drawn on the relationship between UNa and risk of CVD. The Panel considers that, over the range of UNa observed in these studies: There is some evidence for a positive association between UNa and risk of CHD. The positive relationship between UNa and blood pressure levels/incidence of hypertension, which is an established independent risk factor for CHD, supports this association.There is some evidence for an inverse association between UNa and risk of stroke. However, the number of eligible studies available investigating this outcome is small and the mechanisms by which UNa could be inversely associated with the risk of stroke are unclear, particularly considering the positive relationship between UNa and blood pressure, which is an established risk factor for stroke.There is some evidence for a positive association between UNa and risk of CVD. The Panel notes that CVD as a composite outcome combines different diseases that may be differentially affected by sodium intake. The suggestion of a positive association reported by Cook et al. ([2014](#efs25778-bib-0060){ref-type="ref"}), in which MI and coronary revascularisation interventions represented most cases, is consistent with the evidence for a positive association between UNa and risk of CHD and the positive relationship between UNa and blood pressure levels/incidence of hypertension.

### 5.5.3. Bone health {#efs25778-sec-0073}

There is consistent evidence that an increase in sodium intake increases urinary calcium excretion, while a reduction in sodium intake lowers urinary calcium excretion (Afssa, [2001](#efs25778-bib-0006){ref-type="ref"}; EFSA, [2005a](#efs25778-bib-0076){ref-type="ref"}; IOM, [2005](#efs25778-bib-0144){ref-type="ref"}). The increase in urinary calcium excretion with increasing sodium intake may negatively affect bone calcium balance, even when dietary calcium intake is above the PRI for calcium (see Section [2.5.3](#efs25778-sec-0028){ref-type="sec"}). It is biologically plausible that a long‐term increase in urinary calcium excretion leading to negative bone calcium balance would both lower BMD and increase the risk of osteoporotic bone fractures. However, evidence for a relationship between sodium intake and bone health was considered inconclusive in previous assessments (EFSA, [2005a](#efs25778-bib-0076){ref-type="ref"}; IOM, [2005](#efs25778-bib-0144){ref-type="ref"}).

Two articles were eligible for the assessment (Devine et al., [1995](#efs25778-bib-0070){ref-type="ref"}; Ilich et al., [2010](#efs25778-bib-0141){ref-type="ref"}) (Appendix [G.2](#efs25778-sec-0098){ref-type="sec"}). Study characteristics and results and the outcome of the RoB appraisal are presented in Appendices [L.1](#efs25778-sec-0127){ref-type="sec"} and [L.2](#efs25778-sec-0128){ref-type="sec"}, respectively.

Although the two eligible studies were primarily designed as RCTs, they have been categorised as 'prospective cohort studies' because of the type of analyses conducted. Devine et al. ([1995](#efs25778-bib-0070){ref-type="ref"}) used data from a 2‐year RCT investigating the effect of supplemental calcium and physical activity on BMD (Prince et al., [1995](#efs25778-bib-0251){ref-type="ref"}). Sodium intake was observed by means of 24‐h urine collections at baseline and after 1 and 2 years of intervention. Pooled data from all intervention groups were used to explore the association between sodium intake and change in BMD. Ilich et al. ([2010](#efs25778-bib-0141){ref-type="ref"}) aimed at investigating the effect of dietary sodium intake on BMD and other bone‐related outcomes in a 3‐year RCT in which half of the participants were assigned to a group instructed to reduce sodium intake (target 1.5 g sodium/day), while the others maintained their usual diet (\~3 g sodium/day). Sodium intake was estimated by means of 24‐h urinary collection every 6 months. With time, some of the participants in the control group reduced their sodium intake and those in the intervention group did not comply in reducing their sodium intake. Therefore, in the final analyses, all participants were grouped together and data were pooled to be analysed as a longitudinal observational study, regardless of to which group each subject was initially assigned.

The two studies involved postmenopausal women, with mean (SD) baseline sodium excretion of 121 (47) mmol (2,783 (1,081) mg)/day (n = 168, in Australia) (Devine et al., [1995](#efs25778-bib-0070){ref-type="ref"}) and 105 (42) mmol (2,404 (963) mg)/day (n = 136, in the USA) (Ilich et al., [2010](#efs25778-bib-0141){ref-type="ref"}), respectively. In the study from Devine et al. ([1995](#efs25778-bib-0070){ref-type="ref"}), physical activity level and calcium intake varied depending on the intervention groups, while in the study from Ilich et al. ([2010](#efs25778-bib-0141){ref-type="ref"}) participants maintained their usual physical activity and received calcium (\~630 mg/day) and vitamin D (\~400 IU/day) supplements. BMD was measured by DEXA at different sites Devine et al. ([1995](#efs25778-bib-0070){ref-type="ref"}): hip, ankle and lumbar spine; Ilich et al. ([2010](#efs25778-bib-0141){ref-type="ref"}): hip, forearm, lumbar spine and total body.

In multivariate analysis, Devine et al. ([1995](#efs25778-bib-0070){ref-type="ref"}) reported a negative association between average UNa and 2‐year change in BMD at the hip and ankle. No association was found at the lumbar spine. This study was judged to be at moderate RoB (tier 2) because of concerns about the substantial attrition rate (124 out of 168 women included in the analysis) without clear reporting about the characteristics of the subjects excluded, and the lack of information on the quality measures applied for the 24‐h urine collection.

Ilich et al. ([2010](#efs25778-bib-0141){ref-type="ref"}) reported a positive association between the cumulative average of urinary Na/creatinine excretion and BMD at 36 months in total body and total forearm (intention‐to‐treat analysis). Using random‐effects regressions accounting for missing data and repeated measurements, individuals with higher UNa were found to have higher forearm and lumbar spine BMD at baseline and subsequent time points. No association was found with total body or femur BMD. This study was judged to be at low RoB (tier 1).

The Panel notes the limited and inconsistent evidence for an association between sodium intake and BMD provided by these two studies.

The Panel concludes that these data cannot be used to set DRVs for sodium.

### 5.5.4. Scope of the review {#efs25778-sec-0074}

The conclusions described above are based on the evidence eligible for the assessment. In defining the inclusion/exclusion criteria of this review, methodological choices were made to minimise the RoB. In particular, the review was restricted to: RCTs and prospective observational studies;studies that excluded participants with pre‐existing conditions, to minimise the risk of reverse causality;studies that used at least one 24‐h urinary collection to estimate sodium intake, to minimise the RoB related to exposure misclassification.

In relation to observational data, the exclusion of studies that relied on dietary questionnaires or spot urine collections to assess sodium intake resulted in a relatively small number of eligible studies. This precluded any quantitative integration of the evidence relating sodium intake and disease risk (e.g. through meta‐analyses) and limited the exploration and characterisation of sources of heterogeneity in the body of evidence.

6. Data on which to base dietary reference values {#efs25778-sec-0075}
=================================================

6.1. Adults {#efs25778-sec-0076}
-----------

Based on the review of the available evidence, the Panel considers that relevant data to inform the setting of DRVs for sodium is provided by: (i) balance studies on sodium (Section [5.2](#efs25778-sec-0046){ref-type="sec"}); and (ii) studies informing the relationship between sodium intake and blood pressure level or CVD risk (Sections [5.5.1](#efs25778-sec-0054){ref-type="sec"} and [5.5.2](#efs25778-sec-0067){ref-type="sec"}).

The Panel considers that the available evidence cannot be used to determine the sodium requirement nor its distribution in the population (see Section [5](#efs25778-sec-0044){ref-type="sec"}); so, an AR and population reference intake (PRI) for sodium cannot be established.

Data on the relationship between sodium intake and level of blood pressure or CVD risk could inform about the levels of sodium intake associated with a reduced risk of chronic diseases. Balance studies could inform about the levels of sodium intake that are adequate to maintain a null sodium balance.

Because of the limited evidence available and of the associated uncertainties, it is not possible to identify such levels of sodium intake with certainty. The Panel therefore used expert judgement to weigh the available evidence and take account of the associated uncertainties ((a 'weight of evidence' approach EFSA Scientific Committee et al., [2017](#efs25778-bib-0802){ref-type="ref"})). This was achieved by means of a formal EKE (EFSA, [2014](#efs25778-bib-0078){ref-type="ref"}) undertaken with the members of the working group on DRVs for minerals (Appendix [M](#efs25778-sec-1013){ref-type="sec"}). The EKE offers several advantages, since: It supports experts in making evidence‐based judgements about a quantity of interest (typically a parameter) in a structured way, while limiting bias.It allows a representation of the uncertainty about the quantity of interest using a probability distribution to express judgements about the range of possible values and their relative likelihoods.

As a result, the probability distribution generated through the EKE reflects the uncertainty about the 'true' value of the quantity elicited.

The elicitation was carried out using the roulette method and following the Sheffield protocol (see section on Data and Methodologies, part C and Appendix [M](#efs25778-sec-1013){ref-type="sec"}).

In line with the principles for setting DRVs (EFSA NDA Panel, [2010](#efs25778-bib-0084){ref-type="ref"}), the Panel aimed at setting reference values for the general population, excluding diseased populations and subpopulations with extreme and distinct vulnerabilities due to genetic predisposition or other conditions.

Two separate elicitations were conducted and are reported below.

### 6.1.1. EKE on the relationship between sodium intake and blood pressure and CVD {#efs25778-sec-0077}

Evidence on the relationship between sodium intake and blood pressure or CVD risks could inform about the levels of sodium intake associated to a reduced risk of chronic diseases.

From the literature reviewed in Section [5](#efs25778-sec-0044){ref-type="sec"}, there is strong evidence for a positive relationship between sodium and blood pressure levels, which is an established risk factor for CVD risk. The meta‐regression dose--response modelling provided evidence for a linear relationship between blood pressure and UNa in the range covered by the eligible studies (ca. 50--200 mmol/day) (Section [5.5.1.2](#efs25778-sec-0059){ref-type="sec"}); any increase in blood pressure level is considered adverse. Based on eligible prospective observational studies, there is some evidence for a positive association between UNa and risk of hypertension, CHD and CVD. There is some evidence for an inverse association between UNa and risk of stroke, with substantial uncertainty as the number of eligible studies is small and the mechanisms by which UNa could be inversely associated with the risk of stroke are unclear (Section [5.5.2](#efs25778-sec-0067){ref-type="sec"}). So, in view of the available evidence, experts judgement was elicited on the *lowest* level of sodium associated with a reduced risk of stroke and CHD integrating all the relevant evidence, including evidence on blood pressure.

The following question was used for the elicitation: *What is the lowest level of sodium intake at which the risk of chronic disease (i*.*e*. *stroke*,*CHD) is minimised in the majority (≥ 97*.*5%) of the general population of adults*?

Eligible studies in relation to this source of evidence used UNa as marker of sodium intake. So, the scale used for the elicitation referred to UNa and was expressed in mmol/24 h.

The empirical probability distribution obtained after the group achieved a consensus is depicted in Figure [1](#efs25778-fig-0001){ref-type="fig"} and the rationale for the distribution is presented in Table [9](#efs25778-tbl-0009){ref-type="table"}. The distribution reflects the uncertainty of the experts about the *lowest* level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the general population.

![Group consensus uncertainty probability distribution on the lowest level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the general population\
UNa: sodium urinary excretion.EKE question: 'What is the lowest level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the majority (≥ 97.5%) of the general population of adults?'. Experts expressed the probability that each of the proposed ranges of UNa might include the 'true' level of interest. Therefore, the probability distribution reflects the uncertainty about the level elicited. It does NOT represent the probability (or risk) of disease associated to a given range of UNa. Ranges that did not receive any probability are not retained in the figure.](EFS2-17-e05778-g001){#efs25778-fig-0001}

###### 

Rationale for the group consensus uncertainty probability distribution on the *lowest* level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the general population

  UNa range (mmol/24 h)   Probability[a](#efs25778-note-0019){ref-type="fn"}   Rationale
  ----------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **0--40**               1%                                                   Relationship between UNa and blood pressure uncertain in this range (outside the range of the experimental data)
  **40--80**              44%                                                  Positive relationship between UNa and blood pressure (range 50--200 mmol/24 h), based on experimental evidence (high confidence) but blood pressure is an intermediate markerLower risk of hypertension in range ≤ 130 mmol/24 h (TOPH studies)No change in CHD risk up to 120 mmol/24 h for women and 150 mmol/24 h for men (Joosten et al., [2014](#efs25778-bib-0153){ref-type="ref"})Indication from Kieneker et al. ([2018](#efs25778-bib-0163){ref-type="ref"}) that risk of stroke might increase in this range, with substantial uncertainty
  **80--120**             50%                                                  Positive relationship between UNa and blood pressure (range 50--200 mmol/24 h), based on experimental evidence (high confidence) but blood pressure is an intermediate markerLower risk of hypertension in range ≤ 130 mmol/24 h (TOPH studies)No change in CHD risk up to 120 mmol/24 h for women and 150 mmol/24 h for men (Joosten et al., [2014](#efs25778-bib-0153){ref-type="ref"})Indication from Kieneker et al. ([2018](#efs25778-bib-0163){ref-type="ref"}) that risk of stroke might increase below this range of intakeOverall, less confidence for causality from prospective cohort studies as compared with experimental studies and limited number of studies
  **120--200**            5%                                                   Studies show CHD risk and incidence of hypertension to increase with Na intake in this range (Tuomilehto et al., [2001](#efs25778-bib-0302){ref-type="ref"}; Joosten et al., [2014](#efs25778-bib-0153){ref-type="ref"})Positive relationship between UNa and blood pressure (range 50--200 mmol/24 h)Indication of increased risk of CHD and stroke from Stolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"}) below this level of intake

CHD: coronary heart disease; UNa: sodium urinary excretion; TOPH: Trials of Hypertension Prevention.

Consensus judgement of the expert group about the probability that the corresponding range of UNa includes the 'true' level of interest.

John Wiley & Sons, Ltd

### 6.1.2. EKE on balance studies {#efs25778-sec-0078}

As discussed in Section [5.2](#efs25778-sec-0046){ref-type="sec"}, balance studies are based on the assumption that a healthy subject on an adequate diet maintains equilibrium or a null balance, between nutrient intakes and nutrient losses. At this null balance, the intake matches the requirement determined by the physiological state of the individual. When losses exceed intakes (negative balance), nutrient stores are progressively depleted, resulting in deficiency in the long term; when intakes exceed losses (positive balance), there is nutrient accretion. In the case of sodium, a sustained positive balance, albeit small, may lead to a systemic accumulation overtime with, possibly, adverse implications (Section [2.3.3](#efs25778-sec-0018){ref-type="sec"}).

In relation to sodium, the Panel considers that balance studies cannot be used to determine sodium requirements but could be used to inform about the levels of sodium intake that are adequate to maintain a null sodium balance (Section [5.2.4](#efs25778-sec-0050){ref-type="sec"}).

The following question was used for the elicitation: *What is the lowest level of sodium intake which is adequate (i*.*e*. *amount which allows to maintain sodium balance) for the majority (≥ 97*.*5%) of the general population of adults*?

The group consensus probability distribution elicited in response to the question is depicted in Figure [2](#efs25778-fig-0002){ref-type="fig"} and the rationale for the distribution is provided in Table [10](#efs25778-tbl-0010){ref-type="table"}. The distribution reflects the uncertainty of the experts about the *lowest* level of sodium intake which allows to maintain sodium balance for most of the general population.

![Group consensus uncertainty probability distribution on the lowest level of sodium intake which allows to maintain sodium balance for most of the general population\
EKE question: 'What is the lowest level of sodium intake that is adequate (i.e. amount which allows to maintain sodium balance) for the majority (≥ 97.5%) of the general population of adults?'. Experts expressed the probability that each of the proposed ranges of sodium intake might include the 'true' level of interest. Therefore, the probability distribution reflects the uncertainty about the level elicited. It does NOT represent the probability (or risk) of sodium 'imbalance' associated to a given range of sodium intake. Ranges that did not receive any probability are not retained in the figure.](EFS2-17-e05778-g002){#efs25778-fig-0002}

###### 

Rationale for the group consensus uncertainty probability distribution on the *lowest* level of sodium intake which to maintain sodium balance for most of the general population

  Sodium intake range (g/day)   Probability[a](#efs25778-note-0021){ref-type="fn"}   Rationale
  ----------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **0.5--1.0**                  5%                                                   There is a minimum requirement for sodium, which is unknown.Data in Yanomamo Indians indicate that they can sustain a lifelong sodium intake in the order of a few mmol/day (INTERSALT Cooperative Research Group, [1988](#efs25778-bib-0143){ref-type="ref"}); uncertainty associated with the generalisability of these observations to the EU population
  **1.0--1.5**                  32.5%                                                Evidence from the Allsopp study indicates 1.5 g/day (Allsopp, [1997](#efs25778-bib-0012){ref-type="ref"}, [1998](#efs25778-bib-0013){ref-type="ref"}); good quality study (exposure) but uncertainty due to single study, short duration, small number of subjectsReductions in sodium intake resulting in excretions of 100 to 50 mmol/day (2.3 to 1.2 g/day) and lower has been associated with a sharp increase in plasma renin activity and aldosterone concentration in urineDistribution of probability in range 1.0--2.5 g/day reflects:Allsopp indicates 1.5 g/day but uncertainty about the distribution in the populationBody constantly adapts to maintain homeostasis in response to environmental conditions; there is a lack of data on the health effects of a sustained activation of the sympathetic nervous system and the RAAS in the general populationProbability distribution shifted towards range 1.5--2.5 g/day to cover most of the population and considering the lack of data from balance studies below 1.5 g/day
  **1.5--2.0**                  37.5%                                                
  **2.0--2.5**                  20%                                                  
  **2.5--3.5**                  5%                                                   Uncertainty on the distribution in the population: some people may achieve null balance in this range (some indication from Holbrook et al. ([1984](#efs25778-bib-0137){ref-type="ref"}))

INTERSALT: International Cooperative Study on Salt, Other Factors and Blood Pressure; RAAS: renin--angiotensin--aldosterone system.

Consensus judgement of the expert group about the probability that the corresponding range of sodium intake includes the 'true' level of interest.

John Wiley & Sons, Ltd

### 6.1.3. Integration of the evidence and conclusions {#efs25778-sec-0079}

Parametric distributions were fitted to the group consensus uncertainty empirical probability distributions. At this stage, UNa values expressed in mmol/24 h were converted into g/day and a factor of 1.07 was applied to allow for the percentage of dietary sodium excreted through urine. This conversion factor was chosen based on the meta‐analysis of Lucko et al. ([2018](#efs25778-bib-0193){ref-type="ref"}) that estimated that, on average, 93% of daily dietary sodium was excreted in 24‐h urine (Sections [2.3.4.1](#efs25778-sec-0020){ref-type="sec"} and [2.6.1.1](#efs25778-sec-0031){ref-type="sec"}).

The parametric distributions fitted to the centiles of the two group consensus uncertainty distributions were, respectively: a log‐normal distribution with parameters 0.72 (mean) and 0.23 (standard deviation) for the question on sodium intake at which CVD risk is reduced; a log‐normal distribution with parameters 0.5 (mean) and 0.3 (standard deviation) for the question on sodium balance (Appendix [M](#efs25778-sec-1013){ref-type="sec"}). Based on the two fitted parametric distributions, cumulative uncertainty density functions were derived (Figure [3](#efs25778-fig-0003){ref-type="fig"}).

The Panel used the cumulative uncertainty density functions to integrate the evidence and associated uncertainties and derive a reference value for sodium (see Figure [3](#efs25778-fig-0003){ref-type="fig"}). The Panel considered that: A sodium intake of 2.0 g/day represents a level of sodium for which there is sufficient confidence that it is associated within a reduced risk of CVD in the general adult population.A sodium intake of 2.0 g/day is likely to allow most of the general population to maintain sodium balance.

![Cumulative uncertainty density functions\
Log‐normal distributions were fitted to the empirical uncertainty probability distributions elicited through the two EKEs and used to derive the two cumulative density functions depicted above.The red curve is the cumulative density function corresponding to the elicitation of the *lowest* level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the general population. As one goes towards the right of the curve, the uncertainty that the identified range includes the level of sodium intake that 'minimises' the risk of CHD increases; similarly, as one moves towards the left, the uncertainty that the identified range includes the level of sodium intake that 'minimises' the risk of stroke increases. The curve integrates experts' considerations about the strength of the evidence for the respective outcomes and associated uncertainties. At the median level of the distribution (red dot), there is equal certainty that the level of sodium that it is associated with a reduction of CVD risk is neither overestimated (50% probability) nor underestimated (50% probability). So, the Panel considers that there is sufficient confidence in the data that a sodium intake of 2 g/day is associated with a reduction of CVD risk.The blue curve is the cumulative density function corresponding to the elicitation of the *lowest* level of sodium intake that allows to maintain sodium balance for most of the general population. The curve represents the probability/certainty that the 'lowest level of sodium intake that is adequate (i.e. to maintain sodium balance) for the majority (≥ 97.5%) general population of adults' is any value from the lower bound of the range up to the identified value. The interpretation of the curve is unidirectional: as one goes towards the right, the confidence (certainty) that the identified range includes the level of sodium intake that is adequate increases. The Panel considers that a level of sodium intake of 2 g/day (blue dot) is likely (i.e. with a 75% probability) to be adequate to maintain sodium balance for most of the general adult population in the EU.The curves do NOT represent the probability (or risk) of given outcome (i.e. CVD disease, sodium 'imbalance') associated with a given level of sodium intake.](EFS2-17-e05778-g003){#efs25778-fig-0003}

Therefore, the Panel considers that 2.0 g of sodium/day is a safe and adequate intake for the general EU population of adults. BOX‐1 provides an explanation for the terms.

This value provides guidance on a level of sodium intake compatible with good health that can inform population goals for sodium. However, the value has limited utility for assessing and planning the diet of individuals. At the individual level, if the usual intake of sodium exceeds this value, it could be associated with an increased risk of cardiovascular diseases, including concurring risk factors such as primary hypertension.

The Panel recognised several challenges arising from the integration of the available evidence to set any sort of advisory level for sodium intake. One is that, due to the limitations of the evidence, there are substantial uncertainties associated with levels of interest for both sodium balance and stroke/CHD risk. Another challenge arises from the integration of several outcomes that differ in their nature, i.e. physiological requirements versus chronic disease risk. The setting of a single value is a pragmatic choice, which represents a compromise between the different types of evidence and risks.

####  {#efs25778-sec-0080}

**BOX 1 -- Safe and adequate intake: explanation for the terms***Safe:* Although the term 'safe intake' is not defined in the principles on deriving and applying DRVs (EFSA NDA Panel, [2010](#efs25778-bib-0084){ref-type="ref"}), the concept of a safe intake has been used in previous assessments regarding a daily intake of a nutrient which does not give rise to concerns about adverse health effects, in instances when a tolerable upper intake level (UL) could not be established (SCF, [2000](#efs25778-bib-0268){ref-type="ref"}; EFSA NDA Panel, [2012b](#efs25778-bib-0086){ref-type="ref"}). The reference value for sodium is called 'safe' because the value proposed takes account of the evidence describing the relationship between sodium intake and CVD risk in the general population.*Adequate:* An adequate intake (AI) is the value estimated when a population reference intake (PRI) cannot be established because an average requirement (AR) cannot be determined (EFSA NDA Panel, [2010](#efs25778-bib-0084){ref-type="ref"}). The AI is the level of intake that is assumed to be sufficient based on observations from groups of apparently healthy people. The reference value for sodium is called 'adequate' in line with this definition.

6.2. Pregnant and lactating women {#efs25778-sec-0081}
---------------------------------

The Panel considers that the requirement for the daily accretion rate of sodium in fetal and maternal tissues can be met by adaptive changes that maintain sodium homeostasis during pregnancy (Section [5.3](#efs25778-sec-0051){ref-type="sec"}). The Panel also notes that there is no evidence that sodium requirement of lactating women differs from the requirement of non‐lactating women (Section [5.3](#efs25778-sec-0051){ref-type="sec"}).

So, the Panel considers that 2.0 g sodium/day is a safe intake and adequate intake for pregnant and lactating women.

6.3. Infants {#efs25778-sec-0082}
------------

There is a lack of data from which an AR could be derived for infants (Section [5.4](#efs25778-sec-0052){ref-type="sec"}).

Upwards extrapolation from the estimated sodium intake of fully breast‐fed infants during the first 6 months of life of 120 mg/day (Section [2.3.4.4](#efs25778-sec-0023){ref-type="sec"}), based on ARs for energy of infants aged 3 months (2.0 MJ/day for men and women (EFSA NDA Panel, [2013a](#efs25778-bib-0087){ref-type="ref"})) and 9 months (2.8 MJ/day for men and women (EFSA NDA Panel, [2013b](#efs25778-bib-0088){ref-type="ref"})), results in an estimated sodium intake of 168 mg/day.

After rounding to the closest 0.1, an AI of 0.2 g/day is proposed for infants aged 7--11 months.

6.4. Children {#efs25778-sec-0083}
-------------

There is a lack of data from which an AR could be derived for children (Sections [5.2](#efs25778-sec-0046){ref-type="sec"} and [5.4](#efs25778-sec-0052){ref-type="sec"}).

For children, the Panel decided to draw up reference values based on downwards extrapolation from the reference value for adults, based on the AR for energy (EFSA NDA Panel, [2013b](#efs25778-bib-0088){ref-type="ref"}) and including a growth factor to take into account requirements for growth, as follows:

Value~child~ = Value~adult~ × (AR for energy of children/AR for energy of adults aged 18--29 years) ×(1 + growth factor)

The AR for energy varies with age and physical activity level (PAL) (EFSA NDA Panel, [2013b](#efs25778-bib-0088){ref-type="ref"}). For the calculations, the AR for energy of adults aged 18--29 years was taken as a reference. The values calculated by using the ARs corresponding to the different PAL values were close (\< 0.2 g/day difference). Therefore, a single value is proposed that applies to all levels of physical activity.

Growth factors are derived from the proportional increase in protein requirement for growth relative to the maintenance requirement at the different ages (EFSA NDA Panel, [2012a](#efs25778-bib-0085){ref-type="ref"}; EFSA, [2017a](#efs25778-bib-0080){ref-type="ref"}).

The age categories proposed by the EFSA NDA Panel ([2010](#efs25778-bib-0084){ref-type="ref"}) were applied. For each age category, the Panel decided to set a single value for boys and girls and the average of the values calculated for both sexes was taken (Table [11](#efs25778-tbl-0011){ref-type="table"}).

###### 

Safe and adequate intake of sodium for children

                     Safe and adequate intake[a](#efs25778-note-0022){ref-type="fn"} (g/day)
  ------------------ -------------------------------------------------------------------------
  **1--3 years**     1.1
  **4--6 years**     1.3
  **7--10 years**    1.7
  **11--17 years**   2.0

Values for children were derived from the value for adults after adjustment on the basis of differences in average requirement for energy (EFSA NDA Panel, [2013b](#efs25778-bib-0088){ref-type="ref"}) and application of a growth factor (EFSA, [2017a](#efs25778-bib-0080){ref-type="ref"}). The average requirements for energy of adults aged 18 to 29 years was used in the calculations. The average of the values for boys and girls was calculated for each year of age. For each age category, the proposed value corresponds to the average of the values calculated for each year of age. A single value for the age categories 11--14 years and 15--17 years was selected. Values are rounded to the closest 0.1.

John Wiley & Sons, Ltd

Conclusions {#efs25778-sec-0084}
===========

The Panel concludes that the available evidence cannot be used to derive an AR and a PRI for sodium. Evidence on the relationship between sodium intake and level of blood pressure and risk of CVD as well as data from balance studies are used as a basis to determine a safe and adequate intake of sodium of 2.0 g/day for the general population of adults (Table [12](#efs25778-tbl-0012){ref-type="table"}). The Panel proposes that the reference value for adults also applies to pregnant and lactating women. Reference values for children are extrapolated from the reference value for adults based on the energy requirements of the age groups and applying a growth factor. For infants over 6 months of age, an AI is derived by extrapolating the estimated sodium intake of fully breast‐fed infants during the first 6 months of life based on the energy requirement of the respective age groups.

The Panel notes that the mean/median intake of sodium in the European adult populations exceeds the safe and adequate intakes set for sodium (see Appendices [C](#efs25778-sec-1003){ref-type="sec"}, [D](#efs25778-sec-1004){ref-type="sec"} and [E](#efs25778-sec-1005){ref-type="sec"}). The risk of inadequate (insufficient) intake in European populations is low. Concerns for European populations instead relate to 'excess' intake of sodium. Therefore, in practice, the values proposed can be used to inform the setting of population goals for the reduction in sodium intake.

The Panel acknowledges that the concept of a safe and adequate intake is not addressed in the EFSA\'s Scientific Opinion on the principles for deriving and applying DRVs published in 2010 (EFSA NDA Panel, [2010](#efs25778-bib-0084){ref-type="ref"}). The principles were established when the review of DRVs for European populations was initiated and was meant as a guidance document. As for other guidance documents in EFSA, it is a living document that could be updated in the future in the light of the experience gained and new scientific and methodological developments in the field.

###### 

Summary of dietary reference values for sodium

                                                           Safe and adequate intake[a](#efs25778-note-0023){ref-type="fn"} (g/day)
  -------------------------------------------------------- -------------------------------------------------------------------------
  **7--11 months**                                         0.2[b](#efs25778-note-0024){ref-type="fn"}
  **1--3 years**                                           1.1
  **4--6 years**                                           1.3
  **7--10 years**                                          1.7
  **11--17 years**                                         2.0
  **≥ 18 years** [c](#efs25778-note-0025){ref-type="fn"}   2.0

Equivalent to: 9 mmol/day for infants 7--11 months, 48 mmol/day for children aged 1--3 years, 57 mmol/day for children aged 4--6 years, 74 mmol/day for children aged 7--10 years, 87 mmol/day for children aged 11--17 years, 87 mmol for adults, including pregnant and lactating women.

Adequate intake.

Including pregnant and lactating women.

John Wiley & Sons, Ltd

Recommendations for research {#efs25778-sec-0085}
============================

There is a need for studies, using robust assessment methods for sodium intake and the outcome of interest, investigating:

the moderating effect of energy intake on the relationship between sodium intake and blood pressure;the health effects of sodium and of the Na/K ratio at intakes approximating their respective DRVs;the life course effects of sodium intake on blood pressure, in particular the effect of sodium intake on neurohormonal control during childhood and adolescence, including programming;the effect of prolonged exposure to 'low' sodium on the effective functioning of its homeostatic regulation (i.e. SNS and RAAS);the effects of sodium intake on bone health in growing and ageing populations;the role of sodium intake on the pathogenesis of kidney disease in the general population;the characterisation of genes involved in determining 'salt‐sensitive' phenotypes and of moderating factors of 'salt sensitivity'.

Abbreviations {#efs25778-sec-0086}
=============

24‐h DR24‐hour dietary recallAASatomic absorption spectrophotometryADHantidiuretic hormoneADRadrenalineAfssaAgence Française de Sécurité Sanitaire des AlimentsAIadequate intakeALDaldosteroneAnsesFrench Agency for Food, Environmental and Occupational Health and SafetyARaverage requirementBMCbone mineral contentBMDbone mineral densityBMIbody mass indexBPblood pressurebwbody weightCDRRChronic Disease Risk ReductionCHDcoronary heart disease95% CI95% confidence intervalCOMACommittee on Medical Aspects of Food PolicyCVDcardiovascular diseaseCVOscircumventricular organsD--A--CHDeutschland--Austria--Confederation HelveticaDASHDietary approaches to Stop HypertensionDBPdiastolic blood pressureDCSDoetinchem Cohort StudyDEXAdual‐energy X‐ray absorptiometryDGEGerman nutrition societyDHUK Department of HealthDONALDDortmund Nutritional and Anthropometrical Longitudinally Designed studyDRsdietary recallsDRVdietary reference valueEARestimated average requirementECFextracellular fluidEDTAethylenediaminetetraacetateEEDIestimated equilibrated dietary intakeEFCOVALEuropean Food Consumption ValidationEKEexpert knowledge elicitationENaCepithelial sodium channelEPOGHEuropean Project on Genes in HypertensionFAOFood and Agriculture OrganizationFFMfat‐free massFFQfood frequency questionnaireFLEMENGHOFlemish Study on Genes and Health OutcomesFVIfruit and vegetable intakeGDPSGeneral Doetinchem Population SampleGFRglomerular filtration rateGOODGothenburg Obesity and Osteoporosis DeterminantsHRhazard ratioHThypertensiveICP‐AESinductively coupled plasma atomic emission spectroscopyICP‐MSinductively coupled plasma mass spectrometryIHDischaemic heart diseaseInCHIANTIInvecchiare in ChiantiINTERSALTInternational Cooperative Study on Salt, Other Factors and Blood PressureIOMUS Institute of Medicine of the National Academy of SciencesIQRinterquartile rangeLRNIlower reference nutrient intakeMETmetabolic equivalent activityMImyocardial infarctionNASEMNational Academies of Sciences, Engineering, and MedicineN/Anot availableNa^+^/K^+^ ATPasesodium/potassium adenosine triphosphataseNDAEFSA Panel on Nutrition, Novel Foods and Food AllergensNORnoradrenalineNRnot reportedNT‐proBNPN‐terminal pro‐B‐typeOHAT‐NTPOffice of Health Assessment and Translation -- National Toxicology ProgrammeOMIMOnline Mendelian Inheritance in ManPABA*para*‐aminobenzoic acidPALphysical activity levelPREVENDPrevention of Renal and Vascular End‐stage DiseasePRIpopulation reference intakePRISMAPreferred Reporting items for Systematic reviews and Meta‐AnalysesPROMETHEUSPromoting Methods for Evidence Use in Scientific assessmentsPWVpulse wave velocityRArenin activityRAASrenin--angiotensin--aldosterone systemRCTrandomised controlled trialRNIreference nutrient intakeRoBrisk of biasRRrelative riskSACNScientific Advisory Committee on NutritionSBPsystolic blood pressureSCFScientific Committee for FoodSDStandard deviationSDTsuggested dietary targetSEstandard errorSEMstandard error of the meanSINGSalt Intake in northern GreeceSINUItalian Society of NutritionSLANSurvey of Lifestyle, Attitudes and NutritionSNSsympathetic nervous systemSRCstandardised regression coefficientSUAserum uric acidTEItotal energy intakeTOPHTrials of Hypertension PreventionUAlbuminalbumin urinary excretionUCacalcium urinary excretionUCrcreatinine urinary excretionUKpotassium urinary excretionULtolerable upper intake levelUNasodium urinary excretionUNUUnited Nations UniversityWHOWorld Health Organization

Appendix A -- Sodium concentration in breast milk from mothers of term infants in Western countries {#efs25778-sec-1001}
===================================================================================================

 {#efs25778-sec-0087}

ReferenceN women (N samples)CountryStage of lactationSodium concentration mg/L (mmol/L)Analytical methodMean ± SDMedianKoo and Gupta ([1982](#efs25778-bib-0166){ref-type="ref"})45 (5) (8) (8) (9) (5) (9) (9) (52) (52)AustraliaDay 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Days 8--14 Days 15--281,630 ± 262 (70.9 ± 11.4) 1,244 ± 200 (54.1 ± 8.7) 501 ± 71 (21.8 ± 3.1) 651 ± 108 (28.3 ± 4.7) 359 ± 64 (15.6 ± 2.8) 435 ± 92 (18.9 ± 4.0) 398 ± 53 (17.3 ± 2.3) 301 ± 14 (13.1 ± 0.6) 244 ± 14 (10.6 ± 0.6) Milk expressed manually Flame photometryKeenan et al. ([1982](#efs25778-bib-0159){ref-type="ref"})(14) (14) (12)USA3.5--6 weeks 8.5--18 weeks 20--32 weeks182 ± 69 (7.9 ± 3.0) 108 ± 46 (4.7 ± 2.0) 124 ± 30 (5.4 ± 1.3) Milk expressed using an electric breast pump Flame photometryParr et al. ([1991](#efs25778-bib-0242){ref-type="ref"})(71)Hungary3 months105 ± 6 (4.6 ± 0.3) Milk expressed using breast pump AAS(29)Sweden88 ± 17 (3.8 ± 0.7) Holt ([1993](#efs25778-bib-0138){ref-type="ref"})4 (28)UK5--16 weeks107 ± 29 (4.65 ± 1.24) Manual expression Flame photometryWack et al. ([1997](#efs25778-bib-0309){ref-type="ref"})30 (140)USA0--60 days 61--120 days 121--180 days 181--240 days 241--300 days 301--360 days \> 360 days182 ± 83 (7.9 ± 3.6) 129 ± 61(5.6 ± 2.7) 136 ± 76 (5.9 ± 3.3) 139 ± 142 (6.0 ± 6.2) 124 ± 65 (5.4 ± 2.8) 122 ± 123 (5.3 ± 5.3) 126 ± 49 (5.5 ± 2.1) Manual expression or breast pump Plasma emission spectrophotometryMotil et al. ([1997](#efs25778-bib-0218){ref-type="ref"})11 adolescents (16.5 ± 0.6 years)USA6 weeks 12 weeks 18 weeks 24 weeks136 ± 29 (5.9 ± 1.3) 127 ± 34 (5.5 ± 1.5) 93 ± 31 (4.0 ± 1.3) 116 ± 51 (5.0 ± 2.2) Milk expressed by manual or mechanical pumping AAS11 adults (31.1 ± 3.8 years)USA6 weeks 12 weeks 18 weeks 24 weeks94 ± 27 (4.1 ± 1.2) 71 ± 23 (3.1 ± 1.0) 70 ± 16 (3.0 ± 0.7) 75 ± 23 (3.3 ± 1.0) Fly et al. ([1998](#efs25778-bib-0104){ref-type="ref"})14 (28)USA2--8 monthsMean ± SE 115 ± 11 (5.00 ± 0.48) (at rest) 109 ± 5 (4.73 ± 0.22) (after exercise) Milk expressed mechanically (electric breast pump) ICP‐AESGulson et al. ([2001](#efs25778-bib-0125){ref-type="ref"})17 (68)Australia (Australian and migrant subjects)Not reported167.1 ± 62.4 (7 ± 2)170.0Not reportedSavilahti and Saarinen ([2007](#efs25778-bib-0266){ref-type="ref"})Exclusive breast‐feeding \< 0.5 months: 109 (96)Finland1--5 days597 (26) Not reportedExclusive breast‐feeding \> 3.5 months: 119 (106)Finland1--5 days459 (20) Not reportedManganaro et al. ([2007](#efs25778-bib-0202){ref-type="ref"})208[a](#efs25778-note-0028){ref-type="fn"} (208)Italy3 days540 ± 25 (23 ± 1) Mode of expression not reported. Flame photometer.Bauer and Gerss ([2011](#efs25778-bib-0031){ref-type="ref"})10GermanyMixed (1--8 weeks; samples collected at weekly intervals from the first to the eighth week post‐partum)257 ± 48 (11.2 ± 2.1) Milk expressed mechanically (electric breast pump) AAS and colorimetryGalipeau et al. ([2012](#efs25778-bib-0114){ref-type="ref"})151 (151)CanadaDay 3982 ± 508 (42.7 ± 22.1)(range: 333--2,758 (14.5--120.0))Milk expressed manually Gasometry apparatusBjorklund et al. ([2012](#efs25778-bib-0037){ref-type="ref"})60 (840)Sweden14--21 days (samples collected daily for 7 days)217 ± 77 (9.4 ± 3.3)192 (range: 136--480) (8.3 (range: 5.9--20.9))Milk sampled using a manual breast milk pump and/or a passive breast milk sampler ICP‐MS[^1][^2][^3]

Appendix B -- Comparisons of measured 24‐h urinary sodium excretions vs 24‐h urinary sodium excretions estimated from equations based on concentrations of sodium in spot urine samples {#efs25778-sec-1002}
=======================================================================================================================================================================================

 {#efs25778-sec-0088}

ReferencePopulationMethodsEstimated 24‐h Na excretion (extrapolation method) Mean ± SDMeasured 24‐h Na excretion (reference) Mean ± SDCorrelationComparisonBland--Altman analysisKawasaki et al. ([1993](#efs25778-bib-0157){ref-type="ref"}) Japan159 healthy M and W (20--79 years) (Data set used to derive the equation)Collection 3--5 × 2nd morning voiding urine collected within 4 h after the 1st voiding but before breakfast + Kawasaki equation to estimate 24 h Na [Reference:]{.ul} 3--5 × 24‐h urine (same days)NRNR0.728  91 healthy M and W (40--67 years)Collection 1 × 2nd morning voiding urine collected within 4 h after the 1st voiding but before breakfast + Kawasaki equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine (same day)NRNR0.531No statistically significant difference was found between mean estimated 24‐h Na and measured 24‐h Na 15 healthy M and W (21--54 years)Collection 3 successive × 2nd morning voiding urine collected within 4 h after the 1st voiding but before breakfast + Kawasaki equation to estimate 24‐h Na [Reference:]{.ul} 3 successive × 24‐h urine (same days) Procedure repeated 4--6 timesNRNR0.821No statistically significant difference was found between mean estimated 24‐h Na and measured 24‐h Na Tanaka et al. ([2002](#efs25778-bib-0294){ref-type="ref"}) Japan295 M and 296 W (20--59 years) from INTERSALT (Data set used to derive the equation)1 × casual spot urine + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine collection (started after the casual collection)178.9 ± 36.2 mmol/day187.2 ± 65.8 mmol/day0.54Difference between measured 24‐h Na and estimated 24‐h Na 8.3 mmol/day 336 M and W (20--59 years) (Validation data set)1 × casual spot urine + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine collection (started after the casual collection)154.5 ± 32.7 mmol/day178.5 ± 59.5 mmol/day0.32Difference between mean estimated 24‐h Na and mean measured 24‐h Na, by quintile of estimated 24‐h Na Q1: 45.4 mmol/day Q2: 27.6 mmol/day Q3: 25.6 mmol/day Q4: 21.4 mmol/day Q5: 0.5 mmol/day Brown et al. ([2013](#efs25778-bib-0042){ref-type="ref"}) 15 countries from North America and Europe (INTERSALT)2,948 M and W (20--59 years), from 29 cities (Data set used to derive the equation)1 × casual spot urine + INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine collection (undertaken after the casual collection)NRMean (mix, max) M: Belgium, Charleroi: 147.2 mmol/day Poland, Krakow: 240 mmol/day W: Germany, Cottbus: 117.8 mmol/day Italy, Bassiano: 167.5 mmol/dayM: 0.51 W: 0.52  2,745 M and W (20--59 years), from 29 cities (Validation data set)1 × casual spot urine + INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine collection (undertaken after the casual collection)M: USA, Hawaii: 176.3 mmol/day Poland, Krakow: 223.6 mmol/day W: Iceland, Reykjavik: 126.6 mmol/day Italy, Bassiano: 178.0 mmol/dayM: USA, Hawaii: 144.2 mmol/day Poland, Krakow: 239.7 mmol/day W: Iceland, Reykjavik: 115.0 mmol/day Italy, Bassiano: 170.6 mmol/dayM: 0.50 W: 0.51Difference between mean measured 24‐h Na and mean estimated 24‐h Na: M: −1.6 mmol W: +2.3 mmolBland--Altman showed overestimation of excretion at lower levels and underestimation at higher levels for both men and womenMente et al. ([2014](#efs25778-bib-0210){ref-type="ref"}) 11 countries1,083 M and W (35--70 years)1 × fasting morning collection + Kawasaki equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine collection (previous day)4,430 ± 1,253 mg/day4,116 ± 1,978 mg/dayIntraclass correlation coefficient 0.71 (95% CI: 0.65 to 0.76)Difference between estimated 24‐h Na and measured 24‐h Na: 313 (95% CI: 182 to 444) mg/dayBland--Altman plot evidenced a systematic bias towards overestimation at the lower end and underestimation at the higher end1 × fasting morning collection + INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine collection (previous day)3,257 ± 860 mg/day4,116 ± 1,978 mg/dayIntraclass correlation coefficient 0.49 (0.29 to 0.62)Difference between estimated 24‐h Na and measured 24‐h Na: −872 (−728 to −1016) mg/dayBias significantly higher than Kawasaki equation1 × fasting morning collection + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urine collection (previous day)3,569 ± 782 mg/day4,116 ± 1,978 mg/dayIntraclass correlation coefficient 0.54 (0.42 to 0.62)Difference between estimated 24‐h Na and measured 24‐h Na: −548 (−408 to −688) mg/dayBias significantly higher than Kawasaki equationPfister et al. ([2014](#efs25778-bib-0245){ref-type="ref"}) UK163 M and W (EPIC‐Norfolk study)1 × casual spot urine sample + INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} Mean of up to 6 × 24 h collections over 1 yearNRNRNRMean of differences between measured and estimated 24‐h Na: −21 mmol/day (95% CI: −32 to −11 mmol/day)Variance of the differences reasonably constant, with few outliers and most points lying within the calculated limits of agreementCogswell et al. ([2013](#efs25778-bib-0057){ref-type="ref"}) USA407 M and W (18--39 y, 52% white)1 morning spot urine specimen (first specimen after discarding the first void; 08:30--12:30) +INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)3,157 ± 891 mg/day3,323 ± 1,437 mg/day0.47Difference between estimated and measured 24‐h Na: --165 mg (95% CI: −295, −36)Overestimation occurred at the low levels of 24‐h Na excretion and underestimation at the high level1 afternoon spot urine specimen (12:31--17:30) +INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)3,197 ± 824 mg/day3,287 ± 1,408 mg/day0.49−90 mg (95% CI: −208, 28)1 evening spot urine specimen (17:31--23:59) +INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)3,178 ± 846 mg/day3,298 ± 1,399 mg/day0.54−120 mg (95% CI: −230, −11)1 overnight specimen (first void collected the next morning after the longest period of sleep (04:00--12:00)) + INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)3,028 ± 809 mg/day3,295 ± 1,400 mg/day0.44−267 mg (95% CI: −384, −151)Morning as above + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection3,574 ± 893 mg/day3,323 ± 1,437 mg/day0.50251 mg (95% CI: NR)Overestimation occurred at the low levels of 24‐h Na sodium excretion and underestimation at the high levelsAfternoon as above + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)3,655 ± 870 mg/day3,287 ± 1408 mg/day0.51368 mg (95% CI: NR)Evening as above + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)3,553 ± 820 mg/day3,298 ± 1399 mg/day0.59255 mg (95% CI: NR)Overnight as above + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)3,272 ± 779 mg/day3,295 ± 1400 mg/day0.47−23 mg (95% CI: −141, 95)Morning as above + Kawasaki equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h collection (same day)4,623 ± 1,471 mg/day3,323 ± 1,437 mg/day0.521,300 mg (95% CI: 1,152, 1,300)Overestimation appeared to occur across low to high levels of 24‐h Na excretionJi et al. ([2014](#efs25778-bib-0149){ref-type="ref"}) UK/Italy915 untreated M and W (297 white, 326 of black African origin and 292 South Asian; 40--59 years old)1 × timed morning urine sample + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (previous day)NRNRFrom 0.055 in black women to 0.330 in white women Bland--Altman plots indicated consistent bias with overestimate for low and underestimate for high intakes. The bias was mainly due to the inaccuracy of age, weight and height to predict 24‐h creatinine excretion in the three ethnic groups, particularly in those of African origin1 × timed morning urine sample + arithmetic extrapolation to 24‐h scale [Reference:]{.ul} 1 × 24‐h urinary collection (previous day)NRNRFrom 0.116 in black women to 0.367 in white women Bias was detected with both Bland--Altman plots and through quintile analyses (underestimate at low levels and overestimate at high levels)148 white M (mean age 58.3 years), in Italy1 × timed morning urine sample + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (previous day)NRNR0.499 Bland--Altman plot indicated overestimated values in the low 24‐h urinary Na levels and underestimated values in the high 24‐h urinary Na levels indicating consistent bias1 × timed morning urine sample + arithmetic extrapolation to 24‐h scale [Reference:]{.ul} 1 × 24‐h urinary collectionNRNR0.329 Arithmetic extrapolation produced underestimated values in the low 24‐h urinary Na levels and overestimated values in the high 24‐h urinary Na levels indicating consistent biasPolonia et al. ([2017](#efs25778-bib-0248){ref-type="ref"}) Portugal2,399 M and W (51% W; aged 18--96 years)1 × casual urine sample + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (1--7 days before)By quintiles of measured 24‐h Na: Q1: 3,755 ± 876 Q2: 3,973 ± 862 Q3: 3,986 ± 803 Q4: 4,150 ± 837 Q5: 4,342 ± 801By quintiles of measured 24‐h Na: Q1: 2,361 ± 280 Q2: 3,121 ± 192 Q3: 3,825 ± 219 Q4: 4,661 ± 279 Q5: 6,298 ± 9210.232 Intraclass correlation coefficient 0.340 (95% CI: 0.285, 0.391)Difference between measured and estimated 24‐h Na Overall: 11 mg/day (95% CI: −48.6, 70.6) By quintiles of measured 24‐h Na: Q1:−1,394 ± 905 Q2:−852 ± 875 Q3:−161 ± 832 Q4: 511 ± 867 Q5: 1,956 ± 1,140Bias was detected with both Bland--Altman plots and through quintile analyses (overestimate at low levels and underestimate at high levels). Bland--Altman plots indicated that formula‐based estimates seem to have poorer clarification at higher levels than lower levels2,399 M and W (51% W; aged 18--96 years)1 × casual urine sample + Kawasaki equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (1--7 days before)By quintiles of measured 24‐h Na: Q1: 4,844 ± 1,402 Q2: 5,171 ± 1,414 Q3: 5,240 ± 1,363 Q4: 5,524 ± 1,398 Q5: 5,864 ± 1,365By quintiles of measured 24‐h Na: Q1: 2,361 ± 280 Q2: 3,121 ± 192 Q3: 3,825 ± 219 Q4: 4,661 ± 279 Q5: 6,298 ± 9210.25 Intraclass correlation coefficient 0.303 (95% CI: 0.050, 0.475)Overall: −1,277 (95% CI: −1,346.7, −1,206.4) By quintiles of measured 24‐h Na: Q1: −2,483 ± 1,409 Q2: −2,050 ± 1,413 Q3: −1,416 ± 1,380 Q4: −864 ± 1,408 Q5: 434 ± 1,533Bias was detected with both Bland--Altman plots and through quintile analyses (overestimate at low levels and underestimate at high levels)2,399 M and W (51% W; aged 18--96 years)1 × casual urine sample + INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (1--7 days before)By quintiles of measured 24‐h Na: Q1: 3,019 ± 841 Q2: 3,289 ± 848 Q3: 3,467 ± 901 Q4: 3,677 ± 923 Q5: 3,965 ± 894By quintiles of measured 24‐h Na: Q1: 2,361 ± 280 Q2: 3,121 ± 192 Q3: 3,825 ± 219 Q4: 4,661 ± 279 Q5: 6,298 ± 9210.359 Intraclass correlation coefficient 0.457 (95% CI: 0.337, 0.549)Overall: 569 (95% CI: 512.4, 624.7) By quintiles of measured 24‐h Na: Q1: −658 ± 852 Q2: −168 ± 857 Q3: 357 ± 914 Q4: 984 ± 930 Q5: 2,333 ± 1,150Bias was detected with both Bland--Altman plots and through quintile analyses (overestimate at low levels and underestimate at high levels)Zhou et al. ([2017](#efs25778-bib-0331){ref-type="ref"}) China141 M and W (27--64 years)1 morning spot urine specimen + Kawasaki equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (started after the spot collection)246.1 ± 66.8 mmol/day220.8 ± 78.5 mmol/day0.31Median (95% CI) difference between measured and estimated 24‐h Na 6.4 (−17.5, 36.8) mmol/day The individual absolute difference was \> 51.3 mmol/day (3 g salt) in 52.5% of the participants 1 morning spot urine specimen + INTERSALT equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (started after the spot collection)143.6 ± 24.7 mmol/day220.8 ± 78.5 mmol/day0.25−67.3 (−96.5, −46.9) mmol/day The individual absolute difference was \> 51.3 mmol/day (3 g salt) in 63.1% of the participants 1 morning spot urine specimen + Tanaka equation to estimate 24‐h Na [Reference:]{.ul} 1 × 24‐h urinary collection (started after the spot collection)183.7 ± 39.0 mmol/day220.8 ± 78.5 mmol/day0.35−42.9 (−59.1, −24.8) mmol/day The individual absolute difference was \> 51.3 mmol/day (3 g salt) in 48.3% of the participants [^4]

Appendix C -- Daily sodium urinary excretion in children, boys and girls, in European countries {#efs25778-sec-1003}
===============================================================================================

 {#efs25778-sec-0089}

CountryYearMethodologyAge (years)Participants' characteristicsNa excreted in urine (mmol/day)MeanSD95% CIMedian (P50)IQR (P25--P75)Austria (Elmadfa, [2012](#efs25778-bib-0093){ref-type="ref"})2010--2012Casual spot urine samples; 24‐h excretion estimated by multiplying Na concentration by an average urine volume of 1.1 L/day in children7--14392 boys and girlsBoys: 7--9 years: 153 10--12 years: 165 13--14 years: 154 Girls: 7--9 years: 144 10--12 years: 155 13--14 years: 122N/ABoys: 7--9 years: 133--172 10--12 years: 151--178 13--14 years: 122--187 Girls: 7--9 years: 126--163 10--12 years: 143--167 13--14 years: 93--151N/AN/AIceland (Kristbjornsdottir et al., [2012](#efs25778-bib-0171){ref-type="ref"})2002--200324‐h urine collection; Completeness of urine collection assessed by PABA recovery (≥ 85%). For samples with a PABA recovery between 50% and 85%, urinary Na excretion was corrected (formula from Johansson et al. ([1999](#efs25778-bib-0150){ref-type="ref"}))630 boys and 28 girls. A subsample of a national dietary survey, including 6‐year‐old children living in the greater Reykjavik area7123N/AN/AN/AItaly (Campanozzi et al., [2015](#efs25778-bib-0045){ref-type="ref"})2008--201224‐h urine collection with control for urine volume and creatinine6--18766 boys and 658 girls Recruited in participating National Health Service centres in 10 Italian regionsBoys: 129 Girls: 117N/AN/ABoys: 120 Girls: 107Boys: 84--162 Girls: 77--146Spain (Aparicio et al., [2017](#efs25778-bib-0023){ref-type="ref"})201424‐h urine collection; Completeness of urine collection assessed on the basis of Cr excretion (samples with Cr excretion rate \< 0.1 mmol/kg/day considered incomplete (Remer et al., [2002](#efs25778-bib-0255){ref-type="ref"}))7--11Boys: 109 Girls: 96 From five primary schools in various Spanish provincesBoys: 142 Girls: 122Boys: 57 Girls: 41N/ABoys: 136 Girls: 119Boys: 122--177 Girls: 91--154[^5]

Appendix D -- Daily sodium urinary excretion in adult men in European countries {#efs25778-sec-1004}
===============================================================================

 {#efs25778-sec-0090}

Country (reference)YearMethodologyAge (years)N and participants' characteristicsNa excreted in urine (mmol/day)[a](#efs25778-note-0032){ref-type="fn"}MeanSD95% CIMedian (P50)IQR (P25--P75)[d](#efs25778-note-0035){ref-type="fn"}Austria (Elmadfa, [2012](#efs25778-bib-0093){ref-type="ref"})2010--2012Casual spot urine samples; 24‐h excretion estimated by multiplying Na concentration by an average urine volume of 1.75 L/day from a subsample of 19 people from whom 24‐h urine were collected18--64 65--80N/A (total sample: 419 men and women aged 18--64 and 196 men and women aged 65--80) Sample stratified by gender, age and geographical areas18--24 years: 187 25--50 years: 191 51--64 years: 204 65--80 years: 183N/A18--24 years: 152--226 25--50 years: 178--204 51--64 years: 174--235 65--80 years: 139--204N/AN/ABelgium (Koppen et al., [2015](#efs25778-bib-0168){ref-type="ref"})201524‐h urine collection; exclusion of samples with Cr excretion levels outside the normal range of 0.177--0.230 mmol/kg per day for men and self‐reported as incomplete23--6499 Sampled via an occupational health survey centre (random cluster sampling), spread over the different Belgian provinces17963N/A172N/ABelgium2007--20082 × 24‐h urine collection (1 month interval); completeness of urine collection assessed by PABA recovery (≥ 85%). For samples with a PABA recovery between 50% and 85%, urinary Na excretion was corrected (formula from Johansson et al. ([1999](#efs25778-bib-0150){ref-type="ref"}))45--6563209[b](#efs25778-note-0033){ref-type="fn"}N/A195--223N/AN/ACzech Republic[c](#efs25778-note-0034){ref-type="fn"}58252[b](#efs25778-note-0033){ref-type="fn"}78N/A241P5--P95 149--395Norway (De Keyzer et al., [2015](#efs25778-bib-0067){ref-type="ref"})62 Subsamples of the European EFCOVAL study; subjects recruited by convenience sampling through advertisements204[b](#efs25778-note-0033){ref-type="fn"}N/A191--218N/AN/ACroatia (Premužić et al., [2010](#efs25778-bib-0250){ref-type="ref"})200924‐h urine collection; Completeness check not reported46.3 ± 7.3N/A (total sample of 93 men and women) From two out‐patient clinics (one urban, one rural); 'salt‐mapping survey'23174N/AN/AN/ACroatia (Dika et al., [2009](#efs25778-bib-0073){ref-type="ref"})2009Morning spot urine samples; 24‐h Na excretion estimated by applying Kawasaki, INTERSALT and Tanaka equationsN/AN/A (total sample of 1,669 men and women); Random sample (door‐to‐door method) in the continental rural part of CroatiaKawasaki: 22980N/AN/AN/AINTERSALT: 19440N/AN/AN/ATanaka: 18649N/AN/AN/AFinland (Laatikainen et al., [2006](#efs25778-bib-0177){ref-type="ref"})200224‐h urine collection; exclusion of incomplete samples with Cr levels ≤ 5.0 mmol/day or Cr levels ≤ 6.0 mmol/day together with a urine volume \< 1,000 mL25--64423 North Karelia, n = 168 Southwestern Finland, n = 128 Helsinki area, n = 127 Sampled as part of the national FINRISK 2002 study; 10‐year age group and sex‐stratified subsample of the population aged 25--64 years drawn in north Karelia, southwestern Finland and in the Helsinki areaNorth Karelia: 163 Southwestern Finland: 170 Helsinki area: 148N/ANorth Karelia: 153--173 Southwestern Finland: 156--183 Helsinki area: 132--164N/AN/AGermany (Johner et al., [2015](#efs25778-bib-0152){ref-type="ref"})2008--2011Casual spot urine samples; 24‐h Na excretion estimated from the Na:Cr ratio by multiplication with age‐ and sex‐stratified Cr excretion reference values (Remer et al., [2002](#efs25778-bib-0255){ref-type="ref"})18--793,340 18--29 years, n = 507 30--39 years, n = 403 40--49 years, n = 586 50--59 years, n = 630 60--69 years, n = 671 70--79 years, n = 543 Random sample, as part of the German National Health Interview and Examination Survey 2008--2011, representative for the German adult populationN/AN/AOverall: 165--177 18--29 years: 148--173 30--39 years: 163--197 40--49 years: 148--173 50--59 years: 167--189 60--69 years: 165--194 70--79 years: 158--178Overall: 170 18--29 years: 160 30--39 years: 180 40--49 years: 163 50--59 years: 177 60--69 years: 177 70--79 years: 167Overall: 117--252 18--29 years: 113--263 30--39 years: 123--264 40--49 years: 110--231 50--59 years: 115--261 60--69 years: 117--252 70--79 years: 118--245Greece (unpublished data)2013--2014For 7 days, the weight and time of each void was recorded and a sample of urine was collected. For each day, a sample of 10 mL was reconstituted from the individual samples based on the ratio of the volume of each void to the total volume of urinary excretion for the day. Exclusion of samples with Cr levels \> 3,500 mg/day or \< 350 mg/day20--6089 Participants equally divided in each decade of life.15951N/A148 Greece (Vasara et al., [2017](#efs25778-bib-0307){ref-type="ref"})2015--201624‐h urine collection; exclusion of incomplete samples on the basis of (a) Urinary volume \< 500 mL/24‐h, (b) urinary creatinine less than 2 SD from the mean, (c) timing of collection outside the range 23--25 h, (d) self‐reporting of incomplete collection18--74114 Salt intake in northern Greece (SING) Study -- Regional study conducted in Thessaloniki greater metropolitan area. Recruitment was carried out at various sites and venues including churches and workplaces194.376.8180.1--208.6181.9N/AHungary (unpublished data)201024‐h urine collection; completeness of the samples checked on the basis of participants' compliance with the protocolAdults (age not specified)67 Random sample of the Hungarian adult population recruited through primary care physicians19073N/AN/AN/AIreland (Morgan et al., [2008](#efs25778-bib-0215){ref-type="ref"})2007Spot urine samples; daily Na excretion estimated through arithmetic extrapolation (Na concentration (mmol/L) multiplied by 1.97 for men)≥ 18484 Random sample of both Irish citizens and non‐Irish national residents sampled as part of the Survey of Lifestyle, Attitudes and Nutrition (SLAN) 2007, representative of the general population in Ireland≥ 18 years: 176 45--64 years: 188 ≥ 65 years: 158≥ 18 years: 85 45--64 years: 88 ≥ 65 years: 78N/AN/AN/AIreland (Kearney et al., [2013](#efs25778-bib-0158){ref-type="ref"})2010--2011Morning urine samples; daily Na excretion estimated through arithmetic extrapolation (Na concentration (mmol/L) multiplied by 1.97 for men)45--74999 Registered patients attending the Living Health Clinic of Mitchelstown, Ireland, sampled as part of the Cork and Kerry Diabetes and Heart Disease Study Phase IIOverall: 211 45--54 years: 218 55--64 years: 211 65--74 years: 201Overall: 89 45--54 years: 92 55--64 years: 87 55--74 years: 89N/AN/AN/AItaly[e](#efs25778-note-0036){ref-type="fn"} (Donfrancesco et al., [2013](#efs25778-bib-0803){ref-type="ref"}; Cappuccio et al., [2015](#efs25778-bib-0804){ref-type="ref"})2009--201224‐h urine collection; A sample if 24‐h urine volume \< 500 mL or creatinine content referred to body weight \< mean minus 2 SD from the population mean35--791,962 Random samples of the Italian adult population from 20 Italian regions, stratified by age and sex (MINISAL‐GIRCSI Programme)Overall: 183 35--44 years: 184 45--54 years: 190 55--64 years: 182 65--74 years: 180 75--79 years: 176Overall: 70 35--44 years: 72 45--54 years: 70 55--64 years: 70 65--74 years: 70 75--79 years: 60Overall: 180--187 35--44 years: 178--191 45--54 years: 184--197 55--64 years: 176--188 65--74 years: 173--187 75--79 years: 166--185Overall: 175 35--44 years: 174 45--54 years: 182 55--64 years: 173 65--74 years: 170 75--79 years: 172N/ASlovenia (Ribic et al., [2010](#efs25778-bib-0256){ref-type="ref"})200524‐h urine collection; exclusion of incomplete samples with Cr level \< 120 μmol/kg bw per day for men (Osredkar, [1998](#efs25778-bib-0237){ref-type="ref"})25--6561 Participants randomly sampled from census data from all regions, representative of the general population in Slovenia22186N/AN/AN/ASpain (Ortega et al., [2011](#efs25778-bib-0236){ref-type="ref"})200924‐h urine collection; completeness of the samples assessed by considering the correlation between urinary Cr and FFM of each subject; FFM estimated from 24‐h Cr excretion and result compared with measured FFM obtained by electrical bioimpedance method (Lopez‐Sobaler and Quintas et al., [2006](#efs25778-bib-0191){ref-type="ref"})18--60196 Selected as a representative sample of the Spanish young and middle‐aged adult population (from 15 randomly selected provinces; stratified by age and sex)19682N/A196140--250Sweden (Hulthen et al., [2010](#efs25778-bib-0140){ref-type="ref"})200524‐h urine collection; completeness of urine collection assessed by PABA recovery (≥ 85%)18−2079 Participants recruited in the city of Gothenburg, as part of the Gothenburg Obesity and Osteoporosis Determinants (GOOD) study19869N/AN/A Switzerland (Chappuis et al., [2011](#efs25778-bib-0051){ref-type="ref"})2010--201124‐h urine collection; exclusion of incomplete samples on the basis of: (1) urinary volume \< 300 mL/24 h, (2) self‐reporting of incomplete collection, or (3) Cr level ≤ 0.121 mmol/kg bw per day in men≥ 15706 Age‐ and sex‐ stratified sample in various cantons of Switzerland, randomly selected. The low participation rate was compensated by recruiting volunteersOverall: 185 15--29 years: 171 30--44 years: 190 45--59 years: 194 ≥ 60 years: 180N/AN/AN/A Netherlands (Hendriksen et al., [2014](#efs25778-bib-0135){ref-type="ref"})201024‐h urine collection; exclusion of incomplete samples on the basis of (1) Cr excretion ≤ 5 mmol/day, or ≤ 6 mmol/day together with a urine volume \< 1,000 mL or (2) missing or overcollection of more than one urine void19--70180 Individuals participating in an ongoing long‐term monitoring study on chronic disease risk factors (the Doetinchem Cohort Study (DCS)) or randomly drawn from the municipal register of Doetinchem (General Doetinchem Population Sample (GDPS))17463N/A163126--212Netherlands (Hendriksen et al., [2016](#efs25778-bib-0805){ref-type="ref"})201524‐h urine collection; start and end time of the urine collection were recorded. Participants had to report urine losses Based on this data, the researchers determined whether participants had an incomplete urine collection19--70135 Participants aged 50--70 recruited from an ongoing long‐term monitoring study on chronic disease risk factors (the Doetinchem Cohort Study (DCS)); Participants aged 19--49 randomly drawn from the municipal register of Doetinchem (General Doetinchem Population Sample (GDPS)); Exclusion of individuals had participated in the 24‐h urine test in 2006 and 2010 in the study of Hendriksen et al. ([2014](#efs25778-bib-0135){ref-type="ref"}), kidney patients and pregnant womenN/AN/AN/AOverall: 153 19--49 years: 146 50--70 years: 174Overall: 125--202 19--49 years: 110--195 50--70 years: 138--214United Kingdom (Sadler et al., [2011](#efs25778-bib-0262){ref-type="ref"})201124‐h urine collection; exclusion of samples on the basis of PABA recovery (\< 70% (incomplete) or \> 104% (unfeasibly high); individuals who elected not to take PABA, or did not take all PABA tablets, but recorded they had completed a 24‐h urine collection were included if recorded collection time was collected between 23 and 25 h19--64250 Participants from the England National Diet and Nutrition Survey sample and from a 'Na boost' study; stratified sample randomly selected in various regions of England19--34 years: 162 35--49 years: 171 50--64 years: 14119--34 years: 69 35--49 years: 66 50--64 years: 82N/A19--34 years: 159 35--49 years: 165 50--64 years: 133P2.5--P97.5 19--34 years: 72--296 35--49 years: 73--321 50--64 years: 54--308[^6][^7][^8][^9][^10][^11]

Appendix E -- Daily sodium urinary excretion in adult women in European countries {#efs25778-sec-1005}
=================================================================================

 {#efs25778-sec-0091}

CountryYearMethodologyAge (years)N and participants' characteristicsNa excreted in urine (mmol/day)[a](#efs25778-note-1030){ref-type="fn"}MeanSD95% CIMedian (P50)IQR (P25--P75)[b](#efs25778-note-0041){ref-type="fn"}Austria (Elmadfa, [2012](#efs25778-bib-0093){ref-type="ref"})2010--2012Casual spot urine samples; 24‐h excretion estimated by multiplying Na concentration by an average urine volume of 1.75 L/day from a subsample of 19 people from whom 24‐h urine were collected18--64 65--80NA (total sample: 419 men and women aged 18--64 and 196 men and women aged 65--80) Sample stratified by gender, age and geographical areas18--24 years: 157 25--50 years: 161 51--64 years: 130 65--80 years: 152N/A18--24 years: 117--200 25--50 years: 143--178 51--64 years: 104--157 65--80 years: 126--174N/AN/ABelgium (Koppen et al., [2015](#efs25778-bib-0168){ref-type="ref"})201524‐h urine collection; exclusion of samples with Cr excretion levels outside the normal range of 0.133--0.177 mmol/kg per day for women and self‐reported as incomplete23--64106; Sampled via an occupational health survey centre (random cluster sampling), spread over the different Belgian provinces13756N/A122N/ABelgium2007--20082 × 24‐h urine collection (1 month interval); completeness of urine collection assessed by PABA recovery (≥ 85%). For samples with a PABA recovery between 50% and 85%, urinary Na excretion was corrected (formula from Johansson et al. ([1999](#efs25778-bib-0150){ref-type="ref"}))45--6560173[b](#efs25778-note-1031){ref-type="fn"}N/A161--185N/AN/ACzech Republic[a](#efs25778-note-0040){ref-type="fn"}60182[b](#efs25778-note-1031){ref-type="fn"}56 173P5‐P95 101--288Norway (De Keyzer et al., [2015](#efs25778-bib-0067){ref-type="ref"})62 Subsamples of the European EFCOVAL study; subjects recruited by convenience sampling through advertisements151[b](#efs25778-note-1031){ref-type="fn"}N/A141--161N/AN/ACroatia (Premužić et al., [2010](#efs25778-bib-0250){ref-type="ref"})200924‐h urine collection; completeness check not reported46.3 ± 7.3N/A (total sample of 93 men and women); From two out‐patient clinics (one urban, one rural); 'salt‐mapping survey'17773N/AN/A Croatia (Dika et al., [2009](#efs25778-bib-0073){ref-type="ref"})2009Morning spot urine samples; 24‐h Na excretion was estimated by applying Kawasaki, INTERSALT and Tanaka equationsN/AN/A (total sample of 1,669 men and women); Random sample (door‐to‐door method) in the continental rural part of CroatiaKawasaki: 21478N/AN/A INTERSALT: 22256N/AN/A Tanaka: 17869N/AN/A Finland (Laatikainen et al., [2006](#efs25778-bib-0177){ref-type="ref"})200224‐h urine collection; exclusion of incomplete samples with Cr levels ≤ 5.0 mmol/day or Cr levels ≤ 6.0 mmol/day together with a urine volume \< 1,000 mL25--64486 North Karelia, n = 174 Southwestern Finland, n = 156 Helsinki area, n = 156 Sampled as part of the national FINRISK 2002 study; 10‐year age group and sex‐stratified subsample of the population aged 25--64 years drawn in north Karelia, southwestern Finland and in the Helsinki areaNorth Karelia: 128 Southwestern Finland: 127 Helsinki area: 119N/ANorth Karelia: 120--135 Southwestern Finland: 119--135 Helsinki area: 111--127N/A Germany (Johner et al., [2015](#efs25778-bib-0152){ref-type="ref"})2008--2011Casual spot urine samples; 24‐h Na excretion estimated from the Na:Cr ratio by multiplication with age‐ and sex‐stratified Cr excretion reference values (Remer et al., [2002](#efs25778-bib-0255){ref-type="ref"})18--793,622 18--29 years, n = 507 30--39 years, n = 403 40--49 years, n = 586 50--59 years, n = 630 60--69 years, n = 671 70--79 years, n = 543 Random sample, as part of the German National Health Interview and Examination Survey 2008--2011, representative for the German adult populationN/AN/AOverall: 138--148 18--29 years: 116--136 30--39 years: 129--153 40--49 years: 141--165 50--59 years: 146--167 60--69 years: 134--153 70--79 years: 127--144Overall: 143 18--29 years: 126 30--39 years: 139 40--49 years: 155 50--59 years: 156 60--69 years: 146 70--79 years: 134Overall: 92--217 18--29 years: 85--184 30--39 years: 96--205 40--49 years: 103--226 50--59 years: 96--235 60--69 years: 87--212 70--79 years: 90--223Greece (unpublished data)2013--2014For 7 days, the weight and time of each void were recorded and a sample of urine was collected. For each day, a sample of 10 mL was reconstituted from the individual samples based on the ratio of the volume of each void to the total volume of urinary excretion for the day. Exclusion of samples on the basis of Cr excretion (\> 3,500 mg/day or \< 350 mg/day)20--6083 Participants equally divided in each decade of life13048N/A124 Greece (Vasara et al., [2017](#efs25778-bib-0307){ref-type="ref"})2015--201624‐h urine collection; exclusion of incomplete samples on the basis of (a) urinary volume \< 500 mL/24 h, (b) urinary creatinine less than 2 SD from the mean, (c) timing of collection outside the range 23--25 h and (d) self‐reporting of incomplete collection18--75138 Salt intake in northern Greece (SING) Study -- regional study conducted in Thessaloniki greater metropolitan area. Recruitment was carried out at various sites and venues including churches and workplaces158.564.1147.7--169.3151.0 Hungary (unpublished data)201024‐h urine collection; completeness of the samples checked on the basis of participants' compliance with the protocolAdults (age not specified)86 Random sample of the Hungarian adult population recruited through primary care physicians16371N/AN/A Ireland (Morgan et al., [2008](#efs25778-bib-0215){ref-type="ref"})2007Spot urine samples; daily Na excretion estimated through arithmetic extrapolation (Na concentration (mmol/L) multiplied by 1.67 for women)≥ 18611 Random sample of both Irish citizens and non‐Irish national residents sampled as part of the Survey of Lifestyle, Attitudes and Nutrition (SLAN) 2007, representative of the general population in Ireland≥ 18 years: 128 45--64 years: 132 ≥ 65 years: 116≥ 18 years: 72 45--64 years: 75 ≥ 65 years: 62N/AN/AN/AIreland (Kearney et al., [2013](#efs25778-bib-0158){ref-type="ref"})2010--2011Morning urine samples; daily Na excretion estimated through arithmetic extrapolation (Na concentration (mmol/L) multiplied by 1.67 for women)45--741,029 Registered patients attending the Living Health Clinic of Mitchelstown, Ireland, sampled as part of the Cork and Kerry Diabetes and Heart Disease Study Phase IIoverall: 129 45--54: 138 55--64: 128 65--74: 125overall: 64 45--54: 72 55--64: 61 65--74: 59N/AN/AN/AItaly[c](#efs25778-note-0941){ref-type="fn"} (Donfrancesco et al., [2013](#efs25778-bib-0803){ref-type="ref"}; Cappuccio et al., 2015)2009--201224‐h urine collection; A sample if 24‐h urine volume \< 500 mL or creatinine content referred to body weight \< mean minus 2 SD from the population mean35--791,900 Random samples of the Italian adult population from 20 Italian regions, stratified by age and sex (MINISAL‐GIRCSI Programme)Overall: 142 35--44 years: 142 45--54 years: 147 55--64 years: 143 65--74 years: 140 75--79 years: 135Overall: 57 35--44 years: 61 45--54 years: 58 55--64 years: 54 65--74 years: 55 75--79 years: 56Overall: 139--145 35--44 years: 136--148 45--54 years: 141--152 55--64 years: 138--148 65--74 years: 135--145 75--79 years: 126--144Overall: 136 35--44 years: 135 45--54 years: 141 55--64 years: 138 65--74 years: 132 75--79 years: 129 Slovenia (Ribic et al., [2010](#efs25778-bib-0256){ref-type="ref"})200524‐h urine collection; exclusion of incomplete samples with Cr level \< 120 μmol/kg bw per day for men (Osredkar, [1998](#efs25778-bib-0237){ref-type="ref"})25--6582 Participants randomly sampled from census data from all regions, representative of the general population in Slovenia17074N/AN/AN/ASpain (Ortega et al., [2011](#efs25778-bib-0236){ref-type="ref"})200924‐h urine collection; completeness of the samples assessed by considering the correlation between urinary Cr and FFM of each subject; FFM estimated from 24‐h Cr excretion and result compared with measured FFM obtained by electrical bioimpedance method (Lopez‐Sobaler and Quintas et al., [2006](#efs25778-bib-0191){ref-type="ref"})18--60222 Selected as a representative sample of the Spanish young and middle‐aged adult population (from 15 randomly selected provinces; stratified by age and sex)14366N/A13197--178Switzerland (Chappuis et al., [2011](#efs25778-bib-0051){ref-type="ref"})2010--201124‐h urine collection; exclusion of incomplete samples on the basis of: (1) urinary volume \< 300 mL/24 h, (2) self‐reporting of incomplete collection, or (3) Cr level ≤ 0.082 mmol/kg bw per day in women≥ 15742 Age‐ and sex‐ stratified sample in various cantons of Switzerland, randomly selected. The low participation rate was compensated by recruiting volunteersOverall: 137 15--29 years: 135 30--44 years: 140 45--59 years: 144 ≥ 60 years: 125N/AN/AN/AN/ANetherlands (Hendriksen et al., [2014](#efs25778-bib-0135){ref-type="ref"})201024‐h urine collection; exclusion of incomplete samples on the basis of (1) Cr excretion ≤ 5 mmol/day, or ≤ 6 mmol/day together with a urine volume \< 1,000 mL or (2) missing or overcollection of more than one urine void19--70180 Individuals participating in an ongoing long‐term monitoring study on chronic disease risk factors (the Doetinchem Cohort Study (DCS)) or randomly drawn from the municipal register of Doetinchem (General Doetinchem Population Sample (GDPS))12843N/A12296--154Netherlands (Hendriksen et al., [2016](#efs25778-bib-0805){ref-type="ref"})201524‐h urine collection; Start and end time of the urine collection were recorded. Participants had to report urine losses Based on this data, the researchers determined whether participants had an incomplete urine collection19--70154 Participants aged 50--70 recruited from an ongoing long‐term monitoring study on chronic disease risk factors (the Doetinchem Cohort Study (DCS)); Participants aged 19--49 randomly drawn from the municipal register of Doetinchem (General Doetinchem Population Sample (GDPS)); Exclusion of individuals had participated in the 24‐h urine test in 2006 and 2010 in the study of Hendriksen et al. ([2014](#efs25778-bib-0135){ref-type="ref"}), kidney patients and pregnant womenN/AN/AN/AOverall: 120 19--49 years: 122 50--70 years: 113Overall: 93--146 19--49 years: 103--148 50--70 years: 85--140United Kingdom (Sadler et al., [2011](#efs25778-bib-0262){ref-type="ref"})201124‐h urine collection; exclusion of samples on the basis of PABA recovery (\< 70% (incomplete) or \> 104% (unfeasibly high); individuals who elected not to take PABA, or did not take all PABA tablets, but recorded they had completed a 24‐h urine collection were included if recorded collection time was collected between 23--25 h19--64297 Participants from the England National Diet and Nutrition Survey sample and from a 'sodium boost' study; stratified sample randomly selected in various regions of England19--34 years: 122 35--49 years: 116 50--64 years: 11219--34 years: 55 35--49 years: 52 50--64 years: 59N/A19--34 years: 120 35--49 years: 104 50--64 years: 108P2.5--P97.5 19--34 years: 47--261 35--49 years: 57--206 50--64 years: 44--218[^12][^13][^14][^15][^16][^17]

Appendix F -- Balance studies {#efs25778-sec-1006}
=============================

F.1.. Evidence table {#efs25778-sec-0092}
--------------------

StudySubjectsConditionsDurationNa intake (mean)Balance (mean ± SD)Regulatory hormonesLimitations**Data in adults**Holbrook et al. ([1984](#efs25778-bib-0137){ref-type="ref"})12 M/16 F (20--53 years)Free living7 day × 4 (1 week per season)All = 3.4 g (148 mmol)/day M = 4.2 g (183 mmol)/day F = 2.7 g (117 mmol)/dayAll = +0.47 ± 0.32 g (+20 ± 14 mmol)/day M = +0.73 ± 0.83 g (+32 ± 36 mmol)/day F = +0.26 ± 0.48 g (11 ± 21 mmol)/dayNot measuredDermal losses not measuredAllsopp ([1997](#efs25778-bib-0012){ref-type="ref"}); Allsopp et al. ([1998](#efs25778-bib-0013){ref-type="ref"})25 M (18--40 years)Controlled 25°C + 40°C3 day + 5 dayLow = 1.5 g (65 mmol)/day Mod = 4 g (174 mmol)/day High = 8 g (348 mmol)/dayOn day 8 +0.04 ± 0.35 g +0.79 ± 0.64 g +0.67 ± 1.19 gAldosterone ↑/↑ Aldosterone --/↑ Aldosterone --/----Nishimuta et al. ([2012](#efs25778-bib-0226){ref-type="ref"})131 F (18--26 years) (13 studies)Controlled2--4 day + 8--12 day2.5 g (107 mmol)‐4.8 g (209 mmol)/day+6.07 ± 4.06 mg/kg bwNot measuredSweat loss in five studies only**Data in children**Palacios et al. ([2004](#efs25778-bib-0239){ref-type="ref"})36 adolescent girls (14 W, 22 B; 12.4 ± 0.3 years)Semi‐controlled. Summer time3 weeks × 2 (crossover)[Low intake:]{.ul} 1.31 g/day [High intake:]{.ul} 3.95 g/day[Low intake:]{.ul} +0.4 ± 0.07 g/day among blacks (n = 19) +0.2 ± 0.04 g/day among whites (n = 12) [High intake:]{.ul} +1.0 ± 0.14 g/day among blacks (n = 19) +0.3 ± 0.09 g/day among whites (n = 10)Aldosterone ↑ Aldosterone ↑ Aldosterone -- Aldosterone ----[^18]

F.2.. Mechanistic data {#efs25778-sec-0093}
----------------------

###### 

Effect of sodium intake on blood catecholamines and aldosterone concentrations and renin activity -- meta‐analyses of trials of at least 4 weeks

  Ref                                                           Inclusion criteria                                                                        Included studies                                                      N                                                        Pooled effect (95% CI)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------------------------------------------- ----------------------------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- -------------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ------- ----------------------------------------------------------- ------- ------- ------- ------- ---- ----------------------------------------------------------
  He et al. ([2013](#efs25778-bib-0129){ref-type="ref"})        RCTs allocating to a modestly reduced salt intake or usual salt intake                    A reduction in 24‐h urinary sodium within the range of 40--120 mmol   At least 4 weeks                                         Adults (≥ 18 years) (trials in children or pregnant women excluded), irrespective of ethnicityWith normal or raised BP Trials in patients with other diseases than hypertension were excluded                                                                                      Studies with concomitant interventions (i.e. non‐pharmacological interventions, antihypertensive or other medications) were excluded                                                                             RA                                          **X**          **X**           **X**   **X**   **X**                   **X**   **X**   **X**   **X**           **X**                                                               **X**   **X**           **X**   13   0.26 (0.17, 0.36) ng/mL per h
  ALD                                                           **X**                                                                                                                                                                                                                    **X**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **X**                                                                      **X**           **X**           **X**                   **X**           **X**   8       73.20 (44.92, 101.48) pmol/L                                                                     
  NOR                                                                                                                                                                                                                                                                                    **X**                                                                                                                                                                                                                                                                              **X**                                                                                                                                                                                                            **X**                                                              **X**           **X**                                   **X**                           6       31.67 (6.57, 56.77) pg/mL                                                                        
  ADR                                                                                                                                                                                                                                                                                    **X**                                                                                                                                                                                                                                                                              **X**                                                                                                                                                                                                                                                                               **X**                                                   **X**                           4       6.70 (−0.25, 13.64) pg/mL                                                                        
  Graudal et al. ([2011](#efs25778-bib-0118){ref-type="ref"})   RCTs allocating subjects to either a low or a high sodium diet                            Any                                                                   Any. Subgroup analysis restricted to studies ≥ 4 weeks   Any age, irrespective of ethnicityWith normal or raised BP Trials in patients with other diseases than elevated blood pressure were excluded                                                                                                                                       Studies with concomitant interventions were included if the co‐intervention was identical during the low and high sodium diet                                                                                    RA[a](#efs25778-note-0192){ref-type="fn"}   **?**          **?**           **?**   **?**   **?**   **?**   **?**   **?**   **?**           **?**                   **?**                                                       **?**   **?**   **?**   **?**   14   0.47 (0.35, 0.60)[b](#efs25778-note-0193){ref-type="fn"}
  ALD                                                           **X**                                                                                                                                                                                                                    **X**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               **X**                                                      **X**   **X**   **X**           **X**                                   **X**           **X**   9       0.70 (0.37, 1.04)[b](#efs25778-note-0193){ref-type="fn"}                                         
  NOR                                                                                                                                                                                                                                                                                    **X**                                                                                                                                                                                                                                                                              **X**                                                                                                                                                                                                            **X**                                                              **X**                           **X**                   **X**                           6       0.06 (−0.19, 0.32)[b](#efs25778-note-0193){ref-type="fn"}                                        
  ADR                                                                                                                                                                                                                                                                                    **X**                                                                                                                                                                                                                                                                              **X**                                                                                                                                                                                                                                                                               **X**                           **X**                   **X**                           5       0.24 (−0.04, 0.52)[b](#efs25778-note-0193){ref-type="fn"}                                        
  WHO (2012c)                                                   RCTs which included an intervention that planned to or achieved a reduced sodium intake   A reduction in 24‐h urinary sodium \> 40 mmol/day                     At least 4 weeks                                         Adults (≥16 years), irrespective of ethnicityWith normal or raised BPTrials in patients with chronic conditions (e.g. overweight or obesity, diabetes, chronic nephrolithiasis) were included Studies targeting patients who were acutely ill or infected with HIV were excluded   Studies with concomitant interventions (e.g. physical activity, medical treatment (e.g. diuretics or beta blockers)) were included if the co‐intervention was identical in the intervention and control groups   RA                                          Not assessed                                                                                                                                                                                                            
  ALD                                                           Not assessed                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  NOR                                                                                                                                                                                                                           **X**                                                    **X**                                                                                                                                                                                                                                                                              **X**                                                                                                                                                                                                            **X**                                                              **X**           **X**                                   **X**                           7       8.23 (−27.84, 44.29) pg/mL                                                                       
  ADR                                                                                                                                                                                                                                                                                    **X**                                                                                                                                                                                                                                                                              **X**                                                                                                                                                                                                                                                                               **X**                                                   **X**                           4       6.90 (−2.17, 15.96) pg/mL                                                                        

ADR: adrenaline; ALD: aldosterone; BP: blood pressure; NOR: noradrenaline; RA: renin activity; RCT: randomised controlled trial.

Through their systematic review, Graudal et al. ([2011](#efs25778-bib-0118){ref-type="ref"}) retrieved 15 trials lasting ≥ 4 weeks that reported on RA. However, the paper indicates that the pooled analysis for the subgroup of studies lasting ≥ 4 weeks included 14 trials. The list of references included in the pooled analysis is not provided.

Standardised mean difference, calculated for outcome measures with different units. The difference in effect between two treatments is divided by the standard deviation of the measurements.

John Wiley & Sons, Ltd

###### 

Results from long‐term metabolic study from Rakova et al. ([2013](#efs25778-bib-0253){ref-type="ref"})

<table><thead><tr class="header"><th>Refs</th><th>Subjects</th><th>Conditions</th><th>Duration – NaCl target intake</th><th>Na intake (g/day)</th><th>Na excretion<a href="#efs25778-note-0047" data-ref-type="fn">a</a> (g/day)</th><th>Diff = Na intake–UNa (mean ± SD)<a href="#efs25778-note-0048" data-ref-type="fn">b</a></th><th>Regulatory hormones (in urine) (mean ± SD)<a href="#efs25778-note-0048" data-ref-type="fn">b</a></th><th>Comment</th><th></th><th></th></tr></thead><tbody><tr class="odd"><td>Rakova et al. (<a href="#efs25778-bib-0253" data-ref-type="ref">2013</a>)</td><td><u>Mars105</u> <a href="#efs25778-note-0049" data-ref-type="fn">c</a> 4 men</td><td><p>Controlled</p><p>(18–25°C; no rigorous activities)</p></td><td><p><u>105 days, 3 periods:</u></p><p>35 day – 12 g NaCl</p><p>35 day – 9 g NaCl</p><p>29 day – 6 g NaCl</p></td><td><p>4.9 g/day</p><p>3.6 g/day</p><p>2.5 g/day</p></td><td><p>4.3 ± 0.8 g/day</p><p>3.3 ± 0.7 g/day</p><p>2.6 ± 0.9 g/day</p></td><td><p>+0.5 ± 0.9</p><p>+0.3 ± 0.7</p><p>–0.1 ± 0.9</p></td><td><p>12.0 ± 4.8</p><p>13.5 ± 4.7</p><p>15.3 ± 5.5</p></td><td><p>24.8 ± 10.1</p><p>21.6 ± 8.4</p><p>18.8 ± 6.6</p></td><td><p>83.8 ± 21.9</p><p>73.3 ± 20.5</p><p>72.3 ± 21.1</p></td><td>Weekly and monthly rhythms of body Na accumulation and release correlated with fluctuations in aldosterone, cortisol and cortisone – independent of Na intake</td></tr><tr class="even"><td><u>Mars520</u> <a href="#efs25778-note-0049" data-ref-type="fn">c</a> 6 men</td><td>As above</td><td><p><u>205 days, 4 periods:</u></p><p>61 day – 12 g NaCl</p><p>60 day – 9 g NaCl</p><p>60 day – 6 g NaCl</p><p>36 day – 12 g NaCl</p></td><td><p>4.5 g/day</p><p>3.3 g/day</p><p>2.2 g/day</p><p>4.4 g/day</p></td><td><p>4.2 ± 0.8 g/day</p><p>2.9 ± 0.8 g/day</p><p>1.9 ± 0.6 g/day</p><p>4.1 ± 1.0 g/day</p></td><td><p>0.2 ± 0.9</p><p>0.4 ± 0.9</p><p>0.3 ± 0.8</p><p>0.3 ± 1.1</p></td><td><p>11.4 ± 4.8</p><p>13.5 ± 4.4</p><p>15.4 ± 5.3</p><p>9.2 ± 3.6</p></td><td><p>24.0 ± 7.2</p><p>20.1 ± 5.0</p><p>17.4 ± 5.4</p><p>22.8 ± 7.4</p></td><td><p>76.3 ± 16.3</p><p>63.7 ± 16.4</p><p>68.7 ± 18.9</p><p>71.7 ± 19.2</p></td><td></td><td></td></tr></tbody></table>

Na: sodium; NaCl: sodium chloride; SD: standard deviation; UNa: sodium urinary excretion.

Sweat and faecal losses not measured.

Mean over the last 29 days of each period.

The paper reports on two studies named Mars105 and Mars 520.

John Wiley & Sons, Ltd
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QuestionRatingExplanation for expert judgement**1. Was administered dose or exposure level adequately randomised?** **Key question**++There is direct evidence that subjects (or clusters) were allocated to any study group including controls using a method with a random component. Acceptable methods of randomisation include: referring to a random number table, using a computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice, or drawing of lots (Higgins and Green, [2011](#efs25778-bib-0806){ref-type="ref"}). Restricted randomisation (e.g. blocked randomisation) to ensure particular allocation ratios will be considered low risk of bias. Similarly, stratified randomisation and minimisation approaches that attempt to minimise imbalance between groups on significant prognostic factors (e.g. body weight) will be considered acceptable+There is indirect evidence that subjects (or clusters) were allocated to study groups using a method with a random component (i.e. authors state that allocation was random, without description of the method used) **OR** It is deemed that allocation without a clearly random component during the study would not appreciably bias results. For example, approaches such as biased coin or urn randomisation, replacement randomisation, mixed randomisation, and maximal randomisation may require consultation with a statistician to determine risk‐of‐bias rating (Higgins and Green, [2011](#efs25778-bib-0806){ref-type="ref"})NRThere is insufficient information provided about how subjects (or clusters) were allocated to study groups.−There is indirect evidence that subjects (or clusters) were allocated to study groups using a method with a non‐random component. *NOTE: Non‐random allocation methods may be systematic, but have the potential to allow participants or researchers to anticipate the allocation to study groups. Such 'quasi‐random' methods include alternation, assignment based on date of birth, case record number, or date of presentation to study*− --There is direct evidence that subjects (or clusters) were allocated to study groups using a non‐random method including judgement of the clinician, preference of the participant, the results of a laboratory test or a series of tests, or availability of the intervention (Higgins and Green, [2011](#efs25778-bib-0806){ref-type="ref"})**2. Was allocation to study groups adequately concealed?**++There is direct evidence that at the time of recruitment the research personnel and subjects did not know what study group subjects were allocated to, and it is unlikely that they could have broken the blinding of allocation until after assignment was complete and irrevocable. Acceptable methods used to ensure allocation concealment include central allocation (including telephone, web‐based and pharmacy‐controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes; or equivalent methods+There is indirect evidence that the research personnel and subjects did not know what study group subjects were allocated to and it is unlikely that they could have broken the blinding of allocation until after recruitment was complete and irrevocable **OR** It is deemed that lack of adequate allocation concealment would not appreciably bias results (e.g. some crossover designs)NRThere is insufficient information provided about allocation to study groups−There is indirect evidence that at the time of recruitment it was possible for the research personnel and subjects to know what study group subjects were allocated to, or it is likely that they could have broken the blinding of allocation before assignment was complete and irrevocable *NOTE: Inadequate methods include using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes used without appropriate safeguards (e.g. if envelopes were unsealed or non‐opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; or any other explicitly unconcealed procedure. For example, if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed*− --There is direct evidence that at the time of recruitment it was possible for the research personnel and subjects to know what study group subjects were allocated to, or it is likely that they could have broken the blinding of allocation before recruitment was complete and irrevocable**3. Were the research personnel and human subjects blinded to the study group during the study?**++There is direct evidence that the subjects and research personnel were adequately blinded to study group, **AND** it is unlikely that they could have broken the blinding during the study. Methods used to ensure blinding include central allocation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes; or equivalent methods+There is indirect evidence that the subjects and research personnel were adequately blinded to study group, **AND** it is unlikely that they could have broken the blinding during the study **OR** There is direct evidence for no blinding during the study (including where it was not possible to implement) AND it is deemed that no blinding would appreciably bias results BUT bias minimising measures have been adequately implemented **OR** It is deemed that lack of adequate blinding or no blinding during the study would not appreciably bias results (e.g. controls unlikely to behave differently for factors other than sodium intake) (e.g. cross‐over)NRThere is insufficient information provided about blinding to study group during the study (including possible breaking and minimising measures)−There is indirect evidence that it was possible for research personnel or subjects to infer the study group **AND** it is deemed that lack of adequate blinding or no blinding during the study would appreciably bias results (e.g. no comparable treatment of controls, including not comparable exposure to factors other than the interventions of interest; differential behaviour) **AND** no bias minimising measures have been adequately implemented− --There is direct evidence for lack of adequate blinding of the study group (including no blinding or incomplete blinding) of research personnel and subjects **AND** it is deemed that lack of adequate blinding or no blinding during the study would appreciably bias results (e.g. no comparable treatment of controls, including not comparable exposure to factors other than the interventions of interest, differential behaviour) **AND** no bias minimising measures have been adequately implemented**4. Were outcome data complete without attrition or exclusion from analysis?**++There is direct evidence that there was no loss of subjects during the study and outcome data were complete **OR** Loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented when human subjects were removed from a study or analyses. Review authors should be confident that the participants included in the analysis are exactly those who were randomised into the trial. Acceptable handling of subject attrition includes: very few missing outcome data (e.g. less than 10% in each group (Genaidy et al., [2007](#efs25778-bib-0807){ref-type="ref"})) **AND** reasons for missing subjects unlikely to be related to outcome (for survival data, censoring unlikely to be introducing bias) **AND** missing outcome data balanced in numbers across study groups, with similar reasons for missing data across groups (i.e. unlikely to be related to exposure) **OR** Analyses (such as intention‐to‐treat analysis) in which missing data have been imputed using appropriate methods (ensuring that the characteristics of subjects lost to follow up or with unavailable records are described in identical way and are not significantly different from those of the study participants) *NOTE: Participants randomised but subsequently found not to be eligible need not always be considered as having missing outcome data) (Higgins and Green,* [2011](#efs25778-bib-0806){ref-type="ref"}+There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented when human subjects were removed from a study **OR** It is deemed that the proportion lost to follow‐up would not appreciably bias results (e.g. less than 20% in each group in parallel studies (Genaidy et al., [2007](#efs25778-bib-0807){ref-type="ref"})). This would include reports of no statistical differences in characteristics of subjects lost to follow up or with unavailable records from those of the study participants. Generally, the higher the ratio of participants with missing data to participants with events, the greater potential there is for bias. For studies with a long duration of follow‐up, some withdrawals for such reasons are inevitable *NB: For crossover designs, this may be less of an issue*NRThere is insufficient information provided about numbers of subjects lost to follow‐up−There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large (e.g. greater than 20% in each group in parallel studies (Genaidy et al., [2007](#efs25778-bib-0807){ref-type="ref"})) and not adequately addressed− --There is direct evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large and not adequately addressed (e.g. greater than 20% in each group in parallel studies (Genaidy et al., [2007](#efs25778-bib-0807){ref-type="ref"})). Unacceptable handling of subject attrition includes: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across study groups (i.e. likely to be related to the exposure); or potentially inappropriate application of imputation**5. Can we be confident in the exposure characterisation?** **Key question**++There is direct evidence that the exposure (including compliance with the treatment, if applicable) was independently characterised **AND** that exposure was consistently administered (i.e. with the same method and time‐frame) across treatment groups *NOTE: applies to studies that collected single or multiple 24‐h urine samples for each time point AND checked the completeness of the samples (by any kind of method)*+There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was independently characterised AND there is indirect evidence that exposure was consistently administered (i.e. with the same method and time‐frame) across treatment groups *NOTE: applies to studies that collected single or multiple 24‐h urine samples without completeness check of the urine samples (or not reported), but there is no evidence for concern*NRThere is insufficient information provided to judge the exposure characterisation−There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly validated methods (e.g. FFQs, spot urine etc.) **OR** There is indirect evidence that the exposure assessment was probably biased *NOTE: applies to studies for which 24‐h urine samples were collected but there is indirect evidence that the proportion of incomplete samples included in the analysis was substantial*− --There is direct evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly validated methods (e.g. FFQs, spot urine etc.) **OR** There is direct evidence that the exposure assessment was biased *NOTE: applies to studies for which 24 h urine samples were collected but there is direct evidence that the proportion of incomplete samples included in the analysis was substantial*6. Can we be confident in the outcome assessment? Key question++There is direct evidence that the outcome was assessed using well‐established methods (e.g. for office BP: according to a clearly described methodology, including e.g. repeated measurements per visit, trained technician, resting period before each measurement) **AND** There is direct evidence that the outcome assessors were adequately blinded to the study group, and it is unlikely that they could have broken the blinding prior to reporting outcomes+There is indirect evidence that the outcome was assessed using acceptable methods (i.e. deemed valid and reliable but not the gold standard) **OR** it is deemed that the outcome assessment methods used would not appreciably bias results **AND** There is indirect evidence that the outcome assessors were adequately blinded to the study group, and it is unlikely that they could have broken the blinding before reporting outcomes **OR** it is deemed that lack of adequate blinding of outcome assessors would not appreciably bias resultsNRThere is insufficient information provided about blinding of outcome assessors or the method of measurement−There is indirect evidence that the outcome assessment method is an unacceptable method **OR** There is indirect evidence that it was possible for outcome assessors to infer the study group before reporting outcomes− --There is direct evidence that the outcome assessment method is an unacceptable method **OR** There is direct evidence for lack of adequate blinding of outcome assessors (including study subjects if home BP is the outcome), including no blinding or incomplete blinding**7. Were all measured outcomes reported?**++There is direct evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the protocol, methods, abstract, and/or introduction (that are relevant for the evaluation) have been reported+There is indirect evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have been reported **OR** Analyses that had not been planned in advance (i.e. retrospective unplanned subgroup analyses) are clearly indicated as such and it is deemed that the unplanned analyses were appropriate and selective reporting would not appreciably bias results (e.g. appropriate analyses of an unexpected effect). This would include outcomes reported with insufficient detail such as only reporting that results were statistically significant (or not)NRThere is insufficient information provided about selective outcome reporting−There is indirect evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have not been reported **OR** There is indirect evidence that unplanned analyses were included that may appreciably bias result-- --There is direct evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have not been reported. In addition to not reporting outcomes, this would include reporting outcomes based on composite score without individual outcome components or outcomes reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified or reporting outcomes not pre‐specified, or that unplanned analyses were included that would appreciably bias results**8. Were there no other potential threats to internal validity?** ***NOTE:**   Baseline characteristics should be appraised **only if** Q1 (randomisation) was rated with ++/+ and Q2 (allocation concealment) was rated with ++/+/NR*++There is evidence that variables, other than the exposure and outcome, did not differ between groups during the course of the intervention in a way that could bias results [AND, in case randomisation is rated 'probably low'/'definitely low' RoB and allocation concealment is rated 'probably low'/'definitely low' RoB or 'not reported':]{.ul} There is no evidence of differences in baseline characteristics **OR** There is no information on both BUT no concern+1. There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the intervention AND it is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis) [AND, in case randomisation is rated 'probably low'/'definitely low' RoB and allocation concealment is rated 'probably low'/'definitely low' RoB or 'not reported':]{.ul} There is evidence that reported variables differed between groups at baseline ANDIt is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis)‐‐‐‐‐‐‐OR2. There is evidence that variables, other than the exposure and outcome, did not differ between groups during the course of the intervention in a way that could bias results [AND, in case randomisation is rated 'probably low'/'definitely low' RoB and allocation concealment is rated 'probably low'/'definitely low' RoB or 'not reported':]{.ul} There is evidence that reported variables differed between groups at baseline.AND It is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis).‐‐‐‐‐‐OR3. There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the intervention.ANDIt is deemed that these differences would not appreciably bias results (no concern or adequately addressed by analysis) [AND, in case randomisation is rated 'probably low'/'definitely low' RoB and allocation concealment is rated 'probably low'/'definitely low' RoB or 'not reported':]{.ul} There is no evidence of differences in baseline characteristics.ORThere is no information BUT no concern−There is no information on baseline characteristics AND/OR there is no information about differences between groups during the course of the intervention. AND There is concern− --There is evidence that variables, other than the exposure and outcome, differed between groups during the course of the intervention.ANDIt is deemed that these differences appreciably biased results (there is concern (e.g. not adequately addressed by analysis)) [OR, in case randomisation is rated 'probably low'/'definitely low' RoB and allocation concealment is rated 'probably low'/'definitely low' RoB or 'not reported']{.ul}:There is evidence that reported variables differed between groups at baseline.ANDIt is deemed that these differences appreciably biased results (there is concern (e.g. not adequately addressed by analysis))[^19]

### G.3.2.. Prospective observational studies {#efs25778-sec-0104}

QuestionRatingExplanation for expert judgement**Did the study design or analysis account for important confounding?** **Key question**++There is direct evidence that appropriate adjustments or explicit considerations were made for the potential confounders in the final analyses through the study design (e.g. matching, restriction) and/or through the use of statistical models to reduce research‐specific bias including standardisation, adjustment in multivariate model, stratification, propensity scoring, or other methods that were appropriately justified *NOTE: Acceptable consideration of appropriate adjustment factors includes cases when the factor is not included in the final adjustment model because: i) there was evidence indicating that a factor did not need to be included as a confounders (e.g. the author conducted analyses that indicated it did not need to be included; study restricted to males only) OR ii) it is deemed that not considering the factor would not bias the result* **AND**There is direct evidence that confounders were assessed using reliable methods+There is indirect evidence that appropriate adjustments were made, OR it is deemed that not considering or only considering a partial list confounders in the final analyses would not substantially bias results **AND** There is evidence (direct or indirect) that confounders were assessed using reliable methods, OR it is deemed that the methods used would not appreciably bias results (i.e., the authors justified the validity of the methods from previously published research)NRThere is insufficient information provided about the distribution of potential confounders (record 'NR' as basis for answer) **OR** There is insufficient information provided about the methods used to assess confounders (record 'NR' as basis for answer)−There is indirect evidence that the distribution of potential confounders differed between the groups and was not appropriately adjusted for in the final analyses− --There is direct evidence that the distribution of confounders differed between the groups, confounding occurred but was not adjusted for in the final analyses **OR** There is direct evidence that confounders were assessed using non‐reliable methods**2. Were outcome data complete without attrition or exclusion from analysis?**++There is direct evidence that loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented when human subjects were lost or removed from a study *NOTE: Acceptable handling of subject attrition includes: very few missing outcome data AND reasons for missing subjects unlikely to be related to outcome (for survival data, censoring unlikely to be introducing bias) AND missing outcome data balanced in numbers across study groups, with similar reasons for missing data across groups (i.e. unlikely to be related to exposure)*+There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was adequately addressed and reasons were documented when human subjects were removed from a study **OR** It is deemed that the proportion lost to follow‐up would not appreciably bias results, due to the similarity between the characteristics of subjects lost to follow‐up and study participants. Generally, the higher the ratio of participants with missing data to participants with events, the greater potential there is for bias. For studies with a long duration of follow‐up, some withdrawals for such reasons are inevitable−There is indirect evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large and not adequately addressed− --There is direct evidence that loss of subjects (i.e. incomplete outcome data) was unacceptably large and not adequately addressed. Unacceptable handling of subject attrition includes: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across study groups (i.e. likely to be related to the exposure)**3. Can we be confident in the exposure characterisation?** **Key question**++Sodium intake was assessed through multiple 24‐h urinary collection (in a 'reasonably short time‐frame') **AND** There is direct evidence that quality assurance measures were in place for the collection of 24‐h urine (e.g. first and last void at the clinic; careful instructions of the participants) OR incomplete collections were excluded on the basis of any method (e.g. PABA, creatinine, self‐reported, volume...)+Sodium intake was assessed through a single 24‐h urinary collection **AND** There is direct evidence that quality assurance measures were in place for the collection of 24‐h urine (e.g. first and last void at the clinic; careful instructions of the participants) OR incomplete collections were excluded on the basis of any method (e.g. PABA, creatinine, self‐reported, volume...)NRThere is insufficient information provided about the method of exposure assessment--There is indirect evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly validated methods (e.g. FFQs, spot urine etc.) **OR** There is no evidence that quality assurance measures were in place for the collection of 24‐h urine (single or multiple) AND no measures were taken to exclude incomplete samples− --There is direct evidence that the exposure (including compliance with the treatment, if applicable) was assessed using poorly validated methods (e.g. FFQs, spot urine etc.) **OR** There is direct evidence for systematic error in the exposure characterisation (exposure misclassification)**4. Can we be confident in the outcome assessment?** **Key question**++There is direct evidence that the outcome was assessed using well‐established methods+There is indirect evidence that the outcome was assessed using acceptable methods (i.e. deemed valid and reliable but not the gold standard) **OR** It is deemed that the outcome assessment methods used would not appreciably bias resultsNRThere is insufficient information provided about the method of measurement--There is indirect evidence that the outcome assessment method is an unacceptable method− --There is direct evidence that the outcome assessment method is an unacceptable method**5. Were all measured outcomes reported?**++There is direct evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the protocol, methods, abstract, and/or introduction (that are relevant for the evaluation) have been reported. This would include outcomes reported with sufficient detail to be included in meta‐analysis or fully tabulated during data extraction and analyses had been planned in advance+There is indirect evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have been reported **OR**Analyses that had not been planned in advance (i.e. retrospective unplanned subgroup analyses) are clearly indicated as such and it is deemed that the unplanned analyses were appropriate and selective reporting would not appreciably bias results (e.g. appropriate analyses of an unexpected effect). This would include outcomes reported with insufficient detail such as only reporting that results were statistically significant (or not)NRThere is insufficient information provided about selective outcome reporting--There is indirect evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have been reported **OR** There is indirect evidence that unplanned analyses were included that may appreciably bias results− --There is direct evidence that all of the study\'s measured outcomes (primary and secondary) outlined in the methods, abstract, and/or introduction (that are relevant for the evaluation) have not been reported. In addition to not reporting outcomes, this would include reporting outcomes based on composite score without individual outcome components or outcomes reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre‐specified or reporting outcomes not pre‐specified, or that unplanned analyses were included that would appreciably bias results**6. Were the statistical methods applied appropriate?** ++There is direct evidence that the statistical analysis was appropriate+There is indirect evidence that the statistical analysis was appropriateNRThere is insufficient information provided about the statistical analysis--There is indirect evidence that the statistical analysis was not appropriate− --There is direct evidence that the statistical analysis was not appropriate[^20]

### G.3.3.. Algorithm applied to allocate studies to the three tiers of RoB {#efs25778-sec-0105}

The judgements to the RoB questions were combined into an overall RoB judgement for each individual study (by outcome). As a result, studies were classified as being at low (tier 1), moderate (tier 2) or high (tier 3) RoB. Following the OHAT/NTP guidance (OHAT/NTP, [2015](#efs25778-bib-0232){ref-type="ref"}), key questions were identified for each type of design (see Table below) and the following algorithm was applied to allocate the studies to the tiers:

**Tier 1:** study rated as 'definitely low' or 'probably low' risk of bias for the key questions AND most other applicable questions answered 'definitely low' or 'probably low' risk of bias.

**Tier 2:** study met neither the criteria for tiers.

**Tier 3:** study rated as 'definitely high' or 'probably high' risk of bias for the key questions AND most other applicable questions answered 'definitely high' or 'probably high' risk of bias.

Bias Domains and QuestionsRCTProspective observational**Selection Bias**Was administered dose or exposure level adequately randomised?**X** [\*](#efs25778-note-0052){ref-type="fn"}Was allocation to study groups adequately concealed?**XConfounding Bias**Did the study design or analysis account for important confounding?**X** [\*](#efs25778-note-0052){ref-type="fn"}**Performance Bias**Were the research personnel and human subjects blinded to the study group during the study?**XAttrition/Exclusion Bias**Were outcome data complete without attrition or exclusion from analysis?**XXDetection Bias**Can we be confident in the exposure characterisation?**X** [\*](#efs25778-note-0052){ref-type="fn"}**X** [\*](#efs25778-note-0052){ref-type="fn"}Can we be confident in the outcome assessment?**X** [\*](#efs25778-note-0052){ref-type="fn"}**X** [\*](#efs25778-note-0052){ref-type="fn"}**Selective Reporting Bias**Were all measured outcomes reported?**XXOther Sources of Bias**Were there no other potential threats to internal validity?**X**Were the statistical methods applied appropriate?**X**[^21]

Appendix H -- Outcome of the systematic review on blood pressure levels in children {#efs25778-sec-1008}
===================================================================================

H.1.. Evidence tables {#efs25778-sec-0106}
---------------------

*Experimental studies*

References (country)DesignSubject characteristics at baselineUNa (mmol/24 h)BP measurement SBP/DBP (mm Hg)He et al. ([2015](#efs25778-bib-0130){ref-type="ref"}) (China) School‐EduSalt[Study design]{.ul}: cluster‐randomised [Run‐in type]{.ul}: none [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 279/274 [Duration]{.ul}: 14 weeks[% boys]{.ul} G1: 47.5 G2: 48.6 [Age (mean ± SD, years)]{.ul} G1: 10.0 ± 0.5 G2: 10.2 ± 0.5 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} G1: 17.1 ± 3.2 G2: 16.7 ± 2.7 [Ethnicity:]{.ul} NR [BP status]{.ul}: NR [24‐h UK (mean ± SE, mmol)]{.ul} G1: 23.5 ± 0.9 G2: 25.4 ± 0.9 [Energy intake]{.ul}: NR[Type:]{.ul} multiple 24 h Mean ± SE [Beginning of intervention]{.ul} G1: 124.2 ± 5.1 G2: 116.7 ± 5.2 [End of intervention]{.ul} G1: 112.2 ± 5.1 G2: 137.2 ± 5.2[Type]{.ul}: point office, sitting Mean ± SE [Beginning of intervention]{.ul} G1: 106.2 ± 1/67.0 ± 1.1 G2: 106.2 ± 1/66.8 ± 1.1 [End of intervention]{.ul} G1: 110 ± 1/69.4 ± 1.1 G2: 110.6 ± 1/70.2 ± 1.1Miller et al. ([1988](#efs25778-bib-0212){ref-type="ref"}) (USA)[Study design:]{.ul} parallel [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/ completed]{.ul}: 88/NR [Duration]{.ul}: 4 weeks[% boys]{.ul}: NR [Age (years)]{.ul}: NR [BP status:]{.ul} NT [Ethnicity:]{.ul} NR [24‐h UK (mean, mmol)]{.ul} G1: 35.3 G2: 36.7 [Energy intake:]{.ul} NR[Type]{.ul}: multiple 24 h Mean [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 44.4 G2: 72.1[Type]{.ul}: point office, sitting Mean [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 91.7/53.0 G2: 92/52.9[^22]

*Observational studies*

References (country)DesignBaseline characteristicsNa intake assessment methodUNa (mmol/24 h)Outcomes assessedConfounders adjusted forResultsShi et al. (2014) (Germany) DONALDProspective cohort N = 1,107 DONALD initial cohort N = 435 included in the analyses (included: at least 3 BP measurements with three parallel 24‐h UNa and 3‐day weighed dietary records; excluded: preterm children, birth weight and breast‐feeding data missing; taking BP‐lowering treatment; implausible SBP/DBP values) Mean duration: 10 years[Male (%)]{.ul} 51.0 [Age (median (p25--p75), years)]{.ul} b 6 (4--8) g 6 (4--7) [BMI (median (p25--p75), kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} b 15.7 (15.0--16.8) g 15.3 (14.7--16.4) [SBP (median (p25--p75), mm Hg)]{.ul} b 97.1 (90.8--104.0) g 97.0 (90.0--102.0) [DBP (median (p25--p75), mm Hg)]{.ul} b 57.0 (50.0--65.0) g 55.0 (49.6--64.1) [24‐h UK (median (p25--p75), mmol)]{.ul} b 39.1 (29.7--47.8) g 32.4 (26.2--38.9) [24‐h UK UCr (median (p25--p75), mmol/kg bw)]{.ul} b 0.16 (0.14--0.18) g 0.15 (0.13--0.17) [Energy intake (median (p25--p75), MJ/day)]{.ul} b 6.1 (5.3--7.2) g 5.3 (4.8--6.3)Single 24‐h urine sample at yearly intervalsMedian (p25--p75) First assessment b 67.4 (50.6--89.9) g 58.7 (45.9--74.5) Last assessment b 131.0 (96.9--176.0) g 108.0 (81.7--133.0)Longitudinal change in SBP and DBP BP measured every 2 years (2 BP readings averaged at each visit)Age, age 2, age 3, sex, pubertal group, intraindividual change in Na excretion × pubertal group, person‐specific mean‐Na excretion × pubertal group, TEI, TEI × pubertal group, BMI‐SDS, height‐SDS, birth weight, full breast‐feeding status, maternal SBP, FVI, FVI × pubertal group[Change in SBP (mm Hg)/1 mmol/MJ increase in Na excretion (β (95% CI)):]{.ul} Prepubertal group Between person effect −0.2 (−0.4, 0.04) p = 0.1 Within person effect −0.03 (−0.2, 0.09) p = 0.6 Pubertal group Between person effect 0.1 (−0.1, 0.4) p = 0.3 Within person effect 0.1 (−0.004, 0.2) p = 0.06Age, age 2, age 3, sex, pubertal group, intraindividual change in Na excretion × pubertal group, person‐specific mean‐Na excretion × pubertal group, TEI, TEI × pubertal group, BMI‐SDS, height‐SDS, growth velocity, full breast‐feeding status, maternal SBP, FVI, FVI × pubertal group and Ca intake[Change in DBP (mm Hg)/1 mmol/MJ increase in Na excretion (β (95% CI)):]{.ul} Prepubertal group Between person effect −0.1 (−0.4,0.07) p = 0.2 Within person effect −0.1 (−0.2, 0.03) p = 0.1 Pubertal group Between person effect −0.2 (−0.4, 0.04) p = 0.1 Within person effect 0.1 (−0.02, 0.2) p = 0.09Krupp et al. ([2015](#efs25778-bib-0173){ref-type="ref"}) (Germany) DONALDProspective cohort N = NR N = 206 included in the analyses ('included: reached adult age, had a BP measurement and assessed in parallel anthropometrical data between 18 and 25 years, had ≥ 3 parallel plausible dietary records 24 h UNa and ≥ 3 BP measurements during adolescence (11--16 years); excluded: preterm, missing data on birth weight and gestational age, implausible BP data) Mean duration: 7 years[Male (%)]{.ul} 52.0 [Age (median (p25--p75), years)]{.ul} b 12.4 (12.1--13.0) g 12.3 (12.0--13.0) [BMI (mean (SD), kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} b 18.9 (2.3) g 18.7 (2.7) [SBP (mean (SD), mm Hg)]{.ul} b 104 (7) g 103 (8) [DBP (mean (SD), mm Hg)]{.ul} b 62 (6) g 61 (6) [24‐h UK (mean (SD), mmol)]{.ul} b 56 (14) g 51 (13) [24‐h UK UCr (mean (SD), mmol/kg bw)]{.ul} b 0.18 (0.02) g 0.17 (0.02) [Energy intake (mean (SD), MJ/day)]{.ul} b 9.1 (1.5) g 7.9 (0.9)Single 24‐h urine sample at yearly intervals Samples with UCr \< 0.1 mmol/kg BW excluded from the analysisNaCl (mean (SD)) b 116 (27) g 105 (32) calculated as (Na (mmol/day) + Cl (mmol/day))/2Longitudinal change in SBP and DBP BP measured every 2 years (2 blood pressure readings averaged at each examination)Mean pubertal SBP SDS, adult age, standardised energy intake, intake of saturated fat, height‐SDS, maternal education, maternal BP, FVI, adult BMI[Change in SBP (mm Hg)/1 mmol increase in NaCl excretion (ß (95% CI)):]{.ul} b 0.1 (0.03, 0.18) p = 0.01  g ‐0.05 (−0.11, 0.02) p = 0.1Mean pubertal SBP SDS, adult age, standardised energy intake, calcium intake, birth weight, smoking in the household, maternal BP, FVI, adult BMI[Change in DBP (mm Hg)/1 mmol increase in NaCl excretion (ß (95% CI)):]{.ul} b 0.02 (−0.08, 0.04) p = 0.6  g 0.02 (−0.03, 0.08) p = 0.4[^23]

H.2.. Outcome of the RoB appraisal {#efs25778-sec-0107}
----------------------------------

*Experimental studies*

ReferencesRisk of bias domains[a](#efs25778-note-0055){ref-type="fn"}Tier[b](#efs25778-note-0056){ref-type="fn"}RandomisationAllocation concealmentBlindingAttritionExposureOutcomeReportingOther threats to internal validityMiller et al. ([1988](#efs25778-bib-0212){ref-type="ref"})+NR−++++++**1**He et al. ([2015](#efs25778-bib-0130){ref-type="ref"})+++++++++−+++**2**[^24][^25]

*Observational studies*

ReferencesRisk of bias domains[a](#efs25778-note-0057){ref-type="fn"}Tier[b](#efs25778-note-0058){ref-type="fn"}ConfoundingAttritionExposureOutcomeReportingStatisticsKrupp et al. ([2015](#efs25778-bib-0173){ref-type="ref"})++−+++++++**1**Shi et al. ([2014](#efs25778-bib-0276){ref-type="ref"})+++++++++**1**[^26][^27]

Appendix I -- Outcome of the systematic review on blood pressure levels in adults {#efs25778-sec-1009}
=================================================================================

I.1.. Evidence tables {#efs25778-sec-0108}
---------------------

### I.1.1.. Experimental studies {#efs25778-sec-0109}

References (country)DesignSubject characteristics at baselineUNa (mmol/24 h)BP measurement SBP/DBP (mm Hg)Alli et al. ([1992](#efs25778-bib-0011){ref-type="ref"}) (Italy)[Study design]{.ul}: cluster‐randomised [Run‐in type]{.ul}: normal diet [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 77/56 [Duration]{.ul}: 12 months[% men]{.ul} G1: 35 G2: 50 [Age (mean ± SD, years)]{.ul} G1: 44.3 ± 10.2 G2: 51.7 ± 11 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} G1: 25 ± 2.5 G2: 24.8 ± 2.8 [Ethnicity:]{.ul} NR [BP status]{.ul}: HT [24‐h UK (mean ± SD, mmol)]{.ul} G1: 61.2 ± 18.1 G2: 59.8 ± 16.5 [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} G1: 178.7 ± 60.5 G2: 168.8 ± 65 [End of intervention]{.ul} G1: 186.5 ± 73 G2: 163.4 ± 60.7[Type]{.ul}: point office, supine Mean ± SD [Beginning of intervention]{.ul} G1: 148.5 ± 13.5/96.2 ± 4.4 G2: 148.2 ± 10.6/97.9 ± 4.9 [End of intervention]{.ul} G1: 144.4 ± 8.1/90.6 ± 8.2 G2: 146.6 ± 15.1/94.5 ± 5.3ANHMRCDS ([1986](#efs25778-bib-0018){ref-type="ref"}) (Australia)[Study design:]{.ul} parallel [Run‐in type]{.ul}: normal diet [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 107/100 [Duration]{.ul}: 12 weeks[% men]{.ul} G1: 83 G2: 89 [Age (mean ± SE, years)]{.ul} G1: 52.3 ± 0.8 G2: 52.3 ± 0.8 [BP status:]{.ul} mixed [Ethnicity:]{.ul} NR [24‐h UK (mean, mmol)]{.ul} G1: 66 G2: 71 [Energy intake:]{.ul} NR[Type]{.ul}: single 24 h Mean ± SE [Beginning of intervention]{.ul} G1: 142 G2: 157 [End of intervention]{.ul} G1: 85.8 ± 7.1 G2: 155.6 ± 8.3[Type]{.ul}: point office, sitting Mean [Beginning of intervention]{.ul} G1: 150/95 G2: 149/95 [End of intervention]{.ul} G1: 144/89 G2: 148/93ANHMRCDS ([1989](#efs25778-bib-0019){ref-type="ref"}) (Australia) Australian National Health h Medical Research Council Dietary Salt Study[Study design]{.ul}: parallel [Run‐in type]{.ul}: normal diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 111/108 [Duration]{.ul}: 8 weeks[% men]{.ul} G1: 80 G2: 87 [Age (years)]{.ul} G1: 18 +  G2: 18 +  [Ethnicity:]{.ul} NR [BP status:]{.ul} HT [24‐h UK (mean ± SE, mmol)]{.ul} G1: 73 ± 3 G2: 74 ± 3 [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SE [Beginning of intervention]{.ul} G1: 142 ± 6 G2: 134 ± 6 [End of intervention]{.ul} G1: 90 ± 6 G2: 153 ± 6Type: point office, sitting Mean ± SE [Beginning of intervention]{.ul} G1: 155.2 ± 2.2/95.1 ± 0.6 G2: 152.8 ± 2.1/95.4 ± 0.6 [End of intervention]{.ul} G1: 149.1 ± 1.9/91.4 ± 0.7 G2: 152.2 ± 1.9/94.6 ± 0.9Benetos et al. ([1992](#efs25778-bib-0033){ref-type="ref"}) (France)[Study design]{.ul}: cross‐over [Wash out]{.ul}: 1 week [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 22/20 [Duration]{.ul}: 4 weeks[% men:]{.ul} 45 [Age (mean ± SE, years):]{.ul} 41.5 ± 2.4 [Ethnicity:]{.ul} NR [BP status:]{.ul} HT [24‐h UK (mean ± SE, mmol):]{.ul} 70 ± 3 [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SE [Beginning of intervention]{.ul} 173 ± 13 [End of intervention]{.ul} G1: 85 ± 9.6 G2: 163 ± 13.3[Type]{.ul}: point office, supine Mean ± SE [Beginning of intervention]{.ul} 154 ± 2.2/96.1 ± 1.5 [End of intervention]{.ul} G1: 142.6 ± 2.6/89.5 ± 1.5 G2: 149.1 ± 2.3/93.2 ± 1.3Cappuccio et al. ([1997](#efs25778-bib-0047){ref-type="ref"}) (United Kingdom)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 48/47 [Duration]{.ul}: 4 weeks[% men:]{.ul} 51 [Age (mean ± SD, years):]{.ul} 66.8 ± 5.3 [Ethnicity:]{.ul} mixed [BP status:]{.ul} mixed [24‐h UK (mean ± SD, mmol):]{.ul} 66 ± 20 [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SD [Beginning of intervention]{.ul} 72 ± 40 [End of intervention]{.ul} G1: 94 ± 50 G2: 177 ± 49Type: point office, supine Mean ± SD [Beginning of intervention]{.ul} 154.9 ± 20.4/87.1 ± 9.5 [End of intervention]{.ul} G1: 155.9 ± 21.6/86.9 ± 8.8 G2: 163.2 ± 20.6/90.1 ± 10.5Cobiac et al. ([1992](#efs25778-bib-0056){ref-type="ref"}) (Australia)[Study design]{.ul}: parallel [Run‐in type]{.ul}: low sodium diet + sodium tablets [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 57/54 [Duration]{.ul}: 4 weeks[% men]{.ul} G1: 69 G2: 64 [Age (mean ± SE, years)]{.ul} G1: 67 ± 1 G2: 67 ± 1 [BMI (mean ± SE, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} G1: 25 ± 1 G2: 25 ± 1 [Ethnicity:]{.ul} NR [BP status:]{.ul} mixed [24‐h UK (mean ± SE, mmol)]{.ul} G1: 74 ± 4 G2: 68 ± 6 [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SE [Beginning of intervention]{.ul} G1: 166 ± 10 G2: 166 ± 9 [End of intervention]{.ul} G1: 79 ± 7 G2: 152 ± 10[Type]{.ul}: point office, sitting Mean ± SE [Beginning of intervention]{.ul} G1: 132 ± 2/77 ± 2 G2: 135 ± 3/78 ± 2 [End of intervention]{.ul} G1: 127.8/77.1 G2: 132.5/77.3Dickinson et al. ([2014](#efs25778-bib-0072){ref-type="ref"}) (Australia)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 50/25 [Duration]{.ul}: 6 weeks[% men]{.ul}: 32 [Age (years)]{.ul}: 18+  [BMI (range, kg/m]{.ul} ^[2]{.ul}^) : 27--40 [Ethnicity:]{.ul} NR [BP status:]{.ul} NT [24‐h UK (mean ± SD, mmol)]{.ul}: 76 ± 23 [Energy intake (mean ± SD, MJ/d)]{.ul}: 9.1 ± 2.5[Type:]{.ul} multiple 24 h Mean ± SD [Beginning of intervention]{.ul} 154 ± 58 [End of intervention]{.ul} G1: 113 ± 45 G2: 155 ± 58[Type]{.ul}: point office, sitting Mean ± SD [Beginning of intervention]{.ul} 120 ± 13/77 ± 7 [End of intervention]{.ul} G1: 115 ± 10/73 ± 6 G2: 118 ± 16/74 ± 8Erwteman et al. ([1984](#efs25778-bib-0096){ref-type="ref"}) (Netherlands)[Study design]{.ul}: Parallel [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 107/94 [Duration]{.ul}: 4 weeks[% men]{.ul} G1: 61 G2: 62 [Age (mean ± SD, years)]{.ul} G1: 45 ± 11 G2: 46.5 ± 9.5 [Ethnicity]{.ul}: mixed [BP status:]{.ul} HT [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 72 ± 31 G2: 130 ± 50[Type]{.ul}: point office, supine Mean ± SD [Beginning of intervention]{.ul} G1: 157 ± 11.4/101.5 ± 5.4 G2: 156.2 ± 11.8/100.5 ± 3.4 [End of intervention]{.ul} G1: 141 ± 15.4/92.9 ± 10.4 G2: 142.9 ± 16.4/94.4 ± 12.0Fotherby and Potter ([1993](#efs25778-bib-0110){ref-type="ref"}) (United Kingdom)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 18/17 [Duration]{.ul}: 5 weeks[% men]{.ul}: 22 [Age (mean (range), years)]{.ul}: 73 (66--79) [Ethnicity:]{.ul} Caucasian [BP status:]{.ul} HT [24‐h UK (mean ± SD, mmol)]{.ul}: 66 ± 25 [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SD [Beginning of intervention]{.ul} 104 ± 59 [End of intervention]{.ul} G1: 95 ± 36 G2: 174 ± 40Type: point office, supine Mean ± [Beginning of intervention]{.ul} 176 ± 17/96 ± 11 [End of intervention]{.ul} G1: 171 ± 21/96 ± 8 G2: 179 ± 18/96 ± 11Gates et al. ([2004](#efs25778-bib-0115){ref-type="ref"}) (USA)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type:]{.ul} feeding [N participants randomised/completed]{.ul}: 12/12 [Duration]{.ul}: 4 weeks[% men]{.ul}: 50 [Age (mean ± SE, years)]{.ul}: 63 ± 1 [BMI (mean ± SE, kg/m]{.ul} ^[2]{.ul}^): 25.1 ± 1 [Ethnicity:]{.ul} Caucasian [BP status:]{.ul} HT [24‐h UK (mean ± SE, mmol]{.ul}): 72 ± 8 [Energy intake (mean ± SE, MJ/d)]{.ul}: 9.4 ± 0.7[Type:]{.ul} single 24 h Mean ± SE [Beginning of intervention]{.ul} 134.5 ± 13.4 [End of intervention]{.ul} G1: 60.5 ± 6.8 G2: 150.1 ± 17.9[Type]{.ul}: point office, supine Mean ± SE [Beginning of intervention]{.ul} 148.1 ± 2.3/84.0 ± 2.4 [End of intervention]{.ul} G1: 137.1 ± 2.8/79.0 ± 2.1 G2: 144.2 ± 3.7/79.9 ± 2.0Gijsbers et al. ([2015](#efs25778-bib-0116){ref-type="ref"}) (Netherlands)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 37/36 [Duration]{.ul}: 4 weeks[% men]{.ul}: 67 [Age (mean (range), years]{.ul}): 65.8 (40--80) [BMI (mean, kg/m]{.ul} ^[2]{.ul}^): 27.2 [Ethnicity:]{.ul} Caucasian [BP status:]{.ul} mixed [24‐h UK (mean, mmol)]{.ul}: 81.8 [Energy intake (mean, kcal/d)]{.ul}: 2,774[Type:]{.ul} single 24 h mean ± SD [Beginning of intervention]{.ul} 90.8 [End of intervention]{.ul} G1: 105.1 ± 39.7 G2: 202.9 ± 54.8[Type]{.ul}: point office, supine Mean ± SD [Beginning of intervention]{.ul} 133.4/75.7 [End of intervention]{.ul} G1: 125.1 ± 15/72.3 ± 7.7 G2: 132.9 ± 17.6/75.7 ± 7.5Grobbee et al. ([1987](#efs25778-bib-0122){ref-type="ref"}) (Netherlands)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: normal diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 42/40 [Duration]{.ul}: 6 weeks[% men:]{.ul} 85 [Age (mean ± SD, years):]{.ul} 24 ± 3 [Ethnicity]{.ul}: NR [BP status:]{.ul} HT [24‐h UK (mean ± SD, mmol)]{.ul}: 71 ± 22 [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h mean ± SE [Beginning of intervention]{.ul} 141 ± 7 [End of intervention]{.ul} G1: 57 ± 4 G2: 129 ± 5[Type]{.ul}: point office, supine Mean ± SE [Beginning of intervention]{.ul} 143 ± 2.2/78 ± 1.6 [End of intervention]{.ul} G1: 135.9 ± 1.8/73.7 ± 1.5 G2: 136.8 ± 1.8/73.5 ± 1.8He et al. ([2009](#efs25778-bib-0128){ref-type="ref"}) (United Kingdom)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 185/169 [Duration]{.ul}: 6 weeks[% men:]{.ul} 67 [Age (mean ± SD, years):]{.ul} 50 ± 11 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} : 29 ± 5 [Ethnicity:]{.ul} mixed [BP status:]{.ul} HT [24‐h UK (mean ± SD, mmol)]{.ul}: 77 ± 26 [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 110 ± 49 G2: 165 ± 58[Type]{.ul}: point office, sitting Mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 141 ± 12/88 ± 9 G2: 146 ± 13/91 ± 8Jablonski et al. ([2013](#efs25778-bib-0146){ref-type="ref"}) (USA)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 11/11 [Duration]{.ul}: 5 weeks[% men]{.ul}: 73 [Age (mean ± SE, years)]{.ul}: 60 ± 2 [BMI (mean ± SE, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul}: 27.2 ± 1.3 [Ethnicity]{.ul}: mixed [BP status:]{.ul} mixed [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SE [Beginning of intervention]{.ul} 159 ± 13 [End of intervention]{.ul} G1: 77 ± 9 G2: 144 ± 7Type: point office, supine mean ± SE [Beginning of intervention]{.ul} 139 ± 2/83 ± 2 [End of intervention]{.ul} G1: 127 ± 3/77 ± 2 G2: 138 ± 5/81 ± 2Kumanyika et al. ([2005](#efs25778-bib-0175){ref-type="ref"}) (USA) **TOHP II**[Study design]{.ul}: parallel [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 1159/1159 [Duration]{.ul}: 36 months[% men]{.ul} G1: 65 G2: 68 [Age (mean ± SD, years)]{.ul} G1: 44.2 ± 6.1 G2: 43.2 ± 6.1 [BMI (range, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} 24.4--37.4 [Ethnicity:]{.ul} mixed [BP status:]{.ul} NT [24‐h UK (mean ± SD, mmol)]{.ul} G1: 66.8 ± 28.1 G2: 65.3 ± 26.6 [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SD [Beginning of intervention]{.ul} G1: 186.1 ± 80.7 G2: 188.0 ± 80.9 [End of intervention]{.ul} G1: −50.9 ± 86.3 G2: −10.5 ± 88.5Type: point office, sitting Mean ± SD [Beginning of intervention]{.ul} G1: 127.7 ± 6.6/86.1 ± 1.9 G2: 127.3 ± 6.4/85.8 ± 1.9 [End of intervention]{.ul} G1: −0.7 ± 9.2/−3.0 ± 6.5 G2: 0.6 ± 8.5/−2.4 ± 7.0Kumanyika et al. ([1993](#efs25778-bib-0174){ref-type="ref"}) (USA) TOPH I[Study design]{.ul}: parallel [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 744/744 [Duration]{.ul}: 18 months[% men]{.ul} G1: 71 G2: 72 [Age (mean ± SD, years)]{.ul} G1: 43.4 ± 6.6 G2: 42.6 ± 6.5 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} G1: 27.1 ± 3.8 G2: 27.1 ± 3.6 [Ethnicity:]{.ul} mixed [BP status:]{.ul} NT [24‐h UK (mean ± SD, mmol)]{.ul} G1: 61.8 ± 23.4 G2: 62.8 ± 23.8 [Energy intake:]{.ul} NR[Type]{.ul}: single 24 h Mean ± SD [Beginning of intervention]{.ul} G1: 154.6 ± 59.9 G2: 156.4 ± 60.5 [End of intervention]{.ul} G1: 99.4 ± 60.0 G2: 146.5 ± 79.2[Type]{.ul}: point office, sitting Mean ± SD [Beginning of intervention]{.ul} G1: 124.8 ± 8.5/83.7 ± 2.7 G2: 125.1 ± 8.1/83.9 ± 2.8 [End of intervention]{.ul} G1: −5.08 ± 7.94/−4.35 ± 5.65 G2: −3.02 ± 8.31/−3.18 ± 5.8MacGregor et al. ([1982](#efs25778-bib-0199){ref-type="ref"}) (United Kingdom)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 19/19 [Duration]{.ul}: 4 weeks[% men]{.ul}: 74 [Age (mean (range), years)]{.ul}: 49 (30--66) [Ethnicity:]{.ul} mixed [BP status]{.ul}: HT [24‐h UK (mean ± SE, mmol)]{.ul}: 59 ± 5 [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SE [Beginning of intervention]{.ul} 83 ± 11 [End of intervention]{.ul} G1: 86 ± 9 G2: 162 ± 9[Type]{.ul}: point office, supine Mean ± SE [Beginning of intervention]{.ul} 142 ± 3/92 ± 1 [End of intervention]{.ul} G1: 144 ± 4/92 ± 1.5 G2: 154 ± 4/97 ± 2.5MacGregor et al. ([1989](#efs25778-bib-0200){ref-type="ref"}) (United Kingdom)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 20/20 [Duration]{.ul}: 4 weeks[% men:]{.ul} 55 [Age (mean (range), years)]{.ul}: 57 (42--72) [Ethnicity:]{.ul} mixed [BP status]{.ul}: HT [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SE [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 49 ± 8 G2: 108 ± 10 G3: 190 ± 11[Type]{.ul}: point office, supine Mean ± SE [Beginning of intervention]{.ul} 164 ± 4 / 101 ± 2 [End of intervention]{.ul} G1: 147 ± 4/91 ± 2 G2: 155 ± 3/95 ± 2 G3: 163 ± 4/100 ± 2Meland et al. ([1997](#efs25778-bib-0208){ref-type="ref"}) (Norway)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: normal diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 16/16 [Duration]{.ul}: 8 weeks[% men]{.ul}: 81 [Age (mean (range), years)]{.ul}: 50 (20--69) [Ethnicity]{.ul}: NR [BP status]{.ul}: HT [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean (95% CI) [Beginning of intervention]{.ul} 177 (149, 204) [End of intervention]{.ul} G1: 125 (104, 146) G2: 191 (159, 223)[Type]{.ul}: point office, sitting Mean ± (95% CI) [Beginning of intervention]{.ul} 146 (140, 153)/95 (92, 98) [End of intervention]{.ul} G1: 141 (135, 147)/92 (89, 94) G2: 145 (137, 153)/94 (90, 97)Melander et al. ([2007](#efs25778-bib-0209){ref-type="ref"}) (Sweden)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type]{.ul}: feeding N participants randomised/completed: 46/39 [Duration]{.ul}: 4 weeks[% men]{.ul}: 51 [Age (mean ± SD, years)]{.ul}: 53 ± 11 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul}: 26.3 ± 3.1 [Ethnicity:]{.ul} NR [BP status:]{.ul} NT [24‐h UK (mean ± SD, mmol)]{.ul}: 75 ± 22.9 [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} 165 ± 67.4 [End of intervention]{.ul} G1: 50.7 ± 17.3 G2: 140 ± 39.5[Type]{.ul}: point office, supine Mean ± SD [Beginning of intervention]{.ul} 136 ± 12.6/78.2 ± 7.8 [End of intervention]{.ul} G1: 125 ± 12.4/73 ± 7.3 G2: 132 ± 14.7/75.2 ± 7.5Nestel et al. ([1993](#efs25778-bib-0222){ref-type="ref"}) (Australia)[Study design]{.ul}: parallel [Run‐in type]{.ul}: low sodium diet + sodium tablets [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 70/66 [Duration]{.ul}: 6 weeks[% men]{.ul} G1: 50 G2: 50 [Age (mean ± SD, years)]{.ul} G1: 65.5 ± 4 G2: 65.5 ± 4 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} G1: 24.5 ± 3 G2: 24.5 ± 3 [Ethnicity:]{.ul} NR [BP status:]{.ul} NT [24‐h UK (mean ± SD, mmol)]{.ul} G1: 87 ± 26 G2: 76.5 ± 20 [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} G1: 182.5 ± 48 G2: 162 ± 47 [End of intervention]{.ul} G1: 91.5 ± 41 G2: 156 ± 40[Type]{.ul}: point office, sitting Mean ± SD [Beginning of intervention]{.ul} G1: 126.5 ± 10/72.5 ± 7 G2: 127.5 ± 13/73.5 ± 9 [End of intervention]{.ul} G1: 122.5 ± 9/72 ± 8 G2: 127.5 ± 14/74.5 ± 9Parijs et al. ([1973](#efs25778-bib-0241){ref-type="ref"}) (Belgium)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: normal diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 22/17 [Duration]{.ul}: 4 weeks[% men]{.ul}: 46 [Age (mean ± SD, years)]{.ul}: 41.2 ± 8.21 [Ethnicity:]{.ul} NR [BP status:]{.ul} HT [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 92.8 ± 41.8 G2: 191.1 ± 61.2Type: point office, supine mean ± [Beginning of intervention]{.ul} 179.1 ± 17.8/115.2 ± 10.9 [End of intervention]{.ul} G1: 167.8 ± 24.3/115.5 ± 12.45 G2: 174.5 ± 20.02/112.3 ± 15.17Puska et al. ([1983](#efs25778-bib-0252){ref-type="ref"}) (Finland)[Study design]{.ul}: parallel [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 76/72 [Duration]{.ul}: 6 weeks[% men:]{.ul} NR [Age (range, years)]{.ul}: 30--50 [Ethnicity:]{.ul} NR [BP status:]{.ul} mixed [24‐h UK (mean ± SE, mmol)]{.ul} G1: 81 ± 4 G2: 73 ± 3 [Energy intake (mean ± SE, kcal/d)]{.ul} G1: 2,665 ± 120 G2: 2,609 ± 103[Type:]{.ul} single 24 h Mean ± SE [Beginning of intervention]{.ul} G1: 192 ± 11 G2: 165 ± 9 [End of intervention]{.ul} G1: 77 ± 5 G2: 167 ± 8[Type]{.ul}: point office, sitting Mean ± SE [Beginning of intervention]{.ul} G1: 138.9 ± 2.3/89.6 ± 1.7 G2: 137.8 ± 2/89.3 ± 1.5 [End of intervention]{.ul} G1: 137.2 ± 2.7/86.5 ± 1.8 G2: 136 ± 2.1/86.9 ± 1.5Richards et al. ([1984](#efs25778-bib-0257){ref-type="ref"}) (New Zealand)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 16/12 [Duration]{.ul}: 5 weeks[% men]{.ul}: 67 [Age (range, years)]{.ul}: 19--52 [Ethnicity:]{.ul} NR [BP status:]{.ul} HT [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SE [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 94 ± 7.1 G2: 202.8 ± 14.1Type: point office, supine mean ± SE [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 144.7 ± 4/90.6 ± 3.6 G2: 149.9 ± 4.2/92.4 ± 3.5Ruppert et al. ([1993](#efs25778-bib-0259){ref-type="ref"}) (Germany)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 25/25 [Duration]{.ul}: 4 weeks[% men]{.ul}: 40 [Age (mean ± SE, years)]{.ul}: 47 ± 5 [Ethnicity:]{.ul} NR [BP status:]{.ul} NT [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SE [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 82 ± 3.4 G2: 199.6 ± 5.3Type: point office, sitting Mean ± SE [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 112 ± 2.1/73.3 ± 1.4 G2: 110.3 ± 2.6/72.3 ± 1.8Sacks et al. ([2001](#efs25778-bib-0260){ref-type="ref"}) (USA) DASH[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: high sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 204/192 [Duration]{.ul}: 4 weeks[% men]{.ul}: 46 [Age (mean ± SD, years)]{.ul}: 49 ± 10 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul}: 30 ± 5 [Ethnicity:]{.ul} mixed [BP status:]{.ul} mixed (41% HT) [Energy intake:]{.ul} NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} 152 ± 72 [End of intervention]{.ul} G1: 64 ± 37 G2: 106 ± 44 G3: 141 ± 55Type: point office, sitting mean ± [Beginning of intervention]{.ul} 134.8 ± 9.5/85.7 ± 4.5 [End of intervention]{.ul} G1: 126 ± 10/79.8 ± 6 G2: 130 ± 11.7/82 ± 6.4 G3: 132.7 ± 11.9/83.2 ± 6.9Santos et al. ([2010](#efs25778-bib-0265){ref-type="ref"}) (Portugal)[Study design]{.ul}: cross‐over [Wash out]{.ul}: 6 weeks [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 17/17 [Duration]{.ul}: 7 weeks[% men]{.ul}: 47 [Age (range, years)]{.ul}: 24--53 [Ethnicity:]{.ul} NR [BP status:]{.ul} NT [Energy intake (mean (range) kcal/d):]{.ul} 2,290 (1,461--3,646)[Type:]{.ul} single 24 h Median (IQR) [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 115 (87, 162) G2: 138 (123, 170)Type: point office, supine Median (IQR) [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 118.3 (89, 124.3)/68 (51.7, 97.7) G2: 116.7 (92.3, 125)/68.3 (50.3, 81.3)Schorr et al. ([1996](#efs25778-bib-0272){ref-type="ref"}) (Germany)[Study design]{.ul}: cross‐over [Wash out]{.ul}: 2 weeks [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 21/16 [Duration]{.ul}: 4 weeks[% men:]{.ul} 44 [Age (mean ± SD, years):]{.ul} 64.1 ± 3.6 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul}: 26.1 ± 3.6 [Ethnicity:]{.ul} NR [BP status:]{.ul} NT [Energy intake:]{.ul} NR[Type:]{.ul} multiple 24 h Mean ± SD [Beginning of intervention]{.ul} 141.8 ± 33.6 [End of intervention]{.ul} G1: 104.6 ± 21.7 G2: 175.2 ± 29.6Type: point office, NR mean ± [Beginning of intervention]{.ul} 132.5 ± 22.2/73.6 ± 12.5 [End of intervention]{.ul} G1: 125.9 ± 17.3/69.5 ± 10.1 G2: 133.6 ± 23.7/71.2 ± 12.2Swift et al. ([2005](#efs25778-bib-0292){ref-type="ref"}) (United Kingdom)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 46/40 [Duration]{.ul}: 4 weeks[% men]{.ul}: 43 [Age (mean ± SD, years)]{.ul}: 50 ± 10 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul}: 28 ± 4 [Ethnicity]{.ul}: African including African Americans [BP status]{.ul}: HT [24‐h UK (mean ± SD, mmol)]{.ul}: 63 ± 16 [Energy intake:]{.ul} NR[Type:]{.ul} NR Mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 89 ± 52 G2: 167 ± 73[Type]{.ul}: point office, supine Mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 151 ± 13/98 ± 8 G2: 159 ± 13/101 ± 8van Berge‐Landry and James ([2004](#efs25778-bib-0306){ref-type="ref"}) (USA)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: normal diet [Intervention type]{.ul}: counselling [N participants randomised/completed]{.ul}: 48/48 [Duration]{.ul}: 4 weeks[% men]{.ul}: 79 [Age]{.ul}: middle‐aged adults [Ethnicity]{.ul}: mixed [BP status]{.ul}: HT [Energy intake]{.ul}: NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 24 ± 13 G2: 309 ± 88[Type]{.ul}: point office, NR Mean ± SD [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 128 ± 10/85 ± 7 G2: 144 ± 14/93 ± 8Watt et al. ([1983](#efs25778-bib-0311){ref-type="ref"}) (United Kingdom)[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Run‐in type]{.ul}: low sodium diet [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 20/18 [Duration]{.ul}: 4 weeks[% men]{.ul}: 33 [Age (mean, range, years)]{.ul}: 52 (31--64) [Ethnicity:]{.ul} NR [BP status:]{.ul} HT [24‐h UK (mean, mmol)]{.ul}: 59.2 [Energy intake]{.ul}: NR[Type:]{.ul} single 24 h Mean [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 87.2 G2: 142.8[Type]{.ul}: point office, sitting Mean [Beginning of intervention]{.ul} NR [End of intervention]{.ul} G1: 136/82.3 G2: 136.5/82.6Watt et al. ([1985](#efs25778-bib-0312){ref-type="ref"}) (United Kingdom) **High/high**[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 75/66 [Duration]{.ul}: 4 weeks[% men]{.ul}: 37 [Age (mean, years)]{.ul}: 22.3 [Ethnicity]{.ul}: NR [BP status]{.ul}: mixed [24‐h UK (mean ± SD, mmol)]{.ul}: 53.8 ± 18.9 [Energy intake]{.ul}: NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} 129.7 ± 55.3 [End of intervention]{.ul} G1: 56.3 G2: 130.6[Type:]{.ul} point office, sitting mean ± [Beginning of intervention]{.ul} 113.1 ± 13.3/65.2 ± 11.2 [End of intervention]{.ul} G1: 112.2/64.5 G2: 113.6/63.3Watt et al. ([1985](#efs25778-bib-0312){ref-type="ref"}) (United Kingdom) **Low/low**[Study design]{.ul}: cross‐over [Wash out]{.ul}: none [Intervention type]{.ul}: feeding [N participants randomised/completed]{.ul}: 75/66 [Duration]{.ul}: 4 weeks[% men]{.ul}: 45 [Age (mean, years)]{.ul}: 22.7 [Ethnicity:]{.ul} NR [BP status:]{.ul} mixed [24‐h UK (mean ± SD, mmol)]{.ul}: 60 ± 18.3 [Energy intake]{.ul}: NR[Type:]{.ul} single 24 h Mean ± SD [Beginning of intervention]{.ul} 151.1 ± 63.6 [End of intervention]{.ul} G1: 68.4 G2: 128.4[Type]{.ul}: point office, sitting mean ± SD [Beginning of intervention]{.ul} 108.8 ± 11.5/61.9 ± 9.5 [End of intervention]{.ul} G1: 110.2/65 G2: 110.7/63.6[^28]

### I.1.2.. Observational studies {#efs25778-sec-0110}

References (country)DesignBaseline characteristicsNa intake assessment methodUNa (mmol/24 h)Outcomes assessedConfounders adjusted forResults(Stolarz‐Skrzypek et al., [2011](#efs25778-bib-0286){ref-type="ref"}) (Belgium, Czech Republic, Italy, Poland, Russian Federation) FLEMENGHO/EPOGHProspective cohort N = 3,360 FLEMENGHO initial cohort; N = 1,187 EPOGH initial cohort N = 1,499 included in the analyses ('blood pressure cohort') (excluded: participants with treated hypertension, history of CVD, missing/inaccurate 24‐h UNa at baseline) Median duration: 6.1 yearsMale (%) 47.6 Hypertensive (untreated) (%) 9.9 Diabetes mellitus (%) 1.9 Age (mean (SD), years) 38.3 (14.2) BMI (mean (SD), kg/m^2^) 24.6 (4.0) Smokers (%) 30.4 SBP (mean (SD), mm Hg) 120.9 (12.8) DBP (mean (SD), mm Hg) 74.6 (8.9) 24‐h UK (mean (SD), mmol) 66.3 (22.4) 24‐h UCr (mean (SD), mmol) 11.9 (3.7)Single 24‐h urine sample at baseline and at last follow‐up examination Inaccurate urine collections were defined as a volume \< 300 mL/24‐h, a 24‐h UCr \< 4 mmol or \> 25 mmol in women and \< 6 mmol or \> 30 mmol in menMean (SD) 172.7 (62.5)Longitudinal change in SBP and DBP BP measured at baseline and follow‐up examinations (5 blood pressure readings averaged at each examination)Study population, sex, baseline values of and changes in: age, BMI, and alcohol intake, 24‐h UK, use of female sex steroids, and use of non‐steroidal anti‐inflammatory drugs[Change in SBP (mm Hg)/ 100 mmol increase in Na excretion (mean (95% CI)):]{.ul} FLEMENGHO: 2.373 (1.154 to 3.392), p \< 0.001 EPOGH: 0.196 (−1.409 to 1.801), p = 0.81 All: 1.711 (0.786 to 2.637), p \< 0.001 [Change in DBP (mm Hg)/ 100 mmol increase in Na excretion (mean (95% CI)):]{.ul} FLEMENGHO: 0.576 (−0.246 to 1.398) p = 0.17 EPOGH: −0.052 (−1.317 to 1.212), p = 0.94 All: 0.379 (−0.313 to 1.070), p = 0.28[^29]

I.2.. Outcome of the RoB appraisal {#efs25778-sec-0111}
----------------------------------

### I.2.1.. Experimental studies {#efs25778-sec-0112}

ReferencesRisk of bias domains[a](#efs25778-note-0061){ref-type="fn"}Tier[b](#efs25778-note-0062){ref-type="fn"}RandomisationAllocation concealmentBlindingAttritionExposureOutcomeReportingOther threats to internal validityAlli et al. ([1992](#efs25778-bib-0011){ref-type="ref"})+− −− −− −++− −++−**2**ANHMRCDS ([1989](#efs25778-bib-0019){ref-type="ref"})+NR+ ++++ ++ ++**1**Benetos et al. ([1992](#efs25778-bib-0033){ref-type="ref"})+NR++ ++++++**1**Cappuccio et al. ([1997](#efs25778-bib-0047){ref-type="ref"})++NR+ ++++++++++**1**ANHMRCDS ([1986](#efs25778-bib-0018){ref-type="ref"})+NR−+ +++++**1**Cobiac et al. ([1992](#efs25778-bib-0056){ref-type="ref"})NRNR+++++++++**2**Dickinson et al. ([2014](#efs25778-bib-0072){ref-type="ref"})++NR+−++++++**1**Erwteman et al. ([1984](#efs25778-bib-0096){ref-type="ref"})+NR++++ ++ +−**1**Fotherby and Potter ([1993](#efs25778-bib-0110){ref-type="ref"})+NR++ +++++++**1**Gates et al. ([2004](#efs25778-bib-0115){ref-type="ref"})+++ ++ +++++ +++**1**Gijsbers et al. ([2015](#efs25778-bib-0116){ref-type="ref"})+ ++ ++ ++ +++ ++ ++ +**1**Grobbee et al. ([1987](#efs25778-bib-0122){ref-type="ref"})+NR++++++−++**1**He et al. ([2009](#efs25778-bib-0128){ref-type="ref"})+++++++++++++**1**Jablonski et al. ([2013](#efs25778-bib-0146){ref-type="ref"})++++ ++++ ++ +++**1**Kumanyika et al. ([2005](#efs25778-bib-0175){ref-type="ref"})+NR+ ++ +++ ++ +++**1**Kumanyika et al. ([1993](#efs25778-bib-0174){ref-type="ref"})+++++++++++++**1**MacGregor et al. ([1982](#efs25778-bib-0199){ref-type="ref"})+++++++++++++**1**MacGregor et al. ([1989](#efs25778-bib-0200){ref-type="ref"})+NR++ +++ ++ ++ +**1**Meland et al. ([1997](#efs25778-bib-0208){ref-type="ref"})+NR++ +++ ++ ++ +**1**Melander et al. ([2007](#efs25778-bib-0209){ref-type="ref"})+NR++ ++++ +++**1**Nestel et al. ([1993](#efs25778-bib-0222){ref-type="ref"})+NR+ ++++ ++ ++ +**1**Parijs et al. ([1973](#efs25778-bib-0241){ref-type="ref"})NRNR++ ++ +++ ++**2**Puska et al. ([1983](#efs25778-bib-0252){ref-type="ref"})+NR−++−+ ++**1**Richards et al. ([1984](#efs25778-bib-0257){ref-type="ref"})+NR++ ++ +++ +−**1**Ruppert et al. ([1993](#efs25778-bib-0259){ref-type="ref"})−−−+++++**2**Sacks et al. ([2001](#efs25778-bib-0260){ref-type="ref"})+NR++++++++**1**Santos et al. ([2010](#efs25778-bib-0265){ref-type="ref"})++++ +++ ++ +++**1**Schorr et al. ([1996](#efs25778-bib-0272){ref-type="ref"})+NR−+ ++++ ++**1**Swift et al. ([2005](#efs25778-bib-0292){ref-type="ref"})+NR+++++++**1**van Berge‐Landry and James ([2004](#efs25778-bib-0306){ref-type="ref"})+NR+ ++ ++++++ +**1**Watt et al. ([1983](#efs25778-bib-0311){ref-type="ref"})+NR−+ ++NR+ ++**2**Watt et al. ([1985](#efs25778-bib-0312){ref-type="ref"})+NR++ ++++ ++ +**1**[^30][^31]

### I.2.2.. Observational studies {#efs25778-sec-0113}

ReferencesRisk of bias domains[a](#efs25778-note-0063){ref-type="fn"}Tier[b](#efs25778-note-0064){ref-type="fn"}Confounding(a)AttritionExposureOutcomeReportingStatisticsStolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"})−−−++++++2[^32][^33]

I.3.. Random‐effects meta‐analyses of trials of effects of sodium reduction on SBP and DBP {#efs25778-sec-0114}
------------------------------------------------------------------------------------------

![sbp -- all adults, sorted by 24‐h UNa between‐group difference\
95% CI: 95% confidence interval; UNa: sodium urinary excretion.](EFS2-17-e05778-g004){#efs25778-fig-0004}

![SBP -- all adults, subgroups by blood pressure status\
95% CI: 95% confidence interval.](EFS2-17-e05778-g005){#efs25778-fig-0005}

![SBP -- all adults, subgroups by age \< or ≥ 50 years\
95% CI: 95% confidence interval.](EFS2-17-e05778-g006){#efs25778-fig-0006}

![SBP -- all adults, subgroups by trial duration\
95% CI: 95% confidence interval.](EFS2-17-e05778-g007){#efs25778-fig-0007}

![DBP -- all adults, sorted by 24‐h UNa between‐group difference\
95% CI: 95% confidence interval; UNa: sodium urinary excretion.](EFS2-17-e05778-g008){#efs25778-fig-0008}

![DBP -- all adults, subgroups by blood pressure status\
95% CI: 95% confidence interval.](EFS2-17-e05778-g009){#efs25778-fig-0009}

![DBP -- all adults, subgroups by age \< or ≥ 50 years\
95% CI: 95% confidence interval.](EFS2-17-e05778-g010){#efs25778-fig-0010}

![DBP -- all adults, subgroups by trial duration\
95% CI: 95% confidence interval.](EFS2-17-e05778-g011){#efs25778-fig-0011}

###### 

Pooled estimates of the effect of sodium reduction on SBP (mean difference expressed in mm Hg)

                                                   N studies   N particip.   Mean diff.   95% CI   I^2^   p          
  ------------------------ ----------------------- ----------- ------------- ------------ -------- ------ ---------- ----------
  All                      Adults                  35          3,407         −3.9         −5.1     −2.8   62%        \< 0.001
  BP                       Hypertensive            17          721           −5.6         −8.1     −3.1   58%        0.001
  Mixed                    10                      770         −3.5          −5.4         −1.7     67%    0.001      
  Normotensive             8                       1,916       −2.0          −3.3         −0.7     26%    0.218      
  Age                      Adults \< 50 years      16          632           −2.2         −3.3     −1.1   49%        0.014
  Adults ≥ 50 years        19                      2,775       −6.1          −8.2         −4.1     50%    0.007      
  Sex                      \> 55% men              14          2,430         −4.5         −6.5     −2.6   74%        \< 0.001
  45−55% both genders      14                      761         −4.7          −7.0         −2.5     55%    0.007      
  \> 55% women             7                       216         −1.8          −3.6         0.0      20%    0.277      
  BMI                      \< 25                   1           66            −5.0         −10.6    0.6    --         --
  25−29                    10                      1,132       −4.6          −6.3         −2.8     26%    0.207      
  ≥ 30                     2                       384         −5.3          −8.0         −2.7     52%    0.151      
  NR                       22                      1,825       −3.1          −4.7         −1.6     62%    \< 0.001   
  Ethnicity                Caucasian               3           65            −7.6         −12.9    −2.3   0%         0.991
  African (including AA)   1                       40          −8.0          −13.7        −2.3     --     --         
  Mixed                    12                      2,540       −5.7          −8.0         −3.4     82%    \< 0.001   
  NR                       19                      762         −1.7          −2.5         −0.8     0%     0.578      
  Potassium                ≤ 60 mmol/day           4           103           −1.0         −2.1     0.1    9%         0.346
  \> 60−≤ 70 mmol/day      8                       2,008       −3.0          −4.6         −1.4     52%    0.043      
  \> 70−≤ 80 mmol/day      7                       442         −4.3          −6.2         −2.5     0%     0.743      
  \> 80 mmol/day           3                       174         −3.8          −8.7         1.2      41%    0.183      
  NR                       13                      680         −6.4          −9.5         −3.3     59%    0.004      
  Design                   Parallel                8           2,217         −2.0         −3.1     −1.0   20%        0.272
  Crossover                26                      1,134       −5.0          −6.8         −3.3     67%    \< 0.001   
  Cluster‐randomised       1                       56          −2.2          −8.4         4.0      --     --         
  Specific design          Run‐in -- normal diet   7           380           −5.2         −9.6     −0.9   75%        0.001
  Run‐in -- low Na diet    9                       386         −5.8          −8.6         −2.9     43%    0.083      
  Run‐in -- high Na diet   4                       504         −5.3          −7.0         −3.6     0%     0.552      
  No run‐in                15                      2,137       −1.6          −2.5         −0.8     18%    0.254      
  Trial duration           1 month                 20          1,005         −5.1         −7.0     −3.1   72%        \< 0.001
  2--3 months              12                      618         −4.0          −5.5         −2.5     0%     0.755      
  ≥ 1 year                 3                       1784        −1.6          −2.8         −0.4     40%    0.191      
  Intervention type        Feeding                 28          1,309         −4.0         −5.3     −2.7   44%        0.007
  Counselling              7                       2,098       −3.7          −6.2         −1.1     85%    \< 0.001   
  Position                 Supine                  17          517           −5.6         −7.5     −3.6   0%         0.762
  Seated                   16                      2,826       −2.5          −3.6         −1.5     57%    0.003      
  NR                       2                       64          −14.7         −20.6        −8.8     13%    0.284      
  UNa difference           ≤ 50 mmol               6           2,018         −2.0         −3.0     −0.9   23%        0.26
  51−75 mmol               14                      773         −2.4          −3.6         −1.2     27%    0.169      
  76−100 mmol              11                      511         −6.5          −8.3         −4.7     0%     0.814      
  \> 100 mmol              4                       105         −8.6          −19.0        1.7      85%    \< 0.001   
  Tier                     Tier 1                  30          3,171         −3.3         −4.4     −2.2   50%        0.001
  Tier 2                   5                       236         −6.9          −12.8        −1.1     75%    0.003      

BP: blood pressure; 95% CI: 95% confidence interval; diff.: difference; N: number; Na: sodium; NR: not reported; particip.: participants; SBP: systolic blood pressure; UNa: sodium urinary excretion.

John Wiley & Sons, Ltd

###### 

Pooled estimates of the effect of sodium reduction on DBP (mean difference expressed in mm Hg)

                                                   N studies   N particip.   Mean diff.   95% CI   I^2^   p          
  ------------------------ ----------------------- ----------- ------------- ------------ -------- ------ ---------- ----------
  All                      Adults                  35          3,407         −2.0         −2.8     −1.2   61%        \< 0.001
  BP                       Hypertensive            17          721           −2.9         −4.2     −1.6   47%        0.016
  Mixed                    10                      770         −1.7          −3.3         −0.2     75%    \< 0.001   
  Normotensive             8                       1,916       −0.9          −1.6         −0.2     9%     0.365      
  Age                      Adults \< 50 years      16          632           −1.0         −2.0     0.0    61%        0.001
  Adults ≥ 50 years        19                      2,775       −2.9          −4.0         −1.9     40%    0.036      
  Sex                      \> 55% men              14          2,430         −2.7         −3.9     −1.5   70%        \< 0.001
  45−55% both genders      14                      761         −1.9          −3.3         −0.5     53%    0.01       
  \> 55% women             7                       216         −0.6          −2.0         0.8      33%    0.173      
  BMI                      \< 25                   1           66            −3.0         −7.1     1.1    --         --
  25−29                    10                      1,132       −1.9          −2.6         −1.2     0%     0.739      
  ≥ 30                     2                       384         −2.8          −4.0         −1.6     16%    0.276      
  NR                       22                      1,825       −1.7          −2.8         −0.5     69%    \< 0.001   
  Ethnicity                Caucasian               3           65            −2.2         −4.9     0.5    0%         0.579
  African (including AA)   1                       40          −3.0          −6.5         0.5      --     --         
  Mixed                    12                      2,540       −3.0          −4.2         −1.7     74%    \< 0.001   
  NR                       19                      762         −1.2          −2.3         0.0      54%    0.003      
  Potassium                ≤ 60 mmol/day           4           103           0.4          −1.1     1.9    51%        0.105
  \> 60−≤ 70 mmol/day      8                       2,008       −2.2          −3.4         −0.9     66%    0.005      
  \> 70−≤ 80 mmol/day      7                       442         −2.4          −3.5         −1.3     0%     0.742      
  \> 80 mmol/day           3                       174         −2.5          −4.8         −0.2     0%     0.573      
  NR                       13                      680         −2.9          −4.5         −1.2     51%    0.017      
  Design                   Parallel                8           2,217         −1.8         −3.0     −0.7   63%        0.009
  Crossover                26                      1,134       −2.0          −3.1         −0.9     61%    \< 0.001   
  Cluster‐randomised       1                       56          −3.9          −7.6         −0.2     --     --         
  Specific design          Run‐in -- normal diet   7           380           −3.6         −5.4     −1.7   55%        0.036
  Run‐in -- low Na diet    9                       386         −2.7          −4.1         −1.2     38%    0.119      
  Run‐in -- high Na diet   4                       504         −2.7          −3.7         −1.7     0%     0.57       
  No run‐in                15                      2137        −0.5          −1.3         0.3      30%    0.131      
  Duration                 1 month                 20          1,005         −2.1         −3.4     −0.8   67%        \< 0.001
  2--3 months              12                      618         −2.8          −3.7         −1.9     0%     0.501      
  ≥ 1 year                 3                       1,784       −1.1          −2.3         0.1      66%    0.052      
  Intervention type        Feeding                 28          1,309         −1.7         −2.6     −0.9   46%        0.004
  Counselling              7                       2,098       −2.7          −4.4         −1.0     83%    \< 0.001   
  Position                 Supine                  17          517           −2.7         −3.8     −1.5   0%         0.66
  Seated                   16                      2,826       −1.4          −2.3         −0.5     70%    \< 0.001   
  NR                       2                       64          −5.9          −11.7        −0.1     55%    0.138      
  UNa difference           ≤ 50 mmol               6           2,018         −1.3         −2.3     −0.2   52%        0.063
  51−75 mmol               14                      773         −1.5          −2.8         −0.2     64%    0.001      
  76−100 mmol              11                      511         −2.9          −3.9         −1.9     0%     0.869      
  \> 100 mmol              4                       105         −4.6          −10.1        0.8      76%    0.006      
  Tier                     Tier 1                  30          3,171         −1.7         −2.4     −0.9   56%        \< 0.001
  Tier 2                   5                       236         −4.1          −7.0         −1.2     52%    0.081      

BP: blood pressure; 95% CI: 95% confidence interval; diff.: difference; N: number; Na: sodium; NR: not reported; particip.: participants; DBP: diastolic blood pressure; UNa: sodium urinary excretion.

John Wiley & Sons, Ltd

I.4.. Dose--response modelling {#efs25778-sec-0115}
------------------------------

###### 

Multivariable mixed‐effects meta‐regression model on SBP, only fixed effects reported

  Covariate                                                     β coefficient   Std. Err.   p \> \|z\|     95% CI
  ------------------------------------------------------------- --------------- ----------- -------------- ------------------
  Mean UNa -- per 100 mmol/day                                  **5.3**         **0.8**     **\< 0.001**   **(3.6 to 6.9)**
  Age at baseline                                                                                          
  Age \< 40 years old[a](#efs25778-note-0068){ref-type="fn"}    0                                          
  Age 40--49 years old                                          18.2            4.4         \< 0.001       (9.6 to 26.9)
  Age 50--59 years old                                          11.6            4.7         0.013          (2.4 to 20.7)
  Age ≥ 60 years old                                            12.4            4.2         0.003          (4.3 to 20.6)
  Blood pressure status                                                                                    
  Normotensive[a](#efs25778-note-0068){ref-type="fn"}           0                                          
  Hypertensive                                                  11.4            4.5         0.011          (2.6 to 20.1)
  UNa at baseline[b](#efs25778-note-0069){ref-type="fn"}                                                   
  \< 100 mmol/day[a](#efs25778-note-0068){ref-type="fn"}        0                                          
  100--149 mmol/day                                             25.2            6.3         \< 0.001       (12.7 to 37.6)
  ≥150 mmol/day                                                 18.7            6.4         0.004          (6.0 to 31.3)
  Not reported                                                  13.4            5.3         0.012          (3.0 to 23.8)
  BP measurement method                                                                                    
  Point office, supine[a](#efs25778-note-0068){ref-type="fn"}   0                                          
  Point office, sitting                                         −13.2           3.2         \< 0.001       (−19.6 to −6.9)
  Specific trial design                                                                                    
  No Run‐in[a](#efs25778-note-0068){ref-type="fn"}                              0                          
  Run‐in, Normal diet                                           11.9            3.4         \< 0.001       (5.3 to 18.5)
  Run‐in, Low Na diet                                           19.7            5.1         \< 0.001       (9.7 to 29.8)
  Constant                                                      95.5            6.8         \< 0.001       (82.2 to 108.8)

95% CI: 95% confidence interval; Std. Err.: standard error; UNa: sodium urinary excretion.

Reference category.

UNa at baseline: corresponds to UNa at the start of the intervention (i.e. after run‐in, where applicable).

Model centred at 49 mmol/day sodium excretion (minimum mean UNa observed in the data set); total heterogeneity (random effects on trial) estimated from null model = 275.2 (95% CI: 161.4--468.9), residual heterogeneity from full model = 33.4 (95% CI: 13.3--53.5).

John Wiley & Sons, Ltd

![Linear dose--response relationship between mean urinary sodium excretion and mean SBP (mm Hg) from meta‐regression modelling of trials' arms (crude model)\
Circles represents mean SBP by arm and their size is proportional to weights from the mixed‐effects model. The slope from the full model with moderators did not differ substantially (UNa unadjusted coefficient: 5.2 mm Hg per 100 mmol/day, 95% CI: 3.6--6.9).](EFS2-17-e05778-g012){#efs25778-fig-0012}

###### 

Multivariable mixed‐effects meta‐regression model on DBP, only fixed effects reported

  Covariate                                                     β coefficient   Std. Err   p \> \|z\|   95% CI
  ------------------------------------------------------------- --------------- ---------- ------------ -----------------
  Mean UNa -- per 100 mmol/day                                  2.6             0.5        \< 0.001     (1.6 to 3.7)
  Age at baseline                                                                                       
  Age \< 40 years old[a](#efs25778-note-0072){ref-type="fn"}    0                                       
  Age 40--49 years old                                          18.2            3.2        \< 0.001     (11.9 to 24.6)
  Age 50--59 years old                                          11.8            3.5        0.001        (5.1 to 18.6)
  Age ≥ 60 years old                                            7.8             3.1        0.011        (1.8 to 13.8)
  Blood pressure status                                                                                 
  Normotensive[a](#efs25778-note-0072){ref-type="fn"}           0                                       
  Hypertensive                                                  8.7             3.3        0.008        (2.3 to 15.1)
  UNa at baseline[b](#efs25778-note-0073){ref-type="fn"}                                                
  \< 100 mmol/day[a](#efs25778-note-0072){ref-type="fn"}        0                                       
  100--149 mmol/day                                             10.4            4.5        0.022        (1.5 to 19.3)
  ≥ 150 mmol/day                                                10.2            4.7        0.028        (1.1 to 19.4)
  Not reported                                                  10.4            3.8        0.007        (2.9 to 17.9)
  BP measurement method                                                                                 
  Point office, supine[a](#efs25778-note-0072){ref-type="fn"}   0                                       
  Point office, sitting                                         −6.6            2.4        0.005        (−11.3 to −2.0)
  Specific trial design                                                                                 
  No Run‐in[a](#efs25778-note-0072){ref-type="fn"}                              0                       
  Run‐in, Normal diet                                           7.9             2.5        0.002        (3.0 to 12.7)
  Run‐in, Low Na diet                                           7.7             3.7        0.037        (0.5 to 15.0)
  Constant                                                      55.4            4.8        \< 0.001     (45.9 to 64.8)

BP: blood pressure; 95% CI: 95% confidence interval; Std. Err: standard error; UNa: sodium urinary excretion.

Reference category.

UNa at baseline: corresponds to UNa at the start of the intervention (i.e. after run‐in, where applicable).

Model centred at 49 mmol/day sodium excretion (minimum mean UNa observed in the data set); total heterogeneity (random effects on trial) estimated from null model = 129.1 (95% CI: 76.1--218.8), residual heterogeneity from full model = 18.8 (95% CI: 8.1--29.4).

John Wiley & Sons, Ltd

![Linear dose--response relationship between mean urinary sodium excretion and mean DBP (mm Hg) from meta‐regression modelling of trials' arms (crude model)\
Circles represents mean DBP by arm and their size is proportional to weights from the mixed‐effects model. The slope from the full model with moderators did not differ substantially (UNa unadjusted coefficient: 2.6 mm Hg per 100 mmol/day, 95% CI: 1.6--3.7).](EFS2-17-e05778-g013){#efs25778-fig-0013}

Appendix J -- Outcome of the systematic review on incidence of hypertension {#efs25778-sec-1010}
===========================================================================

J.1.. Evidence tables {#efs25778-sec-0116}
---------------------

### J.1.1.. Experimental studies {#efs25778-sec-0117}

References (country)DesignSubjects characteristics at baselineNa intake assessment methodUNa (mmol/24 h)Outcomes assessedResultsWhelton et al. ([1997](#efs25778-bib-0317){ref-type="ref"}) (USA) TOPH IRCT (parallel) G1: sodium reduction counselling (goal \< 80 mmol/24 h) (N = 326) G2: usual care (N = 417) Recruitment criteria: aged 35--54 years, with high‐normal DBP Duration: 18 months[Sex (male,%)]{.ul} G1: 70.9 G2: 71.7 [Age (years, mean ± SD)]{.ul} G1: 43.4 ± 6.6 G2: 42.6 ± 6.0 [Ethnicity (White,%)]{.ul} G1: 78.0 G2: 76.5 [bw (kg, mean ± SD]{.ul}) G1: 82.7 ± 14.3 G2: 82.8 ± 14.0 [SBP (mm Hg, mean ± SD)]{.ul} G1: 124.8 ± 8.5 G2: 125.1 ± 8.1 [DBP (mm Hg, mean ± SD)]{.ul} G1: 83.7 ± 2.7 G2: 83.9 ± 2.8Average of two 24‐h urine collection at baseline single 24‐h urine collection at the 6‐, 12‐ and 18‐month follow‐up visitsMean ± SD [Baseline]{.ul} G1: 154.6 ± 77.9 G2: 156.4 ± 60.5 Diff: --1.8 [At 18 month]{.ul} G1: 99.4 ± 60.0 G2: 146.5 ± 79.2 Diff: --47.2Incident hypertension Hypertension diagnosed when mean of 9 DBP measurements ≥ 90 mm Hg or antihypertensive drug therapy prescribed[Incidence of hypertension during follow‐up]{.ul} G1: 8.6% G2: 11.3% RR = 0.76 (95% CI 0.49, 1.18)The Trials of Hypertension Collaborative Research Group ([1997](#efs25778-bib-0297){ref-type="ref"}) (USA) TOPH IIRCT (parallel) G1: sodium reduction counselling (goal \< 80 mmol/24 h) (N = 594) G2: usual care (N = 596) Recruitment criteria: aged 30--54 years, with high‐normal DBP, overweight Duration: 36 to 48 months[Sex (male,%)]{.ul} G1: 64.8 G2: 68.3 [Age (years, mean ± SD)]{.ul} G1: 44.2 ± 6.1 G2: 43.2 ± 6.1 [Ethnicity (White, %)]{.ul} G1: 81.1 G2: 79.5 [bw (kg, mean ± SD)]{.ul} G1: 94.0 ± 14.3 G2: 93.6 ± 13.5 [SBP (mm Hg, mean ± SD)]{.ul} G1: 127.7 ± 6.6 G2: 127.3 ± 6.4 [DBP (mm Hg, mean ± SD)]{.ul} G1: 86.1 ± 1.9 G2: 85.8 ± 1.9Average of two 24‐h urine collection at baseline single 24‐h urine collection at the 18‐, 36‐month follow‐up visitsMean ± SD [Baseline]{.ul} G1: 186.1 ± 80.7 G2: 188.0 ± 80.9 Diff: --1.9 [At 36 month (change from baseline)]{.ul} G1: −50.9 ± 86.3 G2: −10.5 ± 88.5 Diff: −40.4Incident hypertension Hypertension diagnosed when mean of 9 DBP measurements ≥ 90 mm Hg or mean of 9 SBP measurements ≥ 140 mm Hg or antihypertensive drug therapy prescribedIncidence of hypertension [At 18 month (cases, %)]{.ul} G1: 108 (18.6) G2: 124 (21.1) RR = 0.88 (p = 0.28) [At 36 month (cases, %)]{.ul} G1: 198 (34.4) G2: 229 (39.2) RR = 0.88 (p = 0.09) [At 48 month (cases, %)]{.ul} G1: 211 (38.1) G2: 248 (44.4) RR = 0.86 (p = 0.04)[^34]

### J.1.2.. Observational studies {#efs25778-sec-0118}

References (country)DesignBaseline characteristicsNa intake assessment methodUNa (mmol/24 h)Outcomes assessedConfounders adjusted forResultsForman et al. ([2012](#efs25778-bib-0109){ref-type="ref"}) (Netherlands) PREVENDProspective cohort N = 8,592 initial cohort; IMDM and pregnant women excluded; oversampling of subjects with elevated albumin excretion (\> 10 mg/L) N = 5,556 included (excluded: participants with hypertension, missing 24‐h UNa at baseline) Median duration: 6.4 years[Male (%)]{.ul} Q1 32.5 Q2 43.5 Q3 48.1 Q4 58.4 [Age (median (IQR), years)]{.ul} Q1 43 (36--52) Q2 43 (36--52) Q3 43 (36--51) Q4 44 (37--52) [BMI (median (IQR), kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} Q1 23.7 (21.7--26.2) Q2 24.2 (22.2--26.7) Q3 24.9 (22.6--27.3) Q4 25.7 (23.5--28.4) [Smoking status (never, %)]{.ul} Q1 31.5 Q2 30.5 Q3 31.5 Q4 29.4 [SBP (median (IQR), mm Hg)]{.ul} Q1 116 (108--126) Q2 118 (110--127) Q3 119 (111--128) Q4 121 (112--129) [DBP (median (IQR), mm Hg)]{.ul} Q1 69 (64--74) Q2 70 (65--75) Q3 70 (65--75) Q4 71 (66--76) [UK (median (IQR), mmol/24 h)]{.ul} Q1 56 (43--72) Q2 73 (59--91) Q3 87 (71--109) Q4 114 (87--144) [24‐h UCr (median (IQR), g)]{.ul} Q1 1.1 (0.9--1.3) Q2 1.3 (1.1--1.5) Q3 1.4 (1.2--1.7) Q4 1.6 (1.3--1.9) [24‐h UAlbumin (median (IQR), mg)]{.ul} Q1 7.3 (5.3--11.7) Q2 7.9 (5.8--12.5) Q3 8.4 (6.1--13.6) Q4 8.7 (6.4--13.9)Two 24‐h urine specimens collected at baseline (1997--1998), two 24‐h urine specimens collected during follow‐up first examination (2001--2003) and two 24‐h urine specimens collected during follow‐up second examination (2003--2006)Median (IQR) Overall 137 (106--171) Q1 97 (79--110) (n = 1,389) Q2 142 (132--153) (n = 1,389) Q3 188 (176--203) (n = 1,389) Q4 271 (242--316) (n = 1,389)Incident hypertension BP measured at baseline and at follow‐up Hypertension was defined as a SBP \> 140 mm Hg, a DBP \> 90 mm Hg, or both or the use of antihypertensive medicationsAge, BMI, sex, alcohol intake, smoking status, family history of hypertension, estimated GFR, serum levels of glucose ad cholesterol, and 24‐h UK, 24‐h UCa and 24‐h UCrHR for incident hypertension [By 1 g (43 mmol) increase in UNa]{.ul} HR (95% CI) = 1.05 (1.00--1.10) (878 cases) [By quartile of UNa:]{.ul} Q1 (reference) (incidence 13.9%) Q4 HR (95% CI) = 1.21 (0.98--1.51) (incidence 19.7%) Effect modification by serum uric acid and UAlbumin excretionStolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"}) (Belgium, Czech Republic, Italy, Poland, Russian Federation) FLEMENGHO/EPOGHProspective cohort N = 3,360 FLEMENGHO initial cohort; N = 1,187 initial EPOGH initial cohort N = 2,096 included in the analyses ('hypertension cohort') (excluded: participants with treated/untreated hypertension at baseline, history of CVD, missing/inaccurate 24‐h UNa at baseline) Median duration: 6.5 years[Male (%)]{.ul} T1 45.8 T2 46.0 T3 45.9 [Hypertensive (%)]{.ul} none [Diabetes mellitus]{.ul} w T1 1.9 T2 1.6 T3 1.9  m T1 1.9 T2 2.4 T3 1.9 [Age (mean (SD), years)]{.ul} w T1 38.9 (15.3) T2 38.7 (14.1) T3 36.7 (13.1) m T1 39.3 (16.0) T2 40.1 (15.4) T3 38.2 (13.4) [BMI (mean (SD), kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} w T1 23.6 (4.2) T2 24.1 (4.1) T3 25.0 (4.6) m T1 24.6 (3.4) T2 24.9 (3.3) T3 25.2 (3.6) [Smokers (%)]{.ul} w T1 32.3 T2 23.6 T3 23.9  m T1 37.7 T2 39.0 T3 32.8 [Alcohol intake (5 g/day,%)]{.ul} w T1 8.8 T2 9.9 T3 12.9  m T1 35.2 T2 32.9 T3 39.8 [Higher education (%)]{.ul} w T1 10.7 T2 14.3 T3 16.9  m T1 13.8 T2 12.5 T3 17.7 [SBP (mean (SD), mm Hg)]{.ul} w T1 115.6 (11.2) T2 115.6 (10.7) T3 116.8 (10.0) m T1 121.8 (9.7) T2 121.8 (8.7) T3 122.0 (9.3) [DBP (mean (SD), mm Hg)]{.ul} w T1 71.3 (8.0) T2 72.1 (7.6) T3 73.0 (8.0) m T1 74.8 (8.2) T2 74.0 (7.9) T3 75.5 (7.7) [24‐h UK (mean (SD), mmol)]{.ul} w T1 51.2 (17.2) T2 62.9 (21.1) T3 69.4 (23.4) m T1 62.5 (26.3) T2 73.5 (23.4) T3 84.1 (28.8) 24‐h UCr (mean (SD), mmol) w T1 8.6 (2.2) T2 9.6 (2.0) T3 10.8 (2.5) m T1 12.2 (3.1) T2 14.1 (3.2) T3 16.1 (3.4)Single 24‐h urine sample at baseline and at last follow‐up examination Inaccurate urine collections were defined as a volume \< 300 mL/24‐h, a 24‐h UCr \< 4 mmol or \> 25 mmol in women and \< 6 mmol or \> 30 mmol in menMean (SD) Overall 174.2 (74.1) Women T1 94.4 (21.5) (n = 375) T2 147.4 (14.3) (n = 385) T3 222.1 (47.2) (n = 373) Men T1 121.3 (27.9) (n = 318) T2 185.3 (16.1) (n = 328) T3 282.2 (56.4) (n = 317)Incident hypertension BP measured at baseline and follow‐up Hypertension was defined as SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg use of antihypertensive drugs.Study population, sex, age, BMI, SBP, 24‐h UK, drinking alcohol and educational attainmentHR for incident hypertension [By tertile of UNa (whole population as reference)]{.ul} T1 HR (95% CI) = 1.00 (0.87, 1.16) (incidence 27.0%, 187 cases) T2 HR (95% CI) = 1.02 (0.89, 1.16) (incidence 26.6%, 190 cases) T3 HR (95% CI) = 0.98 (0.86, 1.12) (incidence 25.4%, 175 cases)[^35]

J.2.. Outcome of the RoB appraisal {#efs25778-sec-0119}
----------------------------------

### J.2.1.. Experimental studies {#efs25778-sec-0120}

ReferencesRisk of bias domains[a](#efs25778-note-1021){ref-type="fn"}Tier[b](#efs25778-note-1022){ref-type="fn"}RandomisationAllocation concealmentBlindingAttritionExposureOutcomeReportingOther threats to internal validityWhelton et al. ([1997](#efs25778-bib-0317){ref-type="ref"}) (TOPH I)+++++++++++++**1**The Trials of Hypertension Collaborative Research Group ([1997](#efs25778-bib-0297){ref-type="ref"}) (TOPH II)+++++++++++++**1**[^36][^37]

### J.2.2.. Observational studies {#efs25778-sec-0121}

ReferencesRisk of bias domains[a](#efs25778-note-1023){ref-type="fn"}Tier[b](#efs25778-note-1024){ref-type="fn"}ConfoundingAttritionExposureOutcomeReportingStatisticsForman et al. ([2012](#efs25778-bib-0109){ref-type="ref"})+−+++++++**1**Stolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"})−−−+++++**2**[^38][^39]

J.3.. Descriptive forest plot {#efs25778-sec-0122}
-----------------------------

![Descriptive forest plot of the eligible observational and experimental studies on the incidence of hypertension\
95% CI: 95% confidence interval; HR: hazard ratio.A hazard ratio \> 1 indicates an increased risk of outcome with higher sodium intake.](EFS2-17-e05778-g014){#efs25778-fig-0014}

Appendix K -- Outcome of the systematic review on risk of CVD {#efs25778-sec-1011}
=============================================================

K.1.. Evidence tables {#efs25778-sec-0123}
---------------------

References (country)DesignBaseline characteristicsNa intake assessment methodUNa (mmol/24 h)Outcomes assessedConfounders adjusted forResultsCook et al. ([2014](#efs25778-bib-0060){ref-type="ref"}) (USA) TOPH I/TOPH IIProspective cohort N = 2,974 TOPH I/TOPH II participants not in active Na intervention eligible for follow‐up N = 2,275 included in the analyses (excluded: CVD event during trial period, missing 24‐h UNa) Duration: 10 years (TOPH I)/15 years (TOPH II)[Men (%)]{.ul} TOPH I 71, TOPH II 67 [Hypertensive (treated/untreated):]{.ul} none [Age (mean, years)]{.ul} [TOPH I]{.ul} w Q1 44.6 Q2 44.7 Q3 43.0 Q4 42.7  m Q1 42.1 Q2 42.8 Q3 43.3 Q4 42.7 [TOPH II]{.ul} w Q1 44.4 Q2 43.8 Q3 43.1 Q4 44.0  m Q1 42.7 Q2 43.6 Q3 43.6 Q4 42.5 [bw (mean, lb)]{.ul} [TOPH I]{.ul} w Q1 151.3 Q2 162.4 Q3 174.1 Q4 183.7  m Q1 175.8 Q2 185.4 Q3 198.1 Q4 211.4 [TOPH II]{.ul} w Q1 172.7 Q2 181.4 Q3 192.0 Q4 203.1  m Q1 202.4 Q2 207.5 Q3 213.8 Q4 229.2 [Ethnicity (%, black)]{.ul} w Q1 19.8 Q2 22.6 Q3 28.8 Q4 30.4  m Q1 14.8 Q2 6.5 Q3 8.8 Q4 7.7 [TOPH II]{.ul} w Q1 34.5 Q2 30.4 Q3 28.1 Q4 18.2  m Q1 11.1 Q2 10.6 Q3 9.5 Q4 7.9 [Smokers (%, current)]{.ul} [TOPH I]{.ul} w Q1 14.8 Q2 10.6 Q3 11.0 Q4 21.7  m Q1 10.2 Q2 10.7 Q3 10.5 Q4 10.1 [TOPH II]{.ul} w Q1 10.3 Q2 8.7 Q3 13.5 Q4 9.1  m Q1 22.2 Q2 7.0 Q3 8.3 Q4 8.9 [Alcohol intake (≥ 1 drink/wk,%)]{.ul} [TOPH I]{.ul} w Q1 41.6 Q2 28.8 Q3 23.3 Q4 39.1  m Q1 63.6 Q2 55.2 Q3 52.5 Q4 42.9 [TOPH II]{.ul} w Q1 13.8 Q2 19.9 Q3 14.6 Q4 27.3  m Q1 55.6 Q2 42.2 Q3 44.0 Q4 40.1 [College degree (%)]{.ul} [TOPH I]{.ul} w Q1 46.5 Q2 46.2 Q3 42.5 Q4 39.1  m Q1 84.1 Q2 71.2 Q3 68.8 Q4 66.7 [TOPH II]{.ul} w Q1 62.1 Q2 50.3 Q3 44.9 Q4 45.4  m Q1 100.0 Q2 72.5 Q3 67.1 Q4 62.9 [SBP (mm Hg, mean)]{.ul} [TOPHI]{.ul} W Q1 125.2 Q2 125.7 Q3 125.3 Q4 123.9 M Q1 124.3 Q2 124.2 Q3 125.2 Q4 125.3 [TOPH II]{.ul} W Q1 128.2 Q2 128.4 Q3 128.2 Q4 130.0 M Q1 127.7 Q2 127.5 Q3 126.7 Q4 127.6 [DBP (mm Hg, mean)]{.ul} [TOPH I]{.ul} W Q1 83.7 Q2 83.7 Q3 84.5 Q4 83.6 M Q1 84.0 Q2 83.7 Q3 84.0 Q4 83.7 [TOPH II]{.ul} W Q1 85.7 Q2 85.7 Q3 85.8 Q4 86.2 M Q1 85.8 Q2 86.1 Q3 85.9 Q4 86.2 [24‐h UK (mean, mmol)]{.ul} [TOPH I]{.ul} w Q1 42 Q2 49 Q3 58 Q4 67  m Q1 51 Q2 60 Q3 68 Q4 78 [TOPH II]{.ul} w Q1 39 Q2 50 Q3 56 Q4 68  m Q1 56 Q2 60 Q3 69 Q4 75 [24‐h UCr (mean, g)]{.ul} [TOPH I]{.ul} W Q1 0.9 Q2 1.1 Q3 1.3 Q4 1.5 M Q1 1.3 Q2 1.5 Q3 1.7 Q4 2.0 [TOPH II]{.ul} W Q1 1.0 Q2 1.2 Q3 1.4 Q4 1.5 M Q1 1.5 Q2 1.7 Q3 1.9 Q4 2.23 to 7 24‐h collection scheduled over 18 months in TOPH I and over 3 to 4 years in TOPH II To adjust for potential inaccuracy in collection, controlled for UCr/bw in multivariate model or excluded subjects with CVs of UCr/bw ≥ 20% or 30% (sensitivity analyses)[Men and women]{.ul} Q1 \< 100 Q2 100--156 Q3 157--208 Q4 ≥ 209CVD death or event, including MI, stroke, coronary artery bypass graft, percutaneous transluminal coronary angioplasty. Standardised questionnaires sent at 2‐year intervals; medical records reviewed by study physician (non‐fatal events); search for National Death Index (fatal events)Age, sex, race/ethnicity, clinic and treatment assignment, education status, baseline weight, alcohol se, smoking, exercise, UK, family history of CVD, change in bw, change in smoking and change in exercise during trial periods[HR (95% CI) for fatal and non‐fatal CVD events]{.ul} [By continuous UNa (by 1 g (43‐mmol)/day increase):]{.ul} 1.17 (1.00--1.36) (193 cases, n = 2,275) [By quantiles of UNa:]{.ul} Q1 0.68 (0.34--1.37) (TOPH I 15 events/189 total, TOPH II 2 events/47 total) Q2 0.75 (0.50--1.11) (TOPH I 48 events/590 total, TOPH II 13 events/303 total) Q3 1.00 (reference) (TOPH I 40 events/427 total, TOPH II 34 events/341 total) Q4 1.05 (0.68--1.62) (TOPH I 23 events/191 total, TOPH II 18 events/224 total) No significant deviation from linearity (restricted cubic spline). [Sensitivity analyses:]{.ul} exclusion of subjects based on the CV for UCr/bw: little change in estimated coefficientsStolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"}) (Belgium, Czech Republic, Italy, Poland, Russian Federation) FLEMENGHO/EPOGHProspective cohort N = 3,360 FLEMENGHO initial cohort; N = 1,187 initial EPOGH initial cohort N = 3,681 included in the analyses ('outcome cohort') (excluded: participants with history of CVD, missing/inaccurate 24‐h UNa at baseline) Median duration: 7.9 years[Men (%)]{.ul} T1 47.1 T2 47.4 T3 47.3 [Hypertensive (treated) (%)]{.ul} w T1 14.9 T2 12.5 T3 16.6  m T1 11.1 T2 7.4 T3 8.9 [Diabetes mellitus]{.ul} w T1 3.3 T2 2.9 T3 4.9  m T1 5.0 T2 4.4 T3 4.5 [Age (mean (SD), years)]{.ul} w T1 42.5 (17.6) T2 41.0 (16.0) T3 39.2 (14.7) m T1 41.8 (18.1) T2 41.3 (16.4) T3 39.5 (14.4) [BMI (mean (SD), kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} w T1 24.6 (5.1) T2 24.9 (4.6) T3 25.9 (5.3) m T1 24.7 (3.8) T2 25.2 (3.8) T3 26.1 (4.3) [Smokers (%)]{.ul} w T1 25.9 T2 22.2 T3 22.1  m T1 35.1 T2 37.3 T3 29.1 [Alcohol intake (5 g/day,%)]{.ul} w T1 10.7 T2 10.3 T3 14.0  m T1 34.3 T2 35.6 T3 44.0 [Higher education (%)]{.ul} w T1 11.6 T2 15.1 T3 19.3  m T1 15.3 T2 13.0 T3 19.7 [SBP (mean (SD), mm Hg)]{.ul} w T1 123.3 (19.4) T2 121.0 (16.8) T3 121.7 (15.8) m T1 128.7 (17.9) T2 126.6 (14.9) T3 128.1 (15.3) [DBP (mean (SD), mm Hg)]{.ul} w T1 74.7 (11.0) T2 74.6 (9.7) T3 75.4 (10.2) m T1 77.8 (11.0) T2 76.6 (10.4) T3 79.0 (10.9) [24‐h UK (mean (SD), mmol)]{.ul} w T1 51.6 (17.8) T2 61.0 (20.5) T3 69.1 (24.0) m T1 61.6 (26.3) T2 71.6 (27.1) T3 84.5 (29.2) [24‐h UCr (mean (SD), mmol)]{.ul} w T1 8.4 (2.2) T2 9.5 (2.0) T3 10.6 (2.5) m T1 12.1 (3.2) T2 13.9 (3.4) T3 16.1 (3.8)Single 24‐h urine sample at baseline and at last follow‐up examination Inaccurate urine collections were defined as a volume \< 300 mL/24‐h, a 24‐h UCr \< 4 mmol or \> 25 mmol in women and \< 6 mmol or \> 30 mmol in menMean (SD) [Women]{.ul} T1 95.1 (22.0) (n = 645) T2 150.2 (15.0) (n = 658) T3 231.7 (50.9) (n = 638) [Men]{.ul} T1 120.1 (28.4) (n = 575) T2 188.8 (17.6) (n = 592) T3 290.5 (56.2) (n = 573)CHD events included fatal and non‐fatal MI and coronary revascularisation. Fatal and non‐fatal CVD events comprised CHD events, stroke, fatal and non‐fatal left ventricular HF, aortic aneurysm, cor pulmonale and pulmonary or arterial embolism. Hospitalisations for unstable angina coded as IHD. Standardised questionnaire at follow‐up visits. Physicians ascertained the diseases reported on the death certificates or by the questionnaires against medical recordsStudy population, sex, and baseline variables: age, BMI, 24‐h UK, antihypertensive drug treatment, smoking and drinking alcohol, diabetes, total cholesterol and educational attainmentHRs expressed the risk in each tertile of UNa compared with the overall risk in whole group [HR (95% CI) for fatal CVD events]{.ul} T1 1.41 (0.94, 2.12) (50 events, n = 1,220) T2 0.98 (0.69, 1.40) (24 events, n = 1,250) T3 1.02 (0.71, 1.45) (10 events, n = 1,211)[HR (95% CI) for non‐fatal CVD events]{.ul} T1 1.12 (0.90, 1.41) (100 events, n = 1,220) T2 1.09 (0.89, 1.34) (79 events, n = 1,250) T3 0.92 (0.74, 1.13) (53 events, n = 1,211)[HR (95% CI) for non‐fatal CHD events]{.ul} T1 1.41 (0.99, 2.01) (45 events, n = 1,220) T2 1.15 (0.87, 1.52) (34 events, n = 1,250) T3 0.87 (0.66, 1.15) (19 events, n = 1,211)[HR (95% CI) for non‐fatal stroke events]{.ul} T1 1.05 (0.56, 1.96) (13 events, n = 1,220) T2 1.28 (0.75, 2.17) (13 events, n = 1,250) T3 0.78 (0.46, 1.33) (7 events, n = 1,211)Joosten et al. ([2014](#efs25778-bib-0153){ref-type="ref"}) (Netherlands) PREVENDProspective cohort N = 8,592 initial cohort; IMDM and pregnant women excluded; oversampling of subjects with elevated albumin excretion (\> 10 mg/L) N = 7,543 included (excluded: participants with CVD, renal disease requiring dialysis, malignancies, missing values of covariates at baseline) Median duration: 10.5 years (IQR 9.9--10.8)[Men (%)]{.ul} Q1 48.7 Q2 48.7 Q3 48.7 Q4 48.7 [Age (mean ± SD, years)]{.ul} Q1 50 ± 13 Q2 49 ± 13 Q3 48 ± 12 Q4 47 ± 11 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} Q1 25.0 ± 3.7 Q2 25.5 ± 3.7 Q3 26.1 ± 4.1 Q4 27.5 ± 4.8 [Smoking status (never,%)]{.ul} Q1 30.1 Q2 32.1 Q3 28.6 Q4 29.9 [SBP (mean ± SD, mm Hg)]{.ul} Q1 129 ± 22 Q2 128 ± 20 Q3 128 ± 20 Q4 129 ± 20 [DBP (mean ± SD, mm Hg)]{.ul} Q1 74 ± 10 Q2 74 ± 10 Q3 74 ± 10 Q4 74 ± 9 [Antihypertensive drugs (%)]{.ul} Q1 14.3 Q2 12.6 Q3 12.4 Q4 12.7 [24‐h UK (median (IQR), mmol)]{.ul} Q1 59 (47--73) Q2 67 (56--81) Q3 73 (61--86) Q4 80 (66--95) [24‐h UCr (median (IQR), mmol)]{.ul} Q1 10.3 (8.4--12.7) Q2 11.5 (9.5--13.8) Q3 12.3 (10.1--15.1) Q4 13.6 (11.1--16.8) [24‐h UAlbumin (median (IQR), mmol)]{.ul} Q1 8.1 (5.5--14.7) Q2 9.1 (6.3--16.4) Q3 9.4 (6.4--17.1) Q4 10.3 (7.0--19.3)Two 24‐h urine specimens collected at baseline (1997--1998) Sensitivity analyses excluding 24‐h urine samples with possible over‐ or undercollections (i.e. samples upper and lower 2.5% of the difference between the estimated and measured volume of a subject\'s 24‐h urine sample.)[Men]{.ul} Q1 \< 122 Q2 122--154 Q3 155--190 Q4 \> 190 [Women]{.ul} Q1 \< 95 Q2 95--121 Q3 122--151 Q4 \> 151CHD defined as MI, acute and subacute IHD and coronary artery bypass grafting or percutaneous transluminal coronary angioplasty. Data from Dutch bureau of statistics (fatal events) and Dutch national registry of hospital discharge diagnoses (non‐fatal events)Age, sex, body mass index, smoking status, alcohol intake, parental history of coronary heart disease, type 2 diabetes mellitus, total to HDL cholesterol ratio, and 24‐h UK, magnesium and creatinine excretion[HR (95% CI) for fatal and non‐fatal CHD]{.ul} [By continuous UNa (by 1 g (43‐mmol)/day]{.ul} [increase):]{.ul} 1.07 (0.98--1.18) p = 0.15 (452 cases; 71,491 person‐years) [By sex‐specific quintiles of UNa:]{.ul} Q1 (reference) (123 cases, 17,738 person‐years) Q2 0.99 (0.76--1.29) (111 cases, 17,975 person‐years) Q3 1.09 (0.83--1.44) (112 cases, 17,878 person‐years) Q4 1.19 (0.88--1.62) (106 cases, 18,000 person‐years) No significant deviation from linearity (restricted cubic spline). Evidence for effect modification by mean arterial pressure (P~interaction~ = 0.08) and plasma NT‐proBNP concentration (P~interaction~ = 0.002). [Sensitivity analyses:]{.ul} exclusion of subjects with potential under‐ or overcollections in 24‐h urine samples: results unchanged restricted to subjects with UAlbumin \> 10 mg/L: results unchangedKieneker et al. ([2018](#efs25778-bib-0163){ref-type="ref"}) (Netherlands) PREVENDProspective cohort N = 8,592 initial cohort N = 7,330 included (excluded: participants with CVD, renal disease requiring dialysis, missing values of covariates at baseline) Oversampling of subjects with elevated albumin excretion (\> 10 mg/L) Median duration: 12.5 years (IQR 11.9--12.9)[Men (%)]{.ul} Q1 48.6 Q2 48.6 Q3 48.6 Q4 48.6 Q5 48.6 [Age (mean ± SD, years)]{.ul} Q1 50.5 ± 13.0 Q2 50.1 ± 12.9 Q3 49.2 ± 12.5 Q4 48.2 ± 12.0 Q5 47.0 ± 11.1 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} Q1 25.0 ± 3.8 Q2 25.3 ± 3.6 Q3 25.7 ± 4.0 Q4 26.3 ± 4.0 Q5 27.8 ± 4.9 [Ethnicity (% white)]{.ul} Q1 93.9 Q2 95.2 Q3 96.5 Q4 96.1 Q5 96.0 [Smoking status (current, %)]{.ul} Q1 39.0 Q2 33.1 Q3 33.9 Q4 31.6 Q5 32.3 [Education (higher vocational education or university, %)]{.ul} Q1 31.1 Q2 32.9 Q3 32.2 Q4 31.4 Q5 26.5 [SBP (mean ± SD, mm Hg)]{.ul} Q1 129 ± 21 Q2 129 ± 20 Q3 128 ± 20 Q4 128 ± 20 Q5 129 ± 18 [DBP (mean ± SD, mm Hg)]{.ul} Q1 74 ± 10 Q2 74 ± 10 Q3 74 ± 10 Q4 73 ± 10 Q5 74 ± 9 [Antihypertensive drugs (%)]{.ul} Q1 14.7% Q2 12.0% Q3 12.2% Q4 12.3% Q5 13.0% [24‐h UK (median (IQR), mmol)]{.ul} Q1 57 (46--72) Q2 66 (55--79) Q3 70 (58--83) Q4 74 (62--88) Q5 81 (68--96) [24‐h UCr (median (IQR), mmol)]{.ul} Q1 10.0 (8.3--12.6) Q2 11.2 (9.3--13.6) Q3 11.8 (9.8--14.3) Q4 12.5 (10.3--15.6) Q5 13.8 (11.3--16.8) [24‐h UAlbumin (median (IQR), mmol)]{.ul} Q1 8.0 (5.5--14.4) Q2 8.9 (6.1--16.0) Q3 9.1 (6.3--16.2) Q4 9.5 (6.5--18.1) Q5 10.5 (7.0--19.9)Two 24‐h urine specimens collected at baseline (1997--1998) and two 24‐h urine specimens collected during follow‐up (2001--2003)[Men]{.ul} Q1 \< 116 (712) Q2 116--142 (713) Q3 143--167 (713) Q4 168--201 (713) Q5 \> 201 (713) [Women]{.ul} Q1 \< 89 (753) Q2 89--110 (754) Q3 111--132 (753) Q4 133--160 (753) Q5 \> 160 (753)Haemorrhagic, ischaemic, unspecified stroke, fatal and non‐fatal events Data from municipal registers (fatal events) and Dutch national registry of hospital discharge diagnoses (non‐fatal events)Age, sex, height, weight, race/ethnicity, smoking status, alcohol consumption, education, type 2 diabetes, and total to HDL cholesterol ratio, 24‐h UK, magnesium, creatinine and albumin and estimated GFR[HR (95% CI) for fatal and non‐fatal stroke]{.ul} [By continuous UNa (by 51 mmol/24 h]{.ul} [decrease):]{.ul} 1.44 (1.14--1.82) (183 cases; 83,189 person‐years) [By sex‐specific quintiles of UNa:]{.ul} Q1 1.45 (0.92--2.29) (57 cases, 16,272 person‐years) Q2 1.13 (0.71--1.79) (49 cases, 16,515 person‐years) Q3 (reference) (33 cases, 16,774 person‐years) Q4 1.04 (0.64--1.71) (25 cases, 16,720 person‐years) Q5 0.81 (0.46--1.41) (19 cases, 16,908 person‐years) Adjustment for potential mediators (SBP and antihypertensive medication, plasma renin, aldosterone, and sodium levels) did not change the result. No evidence for effect modification by age, sex, BMI, hypertension, and UK (all P~interaction~ \> 0.10). [Sensitivity analyses:]{.ul} excluding individuals who were taking antihypertensive drugs at baseline (n = 6,388, 126 cases): results unchanged. excluding individuals with malignancies, type 2 diabetes, or chronic kidney disease at baseline (n = 6,054, 112 cases): results unchanged.Lelli et al. ([2018](#efs25778-bib-0185){ref-type="ref"}) (Italy) InCHIANTIProspective cohort N = 1,170 initial cohort N = 514 included (excluded: younger than 65 years, participants with CVD at baseline) Median duration: 9 yearsNR for the subcohortSingle 24‐h urine specimen collected at baseline (1998--2000)NR for the subcohortNon‐fatal CVD event, including angina pectoris, MI, heart failure, stroke Standardised questionnaire at follow‐up visits; clinical documentation reviewedAge, sex, education, CKD‐EPI, SBP, pack/years, hypertension, diabetes, BMI, caloric intake/bw, and antihypertensive drugs and diuretics)[RR (95% CI) for non‐fatal CVD events]{.ul} [By continuous UNa (By NR mmol/day increase):]{.ul} 0.96 (0.90--1.02) (169 cases, n = 514)Tuomilehto et al. ([2001](#efs25778-bib-0302){ref-type="ref"}) (Finland)Prospective cohort N = 3,607 initial cohort [Non‐fatal CHD analysis]{.ul} N = 2,402 (prevalent cases of CHD also excluded) [Non‐fatal stroke analysis]{.ul} N = 2,420 (prevalent cases of stroke also excluded) Duration: up to 14 years[Age (mean ± SD, years)]{.ul} w Q1 45.7 ± 11.6 Q2 45.4 ± 11.8 Q3 44.8 ± 11.1 Q4 45.6 ± 11.3  m Q1 45.4 ± 11.6 Q2 45.3 ± 11.0 Q3 46.2 ± 10.4 Q4 45.4 ± 10.6 [BMI (mean ± SD, kg/m]{.ul} ^[2]{.ul}^ [)]{.ul} w Q1 24.6 ± 4.2 Q2 25.1 ± 4.0 Q3 26.3 ± 4.6 Q4 27.8 ± 5.4  m Q1 25.5 ± 2.4 Q2 26.4 ± 3.3 Q3 26.9 ± 3.3 Q4 28.1 ± 4.2 [Smoking (current,%)]{.ul} w Q1 15% Q2 20% Q3 18% Q4 16% m Q1 31% Q2 40% Q3 33% Q4 44% [SBP (mean ± SD, mm Hg)]{.ul} w Q1 141 ± 22 Q2 140 ± 22 Q3 141 ± 22 Q4 142 ± 22  m Q1 144 ± 22 Q2 145 ± 19 Q3 148 ± 20 Q4 147 ± 19 [DBP (mean ± SD, mm Hg)]{.ul} w Q1 83 ± 12 Q2 83 ± 12 Q3 83 ± 12 Q4 85 ± 22  m Q1 86 ± 11 Q2 86 ± 12 Q3 89 ± 13 Q4 90 ± 13Single 24‐h urine specimens collected at baseline Participants reporting incomplete collection excluded from the analysisMedian (min--max) [Male]{.ul} 205 (25--552) [Female]{.ul} 154 (12--512)Coronary deaths, non‐fatal coronary events, stroke events, cardiovascular deaths Statistics Finland (fatal events) and national hospital discharge register (non‐fatal events)Age, study year, smoking, serum total and HDL cholesterol, SBP and BMI[HR (95% CI) for non‐fatal CHD events]{.ul} [By 100 mmol/24‐h increase in UNa]{.ul} [Men]{.ul} 1.34 (1.06--1.70) (98 cases, n = 1145) [Women]{.ul} 1.35 (0.77--2.35) (30 cases, n = 1257) [Men + Women]{.ul} 1.34 (1.08--1.67) (128 cases, n = 2,402)[HR for non‐fatal stroke events]{.ul} [By 100 mmol/24‐h increase in UNa]{.ul} [Men]{.ul} 1.00 (0.68--1.47) (43 cases, n = 1161) [Women]{.ul} 1.34 (0.87--2.07) (41 cases, n = 1259) [Men + Women]{.ul} 1.13 (0.84--1.51) (84 cases, n = 2,420)[^40]

K.2.. Outcome of the RoB appraisal {#efs25778-sec-0124}
----------------------------------

### K.2.1.. Observational studies {#efs25778-sec-0125}

ReferencesOutcomesRisk of bias domains[a](#efs25778-note-1027){ref-type="fn"}Tier[b](#efs25778-note-1028){ref-type="fn"}ConfoundingAttritionExposureOutcomeReportingStatisticsLelli et al. ([2018](#efs25778-bib-0185){ref-type="ref"})Non‐fatal CVD (any)−+++−++−**2**Joosten et al. ([2014](#efs25778-bib-0153){ref-type="ref"})Fatal and non‐fatal CHD+NR++++++++**1**Kieneker et al. ([2018](#efs25778-bib-0163){ref-type="ref"})Fatal and non‐fatal stroke+NR+++++**1**Stolarz‐Skrzypek et al. ([2011](#efs25778-bib-0286){ref-type="ref"})Fatal CVD Fatal and non‐fatal CVD Fatal and non‐fatal CHD Fatal and non‐fatal stroke+−−+++−**2**Cook et al. ([2014](#efs25778-bib-0060){ref-type="ref"})Fatal and non‐fatal CVD (any)+++++++++++**1**Tuomilehto et al. ([2001](#efs25778-bib-0302){ref-type="ref"})Non‐fatal stroke Non‐fatal CHD−++++++−**2**[^41][^42][^43]

K.3.. **Descriptive forest plots** {#efs25778-sec-0126}
----------------------------------

![Descriptive forest plot of the eligible observational studies on stroke\
95% CI: 95% confidence interval; HR: hazard ratio; HTN: hypertensive; UNa: sodium urinary excretion.A hazard ratio \> 1 indicates an increased risk of outcome with higher sodium intake.](EFS2-17-e05778-g015){#efs25778-fig-0015}

![Descriptive forest plot of the eligible observational studies on coronary heart disease\
CHD: coronary heart disease; 95% CI: 95% confidence interval; HR: hazard ratio; HTN: hypertensive; UNa: sodium urinary excretion.A hazard ratio \> 1 indicates an increased risk of outcome with higher sodium intake.](EFS2-17-e05778-g016){#efs25778-fig-0016}

![Descriptive forest plot of the eligible observational studies on cardiovascular disease\
CVD: cardiovascular disease; 95% CI: 95% confidence interval; HR: hazard ratio; HTN: hypertensive; UNa: sodium urinary excretion.A hazard ratio \> 1 indicates an increased risk of outcome with higher sodium intake.](EFS2-17-e05778-g017){#efs25778-fig-0017}

Appendix L -- Outcome of the systematic review on bone health {#efs25778-sec-1012}
=============================================================

L.1.. Evidence table {#efs25778-sec-0127}
--------------------

References (country)DesignBaseline characteristics mean ± SD (N)Na intake assessment methodUNa (mg/day) Mean ± SD (N)Outcomes assessedConfounders adjusted forKey findingsDevine et al. ([1995](#efs25778-bib-0070){ref-type="ref"}); Prince et al. ([1995](#efs25778-bib-0251){ref-type="ref"}) (Australia)RCT in postmenopausal women (≥ 10 years after menopause) Group 1: Ca suppl. (1 g/day) Group 2: Ca suppl. (1 g/day) + exercise programme Group 3: Placebo Group 4: \~200 mL milk/day (1 g Ca/day) N = 196 screened N = 168 randomised (42/group) Duration: 2 years[Age:]{.ul} 63 (168) [bw:]{.ul} 66 ± 10 (191) [Nutrient intakes based on 4‐day weighed diet records (190):]{.ul} [Protein]{.ul}: 76 ± 16 g/day [Ca (food only):]{.ul} 805 ± 320 mg/day [P:]{.ul} 1,269 ± 311 mg/day [Energy:]{.ul} 1,632 ± 348 kcal/daySingle 24‐h urine samples collected at baseline, year 1 and year 2; excretions averaged over the 2‐year period. No information on instructions to participants or on measures to check completeness of collections.[Baseline UNa:]{.ul} 2,783 ± 1,081 (196) [Average year 1 and 2 UNa:]{.ul} 3,049 ± 808 (127)BMD (total hip, intertrochanter, femoral neck, ultradistal ankle, lumbar spine) By DEXA at baseline, 1 year and 2 yearsBody weight, change in METs/day over the 2‐year period, average daily Ca intakeMultiple regression analysis: Negative associations between average UNa and 2‐year change in BMD for total hip (SRC = −0.20, p = 0.002) and ultradistal ankle (SRC = −0.18, p = 0.016)Ilich et al. ([2010](#efs25778-bib-0141){ref-type="ref"}) (USA)RCT in postmenopausal women (≥ 5 years after menopause); all supplemented with Ca (630 mg/day) and vitamin D (\~ 400 IU/day) Group 1: instructed to reduce Na intake to 1,500 mg/day Group 2: usual Na intake (\~ 3,000 mg/day) N = 136 randomised (68/group) N = 97 completed Duration: 3 years[Age:]{.ul} 68.6 ± 7.1 (136) [bw:]{.ul} 68.0 ± 11.3 (136) [BMI:]{.ul} 26.0 ± 3.8 (136) [Nutrient intakes based on 4‐day weighed diet records (136):]{.ul} [Protein:]{.ul} 70.6 ± 18.6 g/day [Ca (food only):]{.ul} 872 ± 365 mg/day [P:]{.ul} 1,077 ± 351 mg/day [Energy:]{.ul} 1,691 ± 382 kcal/daySingle 24‐h urine samples collected every 6 months. Cumulative Na/Cr used as variable. Careful instructions to participants and use of Cr to screen for errors or incomplete collection[Baseline UNa:]{.ul} 2,404 ± 963 (136) [Baseline UNa/g Cr:]{.ul} 2,465 ± 903 (136)BMD (composite femur, forearm, lumbar spine, total body) By DEXA at baseline and every 6 monthsAge, height, cumulative lean and/or fat tissue, cumulative total calcium intake and cumulative modes of physical activityMultiple regression analysis (ITT): Positive associations between cumulative UNa/Cr and BMD at 36 months at LS (Coeff. = 5.85^e−5^, p = 0.056), at forearm (Coeff. = 8.12^e−5^, p = 0.076) and total body BMD (Coeff. = 2.81^e−5^, p = 0.041) Random‐effects regression analysis (accounting for repeated measures and missing data): Main effect of UNa in the forearm: higher UNa associated with higher BMD at baseline and subsequent time points (t = 2.63, p = 0.0089). Similar observation in the spine. No effect on total body or femoral BMD[^44]

L.2.. **Outcome of the RoB** {#efs25778-sec-0128}
----------------------------

### L.2.1.. Observational evidence {#efs25778-sec-0129}

ReferencesRisk of bias domains[a](#efs25778-note-1030){ref-type="fn"}Tier[b](#efs25778-note-1031){ref-type="fn"}Confounding(a)AttritionExposureOutcomeReportingStatisticsDevine et al. ([1995](#efs25778-bib-0070){ref-type="ref"})+−−++++++**2**Ilich et al. ([2010](#efs25778-bib-0141){ref-type="ref"})++++++++**1**[^45][^46]

Appendix M -- Expert knowledge elicitation {#efs25778-sec-1013}
==========================================

 {#efs25778-sec-0130}

In 2014, EFSA published a guidance on expert knowledge elicitation (EKE) in food and feed safety risk assessment (EFSA, [2014](#efs25778-bib-0078){ref-type="ref"}). The reader is referred to the guidance for general information about the objectives, procedures and methods of EKE methods. Appendix [M](#efs25778-sec-1013){ref-type="sec"} details the specific process used for the two EKEs that were conducted to inform the setting of DRVs for sodium.

M.1.. Principle {#efs25778-sec-0131}
---------------

EKE refers to the drawing out of knowledge from one or more experts, following a transparent, structured and comprehensive method based on rigorous probabilistic judgement techniques (EFSA, [2014](#efs25778-bib-0078){ref-type="ref"}).

Through the EKE, experts can be asked for judgements about an uncertain quantity of interest. The method aims at obtaining from the experts not only their 'best judgement' of the quantity of interest based on the available evidence, but also a representation of the uncertainty surrounding it.

M.2.. The Sheffield protocol {#efs25778-sec-0132}
----------------------------

The Sheffield protocol is an EKE method that is based on behavioural aggregation, i.e. judgements of several experts are combined via a moderated discussion (EFSA, [2014](#efs25778-bib-0078){ref-type="ref"}).[14](#efs25778-note-1032){ref-type="fn"}

The main steps of the protocol are illustrated in Figure [M.1](#efs25778-fig-0018){ref-type="fig"}. It is characterised by two rounds of judgements from the experts. In the first round, experts answer the elicitation question privately, by deriving their individual uncertainty probability distribution. The individual judgements, together with their rationale (see Sections [M.3](#efs25778-sec-0133){ref-type="sec"} and [M.4](#efs25778-sec-0135){ref-type="sec"} below), are then discussed by the group. In the second round, the group agrees on a consensus judgement through a moderated group discussion. To that end, the group is requested to express the reasonable judgement of an impartial expert informed by the range of judgements and rationales expressed in the first round. The final outcome of the EKE is an uncertainty probability distribution that represents the experts aggregated judgement about the quantity of interest.

The protocol requires an experienced facilitator to manage the experts, and to address possible sources of bias in group interactions.

![Main steps of the EKE process following the Sheffield method\
The evidence dossier documents all the evidence and related uncertainties relevant to the formulation of the expert judgement (see Section [M.3](#efs25778-sec-0133){ref-type="sec"} below).In this step, each expert answered the EKE questions individually. To that end, experts had to express the probability that each of the proposed ranges of sodium intake/excretion would include the 'true' level of interest (roulette method, see Section [M.4](#efs25778-sec-0135){ref-type="sec"} below). As a result, each expert provides his/her own uncertainty probability distribution.Following the collective discussion, a consensus uncertainty probability distribution is elicited from the group of experts, which reflect the aggregated view of the experts on the parameter of interest and related uncertainty.](EFS2-17-e05778-g018){#efs25778-fig-0018}

M.3.. Preparatory phase: elicitation questions and evidence dossier {#efs25778-sec-0133}
-------------------------------------------------------------------

Based on the review of the available evidence, it was considered that (i) data on the relationship between sodium intake and level of blood pressure or CVD risk could inform about the levels of sodium intake associated to a reduced risk of chronic diseases; and (ii) balance studies could inform about the levels of sodium intake that are adequate to maintain a null sodium balance. Because of the limited evidence available and of the associated uncertainties, it was not possible to identify such levels of sodium intake with certainty. Two questions were formulated to elicit evidence‐based judgement of the experts about the levels of interest:

[EKE question 1]{.ul}: *What is the lowest level of sodium intake at which the risk of chronic disease (i.e. stroke, CHD) is minimised in the majority (≥ 97.5%) of the general population of adults?*

[EKE question 2]{.ul}: *What is the lowest level of sodium intake which is adequate (i.e. amount which allows to maintain sodium balance) for the majority (≥ 97.5%) of the general population of adults?*

Through the EKE, experts are required to formulate evidence‐based judgements, providing a rationale. An evidence dossier was prepared before the EKE meeting, which assembled all the relevant evidence into a single document, in the form of structured tables and graphical representations (BOX 2). During the process, the experts are requested to provide their rationales behind their probability assessments by referring to the dossier.

The two EKEs were conducted with the seven experts of the EFSA working group on DRVs for minerals,[15](#efs25778-note-1033){ref-type="fn"} who had been in charge of selecting, reviewing and appraising the available evidence. All experts received a training on the method before starting the elicitation process.

###  {#efs25778-sec-0134}

BOX 2 -- Content of the evidence dossier[EKE question 1:]{.ul}All relevant evidence on the relationship between sodium and blood pressure, including:The outcome of the meta‐regression modelling of sodium and blood pressureThe data from the eligible randomised studies on the incidence of hypertensionThe data from the eligible prospective cohort study on blood pressureThe data from the eligible prospective cohort studies on the incidence of hypertensionConsiderations about the reliability, external validity and consistency of each source of evidenceAll relevant evidence on the relationship between sodium and risk of CVD, including:The data from the eligible prospective cohort studies on risk of strokeThe data from the eligible prospective cohort studies on risk of coronary heart diseaseThe data from the eligible prospective cohort studies on risk of CVDConsiderations about the reliability, external validity and consistency of each source of evidenceThe outcome of the risk of bias assessment for each individual studyGraphical representations of the dose‐responses from the eligible observational studies on coronary heart disease and strokeA summary of relevant mechanistic data[EKE question 2:]{.ul}The data from the eligible balance studiesConsiderations about the reliability, external validity and consistency of the available evidenceA summary of relevant mechanistic data

M.4.. Elicitation of the uncertainty probability distributions: the roulette method {#efs25778-sec-0135}
-----------------------------------------------------------------------------------

For illustrative purposes, the uncertain quantity of interest is denoted *X*. The objective of the EKE is to elicit a probability distribution for *X* from the experts. The roulette method was used for the EKEs on sodium (Johnson et al., [2010](#efs25778-bib-0808){ref-type="ref"}; EFSA, [2014](#efs25778-bib-0078){ref-type="ref"}). The range of possible values for *X* was divided into fixed intervals (bins) (Figure [M.2](#efs25778-fig-0019){ref-type="fig"}). In answering the elicitation questions, experts were asked to distribute 20 chips into the bins, with the probability of *X* lying in a particular bin interpreted as the proportion of chips allocated into that bin. As the total number of chips was 20, each chip represented 5% probability.

![Illustration of the roulette method. In this example, a range of possible values for *X* has been set between 5 and 13. Each orange rectangle represents one chip. For instance, by placing four of their 20 chips in the bin (6,7) the expert expresses a probability of 4/20 (20%) that the 'true value' of *X* lies in that bin. The probability that the range 6 to 12 includes the 'true value' of *X* is 100%.](EFS2-17-e05778-g019){#efs25778-fig-0019}

In the first round of judgements, one histogram was obtained from each expert, representing his/her uncertainty probability distribution. In the second round of judgements, the experts built a group histogram, i.e. consensus uncertainty probability distribution, through discussion. The group consensus uncertainty probability distributions elicited in response to the two EKE questions are provided in Figures [1](#efs25778-fig-0017){ref-type="fig"} and [2](#efs25778-fig-0018){ref-type="fig"}. The rationales for the distributions were documented and are reported in Tables [9](#efs25778-tbl-0009){ref-type="table"} and [10](#efs25778-tbl-0010){ref-type="table"}.

M.5.. Derivation of parametric distributions from the group consensus uncertainty probability distributions {#efs25778-sec-0136}
-----------------------------------------------------------------------------------------------------------

Parametric distributions were fitted to the group consensus uncertainty probability distributions to derive probability density functions. This allows the derivation of probabilities for values within the range of each bin used for the elicitation. Several parametric distributions (e.g. normal, log‐normal, truncated normal, gamma, Weibull and logistic) have been considered as possible candidates to estimate the probability density functions that better fit the centiles obtained through the EKE process. Log‐normal distributions were finally chosen based on indicators of goodness of fit (Akaike Information Criterion and Bayesian Information Criterion), with the following parameters: 0.72 (mean) and 0.23 (standard deviation) for the question on sodium intake at which CVD risk is reduced; 0.5 (mean) and 0.3 (standard deviation) for the question on sodium balance.

Based on the two probability density functions, cumulative uncertainty density functions were derived (Figure [3](#efs25778-fig-0003){ref-type="fig"}) and served as the basis to inform the setting of the reference value for sodium.

Annex A -- Protocol for sections 5.5 and 6 of the scientific opinion on DRVs for sodium: Assessment of the relationship between sodium intake and pre‐specified health outcomes, including dose‐response relationships, and integration of different lines of evidence for setting DRVs for sodium {#efs25778-sec-2001}
==================================================================================================================================================================================================================================================================================================

 {#efs25778-sec-0137}

Annex A can be found in the online version of this output ('Supporting information' section): <https://doi.org/10.2903/j.efsa.2019.5778>

Annex B -- Analysis of evidence from published scientific literature as preparatory work for the setting of Dietary Reference Values for Sodium {#efs25778-sec-2002}
===============================================================================================================================================

 {#efs25778-sec-0138}

Annex B can be found in the online version of this output ('Supporting information' section): <https://doi.org/10.2903/j.efsa.2019.5778>

Supporting information
======================

###### 

Protocol for sections 5.5 and 6 of the scientific opinion on DRVs for sodium: Assessment of the relationship between sodium intake and pre‐specified health outcomes, including dose‐response relationships, and integration of different lines of evidence for setting DRVs for sodium

###### 

Click here for additional data file.

###### 

Analysis of evidence from published scientific literature as preparatory work for the setting of Dietary Reference Values for Sodium

###### 

Click here for additional data file.

Scientific Committee for Food, 1993. Nutrient and energy intakes for the European Community. Reports of the Scientific Committee for Food, 31st series. Food -- Science and Technique, European Commission, Luxembourg, 248 pp.

Regulation (EC) No. 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety. OJ L 31, 1.2.2002, pp. 1--24.

Deliverable 1 of PROMETHEUS project -- PROMoting METHods for Evidence Use in Scientific assessments.

<https://www.efsa.europa.eu/en/consultations/call/170929>

<https://www.efsa.europa.eu/en/consultations/call/190403>

Available online: <https://www.omim.org/>

Regulation (EC) No. 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26.

Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51.

Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow‐on formulae and amending Directive 1999/21/EC. OJ L 401, 30.12.2006, p. 1.

Commission Directive 2006/125/EC of 5 December 2006 on processed cereal‐based foods and baby foods for infants and young children. OJ L 339, 6.12.2006, p. 20.

In addition, data were received during the public consultation on the intermediate draft of the Opinion. EFSA (European Food Safety Authority), 2017. Outcome of a public consultation on the Scientific Opinion of EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) on Dietary Reference Values for sodium (intermediate draft) and related protocol. EFSA supporting publication 2017:1356.

A strong recommendation is one for which the guideline development group is confident that the desirable effects of adherence outweigh the undesirable effects.

A secondary analysis of the DASH‐sodium trial indicates that the relationship between absolute sodium intake and blood pressure levels varies with energy intake (Murtaugh et al., [2018](#efs25778-bib-0219){ref-type="ref"}). A higher increase in SBP and DBP with increasing sodium intake was reported at lower energy intakes than at higher ones (p interaction \< 0.001). This suggests that sodium density may reflect the relationship with blood pressure better than does absolute sodium intake.

The Sheffield Elicitation Framework was created by Tony O'Hagan and Jeremy Oakley at the University of Sheffield, UK (<http://www.tonyohagan.co.uk/shelf/>)

<https://www.efsa.europa.eu/en/nutrition/working-groups>

[^1]: Studies were identified by a comprehensive literature search for publications from January 2010 to January 2014 (LASER Analytica, [2014](#efs25778-bib-0181){ref-type="ref"}) and additional searches of the literature before these dates. If studies did not report whether infants were born at term or not, it was presumed that infants were born at term.

[^2]: AAS: atomic absorption spectrophotometry; ICP‐AES: inductively coupled plasma atomic emission spectroscopy; ICP‐MS: inductively coupled plasma mass spectrometry; N: number; SD: standard deviation; SE: standard error.

[^3]: Including five mothers of preterm infants.

[^4]: 95% CI: 95% confidence interval; INTERSALT: International Cooperative Study on Salt, Other Factors and Blood Pressure; M: men; Na: Sodium; N/A: not available; NR: not reported; SD: standard deviation; W: women.

[^5]: 95% CI: 95% confidence interval; Cr: creatinine; IQR: interquartile range; Na: sodium; N/A: not available; PABA: *para*‐aminobenzoic acid; SD: standard deviation.

[^6]: bw: body weight; 95% CI: 95% confidence interval; Cr: creatinine; EFCOVAL: European Food Consumption Validation; FFM: fat‐free mass; INTERSALT: International Cooperative Study on Salt, Other Factors and Blood Pressure; IQR: interquartile range; N: number; Na: sodium; N/A: not available; PABA: *para*‐aminobenzoic acid; SD: standard deviation.

[^7]: For comparison purposes, results provided in g NaCl/day were converted back in mmol/day by multiplying by 0.4 and dividing by 23.

[^8]: Geometric means; based on two 24‐h collection per subject.

[^9]: The values reported are unpublished data provided by the National Institute of Public Health of the Czech Republic.

[^10]: Unless indicated otherwise.

[^11]: The values reported are unpublished data provided by the Italian Instituto Superiore di Sanità.

[^12]: bw: body weight; 95% CI: 95% confidence interval; Cr: creatinine; EFCOVAL: European Food Consumption Validation; FFM: fat‐free mass; IQR: interquartile range; N: number; Na: sodium; N/A: not available; PABA: *para*‐aminobenzoic acid, SD: standard deviation.

[^13]: For comparison purposes, results provided in g NaCl/day were converted back in mmol/day by multiplying by 0.4 and dividing by 23.

[^14]: Geometric means; based on two 24‐h collection per subject.

[^15]: The values reported are unpublished data provided by the National Institute of Public Health of the Czech Republic.

[^16]: Unless indicated otherwise.

[^17]: The values reported are unpublished data provided by the Italian Instituto Superiore di Sanità.

[^18]: B: black; bw: body weight; F: female; M: male; Na: sodium; SD: standard deviation; W: white.

[^19]: ++: Definitely low RoB; +: Probably low RoB; NR: Not Reported; --: Probably high RoB; -- −: Definitely high RoB.

[^20]: ++: Definitely low RoB; +: Probably low RoB; NR: Not Reported; --: probably high RoB; -- −: Definitely high RoB.

[^21]: \* Key question.

[^22]: BMI: body mass index; BP: blood pressure; DBP; diastolic blood pressure; G1: group 1 ('low' sodium); G2: group 2 ('high' sodium); mm Hg: millimetre of mercury; N: number; UNa: sodium urinary excretion; NR: not reported; NT: normotensive; SBP: systolic blood pressure; SD: standard deviation; SE: standard error; UK: potassium urinary excretion.

[^23]: b: boys; BMI: body mass index; BP: blood pressure; bw: body weight; 95% CI: 95% confidence interval; Cl: chloride; DBP: diastolic blood pressure; DONALD: Dortmund Nutritional and Anthropometrical Longitudinally Designed study FVI: fruit and vegetable intake; g: girls; MJ: megajoule; mm Hg: millimetre of mercury; mmol: millimole; N: number; Na: sodium; NR: not reported; SBP: systolic blood pressure; SD: standard deviation; SDS: standard deviation score; TEI: total energy intake; UCr: creatinine urinary excretion; UK: potassium urinary excretion; UNa: sodium urinary excretion.

[^24]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^25]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).

[^26]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^27]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).

[^28]: BMI: body mass index; BP: blood pressure; 95% CI: 95% confidence interval; DBP: diastolic blood pressure; G1: group 1 ('low' sodium); G2: group 2 ('high' sodium); G3: group 3 ('highest' sodium, for studies with three sodium intake levels); HT: hypertensive; IQR: interquartile range; mm Hg: millimetre of mercury; N: number; Na: sodium; NR: not reported; NT: normotensive; SBP: systolic blood pressure; SD: standard deviation; SE: standard error; UK: potassium urinary excretion; UNa: sodium urinary excretion.

[^29]: BMI: body mass index; BP: blood pressure; 95% CI: 95% confidence interval; CVD: cardiovascular disease; DBP: diastolic blood pressure; EPOGH: European Project on Genes in Hypertension; FLEMENGHO: Flemish Study on Genes and Health Outcomes; m: men; mm Hg: millimetre of mercury; N: number; Na: sodium; SBP: systolic blood pressure; SD: standard deviation; UCr: creatinine urinary excretion; UK: potassium urinary excretion; UNa: sodium urinary excretion; w: women.

[^30]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^31]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).

[^32]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^33]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).

[^34]: bw: body weight; 95% CI: 95% confidence interval; DBP: diastolic blood pressure; Diff: difference; G1: group 1 ('low' sodium); G2: group 2 ('high' sodium); mm Hg: millimetre of mercury; N: number; Na: sodium; RCT: randomised controlled trial; RR: relative risk; SBP: systolic blood pressure; SD: standard deviation; TOPH: Trials of Hypertension Prevention; UNa: sodium urinary excretion.

[^35]: BMI: body mass index; BP: blood pressure; 95% CI: 95% confidence interval; CVD: cardiovascular disease; DBP: diastolic blood pressure; EPOGH: European Project on Genes in Hypertension; FLEMENGHO: Flemish Study on Genes and Health Outcomes; GFR: glomerular filtration rate; HR: hazard ratio; IMDM: insulin‐mediated diabetes mellitus; IQR: interquartile range; m: men; mm Hg: millimetre of mercury; N: number; Na: sodium; SBP: systolic blood pressure; PREVEND: Prevention of Renal and Vascular End‐stage Disease; SD: standard deviation; UAlbumin: albumin urinary excretion; UCa: calcium urinary excretion; UCr: creatinine urinary excretion; UK: potassium urinary excretion; UNa: sodium urinary excretion; w: women.

[^36]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^37]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).

[^38]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^39]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).

[^40]: BMI: body mass index; BP: blood pressure; bw: body weight; 95% CI: 95% confidence interval; CKD‐EPI: estimated creatinine clearance; CHD: coronary heart disease; CVD: cardiovascular disease; DBP: diastolic blood pressure; EPOGH: European Project on Genes in Hypertension; FLEMENGHO: Flemish Study on Genes and Health Outcomes; GFR: glomerular filtration rate; HDL: high density lipoprotein; HF: heart failure; HR: hazard ratio; IHD: ischaemic heart disease; IMDM: insulin‐mediated diabetes mellitus; IQR: interquartile range; m: men; mm Hg: millimetre of mercury; MI: myocardial infarction; N: number; Na: sodium; NR: not reported; NT‐proBNP: N‐terminal pro‐B‐type natriuretic peptide; RR: relative risk; SBP: systolic blood pressure; SD: standard deviation; TOPH: Trials of Hypertension Prevention; UAlbumin: urinary albumin; UCr: creatinine urinary excretion; UK: potassium urinary excretion; UNa: sodium urinary excretion; w: women.

[^41]: CHD: coronary heart disease; CVD: cardiovascular disease

[^42]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^43]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).

[^44]: BMD: bone mineral density; BMI: body mass index; bw: body weight; Ca: calcium; Cr: creatinine; DEXA: dual‐energy X‐ray technology; MET: metabolic equivalent activity; IU: international unit; N: number; Na: sodium; NR: not reported; P: phosphorus; RCT: randomised controlled trial; SD: standard deviation; SRC: standardised regression coefficient; UNa: urinary sodium excretion.

[^45]: Expert judgement was translated into a rating scale for each question to be answered as follows: (++): definitely low RoB; (+): probably low RoB; (NR): not reported; (−): probably high RoB; (−−): definitively high RoB.

[^46]: The individual rating for each question was combined by an algorithm and translated to an overall tier of reliability for each individual study (RoB tier 1: low RoB; RoB tier 2: moderate RoB; RoB tier 3: high RoB).
